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Preface
Worldwide, annually approximately 100 million people undergo some form of non-cardiac surgery. 
Cardiac events, such as myocardial infarction are a major cause of perioperative morbidity and mor-
tality in these patients. Though the true incidence of perioperative cardiac complications is difficult 
to assess, it is estimated that approximately 2.0–3.5% of patients undergoing major non-cardiac 
surgery experience a major adverse cardiac event. Furthermore an estimated 0.5–1.5% of patients 
die within 30 days after the surgical procedure due to a cardiovascular cause. The pathophysiology 
of perioperative cardiac events is complex. Similar to the non-operative setting it is thought that 
approximately half of all perioperative myocardial infarctions are attributable to a sustained coro-
nary oxygen demand/supply mismatch. Coronary plaque rupture, leading to thrombus formation 
and subsequent vessel occlusion, is thought to be the other important cause of acute perioperative 
coronary syndromes.
Part 1. Preoperative cardiovascular risk assessment
The risk of perioperative cardiac complications depends on mainly two conditions: (1) the condition 
of the patient prior to surgery, i.e. the presence and severity of co-morbidities, and (2) the type of 
the surgical procedure. The first part of this thesis covers current knowledge and existent data on 
preoperative cardiac risk assessment. In this part adjustments of current risk indices to improve the 
predictive ability, the value of additional cardiac testing and possible new preoperative cardiac risk 
markers are investigated.
Part 2. Perioperative cardiovascular risk reduction
Once perioperative cardiac risk is assessed, the next step is to treat patients with an increased cardiac 
risk optimally to minimize the risk of perioperative cardiac complications. In part 2 of this thesis 
several possible risk reduction strategies are discussed, including beta-blocker therapy, 3-hydroxy-
3-methylglutaryl co-enzyme A reductase inhibitor (statin) therapy, prophylactic coronary revascular-
ization and endovascular treatment modalities.
Beta-blockers have negative chronotropic and negative inotropic effects. Due to the role of sym-
pathetic activation in adverse perioperative cardiac outcomes, beta-adrenergic receptor blocking 
drugs have been proposed as a means for providing cardioprotection. Potential cardioprotective 
mechanisms of beta-blockers include a) reduced heart rate and contractility and subsequently 
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lower myocardial oxygen demand; b) a shift in energy metabolism from free fatty acids to the more 
energy efficient glucose; c) anti-arrhythmic effects; d) anti-renin/angiotensin properties; and e) 
anti-inflammatory effects possibly promoting plaque stability. The effects on heart rate, contractility, 
and energy substrate shift occur almost instantly while the anti-inflammatory effects may only be 
observed after a prolonged beta-blocker usage. Recently the benefits of perioperative beta-blocker 
therapy have been questioned. This part of the thesis describes (1) which patients might benefit from 
perioperative beta-blocker therapy, and (2) what the potential pitfalls of perioperative beta-blocker 
therapy are.
Numerous clinical trials have clearly demonstrated that statin use is associated with a substantial 
long-term reduction in the risk for cardiovascular morbidity and mortality in patients with or at risk of 
coronary heart disease. However, lipid lowering seems not to be the only beneficial effect of statins. 
Other, so-called pleiotropic, effects of statins have recently been described. One of these pleiotropic 
effects may be the stabilization of vulnerable coronary plaques during surgical procedures which 
might result in a substantial reduction of perioperative adverse cardiac events. However, the timing 
of initiation of statin therapy remained a matter of debate. Should the patient start with statin therapy 
at the preoperative screening visit while there is (1) a possibly increased risk for perioperative statin-
induced side effects such as myopathy, as suggested by the ACC/AHA/NHLBI clinical advisory on the 
use and safety of statins, (2) a possibly increased cardiac risk if statin therapy has to be interrupted in 
the perioperative period, as is to be expected in approximately 25% of patients, and (3) the evidence 
supporting the perioperative use of statins is based on retrospective studies? This part of the thesis 
tries to answer these questions.
The role of preoperative coronary revascularization in patients at high cardiac risk undergoing non-
cardiac surgery is ill-defined. The concept of a beneficial effect of prophylactic coronary revasculariza-
tion before non-cardiac surgery is based on the assumption that perioperative myocardial infarctions 
arise at locations in coronary arteries with hemodynamically critical stenosis, elicited by the stress of 
surgery. Evidence for the use of this potentially cardioprotective procedure is based on the results of 
two registries which showed an improved outcome in non-cardiac surgical patients with a history of 
coronary artery bypass grafting (CABG) or percutaneous coronary intervention with stent placement 
(PCI) compared to a similar patient group without a CABG or PCI. It must be noted however that the 
time interval between coronary revascularization and the non-cardiac procedure in these registries 
was 4.1 and 2.4 years respectively. Therefore the indication of prophylactic coronary revascularization 
immediate prior to the non-cardiac surgical procedure remained speculative. Therefore, the potential 
benefit of prophylactic coronary revascularization in high risk patients has been investigated and is 
described in part 2 of this thesis.
Part 3. Long-term cardiovascular risk reduction
After successful non-cardiac surgery certain patient populations remain at increased risk for cardiac 
events. Patients who underwent non-cardiac vascular surgery are particular prone to long-term 
adverse cardiac outcome. The high cardiac risk in this population is attributable to the high prevalence 
of underlying coronary artery disease. As was already shown in 1984 only 8% of patients undergoing 
major non-cardiac vascular surgery have a normal coronary artery tree. In part 3 of this thesis the 
long-term prognosis of patients undergoing non-cardiac vascular surgery is examined. Furthermore 
several risk reduction strategies are studied such as prophylactic coronary revascularization, the use 
of endovascular treatment modalities and the importance of aggressive medical therapy in this high-
risk group of patients. After all, the patient should live long enough to enjoy the benefits of surgery.
Part I
Preoperative Cardiovascular Risk Assessment

Chapter 1
Cardiac complications
Olaf Schouten
Don Poldermans
In: Cronenwett JL and Johnston KW, eds. Rutherford’s Textbook of Vascular Surgery. 7th ed. 
Philadelphia, USA: Elsevier press, 2009.
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Since the landmark publication of Hertzer and colleagues from the Cleveland Clinic in 19841 the 
coexistence of coronary artery disease (CAD) and peripheral arterial disease (PAD) has been accepted 
with almost religious zeal by physicians treating patients with PAD.
EPIDEMIOLOgy
A. Prevalence of cardiac disease
Hertzer’s seminal study, in which 1000 consecutive patients undergoing operations for PAD under-
went preoperative cardiac catheterizations (whether or not they had symptoms of CAD), is unlikely 
ever to be repeated, and the published article is one of the most widely quoted articles in the medical 
and surgical literature. These investigators reported that only 8% of their patients (who were roughly 
divided into thirds—aortic, infrainguinal, and carotid disease) had normal coronary arteries, and 
approximately one third had severe-correctable or severe-inoperable CAD. More recent studies using 
functional tests for CAD such as dobutamine stress echocardiography confirmed these findings. In a 
study population of 1097 vascular surgical patients, the incidence of rest wall motion abnormalities 
was nearly 50%, while one-fifth of patients had stress-induced myocardial ischaemia2.
B. Definition of cardiac complications
Numerous undesirable cardiac events have been evaluated and considered as endpoints in clinical 
reviews of peripheral vascular surgery, including (1) unstable angina pectoris, (2) congestive heart 
failure, (3) arrhythmias, (4) myocardial ischemia (overt and “silent”), (5) nonfatal myocardial infarction, 
and (6) cardiac death. Of these adverse events, the first four endpoints are relatively “soft” compared 
with the last two.
Unstable angina is included as one of the acute coronary syndromes (ACS); however, it does not 
routinely produce lasting cardiac damage, and its definition is variable, ranging from a mere change 
in frequency of chest pain to unrelenting pain unresponsive to standard therapeutic maneuvers, 
such as administration of nitroglycerin and rest.
Congestive heart failure may be the result of fluid overload, which often occurs after vascular pro-
cedures or the use of a narcotic agent as the primary anesthetic. The diagnosis of congestive heart 
failure is often subjective with no consensus regarding the criteria required to confirm the diagnosis 
(i.e. jugular venous distention, dyspnea, rales, gallop rhythm, typical chest x-ray findings, pedal or 
sacral edema, objective measurement of decreased cardiac output—in variable combinations).
Arrhythmias may be brief, self-limiting, hemodynamically benign, and due to factors other than 
cardiac disease, including hypoxia, drug toxicity, or metabolic derangements.
Myocardial infarction and cardiac death are more serious cardiac complications. The Joint European 
Society of Cardiology (ESC) and American College of Cardiology (ACC) Committee for the Redefini-
tion of Myocardial Infarction has made a clear definition of myocardial infarction (TABLE 1.1)3. The 
definition includes the rise and fall of cardiac biomarkers (preferably troponin) with at least one value 
above the 99th percentile of the upper reference limit together with evidence of myocardial ischemia 
with at least one of the following: symptoms of ischemia; ECG changes indicative of new ischemia 
(new ST-T changes or new left bundle branch block); development of pathological Q waves on ECG; 
imaging evidence of new loss of viable myocardium or new regional wall motion abnormalities.
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Cardiac death was defined in the same document: sudden, unexpected cardiac death, involving 
cardiac arrest, often with symptoms suggestive of myocardial ischemia, and accompanied by pre-
sumably new ST elevation, or new left bundle branch block, and/or evidence of fresh thrombus by 
coronary angiography and/or autopsy, but death occurring before blood samples could be obtained, 
or at a time before the appearance of cardiac biomarkers in the blood.
Biomarkers
This definition of myocardial infarction and cardiac death might be sufficient for non-surgical 
patients. However it should be noted that up to 75% of perioperative myocardial infarctions remain 
asymptomatic and may therefore be difficult to assess4. This might be attributable to the disguising 
effects of sedation and the simultaneous occurrence of symptoms directly related to surgery such 
as nausea. This implies a serious underestimation of the true incidence of so-called “hard” cardiac 
endpoints in vascular surgery patients. It also implies a call for routine postoperative measurement 
of cardiac biomarkers in patients scheduled for major vascular surgery since cardiac complications 
are most common in these patients and these patients are most likely the ones not able to indicate 
symptoms of acute coronary syndromes.
Cardiac troponin (I or T) is the preferred biomarker for myocardial injury. It has nearly absolute myo-
cardial tissue specificity as well as high clinical sensitivity5. As stated in the consensus document an 
increased value for cardiac troponin is defined as a measurement exceeding the 99th percentile of 
a normal reference population. Detection of a rise and fall of the measurements is essential to the 
diagnosis of acute myocardial infarction6. The 99th percentile must be determined for each specific 
assay with appropriate quality control. The values for the 99th percentile can be found on the Inter-
national Federation for Clinical Chemistry website7. Blood samples for the measurement of troponin 
should be drawn on first assessment (often some hours after the onset of symptoms) and 6–9 hours 
later8. To establish the diagnosis of myocardial infarction, one elevated value above the decision level 
is required. The demonstration of a rising and/or falling pattern is needed to distinguish background 
elevated troponin levels, e.g. patients with chronic renal failure, from elevations in the same patients 
which are indicative of myocardial infarction6.
CKMB is the best alternative if troponin assays are not available. As with troponin, an increased CKMB 
value is defined as a measurement above the 99th percentile.9 As with troponins, CKMB measure-
ments should be recorded at the time of the first assessment of the patient and 6–9 hours later in 
Table 1.1 Definition of myocardial infarction.
Diagnosis of myocardial infarction if any one of the following criteria is met:
(1) Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least one value above the 99th 
percentile of the upper reference limit (URL) together with evidence of myocardial ischemia with at least one 
of the following:
(1) Symptoms of ischemia;
(2) ECG changes indicative of new ischemia, i.e. new ST-T changes or new left bundle branch block (LBBB)
(3) Development of pathological Q waves in the ECG;
(4) Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
(2) Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial 
ischemia, and accompanied by presumably new ST elevation, or new LBBB, and/or evidence of fresh 
thrombus by coronary angiography and/or at autopsy, but death occurring before blood samples could be 
obtained, or at a time before the appearance of cardiac biomarkers in the blood.
(3) Pathological findings of an acute myocardial infarction.
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order to demonstrate the rise and/or fall exceeding the 99th percentile URL for the diagnosis of 
myocardial infarction.
ECG
The ECG is an integral part of the diagnostic work-up of patients with suspected myocardial infarction 
and also a cornerstone in the consensus document on myocardial infarction10. The acute or evolving 
changes in the ST-T waveforms and the Q-waves when present potentially allow the clinician to date 
the event, to suggest the infarct-related artery, and to estimate the amount of myocardium at risk. The 
diagnosis of myocardial infarction is difficult in the presence of LBBB even when marked ST-T abnormali-
ties or ST elevation are present that exceed standard criteria11,12. In such cases a previous, preoperative 
ECG may be helpful to determine the presence of acute myocardial infarction in this setting. In patients 
with right bundle branch block (RBBB), abnormalities in leads V1–V3 are common, making it difficult 
to assess the presence of ischemia in these leads; however, when ST elevation or Q-waves are found in 
the postoperative period, myocardial ischemia or infarction should be considered10.
C. Incidence of cardiac complications
Although the widespread prevalence of CAD in patients requiring peripheral vascular surgery is well 
accepted, the frequency of adverse cardiac outcomes in unselected groups of vascular patients is 
more controversial. Comparison of cardiac morbidity of vascular operations between different studies 
is often misleading because the frequency of cardiac complications depends on the vigor with which 
the diagnosis is pursued. Prospective trials tend to include only specific patient groups while large 
registries might be less accurate in scoring cardiac complications. Since “soft” cardiac endpoints are 
difficult to assess in a uniform way, in particular in retrospective series, it is probably more accurate 
to look at “hard” cardiac endpoints such as cardiac death and myocardial infarction. Therefore only a 
crude estimate of the magnitude of cardiac complications after vascular and endovascular surgery 
can be given.
Objective measurements such as continuous 12-lead ECG recording in the perioperative period com-
bined with rigorous screening of cardiac biomarkers might give a more accurate estimation of the 
true incidence of perioperative cardiac complications. A few studies have used this modality though 
No cardiac complications
Troponin release                         
24%
MI                                      
2.6%
†
1.8%
Figure 1.1 Incidence of perioperative cardiac complications based on a recent study by Poldermans et al.54
† = cardiac death, MI = Myocardial infarction
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it must be noted that only major vascular procedures were included (FIGURE 1.1). One of these studies 
is a study by Landesberg et al. in which 447 patients scheduled for elective abdominal aortic surgery 
(n=70), peripheral arterial bypass surgery (n=163) or carotid artery surgery (n=214) were followed 
using continuous 12-lead ECG recording and cardiac troponin T and I and CK/CK-MB measurement 
on the first three postoperative days13. In 14.8% of these patients perioperative ST-segment changes 
were observed. Furthermore, 23.9% of patients experienced cardiac troponin T or I release.
Cohort studies tend to report a lower incidence of cardiac events. In a recent report by Welten et al. 
30-day mortality in a group of 2,730 patients undergoing non-cardiac vascular surgery was 1% for 
patients undergoing CEA, 6% for patients undergoing AAA repair and 3% for patients undergoing 
lower extremity arterial revascularization14. Importantly in all three patient groups approximately 
75% of deaths were related to cerebrocardiovascular causes. The percentage of approximately 5% 
cardiac events has been confirmed in the prospective Euro Heart Survey including over 700 patients 
undergoing elective arterial vascular surgery15. In 2002 Krupski et al reviewed all major series 
reporting 100 or more patients, and the average MI rate after aortic, carotid, and infrainguinal opera-
tions were 2.2% (7500 patients), 1.0% (28,000 patients), and 4% (6000 patients), respectively16. To 
demonstrate the difference attributable to the vigor of postoperative screening for cardiac events: 
in prospective studies with routine measurement of cardiac troponins and continuous ECG monitor-
ing perioperative myocardial infarction occurs in as many as 20% of patients as has been shown by 
Landesberg et al13.
Carotid artery surgery seems to be associated with the lowest incidence of adverse cardiac events 
despite the limitations described above. The incidence of myocardial infarction in patients under-
going carotid endarterectomy is estimated to be approximately 1% as has recently been reported 
by Greenstein et al in a group of 9,308 patients (MI 1.1%)17 and the CEA National Surgical Quality 
Improvement Program including 13,622 patients with a cardiac event rate of 1.1%18. In the recently 
published randomized controlled trials carotid stenting does not seem to be superior to endarterec-
tomy in terms of cardiac outcome. Only in the SAPPHIRE trial stenting tended to be associated with 
less perioperative myocardial infarctions 2.4% vs. 6.1% (p=0.1)19.  The CAVATAS trial did not find a 
significant difference in the incidence of myocardial infarctions in patients randomized to either open 
(n=253) or endovascular (n=251) treatment, 1% and 0% respectively20. Unfortunately both SPACE 
and EVA-3S did not report perioperative myocardial infarctions separately21,22. Furthermore, a recent 
Cochrane review did not show any advantage of either procedure in terms of cardiac outcome23. 
Considering the relatively low incidence of major cardiac complications in extracranial carotid sur-
gery it is unlikely that there is a clinically relevant difference in cardiac outcome in patients without 
an extremely high preoperative cardiac risk.
Aortic aneurysm repair is a high-risk surgical procedure. Patients scheduled for AAA repair seem to 
have a clear perioperative survival benefit of endovascular repair, indicating a possible cardiac advan-
tage of endovascular treatment. Interestingly this was not confirmed in the two major randomized 
controlled trials on this subject. Though the overall complication rate was significantly lower in the 
endovascular treated group in the DREAM trial, the incidence of perioperative cardiac complications 
was similar in patients undergoing open or endovascular repair (5.7% vs. 5.3%)24. Also, in a systematic 
review by Drury et al in 2005 no perioperative cardiac benefit could be found in patients undergo-
ing endovascular AAA repair (HR 0.81, 95% CI 0.35-1.86)25. In the EVAR 1 trial overall mortality was 
significantly reduced in patients treated with endovascular stent grafts (1.7% vs. 4.7%), indicating 
a lower perioperative cardiac risk in these patients though nonfatal MIs were not reported26. It is 
unclear why in some reports no perioperative benefit of endovascular procedures was found while 
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in the vast majority of cohort series endovascular repair is associated with less perioperative cardiac 
complications. This has recently been confirmed in the large Medicare database (22,830 patients) 
of Schermerhorn et al.: myocardial infarction occurred in 7.0% and 9.4% in endovascular and open 
procedures respectively (p<0.001)27. To compare open surgical procedures and endovascular proce-
dures for lower extremity arterial revascularization proves to be even more difficult. Indications for 
open or endovascular treatment differ substantially and cardiac complications rates can therefore 
only be considered separately.
Though a reliable figure for perioperative cardiac complications in patients scheduled for elective 
vascular surgery can not be given, overall it is estimated that extracranial carotid procedures are less 
prone to cardiac complications than abdominal aortic and peripheral arterial bypass procedures (1% 
vs. 3-5%).
II.  PAThOgENESIS OF PERIOPERATIVE ACuTE CORONARy SyNDROMES
Although the pathophysiology of perioperative acute coronary syndromes is not entirely clear, it is 
now well accepted that coronary plaque rupture, leading to thrombus formation and subsequent 
vessel occlusion, is an important cause of acute perioperative coronary syndromes (FIGURE 1.2A and 
1.2B). This is similar to the nonoperative setting.
The perioperative surgical stress response includes a catecholamine surge with associated hemo-
dynamic stress, vasospasm, reduced fibrinolytic activity, platelet activation, and consequent hyper-
coagulability28. In patients with significant coronary artery disease (CAD), perioperative myocardial 
infarction (PMI) may also be caused by a sustained myocardial supply/demand imbalance due to 
tachycardia and increased myocardial contractility28.
Lumen
Platelets
Stable Unstable
Endothelium
Lipid rich core
Thick
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Thin
fibrous cap
Thrombus
Figure 1.2a In contrast to atherosclerotic disease of peripheral arteries, in which complications are usually directly 
related to the degree of stenosis and hypoperfusion (e.g., high-grade carotid artery stenoses), lesions 
within the coronary arteries may cause acute events even when stenoses are not critical. This is due 
to relatively unstable or “vulnerable” plaques with a large lipid pool and a thin, weakened fibrous 
cap (shown in the second diagram) infiltrated by macrophages. These plaques are most susceptible 
to disruption and development of platelet-derived thrombosis. Infiltration by macrophages and 
other inflammatory cells produces a vulnerable cap most vulnerable to disruption. Cytokines and 
proteases involved in the balance between synthesis and degradation of collagen and elastin 
determine structural integrity and play an important role in acute coronary events. Identification of 
and intervention for hemodynamically significant coronary artery lesions may not provide secure 
protection against perioperative adverse cardiac events after vascular surgery.
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Episodes of perioperative ST-segment depression, indicating subendocardial myocardial ischemia, 
have been described in up to 41% of vascular surgery patients, mostly occurring within the first 2 
days after surgery29. The association of PMI with myocardial ischemia and nontransmural or circum-
ferential subendocardial infarction supports this mechanism. Landesberg demonstrated that 85% of 
postoperative cardiac complications were preceded by prolonged ST-segment depression30. Fleisher 
et al.  found that 78% of patients with cardiac complications had at least 1 episode of prolonged 
myocardial ischemia (i.e. >30 minutes), either before or at the same time as the cardiac event. In 
the majority of cases, it presents without Q waves31. The hypothesis that ST-segment depression can 
lead to PMI is further supported by increased troponin T levels during or shortly after prolonged ST-
segment depression ischemia32. ST-segment elevation–type ischemia is considered to be relatively 
uncommon, confirmed by the incidence (12%) of intraoperative ST-segment elevation in a study by 
London et al33.
Plaque disruption, defined as fissure or rupture of plaque and hemorrhage into the plaque cavity34, 
is the cause of fatal PMIs in approximately half of the cases as was demonstrated in the autopsy 
study by Dawood et al.  Similar autopsy results were found in the study by Cohen and Aretz35; a 
plaque rupture was found in 46% of patient with post-operative MI. “Unstable” plaques have a large 
lipid core and a thin, weakened fibrous cap infiltrated by macrophages (FIGURE 1.2A and 1.2B). It is 
hypothesized that these plaques with a large lipid pool and a thin, weakened fibrous cap infiltrated 
by macrophages and other inflammatory cells are the most vulnerable to disruption. Cytokines and 
proteases involved in the balance between synthesis and degradation of collagen and elastin, which 
determines the structural integrity of the plaque cap, play an important role in perioperative acute 
coronary events.
Figure 2B.tif
Figure 1.2b Electron micrograph showing extraordinary infiltration of myeloperoxidase-laden neutrophils into a 
section of coronary artery from a patient with unstable angina. This is a diffuse process, not localized to 
a single vulnerable plaque. The implications are that focused therapy (e.g., percutaneous transluminal 
coronary angioplasty or coronary artery bypass graft surgery) may not be protective against coronary 
events in the vascular patient; instead, anti-inflammatory (e.g., antiplatelet therapy) treatment, 
stabilization with antilipid treatments, and beta blockers to decrease myocardial oxygen consumption 
may be more beneficial than mechanical approaches.
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In a study of Feringa et al., vascular surgery patients were evaluated by continuous 12-lead elec-
trocardiographic monitoring during surgery and studied for the presence and location of ischemia. 
The relationship with the pre-operatively assessed culprit coronary artery lesion using noninvasive 
cardiac imaging was studied. In patients with perioperative ST-segment depression, the location cor-
responded with the pre-operatively assessed coronary lesion in 89%, and only in 53% of those with 
ST-segment elevation (p<0.001). This study showed one of the limitations of pre-operative cardiac 
risk assessment focusing on the identification of the culprit coronary artery lesion. Using cardiac test-
ing, one can identify the patient at risk; however, the location of the PMI is difficult to foresee owing 
to the unpredictable progression of (asymptomatic) coronary artery lesions toward unstable plaques 
owing to the stress of surgery.
III. CLINICAL PRESENTATION
In postoperative patients, symptoms of cardiac complications might very well be atypical or absent 
even when ECG and/or biomarkers are abnormal. It is important to realize that myocardial infarc-
tion might occur with atypical symptoms, or even without symptoms, being detected only by ECG, 
biomarker elevations, or cardiac imaging. An estimated 75% of patients who have objective evidence 
of MI are not diagnosed as such because symptoms are masked by residual anesthetic effects, admin-
istration of analgesic agents, competing somatic stimuli such as incisional pain, and other factors.
Classical symptoms of myocardial ischemia include various combinations of chest, upper extremity, 
jaw, or epigastric discomfort with exertion or at rest. Often, the discomfort is diffuse, not localized, not 
positional, not affected by movement of the region, and it may be accompanied by dyspnea, diapho-
resis, nausea, or syncope. Considering these classical symptoms it is hardly surprising that such a large 
number of episodes of myocardial ischemia and infarction are missed in the perioperative period. 
Physicians should therefore be liberal in the ordering of laboratory tests such as cardiac troponin 
measurements in patients who underwent vascular surgery. This becomes even more important as 
even asymptomatic troponin release has severe implications for patients’ outcome (see below).
IV. PREOPERATIVE CARDIAC EVALuATION
A. Clinical risk factor indices
Adequate preoperative cardiac risk assessment is essential for identifying high-risk patients for peri-
operative cardiac events. Several risk indices were developed to stratify vascular surgical patients, 
based on clinical cardiac risk factors.
The cardiac risk index of Goldman et al in 1977 was the first multifactorial model specifically for peri-
operative cardiac complications to be widely used36. This risk index was developed in a non-cardiac 
surgical population. The authors identified nine independent risk factors correlated with postop-
erative serious or fatal cardiac complications: (1) preoperative third heart sound or jugular venous 
distention; (2) MI in the preceding 6 months; (3) >5 premature ventricular contractions per minute 
documented at any time before operation; (4) rhythms other than sinus rhythm or the presence of 
premature atrial contractions on preoperative electrocardiogram (ECG); (5) age >70 years; (6) an intra-
peritoneal, intrathoracic, or aortic operation; (7) emergency operation; (8) important valvular aortic 
stenosis; and (9) poor general medical condition. This index was modified by Detsky et al in 198637, 
who added the presence of angina and a remote history of MI to the original model of Goldman et al. 
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They used a Bayesian approach involving pretest probabilities, and presented the modified cardiac 
risk index in a simple normogram.
The Glasgow aneurysm score, described in 1994, was one of the first cardiac risk scores only intended 
for vascular surgical procedures. In a retrospective study of 500 randomly chosen patients scheduled 
for open abdominal aortic aneurysm repair, potential preoperative risk factors were related to post-
operative in-hospital mortality38. One year later, the Leiden Risk Model for perioperative mortality in 
patients with an abdominal aortic aneurysm was developed by Steyerberg et al39. This clinical predic-
tion rule was based on several risk factors obtained from the literature, and validated in a cohort of 
246 patients undergoing open abdominal aortic aneurysm repair.
In 1996, L’Italien et al developed and validated a Bayesian model for preoperative cardiac risk assess-
ment in a total of 1081 consecutive patients undergoing elective major vascular surgery40. This study 
had a combined endpoint of nonfatal MI or cardiac death. Using 567 patients as a derivation cohort, 
the following risk factors were identified as predictors of adverse postoperative outcome: myocar-
dial infarction, congestive heart failure, angina pectoris, prior coronary revascularization, diabetes 
mellitus, and age >70 years. Importantly, the validation cohort (514 patients) exhibited a prognostic 
accuracy of 74%. Patients classified as low-risk, intermediate-risk, and high-risk had cardiac event 
rates of 3%, 8%, and 18%, respectively.
Lee et al developed the largest and currently most widely used model of risk assessment, the Revised 
Cardiac Risk Index in 199941. This index identifies six predictors of major cardiac complications: (1) 
high-risk type of surgery, (2) history of ischemic heart disease, (3) history of congestive heart failure, 
(4) history of cerebrovascular disease, (5) preoperative treatment with insulin, and (6) preoperative 
serum creatinine >2.0 mg/dL. Based on the presence of none, 1, 2, or ≥ 3 predictors, the rate of major 
cardiac complications in the validation cohort (n = 1422) was estimated to be 0.4%, 0.9%, 7%, and 
11%, respectively.
The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo (DECREASE) I Trial identi-
fied comparable independent clinical risk factors associated with major vascular surgery: a history of 
myocardial infarction, angina, congestive heart failure, diabetes, renal dysfunction, cerebrovascular 
events, and age >70 years2. Recently, Kertai et al developed a Bayesian model for the prediction of all-
cause perioperative mortality in 1537 patients undergoing all types of open vascular surgery (TABLE 
1.2)42. Risk factors associated with postoperative all-cause death included ischemic heart disease, 
congestive heart failure, cerebrovascular events, hypertension, renal dysfunction, chronic pulmonary 
disease, and type of vascular surgery, i.e. ruptured aneurysm of the abdominal aorta (AAA), elective 
AAA, lower extremity, and carotid vascular surgery. The final logistic regression model with nine 
independent predictors (including beta-blocker and statin use) of perioperative mortality was used 
to create a variable-weight index, the Customized Probability Index, where scores were assigned 
based on parameter estimates of individual predictors. The sum of scores of surgical risk (0-46 points), 
medical history (0-67 points), and cardioprotective medication (statins -10 points and beta-blockers 
-15 points) was calculated for an overall cardiac risk.
B. Laboratory
Apart from those measurements indicating clinical risk factors (for example, serum creatinine for 
renal failure, fasting glucose for diabetes mellitus, etc) currently no routine laboratory measurements 
are related to perioperative cardiac complications. Plasma N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) or B-type natriuretic peptide (BNP) have been shown to be associated with adverse 
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postoperative outcome in recent studies. NT-proBNP is increased in patients with left ventricular dila-
tation caused by fluid overload (e.g. heart failure and renal dysfunction), pressure overload (e.g. aortic 
valve stenosis), and myocardial ischemia, which might explain the excellent relation with adverse 
postoperative outcome. In a study by Dernellis et al. of 1590 patients scheduled for all types of non-
cardiac general surgery elevated levels of BNP, i.e. >189 pg/mL, were independently associated with 
a staggering 34-fold increased risk for postoperative cardiac events43. Similar results were found 
by Feringa et al in their report on the prognostic value of NT-proBNP in 170 patients scheduled for 
major vascular surgery44. Patients with a NT-proBNP level >533 pg/mL had an independent 17-fold 
increased risk for postoperative cardiac events, even after adjustment for preoperative dobutamine 
stress echocardiography results. Gibson et al confirmed the predictive value of BNP in 149 major 
vascular surgical patients: using receiver-operator curve analysis a BNP concentration of 108.5 pg/
mL best predicted the likelihood of cardiac events, with a sensitivity and specificity of 87%45. The true 
value of either BNP or NT-proBNP in the preoperative screening setting must be confirmed in large 
scale prospective trials such as the recently started multinational DECREASE VI trial.
Diabetes mellitus is a common risk factor in patients scheduled for vascular surgery with a prevalence 
of approximately 50% if all patients are thoroughly screened46. Diabetes mellitus is known to be a 
strong predictor for perioperative events. Therefore fasting glucose values should be obtained in 
all patients scheduled for vascular surgery and glucose loading testing should be considered in all. 
Recently it was shown that the level of preoperative glycosylated hemoglobin in diabetic patients is 
strongly related to perioperative cardiac outcome. In the same patient population it was also shown 
that in patients with high preoperative glycosylated hemoglobin it is more difficult to regulate 
Table 1.2 Customized Probability Index (derived from Kertai et al.42)
- 15
- 10
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glucose values in the perioperative period47,48. This might partly explain the strong relation between 
preoperative glycosylated hemoglobin and outcome, since it is known from critically ill patients and 
patients with myocardial infarction that tight glucose control is of imminent importance. In a large 
case-control study by Noordzij et al. in non-cardiac nonvascular surgical patients it was also shown 
that random preoperative glucose levels were associated with postoperative outcome49. Those with 
a random glucose level ≥ 11.1 mmol/L had a 4-fold increased risk for perioperative cardiovascular 
death. Importantly, glucose levels of 5.6-11.1 mmol/L were independently associated with a 3-fold 
increased risk for perioperative cardiovascular events.
Preoperative asymptomatic troponin release in patients with symptomatic peripheral arterial disease 
is associated with a poor postoperative prognosis50. Preoperative troponin release may occur because 
of asymptomatic myocardial ischemia, a condition often observed in patients scheduled for major 
vascular surgery. As was already noted by Landesberg et al. in 1993, over 40% of patients planned for 
major vascular surgery experience silent myocardial ischemia preoperatively as assessed by continu-
ous 12-lead ECG recording, including in asymptomatic patients30. Notably, both Landesberg et al. 
and Kertai et al. previously showed that even low levels of asymptomatic troponin elevations in the 
perioperative period are associated with worse long-term outcome in patients undergoing major 
vascular surgery13,51.
Renal insufficiency is taken into account in most risk indices. For example, the serum creatinine cut-
off value Lee et al used was 2.0 mg/dL (177 mmol/L)41. However, it might be argued that patients with 
less pronounced renal insufficiency also do worse compared to patients with normal serum creatinine 
values. A continuous variable for creatinine would probably be better, though not very user-friendly 
in every day practice. Recent studies have also shown that glomerular filtration rate might be a better 
predictor than serum creatinine since this takes into account the different creatinine concentrations 
between sexes52.
C. Non-invasive (stress) testing
Once the assessment of risk factors indicates an increased cardiac perioperative risk, or if there is a 
suspicion of CAD upon examination, further cardiac testing is warranted. According to the current 
guidelines of the American College of Cardiology/American Heart Association, preoperative cardiac 
exercise or pharmacologic stress testing is recommended for (1) patients with an intermediate 
pretest probability of CAD, (2) patients undergoing initial evaluation for suspected or proven CAD, 
(3) subjects with a significant change in clinical status, (4) demonstration of proof of myocardial 
ischemia before coronary revascularization, (5) evaluation of adequacy of medical treatment, and (6) 
prognostic assessment after an acute coronary syndrome.53
One of the main issues in preoperative cardiac risk assessment is to identify those patients who should 
undergo additional stress testing before surgery. The randomized, multicenter DECREASE II study54 
assessed the value of preoperative cardiac testing in intermediate-risk patients receiving beta-
blocker therapy with tight heart-rate control. In total, 1476 vascular surgical patients were divided 
into three risk groups based on the risk score of Boersma et al2. All 770 intermediate-risk patients 
were randomly assigned to preoperative cardiac stress testing or no testing. Importantly, all patients 
in the DECREASE II study received beta-blocker therapy, irrespective of stress-test results, aiming at 
tight heart-rate control, i.e. a heart rate of 60 to 65 beats per minute. This study demonstrated no 
differences in cardiac death and MI at 30 days between patients assigned to no testing versus cardiac 
stress testing (1.8% versus 2.3%; odds ratio [OR], 0.78; 95% confidence interval [CI], 0.28 to 2.1). These 
results indicate that intermediate-risk patients undergoing major vascular surgery are at a relatively 
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low perioperative risk and do not benefit from preoperative cardiac testing when receiving beta-
blocker therapy with tight heart-rate control.
For those patients who require cardiac testing, several noninvasive and physiological (and nonphysi-
ological) stress tests are available for the evaluation of perioperative risk. Nonphysiological stress 
tests are especially recommended to detect preoperative myocardial ischemia in asymptomatic 
vascular surgery patients (FIGURE 1.3).
C1. Rest Electrocardiography
Different studies have shown an association between abnormal ECG findings and perioperative car-
diac complications36,37. In a large prospective study by Lee et al involving 4315 patients undergoing 
major non-cardiac surgery, a history of ischemic heart disease was one of the six independent predic-
tors of major cardiac complications41. Pathological Q-waves, as an electrocardiographic sign of MI in 
the past, were found in 17% of patients, with a 2.4-fold increased risk of perioperative events. A recent 
retrospective study confirmed the prognostic value of routine preoperative electrocardiography in 
22,457 non-cardiac operations55. Patients with abnormal ECG findings had a higher incidence of 
30-day cardiovascular death compared with patients with a normal ECG (1.8% versus 0.3%; adjusted 
OR, 3.4; 95% CI, 2.4 to 4.5). In addition, it was demonstrated that a preoperative ECG is also predictive 
of long-term outcome, independent of clinical findings and perioperative ischemia, in CAD patients 
undergoing major non-cardiac surgery56.
C2. ST-segment Holter recording
The use of ambulant 24-hour ST-segment registration for evaluation of perioperative cardiac risk was 
first described by Raby et al.57 They reported a sensitivity of 75% and a specificity of 83% for the 
prediction of a combined endpoint of cardiac death and nonfatal MI. A large meta-analysis showed 
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Figure 1.3 Sensitivity and specificity of different types of preoperative non-invasive cardiac testing modalities 
(derived from Kertai et al.57)
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lower values, comprising eight studies with a total of 893 patients, with a weighted sensitivity of 52% 
(95% CI, 21% to 84%) and a specificity of 70% (95% CI, 57% to 83%)58. The advantages of ST-segment 
Holter include its low cost and wide availability.
C3. Exercise Electrocardiogram
The most commonly used physiologic stress test for detecting myocardial ischemia uses a treadmill 
or cycle ergometer. Among its advantages, this test provides an estimate of functional capacity, and 
hemodynamic response, and detects myocardial ischemia through ST-segment changes. The accu-
racy of an exercise ECG varies widely among studies. A meta-analysis by Kertai et al for the detection of 
myocardial ischemia with treadmill testing in vascular surgery patients showed a rather low sensitivity 
(74%; 95% CI, 60% to 88%) and specificity (69%; 95% CI, 60% to 78%) (FIGURE 1.3) comparable to daily 
clinical practice58. However, important limitations in patients with peripheral vascular disease involve 
their frequently limited exercise capacity. Furthermore, preexisting ST-segment deviations, especially 
in the precordial leads V5 and V6 at the rest ECG, make a reliable ST-segment analysis more difficult59.
C4. Stress Echocardiography
Because most patients with peripheral vascular disease are unable to exercise maximally, stress 
echocardiography with pharmacologic stressors (such as dobutamine) is a good alternative. Although 
vasodilators (e.g. dipyridamole or adenosine) may have advantages for the assessment of myocardial 
perfusion, dobutamine is the preferred pharmacological stressor when the test is based on an assess-
ment of regional wall-motion abnormalities60.
Dobutamine is a synthetic catecholamine with predominantly β1-receptor-stimulating properties, 
resulting in a strong positive inotropic effect and modest chronotropic effect on the heart. During 
the stress test, dobutamine is intravenously administered. A graded dobutamine infusion starting at 
5 μg/kg/min, and increasing at 3-minute intervals to 10, 20, 30, and 40 μg/kg/min, is the standard for 
dobutamine stress echocardiography (DSE). During dobutamine infusion, contractility and heart rate 
increase, leading to increased myocardial oxygen demand. Myocardial ischemia leading to systolic 
contractile dysfunction, detectable by echocardiography, occurs in regions supplied by hemody-
namically significant stenotic coronary arteries.
Tissue harmonic imaging is advised for stress echocardiography. This special imaging setting reduces 
near-field artifacts, improves resolution, enhances myocardial signals, and is superior to fundamental 
imaging for endocardial border visualization. The improvement in endocardial visualization is further 
enhanced by the use of contrast agents for left-ventricular (LV) opacification. Contrast agents increase 
the number of interpretable LV wall segments. These recent developments exhibit decreased inter-
observer variability, and have improved the sensitivity of stress echocardiography61.
Many reports demonstrated that DSE predicts perioperative events in patients undergoing vascular 
surgery62,63. The negative predictive value of dobutamine stress tests is high, although the positive 
predictive value is much lower.
Kertai et al reported a weighted sensitivity of 85% (95% CI, 74% to 97%) and a specificity of 70% (95% 
CI, 62% to 69%) for DSE in 850 patients from eight studies (FIGURE 1.3).58 A recent meta-analysis by 
Beattie et al analyzed the predictive value of pharmacological stress testing compared with myocar-
dial perfusion scintigraphy64. This report included 25 studies (3373 patients) of mainly dobutamine 
as well as dipyridamole stress echocardiography. The likelihood ratio of a perioperative event with a 
positive stress echocardiography was 4.09 (95% CI, 3.21 to 6.56).
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C5. Myocardial Perfusion Scintigraphy
Myocardial perfusion scintigraphy (MPS) is a widely used technique in the preoperative risk assess-
ment of patients undergoing vascular surgery. The technique involves intravenous administration 
of a small quantity of a radioactive tracer. The detection of CAD is based on a difference in blood-
flow distribution through the LV myocardium. These differences in perfusion can be explained by 
insufficient coronary blood flow based on coronary stenosis. Nowadays, technetium-99m-labeled 
radiopharmaceutical is the most widely used tracer.
Myocardial perfusion scintigraphy is used in combination with exercise or pharmacologic stress test-
ing to diagnose the presence of CAD. If there is a decrease or loss in regional perfusion after maximal 
vasodilatation with, for example, adenosine, as seen in hemodynamically significant CAD or in 
transmural MI, a reduced radiopharmaceutical signal is observed. Stress and rest MPS are compared 
for reversible abnormalities. A positive MPS is associated with an increased risk of perioperative and 
postoperative cardiac complications. A meta-analysis by Etchells et al investigated the prognostic 
value of semiquantitative dipyridamole MPS for perioperative cardiac risk in patients undergoing 
non-cardiac vascular surgery65. They included nine studies, involving a total of 1179 vascular surgery 
patients, with a 7% cardiac complication rate. One of the most important findings in this study was 
that reversible ischemia in <20% of the myocardial segments did not change the likelihood of periop-
erative complications. The previously mentioned meta-analysis which assessed the prognostic value 
of six diagnostic tests reported a sensitivity of 83% (95% CI, 77% to 89%) and a much lower specificity 
of 47% (95% CI, 41% to 57%) for MPS (FIGURE 1.3).58
D. Invasive testing
Guidelines of the American College of Cardiology /American Heart Association (ACC/AHA) recom-
mend coronary angiography for patients with high-risk noninvasive test results, and myocardial 
revascularization in patients with prognostic high-risk anatomy in whom long-term outcome is likely 
to be improved53. This recommendation was supported by the Coronary Artery Surgery Study that 
showed a reduced incidence of non-fatal myocardial infarctions after previous bypass surgery among 
vascular surgery patients compared to those treated medically, 8.5% versus 0.6% (p=0.001)66. More 
recently, the data from the Bypass Angioplasty Revascularization Investigation trial showed that 
patients undergoing coronary bypass surgery and percutaneous coronary intervention experienced 
similar low rates of postoperative cardiac events in non-cardiac surgery67. However, these studies 
were not designed to assign the optimal strategy in severely ill patients with extensive coronary artery 
disease immediately prior to major non-cardiac surgery. In addition, these studies could not address 
the concern of delaying the non-cardiac surgical procedure because of testing, revascularization, and 
initiation of antiplatelet therapy since the time between revascularization and non-cardiac surgery in 
these studies was 4.1 and 2.4 years, respectively. These concerns raise the question whether invasive 
test results would alter pre- and perioperative management.
The randomized Coronary Artery Revascularization Prophylaxis (CARP) trial was the first study that 
addressed the strategy of prophylactic revascularization, the ultimate consequence of invasive test-
ing, compared to optimal medical therapy in patients with clinically stable coronary artery disease 
who were scheduled for major non-cardiac vascular surgery68. This trial showed that prophylactic 
revascularization was safe but did not improve perioperative or long-term outcome. The long-term 
(median follow-up 2.7 years) mortality was 22% in patients allocated to prophylactic coronary revas-
cularization, compared to 23% in the medical only strategy, p=0.92 (FIGURE 1.4). Also, the incidence 
of perioperative non-fatal myocardial infarction was similar, respectively 12% and 14%, p=0.37. How-
ever, it must be noted that the majority of patients in the CARP trial had only 1 or 2 vessel disease.
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The recently conducted DECREASE V randomized pilot study in which the majority of patients had 
3-vessel disease also showed no perioperative and long-term (follow-up 1 year) benefit of prophy-
lactic coronary revascularization69. The findings of both CARP and DECREASE V support the current 
guidelines of the ACC/AHA on perioperative management in high-risk patients to reserve revascular-
ization only for cardiac unstable patients. After successful non-cardiac surgery these patients should 
be regularly screened for the presence of ischemic complaints and aggressive anti-ischemic therapy, 
both medical and invasive, should be considered. In these patients at high risk scheduled for major 
non-cardiac vascular surgery prophylactic revascularization might be switched to late revasculariza-
tion, thus obviating the delay of surgery.
V.  PREVENTION
Medical management
A1. Beta-blockers
Although beta-blockers are widely prescribed as a means for reducing perioperative cardiac events, 
randomized controlled trials of beta-blockers have shown divergent results.
Evidence supporting the use of beta-blockers is based mainly on two small, prospectively random-
ized clinical trials and several observational studies. In the first study, Mangano et al. randomized 200 
patients with either known or suspected coronary artery disease undergoing high-risk non-cardiac 
surgery to receive atenolol (50 mg or 100 mg) or placebo70. Atenolol therapy was not associated 
with an improved in-hospital outcome (cardiac death or MI); however, it was associated with a 50% 
reduction in electrocardiogram evidence of myocardial ischemia detected with continuous 3-lead 
Holter monitoring during the first 48 h after surgery. Interestingly, patients receiving perioperative 
atenolol had a reduced rate of cardiac events 6 to 8 months after surgery compared with the placebo 
group, suggesting a delayed beneficial response71.
In the second trial, the DECREASE (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress 
Echocardiography Study)-I trial, of 112 vascular surgery patients with evidence of myocardial ischemia 
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Figure 1.4 Results of the CARP trial68.
At a median follow-up of 2.7 years there was no survival benefit in patients who underwent 
preoperative coronary revascularization (RR=0.98 95% CI 0.70-1.37, p=0.92).
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on preoperative dobutamine stress-echocardiography, Poldermans et al. showed a 10-fold reduction 
in the incidence of perioperative cardiac death and MI with perioperative bisoprolol use compared 
with placebo (3.4% versus 34%; P < 0.001)72. The high incidence of perioperative cardiac events was 
explained by the selection of high-risk patients for study. From a population of 1351 patients, only 
112 met entrance criteria of inducible myocardial ischemia.
In the POBBLE (PeriOperative Beta-BLockadE) trial, only low-risk patients (history of ischemic heart 
disease was an exclusion) scheduled for vascular surgery were studied73. This low-risk population 
was randomized to receive either metoprolol 25 mg or 50 mg (n = 55) or placebo (n = 48) starting 
the day before surgery and continued during the first 7 days after surgery. There was no difference 
in the incidence of perioperative cardiovascular events between the placebo and metoprolol groups 
(34% versus 32%). The duration of hospitalization though was shorter for those patients receiving 
metoprolol versus placebo (10 days versus 12 days).
In the DIPOM (Diabetic Postoperative Mortality and Morbidity) study the cardioprotective effect 
of 100 mg metoprolol started the evening before major non-cardiac surgery was compared with 
placebo in 921 diabetic patients74. In that study, there were no differences in 30-day morbidity and 
mortality (21% versus 20%; p = 0.66). A limitation of the DIPOM study was that it was only powered 
to detect a 10% difference in mortality after 1 year of follow-up.
Recently the results of the large randomized POISE trial were presented. A total of 8351 patients 
were randomized to controlled-release oral metoprolol succinate or placebo. The primary endpoint 
of cardiac death, myocardial infarction, or cardiac arrest was reduced in the metoprolol group, com-
pared to placebo (5.8% vs. 6.9%, hazard ratio 0.83, 95% CI 0.70-0.99, p=0.04), driven by a reduction of 
non-fatal myocardial infarctions, albeit, at the costs of an increased incidence of total mortality and 
stroke. Stroke was associated with perioperative bradycardia, hypotension, and bleeding in patients 
randomized to metoprolol with a diseased cerebrovascular tree, suggestive of an over treatment 
effect.
There are several explanations for the divergent findings from randomized trials of perioperative beta-
blockers, including the use of a fixed versus individualized dose titrated to the patients heart rate. In 
a study of 150 patients, Raby et al. assessed the heart rate threshold for myocardial ischemia before 
surgery using Holter monitoring75. Patients with myocardial ischemia (n = 26) were then randomized 
to receive IV esmolol titrated to aiming at tight heart rate 20% less than the ischemic threshold but 
>60 bpm or placebo. Of the 15 patients receiving esmolol, 9 had mean heart rates below the ischemic 
threshold and none experienced postoperative ischemia. Four of 11 patients receiving placebo had 
a mean heart rate below the ischemic threshold, and 3 of the 4 had no postoperative ischemia. 
Together, of the 13 patients with heart rates below the ischemic threshold, 1 (7.7%) had postop-
erative myocardial ischemia versus 12 of 13 (92%) patients with heart rates exceeding the ischemic 
threshold. Feringa et al. found similar results in a study of 272 patients receiving beta-blocker therapy 
and undergoing vascular surgery76. In that study it was shown that higher doses of beta-blockers and 
lower heart rate were associated with reduced Holter monitoring-detected perioperative myocardial 
ischemia (HR, 0.40; 95% confidence interval [CI] 0.21-0.56) and troponin T release (HR, 0.65; 95% CI 
0.49-0.86). These data suggest that monitoring of the heart rate and consequent beta-blocker dose 
adjustment is of critical importance.
The conflicting results of perioperative beta-blocker trials might be further explained by varying dura-
tions of therapy. As mentioned, although the sympathico-inhibitory effects of beta-blockers occur 
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almost instantly, the anti-inflammatory effects may be observed only after prolonged treatment. As 
mentioned, in the Mangano et al. study, the major benefits of atenolol were observed in the months 
after surgery70. In the DIPOM, POBBLE and POISE trials, beta-blocker therapy was initiated on the day 
before surgery. The DECREASE-I trial showed the largest effect of perioperative beta-blocker therapy. 
The time between beta-blocker therapy initiation and surgery was 37 days in this trial72.
Further, withdrawal of beta-blocker therapy shortly before surgery, or in the immediate postoperative 
period, might contribute to adverse myocardial effects resulting from a “rebound” effect resulting in 
increased arterial blood pressure, heart rate, and plasma noradrenalin concentrations77. Redelmeier 
et al. have recently shown that the long-acting agent atenolol was superior to the short-acting drug, 
metoprolol, when given perioperatively, probably as the result of acute withdrawal effects from 
missed doses of short-acting beta-blockers78. On the other hand care should be taken not to over 
treat the patient. In the POISE study, metoprolol succinate, a long-acting β-blocker, dose was used 
with a starting dose of 100 mg, 2 to 4 hours prior to surgery, again 100 mg 0 to 6 hours after surgery, 
and a dose of 200 mg 12 hours after the first postoperative dose. Thereafter the daily maintenance 
dose was started at 200 mg. Medication was withheld if blood pressure dipped below 100 mmHg or 
heart rate was below 50 bpm. So, on the first day of surgery metoprolol succinate could have been 
administered at a dose up to 400 mg on the day of surgery, 100% of the maximum daily therapeutic 
dose (MDTD). In the non-surgical setting, much lower starting doses are recommended, for instance 
in patients with NYHA Class II heart failure 12.5 to 25 mg daily is started for two weeks and for hyper-
tension the initial dose is 25 to 100 mg, usually increased at weekly intervals.
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Figure 1.5 Evolving guideline recommendations on the use of perioperative beta-blockade in the last decade.
Based on the ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for non-
cardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American 
College of Cardiology/American Heart Association Task Force on Practice Guidelines.
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Proposed recommendations. In patients with Class I indications for β-blockers for secondary preven-
tion of heart disease, therapy is recommended independent of the non-cardiac surgery (FIGURE 1.5). 
However, further study is required to determine the optimal dose and time to initiate the drug before 
surgery. This is particularly relevant in patients with cerebrovascular disease.
We believe that the protocol utilized in the DECREASE studies (low dose long-acting agents titrated 
to effect at least 7 days in advance) is associated with overall benefit compared to risk, while high 
dose therapy started the morning of surgery is associated with greater risk than benefit.
What do we do for those with indications for perioperative β-blocker therapy, but in whom there is 
insufficient time to appropriately titrate the medication? The overriding theme is that tachycardia due 
to perioperative events, i.e. bleeding, hypovolemia, inadequate control of pain or infection, should 
not be initially treated with additional β-blocker; the underlying cause of these conditions should be 
treated first. If tachycardia persists, then β-blocker can be used cautiously in high-risk patients with 
proven or suspected coronary artery disease, preferable supervised in the perioperative setting by 
physicians who have experience with perioperative hemodynamics.
A2. Statins
Several recent retrospective studies have shown a beneficial effect of statins on perioperative cardiac 
outcome with adjusted Hazard ratio’s ranging from 0.20 to 0.62 (TABLE 1.3).79-81,83,84 Importantly, 
Kertai et al also found the effect of statins to be independent of β-blocker use.81 The first blinded, 
placebo-controlled, randomized trial that investigated the influence of statin use on perioperative 
cardiovascular complications has been reported by Durazzo et al.82 This research group randomly 
assigned 100 patients to treatment with either 20 mg of atorvastatin or placebo. Patients received 
treatment for 45 days and at least 2 weeks before surgery. One month after surgery, patients with 
Table 1.3 Studies of the effectiveness of perioperative statin use in major vascular, non-cardiac surgery.
Author year Type of study N Type of surgery Rx prior to 
surgery
Poldermans et al.80 2003 Case-control 480 Vascular Chronic use
Kertai et al.81 2004 Cohort 570 Vascular Chronic use
Durazzo et al.82 2004 RCT 100 Vascular 30 days
Lindenauer et al.83 2004 Cohort 780,591 General Chronic use
O’Neil-Callahan et al.84 2005 Cohort 1,163 Vascular Chronic use
Cont’d End Point Event rate in 
controls
Odds Ratio NNT
Poldermans et al.80 30-day all cause mortality Not reported 0.22 Not reported
Kertai et al.81 30-day mortality or nonfatal MI 11.0% 0.24 14
Durazzo et al.82 Death, nonfatal MI, ischemic 
stroke, unstable angina within 6 
months after surgery
26% 0.31 6
Lindenauer et al.83 In-hospital all cause mortality 3.2% 0.71 109
O’Neil-Callahan et al.84 Composite of death, MI, 
ischemia, congestive heart 
failure, ventricular tachycardia 
during hospitalization
16.5% 0.52 15
RCT = Randomized Controlled Trial; CEA = Carotid Endarterectomy; MI = Myocardial Infarction; NNT = Number Needed to 
Treat
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elevated cholesterol levels were advised to continue or start statin therapy. The outcome of this trial 
was the end point of cardiovascular events, defined as cardiac death, nonfatal myocardial infarction, 
stroke, or unstable angina pectoris. Patients were monitored up to 6 months after the surgical pro-
cedure. Of 100 patients, 44 statin users and 46 nonusers underwent elective vascular surgery. The 
6-month incidence of cardiovascular events was reduced by 3.1-fold in statin users compared with 
nonusers (p=0.022).
A major concern of perioperative statin therapy has been the risk of statin-induced elevated serum 
transaminases, myopathy, and rhabdomyolysis. An important potential risk factor in the periopera-
tive setting is the use of concomitant medications. The risk of myopathy might increase with con-
comitant drugs that are myotoxic or increase serum statin levels. Besides concomitant medication 
use, numerous other factors in the perioperative setting might increase the risk of statin-induced 
myopathy, including impairment of renal function after major surgery, the use of analgesic agents, 
and postoperative pain that might mask signs of myopathy. Failure to detect statin-induced myopa-
thy may then lead to continuous statin use and the subsequent development of rhabdomyolysis and 
acute renal failure. In a retrospective study of 885 consecutive patients undergoing major vascular 
surgery, no case of rhabdomyolysis or a significant higher creatine kinase level in the 211 statin users 
was observed87. Considering that the risk of cardiovascular complications is far greater than the 
risk of statin-induced myopathy and rhabdomyolysis, the potential benefits of perioperative statin 
use seem to outweigh the potential hazards. The safety of statins should be confirmed in blinded, 
randomized trials, however.
A3. Antiplatelet therapy
Studies on the effectiveness of antiplatelet therapy to prevent cardiac complications in patients 
undergoing vascular surgery are non-existent. However, a large proportion of patients with periph-
eral arterial disease are on antiplatelet therapy as a means of secondary prevention.
What should be done with antiplatelet therapy in the perioperative setting? In their extensive review 
on the impact of antiplatelet therapy on perioperative bleeding complications, Harder et al. concluded 
that monotherapy with aspirin or clopidogrel alone usually does not have to be discontinued in the 
perioperative period88. This conclusion was confirmed in the meta-analysis of Burger et al.89 In 41 
studies including a total of 49 590 patients undergoing a variety of non-cardiac surgical procedures 
(14 981 on perioperative aspirin and 34 609 not on aspirin) they found that aspirin continuation led 
to a 1.5 times increased risk of bleeding complication, but not to a higher level of the severity of 
bleeding complications. They concluded that based on their meta-analysis aspirin should only be 
discontinued perioperatively if bleeding risks with increased mortality or sequels are comparable to 
the observed cardiovascular risks after aspirin withdrawal.
This issue is of particular relevance to patients with (recent) coronary stent placement. Surgery 
increases the in-stent thrombosis risk in these patients due to a perioperative stress response includ-
ing sympathetic activation promoting sheer stress on arterial plaques, enhanced vascular reactivity 
conducive to vasospasm, reduced fibrinolytic activity, platelet activation, and hypercoagulability. In 
addition, while the surgical patient is in a hypercoagulable state dual antiplatelet therapy is often 
interrupted because of the fear for excessive bleeding complications during surgery. This double-
edged sword of dual antiplatelet therapy, prevention of cardiac complications on one hand and an 
excess of bleeding risk on the other, remains a controversial issue in perioperative management. Is 
has recently been suggested that non-cardiac surgery after PCI with stenting should be delayed at 
least 6 weeks and dual antiplatelet therapy is associated with improved outcome90. It is advisable to 
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continue at least single antiplatelet therapy in patients with a history of coronary stent placement. 
Obviously for each patient a personalized decision should be made based on the possibility and 
anticipated severity of perioperative bleeding complications and the risk of in-stent thrombosis with 
subsequent myocardial infarction and cardiac death.
Preoperative coronary revascularization
The randomized Coronary Artery Revascularization Prophylaxis (CARP) trial was the first study that 
addressed the strategy of prophylactic revascularization compared to optimal medical therapy in 
patients with clinically stable coronary artery disease who were scheduled for major non-cardiac 
vascular surgery68. This trial showed that prophylactic revascularization was safe but did not improve 
perioperative or long-term outcome. The long-term (median follow-up 2.7 years) mortality was 22% 
in patients allocated to prophylactic coronary revascularization, compared to 23% in the medical 
only strategy, p=0.92 (FIGURE 1.4). In addition, the incidence of perioperative non-fatal myocardial 
infarction was similar, respectively 12 and 14%, p=0.37. However, it must be noted that the majority 
of patients in the CARP trial had only 1 or 2 vessel disease. In the nonrandomized cohort of the CARP 
trial 48 patients (4.6%) had left main stenosis. In this cohort, patients who had undergone preopera-
tive revascularization did seem to have an improved 2.5 year survival (84% vs. 52%). In a post-hoc 
analysis coronary artery bypass grafting was associated with fewer myocardial infarctions and a 
shorter hospital stay compared to percutaneous coronary interventions in patients receiving multi-
vessel coronary artery revascularization as prophylaxis91. However, more complete revascularization 
accounted for these intergroup differences.
For the DECREASE V study, a total of 1880 patients scheduled for major non-cardiac vascular surgery 
were screened69. Those with 3 or more clinical risk factors (age > 70 yrs, myocardial infarction, angina 
pectoris, congestive heart failure, diabetes mellitus, renal failure, and cerebrovascular events) all 
underwent preoperative cardiac stress testing. Those with extensive stress-induced ischemia (≥ 5 
segments or ≥ 3 walls) were randomly assigned for additional revascularization. All received beta-
blockers aiming at a heart rate of 60-65 bpm and antiplatelet therapy was continued during surgery. 
Of 430 high-risk patients, 101 (23%) showed extensive ischemia and were randomly assigned to 
revascularization (N=49) or no-revascularization (n=52). Coronary angiography showed 2-vessel 
disease in 12 (24%), 3-vessel disease in 33 (67%), and left main in 4 (8%). This study population reflects 
the patients at highest cardiac risk in the perioperative period. Compared to the CARP trial the 
perioperative cardiac risk in the DECREASE V population was even higher; all patients had extensive 
stress induced myocardial ischemia and 75% had 3-vessel or left main disease. If a beneficial effect on 
postoperative outcome could have been expected of prophylactic coronary revascularization, then it 
would be seen at least in this group of patients. However, the results of the trial were disappointing. 
Two patients died after revascularization, but prior to operation because of a ruptured aneurysm. 
Revascularization did not improve perioperative outcome, the incidence of cardiac death and 
myocardial infarction was 43 vs. 33%, OR 1.4, 95% CI 0.7-2.8 (p=0.30). Also no benefit during 1-year 
follow-up was observed after coronary revascularization, 49 vs. 44%, OR 1.2, 95% CI 0.7-2.3 (p=0.48).
The apparent lack of benefit of prophylactic coronary revascularization is not fully understood. Most 
likely patients with stress induced ischemia not only suffer from a blood flow limiting coronary lesion 
but also from (multiple) non-significant lesions which are vulnerable to rupture due to the stress of 
surgery. The perioperative stress response, which includes a cytokine response, catecholamine surge 
with associated hemodynamic stress, vasospasm, reduced fibrinolytic activity, platelet activation and 
consequent hypercoagulability triggers coronary plaque rupture, leading to thrombus formation 
and subsequent vessel occlusion.
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Autopsy results have shown that this mechanism is responsible for at least half of all perioperative 
infarctions. These findings are in line with dobutamine echocardiography results that show a cor-
relation between the assessment of the preoperative culprit coronary lesion and the location of the 
perioperative myocardial infarction in only half of all cases. Surgical or percutaneous treatment of the 
culprit coronary lesion(s) apparently provides insufficient extra protection on top of medical treat-
ment for rupture of these instable lesions.
VI.  TREATMENT
The treatment of perioperative cardiac complications often is more challenging and less straightfor-
ward compared to the treatment of acute coronary syndromes in the nonoperative setting. Where 
aggressive anti-coagulation or antiplatelet therapy is standard in nonoperative patients, in those 
who recently underwent vascular surgery a delicate balance between bleeding and thrombotic 
complications must be found. In this setting the choice of treatment for cardiac complications in 
vascular surgery should be appreciated.
For patients in the non-operative setting, recently new guidelines have been developed for acute 
coronary syndromes92-95. One of the criteria upon which the treatment decision is based is the type 
of acute coronary syndrome; i.e. non ST-segment elevation myocardial infarctions or ST-segment 
elevation myocardial infarctions.
In general for patients with non-ST segment elevation infarction, medical therapy is sufficient. This 
should consist of adequate beta-blockade, and anticoagulation in addition to antiplatelet therapy 
and statin therapy. In case of non-ST segment elevation infarction in the perioperative setting a 
physician experienced in this type of complications should be consulted.
The ST-segment elevation myocardial infarction is an absolute emergency both in nonoperative and 
operative patients. Depending on several factors immediate reperfusion strategies, e.g. fibrinolytic 
therapy and PTCA with stenting, should be considered. The indications for therapy are described in 
the ESC and ACC guidelines and a cardiologist should be consulted immediately to discuss the pros 
and cons of the different treatment strategies for each individual postoperative patient.
VII.  IMPACT OF CARDIAC COMPLICATIONS ON OuTCOME
A. Acute
The acute impact of cardiac complications, in particular myocardial infarction, is significant. Sprung 
and colleagues analyzed 6948 vascular operations at the Cleveland Clinic and found 107 patients 
with postoperative transmural MIs96. The overall in-hospital mortality rate was 20.6% with the highest 
mortality on postoperative day 0. In a similar series, Badner and coworkers reported a 17% post-
MI mortality rate after non-cardiac surgery97. Although these mortality rates are better than rates 
reported in older series (presumably owing to improved anesthetic care, beta blockers, and so forth), 
a death rate from MI of almost one in five remains startlingly high.
B. Long-term
Some authors have questioned the long-term clinical importance of non–Q wave MIs (i.e. “chemical” 
MIs) in vascular surgery patients. Yeager and colleagues followed 8 of 31 patients who sustained a 
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perioperative MI with “chemical MIs” in which enzyme elevation was the sole indicator of postopera-
tive MI. At a mean follow-up of 27.7 months, survival for patients with nonfatal perioperative MI at 
1 and 4 years was 80% and 51%, which did not differ significantly from that of control patients (90% 
and 60%; p>0.05)98. Although these investigators concluded that “a perioperative chemical MI” may 
not be a clinically significant event, patients surviving nonfatal perioperative MIs after peripheral 
vascular surgery did have a higher incidence of subsequent adverse cardiac events and subsequent 
coronary artery revascularization. Similarly, McFalls and coworkers reported that even in vascular 
patients with perioperative transmural MIs, nonfatal perioperative MI was only a marginally signifi-
cant independent predictor of 1-year mortality (p=0.06), whereas the extent of vascular disease at 
presentation was a more important determinant of survival68. However after 2.5 years of follow-up 
survival of patients without a perioperative MI turned out to be significantly better than in those with 
a perioperative MI99.
These optimistic reports have not been supported by more recent publications using more sensitive 
cardiac biomarkers such as cardiac troponin. As was already shown in a series of 2003 patients, a 
perioperative troponin T release >0.03 ng/ml and/or a troponin I release >0.6 ng/ml had a significant 
independent 2-fold increased risk for long-term mortality during a mean follow-up of 32 months13. 
This has been confirmed in a study of 393 vascular surgery patients by Kertai et al.: an increase in 
troponin T level > 0.1 ng/ml was associated with a 1.9-fold increased risk for all-cause mortality dur-
ing a median follow-up of 4 years51. Overall, the incidence of death, myocardial infarction, stroke, 
or severe myocardial ischemia requiring coronary reperfusion after perioperative troponin release 
within 1 year after hospital discharge is as high as 20-40% in several studies.
Finally it should be emphasized that patients undergoing non-cardiac vascular surgery are at high risk 
for long-term cardiac events, even those without perioperative cardiac complications. In fact, patients 
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Figure 1.6 Long-term survival after vascular surgery or after an acute coronary event (derived from Welten 
et al.14).
CAD = patients with an acute coronary event but without vascular surgery
CEA = patients who underwent carotid endarterectomy
LLR = patients who underwent lower limb arterial reconstructions
AAA = patients who underwent abdominal aortic aneurysm repair
r-AAA = patients who underwent ruptured abdominal aortic aneurysm repair
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who undergo vascular surgery have a worse prognosis compared to patients who experienced an 
acute coronary event (FIGURE 1.6). This difference is partially caused by a marked undertreatment 
of patients with PAD compared to patients with established, symptomatic coronary artery disease. 
Optimal medical treatment of these patients is of critical importance and recent guidelines such as 
the ACC/AHA guidelines and the TASC2 guidelines should be adhered to so that the patient lives long 
enough to enjoy the benefits of vascular surgery100,101.
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Cardiac complications are a major cause of perioperative morbidity and mortality in patients under-
going non-cardiac surgery. It is estimated that the incidence of such complications is between 0.5 
and 1.0 per cent1. Worldwide, about 100 million adults undergo some form of non-cardiac surgery 
each year, and so between 500,000 and 1,000,000 people will suffer from perioperative cardiac com-
plications; one of four of them will die from this cause.
In recent years the scope of perioperative cardiac risk stratification and cardioprotective therapy 
has changed. In addition to localized treatment of culprit coronary artery lesions, systemic therapy 
focusing on coronary plaque stabilization has been introduced. Although the pathophysiology of 
perioperative myocardial infarction (MI) is not entirely clear, plaque rupture, leading to thrombus 
formation and subsequent vessel occlusion, is implicated in a similar manner to that causing MI in 
the non-operative setting. The incidence of plaque rupture may be increased by the stress response 
to major surgery. This response includes sympathetic activation promoting sheer stress on arterial 
plaques, enhanced vascular reactivity conducive to the development of vasospasm, reduced fibrin-
olytic activity, platelet activation and hypercoagulability. Heightened sympathetic tone also increases 
myocardial oxygen requirements (for example through tachycardia and increased contractility), 
leading to a mismatch between oxygen supply and demand that, when sustained, can lead to infarc-
tion. Several studies of the pathophysiology of perioperative MI using non-invasive tests, coronary 
angiography and autopsy have shown that coronary plaque rupture and thrombus formation occur 
in 50 per cent of all fatal MIs, whereas a sustained oxygen supply-demand mismatch is responsible for 
the other 50 per cent. Lesions causing stenosis severe enough to lead to an oxygen supply-demand 
mismatch are also considered to be a marker for the presence of other non-obstructive lesions. These 
other lesions are also at risk of inflammation and rupture, and are likely to trigger a perioperative 
acute coronary syndrome. These findings explain why patients at risk can be identified by preopera-
tive cardiac stress testing and why the site promoting the perioperative event may not be identical to 
the culprit coronary artery lesion identified before surgery.
The unpredictability of vulnerable coronary plaque rupture produces new challenges in periop-
erative cardiac risk stratification and cardiac risk modification in the surgical setting. Traditionally, 
stratification has been based on a combination of clinical risk factors and additional cardiac testing, 
and indices such as the Revised Cardiac Risk Index have proven their reliability and reproducibility 
in clinical practice1. For patients suspected to be at high cardiac risk, additional tests, such as dobu-
tamine stress echocardiography, may further refine risk stratification2.
Although traditional imaging tools identify major coronary stenoses, they generally overlook those 
relatively mild coronary lesions that, as noted above, are responsible for half of all perioperative 
cardiac events. Inflammation is one of the key features of these unstable, vulnerable coronary 
plaques. In the non-operative setting, the role of several inflammatory biomarkers for the prediction 
of coronary events has been studied both in healthy people and in patients with stable coronary 
artery disease, acute coronary syndromes or requiring secondary prevention. These markers include 
C-reactive protein, interleukin 6, serum amyloid A, tumor necrosis factor, soluble intercellular adhe-
sion molecule 1, macrophage inhibitory cytokine 1, soluble P-selectin and CD40 ligand. However, 
studies of inflammatory biomarkers for the prediction of adverse perioperative cardiac events are 
scarce; future research into perioperative cardiac risk prediction must focus on these biomarkers.
The nature of perioperative cardiac events has implications for perioperative cardioprotective 
therapy. Local therapy may be the best option for the culprit lesion. In high-risk patients myocardial 
oxygen-supply mismatch might be counteracted by beta-blockers, and in this context it is important 
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to appreciate that only adequate beta-blocker use (that achieving a target heart rate of less than 65 
beats per min) seems to lower the perioperative cardiac event rate3. However, for those with multiple 
coronary artery lesions suggestive of left main or three-vessel disease, beta-blocker therapy alone 
may prove sufficient. Although previously considered as an appropriate preoperative treatment for 
these patients, prophylactic preoperative coronary revascularization is now known not to reduce the 
incidence of perioperative cardiac events sufficiently4,5. This is probably because such revasculariza-
tion cannot prevent the rupture of vulnerable plaques.
Systemic therapy should be considered for the prevention of vulnerable plaque rupture and it is 
noteworthy in the non-operative setting that the recently published Medicine, Angioplasty, or 
Surgery Study (MASS) II and Clinical Outcomes Utilizing Revascularization and Aggressive druG 
Evaluation (COURAGE) trials6,7 both found no additional benefit from coronary revascularization 
over best medical treatment only in patients with stable multivessel coronary artery disease. Medical 
treatment in both trials included rigorous statin and aspirin therapy. Recent literature also suggests 
an important role for this type of anti-inflammatory medication in surgical patients. For example, 
perioperative statin therapy in vascular surgical patients seems to be safe and effective for the pre-
vention of perioperative cardiac events8. This cardioprotective effect of statins is independent of their 
lipid-lowering effect and is attributed to their so-called pleiotropic potential. The pleiotropic effects 
of statins depend on several possible plaque-stabilizing mechanisms, such as increased production 
of endothelin 1 and generation of reactive oxygen expression of endothelial nitric oxide synthase, 
reduced species, improvement of thrombogenic profile and, importantly, reduction in inflammation 
by reduced expression of inflammatory cytokines, chemokines and adhesion molecules, and a lower-
ing of C-reactive protein levels.
What are the implications of these new insights for surgical practice? Recent improvements in periop-
erative medical therapy have diminished the need for extensive cardiac assessment in most patients; 
this reduces any delay to surgery. Medical therapy to improve the balance of myocardial oxygen 
supply and demand, such as beta-blockade, does not interfere with any planned operation; cardi-
oselective beta-blockers, in particular, are safe even for patients with chronic obstructive pulmonary 
or peripheral arterial disease. Statin therapy aimed at coronary plaque stabilization also seems to be 
safe. The use of antiplatelet agents in the perioperative period is more controversial. A meta-analysis 
of 41 studies, including a total of 49 590 patients undergoing a variety of non-cardiac operations, has 
shown that aspirin continuation is associated with a 1.5-fold increased risk of bleeding complications 
but not with a higher level of severity of such complications9.
In summary, to improve postoperative cardiac outcome after non-cardiac surgery a dual approach is 
required. First, one must focus on correcting the mismatch of myocardial oxygen supply and demand. 
Second, one must stabilize the coronary artery atheromatous plaque. At present, these needs are 
best met with a combined medical therapy of cardioselective beta-blockers, statins and, if possible, 
aspirin.
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INTRODuCTION
Patients scheduled for non-cardiac vascular surgery are at significant risk of cardiovascular morbid-
ity and mortality due to underlying symptomatic or asymptomatic coronary artery disease. As was 
shown by Hertzer et al. in their landmark study in 1984 of 1000 patients undergoing non-cardiac 
vascular surgery, 61% of all patients did have at least one coronary artery with a stenosis of 50% or 
more1. In fact, only 8% of all patients did have a normal coronary angiogram. Importantly, there was 
no difference between patients who presented with an abdominal aortic aneurysm, lower extremity 
ischemia, or cerebrovascular disease. More recent studies using functional tests such as dobutamine 
stress echocardiography confirmed the high incidence of coronary artery disease in vascular surgical 
patients. In a study population of 1097 vascular surgical patients with at least one cardiac risk factors, 
the incidence of wall motion abnormalities at rest was nearly 50% while one fifth of patients had 
stress induced myocardial ischemia2.
The high prevalence of coronary artery disease in vascular surgical patients explains the high 
incidence of perioperative cardiac events in this patient population. Though recent developments 
in anesthesiological and surgical techniques, e.g. locoregional anesthesia and endovascular treat-
ment modalities, have improved postoperative cardiac outcome considerably, perioperative cardiac 
complications remain a significant problem. The incidence of perioperative myocardial infarction is 
around 5% and the prevalence of (a-) symptomatic perioperative myocardial ischemia as assessed by 
serum troponin I or serum troponin T in major vascular surgery is even 15 to 25%2-4.
Patients undergoing vascular surgery are also susceptible to cardiovascular events during long-term 
follow-up after the surgical procedure. Over half of all long-term deaths in this population are attrib-
utable to cardiac events. The preoperative work up of vascular patients should be considered as an 
excellent opportunity to identify patients at increased long-term risk and treat them appropriately 
to lower the long-term risk for cardiovascular events. After all, the patient should live long enough to 
enjoy the benefits of the vascular surgical intervention.
This review will provide an overview of the current status of preoperative work-up of patients under-
going non-cardiac vascular surgery.
CLINICAL CARDIAC RISk SCORES
Non-cardiac surgery
The first, most simple and least costly step in preoperative cardiac risk stratification is the identifica-
tion of clinical cardiac risk factors. In the last three decades much attention has been given to the 
identification of patients at risk by using simple clinical cardiac risk factors. This research has led to 
numerous cardiac risk indices for non-cardiac surgical procedures (TABLE 3.1).
In 1977 Goldman et al. proposed the first cardiac risk stratification model based on prospectively col-
lected data5. In this study of 1001 patients, nine independent predictors were found to be correlated 
with postoperative life-threatening and fatal cardiac complications: preoperative third heart sound 
or jugular venous distention; myocardial infarction in the preceding six months; more than five pre-
mature ventricular contractions per minute documented at any time before operation; rhythm other 
than sinus rhythm or presence of premature atrial contractions on preoperative electrocardiogram; 
age over 70 years; intraperitoneal, intrathoracic or aortic operation; emergency operation; important 
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valvular aortic stenosis; and poor general medical condition. The incidence of adverse cardiac events 
was 1% in the group at lowest risk (class I), and increased to 7%, 14%, and 78% in class II, III, and IV 
patients respectively. However, it must be noted that only 18 patients were in the group at highest 
risk. The Goldman index has a 96.8% negative predictive value, and thus is an excellent tool to rule 
out CAD. The value of the Goldman index for diagnosing patients with CAD on the other hand was 
less optimal, i.e. a positive predictive value of 21.6%.
In 1986 Detsky et al. prospectively validated and modified the Goldman index and presented a 
simple normogram, introducing the pre-test likelihood of perioperative cardiac events for cardiac 
risk stratification6. The Detsky modified multifactorial risk index has been in use ever since and is 
considered to be a good and practical index.
In 1999 Lee et al. reviewed the performance of several clinical risk indices in patients who underwent 
elective non-cardiac surgery7. They found that the Goldman risk index and the Detsky modified cardiac 
risk index had a similar performance for predicting major cardiac complications. However, when the 
Goldman risk index was revised and validated, the predictive value of the risk index had substantially 
improved. In the validation cohort the ROC area improved form 0.70 for the original Goldman index 
to 0.81 for the Revised Cardiac Risk Index by Lee et al. The Revised Cardiac Risk Index identified 6 pre-
dictors (high-risk surgery, ischemic heart disease, congestive heart failure, cerebrovascular disease, 
insulin dependent diabetes mellitus, and renal failure) of major cardiac complications, and based 
on the presence of 0, 1, 2, or 3 or more of these predictors, the rate of major cardiac complications 
was estimated to be 0.4%, 0.9%, 7%, and 11%, respectively. Interestingly the Lee index has better 
prognostic value than the Goldman and Detsky indices though the number of cardiac risk factor 
variables in the Lee index is smaller. This might be explained by the improvement of perioperative 
Table 3.1 Risk factors according to the classifications of Goldman, Lee, and Boersma for adverse postoperative 
outcome in patients undergoing all types of non-cardiac surgical procedures.
goldman et al.5
1977
Lee et al.7
1999
Boersma et al.8
2005
Life-threatening and fatal cardiac 
complication
Major adverse cardiac event Cardiovascular death
Third heart sound or jugular venous 
distention
Congestive heart failure Congestive heart failure
Myocardial infarction in the preceding 
six months
Ischemic heart disease Ischemic heart disease
> 5 PVCs per minute at any time before 
operation
Cerebrovascular disease Cerebrovascular disease
Other than sinus rhythm or presence PACs Insulin dependent diabetes mellitus Insulin dependent diabetes mellitus
Age over 70 years Renal failure Renal failure
Intraperitoneal, intrathoracic or aortic 
operation
High-risk surgery Surgical risk according to the AHA/
ACC classification
Emergency operation Age: <40 yrs, 40-50, 50-60, 60-70,70-
80, ≥80
Important valvular aortic stenosis
Poor general medical condition
No. patients in original report: 1001 No. patients in original report: 2893 No. patients in original report: 108 593
AUC in original report: 0.77 AUC in original report: 0.85
PVC = Premature Ventricular Contraction; PAC = Premature Atrial Contraction
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care in the time between the development of the Goldman and Lee risk indices. Nowadays, the Lee 
index is considered the most relevant index for predicting perioperative cardiac risk in non-cardiac 
surgery by many clinicians and researchers. However, the patients studied by Lee et al. can hardly be 
considered as an average non-cardiac surgical population. Thoracic, vascular and orthopedic patients 
were overrepresented in this study population.
Recently, Boersma et al. developed the Erasmus Risk Index, a further refinement of the Revised Car-
diac Risk Index8. This index was based on an administrative database of 108 593 patients undergoing 
all types of non-cardiac surgery during a period of 10 years at a university medical center in the 
Netherlands. Of these patients 1877 (1.7%) died in hospital, including 543 cardiovascular deaths. 
Applying the Revised Cardiac Risk Index in this population the corresponding odds ratios for patients 
without risk factors, 1, 2, or ≥ 3 were 1 (reference), 2.0, 5.1, and 11.0 respectively, with a C statistic 
for the prediction of cardiovascular mortality of 0.63. Importantly, if more precise data about the 
type of operation was introduced in the model the C statistic significantly increased to 0.79. Add-
ing age resulted in an even better C index of 0.83. These data suggest that the Revised Cardiac Risk 
Index by Lee et al. is probably suboptimal for identifying patients with greater cardiac risk, perhaps 
because it excluded emergency operations and perhaps because the type of surgery, which is one 
of the main determinants of adverse cardiovascular outcome, was considered in only 2 subtypes: 
high risk, including intraperitoneal, intrathoracic and suprainguinal vascular procedures; and all 
remaining nonlaparascopic procedures, mainly including orthopedic, abdominal, and other vascular 
procedures. In the study by Boersma et al. it was found that a more subtle classification, as suggested 
by the American Heart Association/American College of Cardiology guideline committee, resulted, at 
least retrospectively, in a substantially better risk discrimination.
Non-cardiac vascular surgery
Patients undergoing non-cardiac vascular surgery are at high risk for postoperative cardiac com-
plications due to underlying coronary artery disease. Several risk indices have been developed to 
stratify vascular surgical patients based on clinical cardiac risk factors (TABLE 3.2). In general, patients 
undergoing carotid artery stenosis repair have the least cardiac risk, followed by lower extremity 
revascularization procedures and abdominal aortic procedures. Some risk indices only describe major 
non-cardiac vascular surgical procedures, a term commonly used for lower extremity and abdominal 
aortic surgery.
The Glasgow aneurysm score, described in 1995, was one of the first cardiac risk scores dedicated 
to only vascular surgical procedures9. In a retrospective study of 500 randomly chosen patients 
scheduled for open abdominal aortic aneurysm repair potential preoperative risk factors were 
related to postoperative in-hospital mortality. In multivariate analysis age, shock, myocardial disease, 
cerebrovascular disease, and renal disease were independently associated with adverse periopera-
tive outcome.
One year after the introduction of the Glasgow aneurysm score, the Leiden Risk Model was proposed 
by Steyerberg et al.10 This study group composed a clinical prediction rule for perioperative mortality, 
using several risk factors obtained from literature. These risk factors included age, gender, a history 
of myocardial infarction, congestive heart failure, ischemia on the electrocardiogram, pulmonary 
disease, and renal dysfunction. Data from 246 patients undergoing open abdominal aortic aneurysm 
repair were used to validate the prediction rule. In the prediction rule, cardiac, renal, and pulmonary 
co-morbidity were found to be the most important risk factors, while age had only a moderate effect 
on perioperative mortality.
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A total of 1081 consecutive patients undergoing major elective vascular surgery were used for the 
development and validation of a Bayesian model for preoperative cardiac risk assessment by L’Italien 
et al. in 199611. The outcome for this study was a combination of nonfatal myocardial infarction and 
cardiac death. Using 567 patients as a derivation cohort the following risk factors were identified as 
predictors for adverse postoperative outcome: myocardial infarction, congestive heart failure, angina 
pectoris, prior coronary revascularization, diabetes mellitus, and age > 70 years. Importantly, the 
validation cohort of 514 patients showed a prognostic accuracy of 74%. Patients classified as low, 
intermediate and high risk had cardiac event rates of 3%, 8%, and 18% respectively.
Patients enrolled in the DECREASE I trial were used for the development of a risk score for elective 
major vascular surgery in 20012. This study identified 7 independent clinical risk factors for the com-
bination of postoperative cardiac death and nonfatal myocardial infarction: a history of myocardial 
infarction, angina pectoris, congestive heart failure, diabetes mellitus, renal dysfunction, cerebrovas-
cular events, and age > 70 years. For patients not on beta-blocker therapy the risk of perioperative 
cardiac events increased by each risk factor added, ranging from 1.0% in patients without risk factors, 
to 2.2%, 4.5%, 9.2%, 18.0%, and 32.0% for 1, 2, 3, 4, and ≥ 5 risk factors respectively.
Recently Kertai et al. used a total of 2310 patients to develop a Bayesian model for the prediction of 
all-cause perioperative mortality in patients undergoing all types of open vascular surgery, including 
Table 3.2 Risk factors in vascular surgical procedures.
Glasgow Aneurysm Score9
1994, major vascular surgery
Leiden Risk Model10
1995, major vascular surgery
L’Italien et al.11
1996, major vascular surgery
All-cause perioperative mortality All-cause perioperative mortality Cardiac death and nonfatal MI
Myocardial disease Myocardial Infarction Myocardial Infarction
Cerebrovascular disease Congestive Heart Failure Congestive Heart Failure
Renal dysfunction ECG evidence of ischemia Angina Pectoris
Age Female gender Prior Coronary Revascularization
Renal dysfunction Diabetes Mellitus
Chronic pulmonary disease Age > 70 years
Age (<60; 60-70; >70 years)
No. patients in original report: 500 No. patients in original report: 246 No. patients in original report: 1081
AUC in original report: 0.74
Boersma et al.2
2001, major vascular surgery
Customized Probability Index12
2005, vascular surgery
Cardiac death and nonfatal MI All-cause perioperative mortality
Myocardial Infarction Ischemic heart disease
Congestive Heart Failure Congestive heart failure
Angina Pectoris Cerebrovascular events
Cerebrovascular events Hypertension
Renal dysfunction Renal dysfunction
Diabetes Mellitus Chronic pulmonary disease
Age > 70 years Type of vascular surgery (ruptured AAA; elective AAA; lower 
extremity; carotid)
No. patients in original report: 1097 No. patients in original report: 2310
AUC in original report: 0.78 AUC in original report: 0.85
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emergent surgery12. 1537 patients were used to develop the risk score: the “customized probabil-
ity index”. Risk factors associated with postoperative all-cause death were ischemic heart disease, 
congestive heart failure, cerebrovascular events, hypertension, renal dysfunction, chronic pulmonary 
disease, and type of vascular surgery, i.e. ruptured AAA, elective AAA, lower extremity, and carotid. 
The final logistic regression model with the 9 independent predictors (including beta-blocker and 
statin use) of perioperative mortality was used to create a variable-weight index where scores were 
assigned on the basis of parameter estimates of the individual predictors. The type of surgery was 
a strong risk factor; patients with a ruptured abdominal aortic aneurysm had the worst outcome 
(43 points), followed by elective thoracoabdominal and abdominal aortic surgery (26 points), lower 
extremity arterial bypass surgery (15 points), and carotid surgery (0 points). It should be noted that 
all procedures in the risk model were open surgical procedures. Risk factors based on medical history, 
ordered in descending risk, were: renal dysfunction (16 points), congestive heart failure (14 points), 
ischemic heart disease (13 points), cerebrovascular event (10 points), hypertension (7 points), and 
pulmonary disease (7 points). Based on the sum of scores of surgical risk (0-46 points), medical history 
(0-67 points), and the score for cardioprotective medication (statins -10 points and beta-blockers -15 
points) an overall cardiac risk can be calculated.
ADDITIONAL LABORATORy TESTINg
Apart from those measurements indicating clinical risk factors (for example, serum creatinine for 
renal failure, fasting glucose for diabetes mellitus, etc) currently no routine laboratory measurements 
are related to perioperative cardiac complications.
Recent studies showed that increased plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
or B-type natriuretic peptide (BNP) are associated with adverse postoperative outcome13-16. NT-
proBNP is increased in patients with left ventricular dilatation caused by fluid overload (e.g. heart 
failure and renal dysfunction), pressure overload (e.g. aortic valve stenosis) and myocardial ischemia, 
which might explain the excellent relation with adverse postoperative outcome. In a study of 1590 
patients scheduled for all types of non-cardiac general surgery by Dernellis et al. raised levels of BNP, 
i.e. > 189 pg/ml, were independently associated with a staggering 34 fold increased risk for postop-
erative cardiac events14. Similar results were found by Feringa et al. in their report on the prognostic 
value of NT-proBNP in 170 patients scheduled for major vascular surgery. Patients with a NT-proBNP 
level > 533 pg/ml had an independent 17-fold increased risk for postoperative cardiac events, even 
after adjustment for preoperative dobutamine stress echocardiography results13. Gibson et al. con-
firmed the predictive value of BNP in 149 major vascular surgical patients: using receiver-operator 
curve analysis a BNP concentration of 108.5 pg/ml best predicted the likelihood of cardiac events, 
with a sensitivity and specificity of 87%15. The true value of either BNP or NT-proBNP in the preopera-
tive screening setting must be confirmed in large-scale prospective trials such as the recently started 
multinational DECREASE VI trial.
Diabetes mellitus is a common risk factor in patients scheduled for vascular surgery with prevalence 
of approximately 50% if all patients are thoroughly screened17. Diabetes mellitus is known to be a 
strong predictor for perioperative events. Therefore fasting glucose values should be obtained from 
all patients scheduled for vascular surgery and glucose loading testing should be considered in all. 
Recently it was shown that the level of preoperative glycosylated hemoglobin in diabetic patients 
is strongly related to perioperative cardiac outcome18,19. In the same patient population it was also 
shown that in patients with high preoperative glycosylated hemoglobin it is more difficult to regulate 
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glucose values in the perioperative period. This might partly explain the strong relation between 
preoperative glycosylated hemoglobin and outcome, since it is known from critically ill patients and 
patients with myocardial infarction that tight glucose control is of imminent importance. In a large 
case-control study by Noordzij et al. in non-cardiac nonvascular surgical patients it was also shown 
that random preoperative glucose levels were associated with postoperative outcome20. Those with 
a random glucose level > 11.1 mmol/l had a 4-fold increased risk for perioperative cardiovascular 
death. Importantly, also glucose levels of 5.6-11.1 mmol/l were independently associated with a 
3-fold increased risk for perioperative cardiovascular events.
Recently Sarveswaran et al. found that preoperative asymptomatic troponin release in patients with 
symptomatic peripheral arterial disease is associated with a poor postoperative prognosis21. Preop-
erative troponin levels may be elevated because of asymptomatic myocardial ischemia, a condition 
often observed in patients scheduled for major vascular surgery. As was already noted by Landesberg 
et al. in 1993, over 40% of patients planned for major vascular surgery experience silent myocardial 
ischemia preoperatively as assessed by continuous 12-lead ECG recording, also in asymptomatic 
patients22. Notably, both Landesberg et al. and Kertai et al. previously showed that even low levels of 
asymptomatic troponin elevations in the perioperative period are associated with worse long-term 
outcome in patients undergoing major vascular surgery23,24.
In most risk indices renal insufficiency is taken into account. For example, the serum creatinine cut-off 
value Lee et al used is 2.0 mg/dL (177 mmol/l)7. However, it might be argued that patients with less 
pronounced renal insufficiency also do worse compared to patients with normal serum creatinine 
values. A continuous variable for creatinine would probably be better, though not very user-friendly 
in every day practice. Recent studies have also shown that glomerular filtration rate might be a better 
predictor than serum creatinine since this takes into account the different creatinine concentrations 
between sexes25.
ADDITIONAL NONINVASIVE CARDIAC TESTINg
If there is evidence or suspicion of CAD at physical examination, e.g. valve abnormalities or left ven-
tricular dysfunction, or a high cardiac risk score further cardiac testing might be required. The most 
simple, inexpensive form of cardiac imaging is resting echocardiography, for the detection of impaired 
left ventricular function and valve stenosis and sclerosis. Impaired left ventricular function was long 
considered a strong predictor for adverse perioperative cardiac events. However, due to improved 
perioperative care it is no longer a strong predictor for short-term outcome but remains a significant 
predictor for long-term adverse cardiac events. The presence of aortic stenosis is associated with a 
fivefold increased risk of perioperative cardiac events26. Also, the severity of aortic stenosis is related 
to an increased risk of perioperative events. Considering this, it is important to detect the presence 
and significance of valve disease. Though physical examination is reliable in detecting abnormal 
heart sounds, the estimation of the severity of stenosis by physical examination alone is difficult and 
echocardiography is recommended in patients with abnormal heart sounds.
ADDITIONAL NONINVASIVE CARDIAC STRESS TESTINg
According to the guidelines of the American College of Cardiology/American Heart Association, 
preoperative cardiac exercise or pharmacological stress testing is recommended for: patients with 
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intermediate pre-test probability of CAD; prognostic assessment of patients undergoing initial evalu-
ation for suspected or proven CAD; evaluation of subjects with significant change in clinical status; 
demonstration of proof of myocardial ischemia before coronary revascularization; evaluation of 
adequacy of medical treatment; and prognostic assessment after an acute coronary syndrome27. For 
stress testing, the evaluation of exercise capacity when subjective assessment is unreliable seems to 
be a valid reason as well. Patients with CAD or at risk for CAD can be frequently found in the group of 
patients with limited every day exercise—for example, patients with severe intermittent claudication. 
In these patients pharmacological stress echocardiography or nuclear imaging are elegant ways to 
exclude subclinical CAD.
The sensitivity and specificity of available exercise and pharmacological stress tests were compared 
in several meta-analyses. The meta-analysis of Kertai et al showed a trend in favor of dobutamine 
stress echocardiography, though other tests had satisfying sensitivity and specificity as well28. An 
upcoming elegant new diagnostic tool is dobutamine stress magnetic resonance imaging, though 
no randomized trials or large series have reported the sensitivity and specificity of this test yet.
In this era of new cardioprotective medical therapies, i.e. beta-blockers and statins, the key ques-
tion is which patient should undergo additional stress testing and which patient can be send for 
surgery without prior cardiac stress testing. The recently published Dutch Echocardiographic Cardiac 
Risk Evaluation Applying Stress Echo Study II (DECREASE II) evaluated the value of preoperative 
cardiac testing in intermediate-risk patients on beta-blocker therapy with perioperative tight heart 
rate control scheduled for major vascular surgery29. A total of 1476 vascular surgical patients were 
screened for this study. Based on the risk score of Boersma et al. patients were divided into 3 risk 
groups: low cardiac risk (no risk factors), intermediate cardiac risk (1 or 2 risk factors), and high cardiac 
risk (> 3 risk factors).  All 770 intermediate risk patients were randomly assigned to preoperative 
cardiac stress-testing or no-testing.  Results of preoperative testing and coronary revascularization 
were discussed with the attending physicians, and hemodynamic management was implemented 
accordingly. Importantly all patients in the DECREASE II study received beta-blocker therapy aiming 
at a tight heart rate control, i.e. a heart rate of 60–65 beats per minute, irrespective of stress test 
results. Of the 386 patients randomized to cardiac stress-testing, 287 (74%) had no stress inducible 
myocardial ischemia, 65 (17%) had limited ischemia, and 34 (9%) had extensive ischemia. No differ-
ence in 30-day outcome was observed in intermediate-risk patients with and without testing, 2.3 
vs. 1.8 percent (odds ratio 0.78, 95 percent confidence interval 0.28 to 2.1). The upper limit of the 
90 percent confidence interval of the absolute risk difference in favor of cardiac testing was 1.2%, 
indicating non-inferiority of the no-testing strategy. In intermediate-risk patients with extensive 
ischemia revascularization did not improve 30-day outcome (25.0 versus 9.1 percent events, odds 
ratio 3.3, 95 percent confidence interval 0.5 to 24; p=0.32). Also, no difference in 2-year outcome 
was observed in intermediate-risk patients with and without testing, 4.3 versus 3.1 percent (p-value 
0.30). The DECREASE II study indicates that cardiac testing of intermediate-risk patients prior to major 
vascular surgery, as recommended by the guidelines of the ACC/AHA, provided no benefit in patients 
on beta-blocker therapy with tight heart rate control. Importantly, the strategy of no-testing brought 
the operation almost 3 weeks forward.
ADDITIONAL INVASIVE CARDIAC TESTINg
Guidelines of the American College of Cardiology /American Heart Association (ACC/AHA) recom-
mend coronary angiography for patients with high-risk noninvasive test results, and myocardial 
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revascularization in patients with prognostic high-risk anatomy in whom long-term outcome is likely 
to be improved27. This recommendation was supported by the Coronary Artery Surgery Study that 
showed a reduced incidence of non-fatal myocardial infarctions after previous bypass surgery among 
vascular surgery patients compared to those treated medically, 8.5 vs. 0.6% (p=0.001)30. More recently, 
the data from the Bypass Angioplasty Revascularization Investigation trial showed that bypass sur-
gery and percutaneous coronary intervention had similar low rates of postoperative cardiac events 
in non-cardiac surgery31. However, these studies were not designed to assign the optimal strategy in 
severely ill patients with extensive coronary artery disease immediately prior to major non-cardiac 
surgery. In addition, these studies could not address the concern of delaying the non-cardiac surgical 
procedure because of testing, revascularization, and initiation of antiplatelet therapy since the time 
between revascularization and non-cardiac surgery in these studies was respectively 4.1 and 2.4 
years.
The randomized Coronary Artery Revascularization Prophylaxis (CARP) trial was the first study that 
addressed the strategy of prophylactic revascularization compared to optimal medical therapy in 
patients with clinically stable coronary artery disease who were scheduled for major non-cardiac 
vascular surgery32. This trial showed that prophylactic revascularization was safe but did not improve 
perioperative or long-term outcome. The long-term (median follow-up 2.7 years) mortality was 22% 
in patients allocated to prophylactic coronary revascularization, compared to 23% in the medical 
only strategy, p=0.92. Also the incidence of perioperative non-fatal myocardial infarction was similar, 
respectively 12 and 14%, p=0.37. However, it must be noted that the majority of patients in the CARP 
trial had only 1 or 2 vessel disease. The recently conducted DECREASE V randomized pilot study in 
which the majority of patients had 3-vessel disease also showed no perioperative and long-term 
(follow-up 1 year) benefit of prophylactic coronary revascularization33. The findings of both CARP 
and DECREASE V support the current guidelines of the ACC/AHA on perioperative management in 
high-risk patients to reserve revascularization only for cardiac unstable patients. After successful non-
cardiac surgery these patients should be regularly screened for the presence of ischemic complaints 
and aggressive anti-ischemic therapy, both medical and invasive, should be considered. In these 
patients at high risk scheduled for major non-cardiac vascular surgery prophylactic revascularization 
might be switched to late revascularization, preventing the delay of surgery.
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INTRODuCTION
In the last decades developments in anesthesiological and surgical techniques, i.e. loco-regional 
anesthesia and minimally invasive surgery, have improved postoperative cardiac outcome consider-
ably. For example patients with a severely reduced left ventricular function used to be at increased 
risk, but because of the implementation of these new techniques are now scheduled for surgery at 
relatively low risk. In other words, the improvement of perioperative care has altered the impact of 
established cardiac risk factors.
However, as more patients with cardiac co-morbidity survive surgery, long-term cardiac outcome 
has gained interest. Therefore, the focus of preoperative risk evaluation should also take into consid-
eration the impact of cardiac co-morbidity on long-term survival. After all, patients should live long 
enough to enjoy the benefits of surgery.
It is estimated that the incidence of cardiac complications after non-cardiac surgical procedures is 
between 0.5% and 1.0%1,2. Annually around 100 million adults undergo some form of non-cardiac 
surgery. Consequently, approximately 500,000 to 1,000,000 people will suffer from perioperative 
cardiac complications. Moreover, one out of every four of these patients will die. For the prevention 
of perioperative cardiac complications it remains of critical importance to identify those at increased 
risk and treat them accordingly, to improve both perioperative and long-term survival.
This article gives an overview of the current status of preoperative cardiac screening. In a step-wise 
approach the use and prognostic value of clinical cardiac risk factors, laboratory measurements, non-
invasive and invasive coronary testing, and consequently medical and interventional strategies to 
alter cardiac risk will be discussed (TABLE 4.1).
STEP 1.  IDENTIFICATION OF CLINICAL RISk FACTORS
The first, most simple and least costly step in preoperative cardiac risk stratification is the identifica-
tion of clinical cardiac risk factors. In the last three decades much attention has been given to the 
identification of patients at risk by using simple clinical cardiac risk factors. This research has led to 
numerous cardiac risk indices for non-cardiac surgical procedures. In 1977 Goldman et al. proposed 
the first cardiac risk stratification model based on prospectively collected data3. In this study of 1001 
patients, nine independent predictors were found to be correlated with postoperative life-threatening 
and fatal cardiac complications: preoperative third heart sound or jugular venous distention; myocar-
dial infarction in the preceding six months; more than five premature ventricular contractions per 
minute documented at any time before operation; rhythm other than sinus rhythm or presence of 
premature atrial contractions on preoperative electrocardiogram; age over 70 years; intraperitoneal, 
intrathoracic or aortic operation; emergency operation; important valvular aortic stenosis; and poor 
general medical condition. The incidence of adverse cardiac events was 1% in the group at lowest 
risk (class I), and increased to 7%, 14%, and 78% in class II, III, and IV patients respectively. However, 
it must be noted that only 18 patients were in the group at highest risk. As pointed out by Ridley 
the Goldman index has a 96.8% negative predictive value, and thus is an excellent tool to rule out 
CAD4. The value of the Goldman index for diagnosing patients with CAD on the other hand was less 
optimal, i.e. a positive predictive value of 21.6%. In 1986 Detsky et al. prospectively validated and 
modified the Goldman index and presented a simple normogram, introducing the pre-test likelihood 
of perioperative cardiac events for cardiac risk stratification5. The Detsky modified multifactorial risk 
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index has been in use ever since and is considered to be a good and practical index. In 1999 Lee 
et al. reviewed the performance of several clinical risk indices in patients who underwent elective 
non-cardiac surgery2. They found that the Goldman risk index and the Detsky modified cardiac risk 
index had a similar performance for predicting major cardiac complications. However, when the 
Goldman risk index was revised and validated, the predictive value of the risk index had substantially 
improved. In the validation cohort the ROC area improved form 0.70 for the original Goldman index 
to 0.81 for the Revised Cardiac Risk Index by Lee et al. The Revised Cardiac Risk Index identified 6 pre-
dictors (high-risk surgery, ischemic heart disease, congestive heart failure, cerebrovascular disease, 
insulin dependent diabetes mellitus, and renal failure) of major cardiac complications, and based 
on the presence of 0, 1, 2, or 3 or more of these predictors, the rate of major cardiac complications 
was estimated to be 0.4%, 0.9%, 7%, and 11%, respectively. Interestingly the Lee index has better 
prognostic value than the Goldman and Detsky indices though the number of cardiac risk factor 
Table 4.1 Nine steps to optimal preoperative cardiac risk evaluation and modification.
Step 1. Identification of clinical cardiac risk factors
Step 2. Identification of surgery related risk
Intermediate and high cardiac risk Low cardiac risk
Step 3. Electrocardiogram
Step 4. Laboratory measurements
Step 5. Non-invasive resting cardiac imaging
Step 6. Non-invasive stress testing
Step 7. Optimal medical therapy
Step 8. Coronary revascularization
Step 9. Elective non-cardiac surgery
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variables in the Lee index is smaller. This might be explained by the improvement of perioperative 
care in the time between the development of the Goldman and Lee risk indices. Nowadays, the Lee 
index is considered the most relevant index for predicting perioperative cardiac risk in non-cardiac 
surgery by many clinicians and researchers. However, the patients studied by Lee et al can hardly be 
considered as an average non-cardiac surgical population. Thoracic, vascular and orthopedic patients 
were overrepresented in this study population.
STEP 2. TyPE OF SuRgERy
After specifying patients’ clinical cardiac risk factors it is important to consider the surgical procedure 
the patient is scheduled for. However, the clinical cardiac risk indices of Lee, Detsky and Goldman 
include only high-risk surgery in their models as other types of surgery were not associated with 
adverse outcome. However, this simplification might not be sufficient to accurately predict peri-
operative cardiac outcome. Recently Boersma et al. validated the Lee risk index in a large cohort 
(n=108,593) of all types of non-cardiac surgical procedures1. When the Lee index was adapted and 
more detailed information on the surgical risk of the procedure was added, the predictive value 
improved substantially (C-statistic improved from 0.63 to 0.85). In this model surgical procedures 
were classified as low-risk, intermediate-low, intermediate-high, and high-risk surgical procedures.
STEP 3. ELECTROCARDIOgRAM
Recently, Noordzij et al. showed that the addition of a simple classification of preoperative ECG (i.e. 
normal or abnormal) improved the predictive value of the combination of clinical cardiac risk fac-
tors and type of surgery6. An ECG was considered abnormal in case of atrial fibrillation, left or right 
bundle branch block, left ventricular hypertrophy, premature ventricular complexes, pacemaker 
rhythm, Q-wave, or ST changes. This study was performed in a group of 23,036 patients undergoing 
non-cardiac surgery. Though ECGs added extra information on perioperative cardiac risk, it was also 
shown that in absolute numbers, the increase in predictive value was small in patients undergoing 
low-risk or intermediate-risk procedures and a “routine preoperative ECG” in this population should 
be precluded.
Summarizing steps 1 to 3
With these simple risk predictors (i.e. clinical risk factors; type of surgery; and ECG) it is possible to 
make an initial crude assessment of a patient’s perioperative cardiac risk. This risk estimation can 
be used to identify those patients at increased risk who should undergo further cardiac testing. 
Recently Boersma et al. proposed an interesting risk estimation based on the evaluation of 108,593 
non-cardiac surgical procedures7. In this model clinical risk factors, type of surgery, and ECG are all 
included (TABLE 4.2).
STEP 4. LABORATORy MEASuREMENTS
Apart from those measurements indicating clinical risk factors (e.g. serum creatinine for renal failure, 
fasting glucose for diabetes mellitus etc.) currently no routine laboratory measurements are related to 
perioperative cardiac complications. However, two recent studies showed that increased plasma NT-
pro-BNP was associated with adverse postoperative outcome8,9 NT-pro-BNP is increased in patients 
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with left ventricular dilatation due to fluid overload (i.e. heart failure and renal dysfunction), pressure 
overload (i.e. aortic valve stenosis) and myocardial ischemia, which might explain the excellent rela-
tion with adverse postoperative outcome10. Diabetes mellitus is known to be a strong predictor for 
perioperative events. Therefore fasting glucose levels should be obtained from all patients. Recently 
it was shown that the level of preoperative glycosylated hemoglobin in diabetic patients is strongly 
related to perioperative cardiac outcome11. In the same patient population it was also shown that 
in patients with high preoperative glycosylated hemoglobin it is more difficult to regulate glucose 
levels in the perioperative period. This might in part explain the strong relation between preopera-
tive glycosylated hemoglobin and outcome since it is known from critically ill patients and patients 
with myocardial infarction that tight glucose control is of imminent importance.
In the Lee risk index renal insufficiency is taken into account. The serum creatinine cut-off value 
Lee et al. used is 2.0 mg/dL. However, it might be argued that patients with less pronounced renal 
insufficiency also do worse compare to patients with normal serum creatinine levels. A continuous 
variable for creatinine would probably be better, though not very user-friendly in every day practice. 
Recent studies have also shown that glomerular filtration rate might be a better predictor than serum 
creatinine since this takes into account the different creatinine levels between sexes12.
Table 4.2 Example of a risk model including clinical risk factors, type of surgery, and ECG to assess perioperative 
cardiac risk (derived from Boersma et al). CVD, cardiovascular disease; PVC, premature ventricular 
contractions.
Clinical risk factors
Coronary artery disease
Renal failure
Diabetes mellitus
Hypertension
Heart failure
Type of surgery
Breast; Dental; Eye;
Gyneacology; Urologic
Endocrine; Orthopedic;
Plastic / Reconstructive
Abdominal; Ear, Nose,
Throat; Pulmonary
Neuro; Renal transplant;
Vascular
Age (yr)
40
41 - 50
51 - 60
61 - 70
71 - 80
>80
Gender
Female
Male
Procedure
Laparoscopic
Non-laparoscopic
Elective
Acute
2
2
5
5
10
0
20
25
30
0
5
10
15
20
25
0
1
0
5
0
15
+
+
+
+
+
31 - 40
0-30
41 - 50
51 - 60
7.2%
2.5%
0.8%
0.03%
87 per 1,205
221 per 8,768
195 per 23,157
13 per 47,954
61-100
0.2%
57 per 27,509
0 2.5 5.0 7.5
CVD mortality (%) CVD mortality (%)
0 2.5 5.0 7.5 10.0
Resting ECG
The resting ECG is abnormal in case of atrial fibrillation/flutter, left ventricular 
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STEP 5. NON-INVASIVE RESTINg CARDIAC IMAgINg
If steps 1 to 4 indicate an increased cardiac risk or if there is evidence or suspicion of coronary artery 
disease at physical examination, e.g. peripheral atherosclerotic disease, valve abnormalities or left 
ventricular dysfunction further cardiac testing might be required. The most simple, inexpensive form 
of cardiac imaging is resting echocardiography, for the detection of impaired left ventricular func-
tion and valve stenosis and sclerosis. Impaired left ventricular function was long considered a strong 
predictor for adverse perioperative cardiac events. However, due to improved perioperative care it is 
no longer a strong predictor for short-term outcome but remains a significant predictor for long-term 
adverse cardiac events.
The presence of aortic stenosis is associated with a 5-fold increased risk of perioperative cardiac 
events13. Also, the severity of aortic stenosis is related to an increased risk of perioperative events. 
Considering this, it is important to detect the presence and significance of valve disease. Though 
physical examination is reliable in detecting abnormal heart sounds, the estimation of the severity of 
stenosis by physical examination alone is difficult and echocardiography is recommended in patients 
with abnormal heart sounds.
STEP 6. NON-INVASIVE STRESS CARDIAC IMAgINg
According to the guidelines of the ACC/AHA14 preoperative cardiac exercise or pharmacological 
stress testing is recommended for patients with intermediate pretest probability of CAD; for prog-
nostic assessment of patients undergoing initial evaluation for suspected or proven CAD; evaluation 
of subjects with significant change in clinical status; demonstration of proof of myocardial ischemia 
before coronary revascularization; evaluation of adequacy of medical therapy; and prognostic assess-
ment after an acute coronary syndrome. For stress testing, the evaluation of exercise capacity when 
subjective assessment is unreliable seems to be a valid reason as well. Patients with CAD or at risk for 
CAD can be frequently found in the group of patients with limited every day exercise, e.g. patients 
with severe intermittent claudication. In these patients pharmacological stress echocardiography or 
nuclear imaging are elegant ways to exclude sub clinical CAD. However, stress testing should not be 
performed in asymptomatic patients without evidence of CAD; patients with severe co-morbidity 
likely to limit the life expectancy or candidacy for revascularization; patients with resting ECG-abnor-
malities that preclude adequate assessment. The sensitivity and specificity of available exercise and 
pharmacological stress tests (including exercise electrocardiography, radionuclide ventriculography, 
myocardial perfusion scintigraphy, and dobutamine stress echocardiography) were compared in 
several meta-analyses. The meta-analysis of Kertai et al. showed a trend in favor of dobutamine stress 
echocardiography though other tests had satisfying sensitivity and specificity as well (FIGURE 4.1)15. 
An upcoming elegant new diagnostic tool is dobutamine stress MRI though no randomized trials or 
large series have reported the sensitivity and specificity of this test yet.
STEP 7. MEDICAL ThERAPy
Beta-blocker therapy
Although widely prescribed during non-cardiac surgery, the evidence for perioperative beta-blocker 
use is mainly based on only two landmark studies and several observational studies. The first trial 
evaluated the effect of atenolol in high-risk patients undergoing non-cardiac surgery16. In this study 
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200 patients with risk factors for or known ischemic heart disease were randomized for atenolol or 
placebo prior to surgery. Atenolol therapy was not associated with an improved in-hospital outcome 
(cardiac death or myocardial infarction), however, continuous 3-lead Holter monitoring showed a 
50% reduction of myocardial ischemia in the atenolol treated group during the first 48 hours after 
surgery. The second trial showed in a selected high-risk, i.e. stress-induced myocardial ischemia 
during preoperative dobutamine echocardiography, population of 112 vascular surgery patients a 
tenfold reduction of incidence of perioperative cardiac death and myocardial infarction, compared 
to patients without beta-blockers (3.4% vs. 34%)17. These promising results were confirmed by a 
meta-analysis, of prospective randomized studies, evaluating the incidence of perioperative isch-
emic episodes in 1077 patients in 15 studies (FIGURE 4.2). Beta-blocker therapy was associated with 
a 65% relative risk (RR) reduction in perioperative myocardial ischemia and a 56% RR reduction in 
non-fatal MIs. Also, beta-blocker therapy was associated with a significant RR reduction of 67% in 
the composite endpoint of cardiac death and non-fatal MI. Though other meta-analyses found a 
similar benefit of beta-blockers18,19, a recent meta-analysis by Devereaux et al. reported no benefit of 
beta-blockers on perioperative outcome20. However, in that meta-analysis studies that had not yet 
undergone peer-review were also included which might have seriously influenced the outcome of 
their meta-analysis.
The promising results were not supported by two recent trials evaluating the effect of beta-blockers 
in patients at intermediate cardiac risk. In the POBBLE trial low-risk patients, those with a history of 
ischemic heart disease were excluded, scheduled for vascular surgery were randomized for a fixed 
dose of  metoprolol (n=55) or placebo (n=48). No difference was observed in the incidence of periop-
erative cardiovascular events. The only difference was observed in the length of hospital stay, which 
was significantly shorter in those taking metoprolol, 10 vs. 12 days. More recently, the DIPOM study, 
evaluating the cardioprotective effect of a fixed dose of metoprolol on the evening before major non-
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Figure 4.1 Sensitivity and specificity of different types of preoperative non-invasive cardiac testing modalities 
(derived from Kertai et al15).
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cardiac surgery in 921 diabetics showed no difference in 30-day morbidity and mortality. However, 
this study was powered for a 1 year follow-up period. Currently at least two large trials, POISE and 
DECREASE-IV, are ongoing, evaluating the effect of beta-blockers in patients at intermediate risk for 
perioperative cardiac events. Though the results of these trials have to be awaited, in the mean time, 
it seems to be safe and effective to prescribe beta-blockers in patients with a Lee index score of 2 or 
more, as Lindenauer found in a large cohort study of 663,635 patients21.
Statin therapy
Several recent studies address the beneficial effect of statin use in patients undergoing non-cardiac 
surgery (FIGURE 4.3). In a case-control study among 2,816 patients who underwent major vascular 
surgery statin use was associated with a significant four-fold reduction in all-cause mortality com-
pared to patients with no statin use22. The first blinded, placebo-controlled, randomized trial, in 
which the influence of statin use on perioperative cardiovascular complications was investigated, 
was reported by Durazzo et al.23 In their study, 100 patients were randomly assigned to treatment 
with either 20 mg atorvastatin or placebo. Patients received treatment for 45 days and started at 
least 2 weeks before surgery. The outcome of this trial was the endpoint of cardiovascular events, 
defined as cardiac death, non-fatal MI, stroke or unstable angina pectoris. Patients were followed 
up to 6 months after the surgical procedure. Of 100 patients 90, 44 statin users and 46 non-users, 
underwent elective vascular surgery. The 6-month incidence of cardiovascular events was 3.1-fold 
reduced in statin users compared with non-users. Finally, Lindenauer et al.24 and O’Neil-Callahan et 
al.25 confirmed the beneficial effects of statins based on the results of their large-scale retrospective 
studies. Lindenauer performed a retrospective cohort study based on the hospital discharge and 
pharmacy records of over 780,000 (70,159 statin users) patients in 329 hospitals throughout the 
United States. All patients underwent elective major surgical procedures and survived at least the 
first two postoperative days. After correction for numerous baseline differences, statin users had a 
1.4-fold reduced risk of in-hospital mortality. Subsequently, Lindenauer concluded that perioperative 
statin use might result in a reduced risk of death after major surgical procedures. Though the studies 
published so far are in favor of perioperative statin treatment, this needs to be confirmed in large, 
adequately powered randomized trials, such as the recently started DECREASE-IV trial.
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Figure 4.2 Meta-analysis of 15 randomised β-blocker trials. Odds ratio of β-blocker treatment for cardiovascular 
outcome per type of non-cardiac surgery. Derived from Schouten et al, Cor Artery Dis 2006;17:173–9.
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Other medical therapy
A meta-analysis by Nishina showed that clonidine, an alpha-2-agonists, use was associated with a 
reduction in the incidence of perioperative ischemia26. However, this study was underpowered (358 
non-cardiac surgical patients in two studies) and effects were only reported on ischemia. In two more 
recent meta-analyses, the beneficial effect of perioperative alpha-2-agonists use was shown for the 
reduction of myocardial ischemia and perioperative cardiovascular complications. But similarly to 
the study of Nishina the results of these two meta-analyses were mainly driven by the European 
Mivazerol trial, the only large-scale study available to date27. The results of the European Mivazerol 
trial showed no overall effect of mivazerol on the pre-specified combined endpoint of cardiac death 
and myocardial infarction in the total study population of 2,854 patients. Only a post-hoc analysis 
revealed that in 904 patients who underwent high-risk major vascular surgery mivazerol use was 
associated with a significantly lower incidence of cardiac death and myocardial infarction.
Nitrates are the most frequently used drugs in case of myocardial ischemia. However, studies about 
the prophylactic use of intravenous nitroglycerin failed to find any difference in the incidence of 
intraoperative and perioperative myocardial ischemia in patients receiving nitroglycerin compared 
to placebo. A potential harmful effect might be a vagal withdraw due to peripheral vasodilatation 
and subsequent cardiac stimulation and induction of myocardial ischemia in patients with CAD.
In the perioperative setting calcium channel blockers are effectively used in cardiac surgery, reducing 
myocardial ischemia and arrhythmias. In a meta-analysis Wijeysundera evaluated the use of calcium 
channel blockers in 11 studies, 1007 patients, all undergoing non-cardiac surgery28. Calcium channel 
blockers significantly reduced perioperative myocardial ischemia (RR 0.49, 95% CI 0.30-0.80) and 
supra ventricular arrhythmias (RR 0.52, 95% CI 0.37-0.72). However, mortality was not significantly 
reduced (RR 0.40, 95% CI 0.14-1.16).
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Figure 4.3 Overview of odds ratios and 95% confidence intervals of currently known studies on the influence of 
statins on perioperative cardiac outcome in non-cardiac surgical procedures.
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STEP 8. PREOPERATIVE CORONARy INTERVENTIONS
Recent findings of the Coronary Artery Revascularization Prophylaxis Trial showed no survival benefit 
of preoperative coronary revascularization in cardiac stable patients29. Among 5,859 patients sched-
uled for elective vascular operations a selection was made of patients considered at increased risk 
for cardiac events with evidence of severe coronary stenosis at coronary angiography. Anatomical 
criteria of exclusion included: > 50% stenosis of the left main coronary artery, left ventricular ejec-
tion fraction < 20% and severe stenosis of the aorta. The 510 patients selected were randomized 
to optimal medical therapy (more than 80% were on beta-blocker therapy in both groups) with or 
without coronary revascularization; either percutaneous coronary intervention (59%, mean 18 days 
prior to surgery) or CABG (41%, mean 54 days prior to surgery). No differences in mortality in the 
long-term outcome (median follow up of 2.7 years) were found: 22% in the revascularization group 
vs. 23% in the non-revascularization group. Although the primary end point was late mortality, even 
the findings at 30 days did not show any difference in terms of mortality or postoperative MI nor 
did “prophylactic” revascularization result in a reduction of the length of hospital stay. Other, non-
randomized studies, on preoperative coronary revascularization are conflicting. The study by Eagle 
et al. based on the Coronary Artery Surgical Study (CASS) database showed a significant benefit in 
patients with previous CABG. The same was found by the BARI investigators after both PCI and CABG. 
However, the time interval between coronary revascularization and non-cardiac surgery in these 
non-randomized studies was relatively long. Two studies by Kaluza et al. and Wilson et al. showed that 
perioperative complications after PCI occur mainly when the patient undergoes non-cardiac surgery 
within 6 weeks after PCI. Placement of coronary stents induces a denudation of the endothelial sur-
face of the coronary artery, thereby greatly increasing the risk of thrombosis. This is further reinforced 
by the hypercoaguability state during surgery and the problematic use of antiplatelet therapy during 
surgery.
CONCLuSION
Clinical cardiac risk markers combined with ECG and the risk of the planned surgical procedure can 
effectively divide patients in a truly low-risk, intermediate and high-risk population. Low-risk patients 
probably can be operated without any additional cardiac testing since these tests will not alter 
perioperative management. Beta-blockers are recommended in patients with ischemic heart disease 
and should be continued in patients on chronic beta-blocker therapy. Intermediate-risk patients are 
referred for cardiac testing to exclude extensive stress induced myocardial ischemia, as beta-blockers 
provide insufficient myocardial protection in this case and preoperative coronary revascularization 
should be considered taken into account the coronary anatomy and the delay of the index surgical 
procedure due to revascularization. Whether patients at intermediate risk without ischemic heart 
disease should be treated with statins and/or beta-blockers is still subject of debate. The currently 
ongoing POISE and DECREASE IV studies will probably provide us with the necessary evidence for 
this group of patients. Furthermore preoperative screening should not only focus on perioperative 
cardiac risk reduction but should also be considered as a unique opportunity to improve patients’ 
long-term cardiac outcome by proper medical therapy such as statins and beta-blockers.
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ABSTRACT
Background: The Lee risk index was developed to predict major cardiac complications in non-cardiac 
surgery. We retrospectively evaluated its ability to predict cardiovascular death in the large cohort of 
patients who recently underwent non-cardiac surgery in our institution.
Methods: The administrative database of the Erasmus MC, Rotterdam, The Netherlands, contains 
information on 108 593 non-cardiac surgical procedures performed from 1991 to 2000. The Lee index 
assigns 1 point to each of the following characteristics: high-risk surgery, ischemic heart disease, 
heart failure, cerebrovascular disease, renal insufficiency, and diabetes mellitus. We retrospectively 
used available information in our database to adapt the Lee index, calculated the adapted index for 
each procedure, and analyzed its relation to cardiovascular death.
Results: A total of 1877 patients (1.7%) died perioperatively, including 543 (0.5%) classified as cardio-
vascular death. The cardiovascular death rates were 0.3% (255/75 352) for Lee Class 1, 0.7% (196/28 
892) for Class 2, 1.7% (57/3380) for Class 3, and 3.6% (35/969) for Class 4. The corresponding odds 
ratios were 1 (reference), 2.0, 5.1, and 11.0, with no overlap for the 95% confidence interval of each 
class. The C statistic for the prediction of cardiovascular mortality using the Lee index was 0.63. If 
age and more detailed information regarding the type of surgery were retrospectively added, the C 
statistic in this exploratory analysis improved to 0.85.
Conclusion: The adapted Lee index was predictive of cardiovascular mortality in our administrative 
database, but its simple classification of surgical procedures as high-risk versus not high-risk seems 
suboptimal. Nevertheless, if the goal is to compare outcomes across hospitals or regions using 
administrative data, the use of the adapted Lee index, as augmented by age and more detailed clas-
sification of type of surgery, is a promising option worthy of prospective testing.
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INTRODuCTION
Patients undergoing major non-cardiac surgery are at high risk of cardiovascular morbidity and mor-
tality. Evidence suggests that perioperative myocardial infarction is commonly caused by rupture of 
a coronary plaque, leading to thrombus formation and subsequent vessel occlusion, similar to what 
occurs in nonsurgical settings1,2. The clinical importance of perioperative cardiovascular complica-
tions is well recognized, and numerous investigations have described the relation between patient’s 
characteristics and the risk of adverse cardiovascular outcome3-11.
In the 1990s, Lee and colleagues systematically analyzed the risk of major cardiac complications 
(which included myocardial infarction, cardiogenic pulmonary edema, cardiac arrest, and cardiac 
death) in 4315 patients undergoing non-cardiac surgery, the largest cohort ever described8. The 
resulting Lee index, which is a modification of the original Goldman index, is now considered by 
many clinicians and researchers to be the most relevant index to predict cardiac risk. However, the 
patients studied by Lee and colleagues cannot be considered as an average, unselected surgical 
cohort because their study included only patients with a several-day expected length of hospital 
stay and excluded neurologic surgery; as a result, it was relatively dominated by patients undergoing 
thoracic (12%), vascular (21%), and orthopedic surgery (35%).
The current study evaluates the Lee index in 108 593 patients who underwent non-cardiac surgery in 
the Erasmus Medical Center from 1991 to 2000. Because we relied on medical records and administra-
tive data gathered as part of routine medical care, rather than duplicating the prospective methods 
of the Lee study, we used cardiovascular mortality, instead of the broader range of clinical cardiac 
complications that were considered in the original Lee study, as our primary endpoint.
METhODS
hospital setting, procedures and patients
The Erasmus Medical Center, a metropolitan university hospital that serves a population of approxi-
mately 3 million people in the southwestern area of The Netherlands, acts as a tertiary referral center 
for approximately 30 affiliated hospitals. Between January 1, 1991, and December 31, 2000, 122 860 
non-cardiac surgical procedures were performed in patients above the age of 15 years in the Erasmus 
Medical Center. We excluded 14 267 planned and unplanned procedures that were conducted within 
30 days after an initial operation, and analyzed the perioperative course of the remaining 108 593 
procedures, which were performed in 75 581 different patients. Over the 10-year observation period, 
20 885 patients had multiple surgeries in the Erasmus Medical Center. They were included as many 
times as they had surgeries that were more than 30 days apart. The median span between 2 succes-
sive procedures was 297 days (interquartile range, 123 to 677 days). The operation (not the patient) 
was the unit of analysis because this approach is consistent with clinical practice, wherein the risk of 
perioperative complications is assessed in relation to a specific procedure.
Sources of data
For each patient undergoing surgery, a number of data items are routinely entered into the comput-
erized hospital information system at the time the patient is hospitalized. First, surgical techniques 
are classified by the treating physician according to a standardized national coding system, which 
was developed in cooperation with the National Health Service and medical insurance companies. 
This system is used for reimbursement and to record and monitor the experience of surgeons and 
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surgical residents. Using this classification, we grouped surgical procedures into 14 categories, with a 
total of 11 969 procedures (11.0%) classified into multiple categories.
Second, from written information that is provided by the patient’s general practitioner, referring phy-
sician, or hospital physicians involved in perioperative care, each patient’s medical history is classified 
according to the International Classification of Diseases, Ninth Revision (ICD-9)12. The classification 
and the entry of the data in the electronic database are performed by dedicated administrative per-
sonnel who have completed in-depth training on medical data registration. We recorded the follow-
ing medical conditions: history of diabetes mellitus (ICD-9250), myocardial infarction (ICD-9410, 411, 
and 412), angina pectoris (ICD-9413 and 414), prior heart failure (ICD-9428), cerebrovascular accident 
(ICD-9430), and renal disease (ICD-9580). These recorded diagnoses served as surrogates for 5 more 
detailed criteria used in the Lee index8 in which ischemic heart disease was defined as a history of 
myocardial infarction or positive exercise test, current complaint of ischemic chest pain, or use of 
nitrate therapy, or Q waves on the electrocardiogram, but patients with a history of coronary bypass 
surgery or angioplasty were included only if they had current complaints of chest pain presumed to 
be due to ischemia; heart failure was defined as a history of heart failure, pulmonary edema, or par-
oxysmal nocturnal dyspnea, a physical examination showing an S3 gallop or bilateral riles, or a chest 
radiograph showing pulmonary vascular redistribution; renal failure was a creatine level >2.0 mg/dL; 
diabetes was insulin requiring; and cerebrovascular disease was defined as a history of a stroke or 
transient ischemic attack. For the score criterion, high-risk surgery, we categorized procedures in the 
same way as the Lee index: retroperitoneal, intrathoracic, or suprainguinal vascular procedures were 
defined as high risk.
Endpoint definition
The hospital information system also contains the patient’s vital status at hospital discharge and 
clinical postoperative diagnoses. For example, diagnosed perioperative myocardial infarctions are 
reported, but the patients do not routinely have serial postoperative electrocardiograms or blood 
sampling for determination of cardiac biomarkers. Consequently, clinically unsuspected or painless 
perioperative myocardial infarctions may well be missed. Similarly, clinically apparent strokes were 
reported, but systematic neurological evaluations were not performed. In view of these limitations, 
we chose cardiovascular death as the primary endpoint of our analyses. Cardiovascular death, 
which was defined as any death with a cardiovascular complication as the primary or secondary 
cause (according to the definitions of the World Health Organization), included deaths following 
myocardial infarction, cardiac arrhythmia, resuscitation, heart failure, or stroke. Noncardiovascular 
death was defined as any death with a principal noncardiovascular cause, including surgery-related 
bleeding complications, cancer, trauma, and infection. Sudden death in a previously stable patient 
was considered as cardiovascular.
To obtain the cause of death, 2 investigators (MDK, DP) independently reviewed all available periop-
erative data but were blind to preoperative characteristics and aimed to reach consensus. If consensus 
could not be reached, the opinion of a third, independent investigator (OS) was final. Events were 
counted until hospital discharge or 30 days after surgery, whichever day came first.
Data quality and ethical considerations
We should emphasize that the data that we used were collected for administrative purposes and not 
for the purposes of this study by clinicians using standardized data collection forms. We designed and 
undertook this study several years after the last patient was enrolled, and we were not able to verify 
the completeness or the correctness of the data. By necessity, we had to rely on the information that 
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was provided by the clinicians who took care of the patients during everyday clinical practice. This 
study was approved by the Medical Ethics Committee of the Erasmus Medical Center. However, given 
the retrospective nature of our study, informed consent could not be obtained from each patient.
Statistical analysis
Continuous data are described as median values and corresponding 25th and 75th percentiles, and 
dichotomous data are described as numbers and percentages. With the limitations noted previously, 
we estimated the Lee index for each patient in our dataset. Univariable logistic regression analyses 
were used to evaluate the relation among the adapted Lee index (with individual dummy variables 
for each score category) as calculated with information in our administrative database, the clinical 
characteristics that are part of this index, and our primary endpoint, which was cardiovascular death 
including stroke, rather than the endpoint of Lee and colleagues, who considered the composite 
endpoint of myocardial infarction, cardiogenic pulmonary edema, cardiac arrest, or cardiovascular 
death. Crude, unadjusted odds ratios and corresponding 95% confidence intervals are reported. 
Subsequently, multivariable logistic regression analyses were performed to evaluate if the predictive 
power of the adapted Lee index could be improved retrospectively in our dataset by adding age or 
more detailed information on the type of surgery, according to the classification recommended by the 
American Heart Association/American College of Cardiology13. The 4 categories were low risk (breast, 
carotid, dental, endocrine, eye, gynecology, reconstructive), low-intermediate risk (orthopedic, uro-
logic), intermediate-high risk (abdominal; ear, nose, throat; neurological; pulmonary; renal transplant; 
vascular, excluding aortic and carotid), and high risk (aortic). Adjusted odds ratios and corresponding 
95% confidence intervals were calculated. The performance of risk models was determined by the 
C statistic, which indicates how well a model rank orders patients with respect to their outcomes, 
where 0.5 indicates no predictive value and 1.0 indicates perfect performance14. Because our dataset 
involved patients with multiple operations, independence of observations could not be excluded 
beforehand. Therefore, to examine this phenomenon, all regression analyses were first performed 
using conventional techniques and repeated using generalized estimation equations15, with “patient” 
as the classification factor. No relevant differences were observed between the parameter estimates as 
determined according to both methodologies. Therefore, we concluded that interobservation correla-
tion was not a major issue in our dataset, and we present only the results based on classical methods.
RESuLTS
A total of 52 387 surgical procedures were performed in men, including 12 378 orthopedic surgeries 
(24%); 9273 ear, nose, and throat surgeries (18%); and 8637 abdominal surgeries (16%). Among the 56 
206 procedures in women, gynecological surgery was most common with 15 312 procedures (27%), 
followed by orthopedic surgery with 9840 (18%), and abdominal surgery with 7816 (14%). Because 
of reallocation of patients among regional hospitals, the annual volumes of ophthalmic and gyneco-
logical procedures decreased in the early 1990s. During the study period, the volume of orthopedic 
surgery gradually increased, whereas the volume of abdominal surgery decreased slightly.
With a median age of 51 years (25th to 75th percentile: 34-65 years), men were 7 years older than 
were women (median 44 years; 25th to 75th percentile: 32-62 years). The majority of patients had 
a score of 0 points on the adapted Lee index (FIGURE 5.1). During the study period, no systematic 
change in scores on the adapted Lee index was observed in men. By comparison, scores in women 
worsened slightly in 1993 and remained constant thereafter, a shift that was strongly related to the 
decline in the number of gynecological procedures.
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A total of 1877 patients (1.7%) died perioperatively. A cardiovascular complication was the principal 
(405 patients) or the secondary (138 patients) cause of death in 543 patients (0.5% of the sample; 29% 
of deaths). Patients in whom an autopsy report was available (326 patients; 17% of deaths) were more 
often labeled as having cardiovascular death than patients in whom no such report was available 
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Figure 5.1 Time trends in the cardiovascular risk profile.
Data indicate the percentage of patients with a score of 1 point (white portion of the bar), 2 points 
(grey portion), and ≥3 points according to the cardiovascular risk index as developed by Lee and 
colleagues8.
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Figure 5.2 Time trends in the incidence of perioperative all-cause mortality (open circles) and cardiovascular 
death (closed circles).
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(37% [122/326] vs. 27% [421/1551] patients; p <0.001). Infection, the most common noncardiovas-
cular cause of death, was the primary cause in 231 patients and the secondary cause in 308 patients, 
representing 29% of deaths.
All-cause mortality and cardiovascular mortality were higher in men than in women: 2.2% (1167/52 
387) versus 1.3% (710/56 206) (p <0.001), and 0.7% (350/52 387) versus 0.3% (193/56 206) (p <0.001). 
During the study period, no systematic change in all-cause mortality was observed in men (FIGURE 
5.2). In contrast, all-cause mortality in women increased significantly from 0.9% (55/6280) in 1991 to 
1.3% (69/5151) in 1993 and 1.5% (79/5315) in 2000 (71% increase; p <0.001). There were no significant 
changes in cardiovascular mortality over time in either men or women.
Important differences in the incidence of perioperative cardiovascular death were observed in rela-
tion to type of surgery (TABLE 5.1). Patients undergoing vascular surgery, especially those undergo-
ing aortic surgery, had the highest cardiovascular mortality (1.8%), followed by patients undergoing 
neurological surgery (1.7%), renal transplant (about 1.1%), and pulmonary surgery (1.1%). Breast, 
dental, eye, and gynecology surgery were associated with cardiovascular mortality rates below 0.1%. 
The 15 318 patients (14%) who had laparoscopic procedure had a lower incidence of cardiovascular 
death than did patients who had open surgery (0.2% vs. 0.6%; p <0.001) (TABLE 5.2). The 774 patients 
Table 5.1
Perioperative cardiovascular and all-cause death in patients undergoing non-cardiac surgery for various 
indications.
Cardiovascular death All-cause death
Number of 
procedures
Primary cause Secondary cause Total
Type of surgery Number (%) Number (%) Number (%) Number (%)
Abdominal 16,453 63 (0.4) 50 (0.3) 113 (0.7) 606 (3.7)
  Hepatico, pancreatico, 
biliary
2752 10 (0.4) 4 (0.1) 14 (0.5) 129 (4.7)
 Esophagogastric 11,982 53 (0.4) 44 (0.4) 97 (0.8) 488 (4.1)
 Other abdominal 3714 12 (0.3) 7 (0.2) 19 (0.5) 122 (3.3)
Breast 2411 0 0 0 0
Dental 1225 1 (0.1) 0 2 (0.1) 2 (0.2)
Ear, Nose, Throat 15,291 114 (0.7) 22 (0.1) 136 (0.9) 411 (2.7)
Endocrine 1029 1 (0.1) 2 (0.2) 3 (0.3) 6 (0.6)
Eye 9163 1 (0.0) 0 1 (0.0) 11 (0.1)
Gynecology 15,343 2 (0.0) 1 (0.0) 3 (0.0) 20 (0.1)
Neurologic 5797 87 (1.5) 14 (0.2) 101 (1.7) 381 (6.6)
Orthopedic 22,218 34 (0.2) 9 (0.0) 43 (0.2) 116 (0.5)
Reconstructive 4157 5 (0.1) 2 (0.0) 7 (0.2) 12 (0.3)
Pulmonary 1965 14 (0.7) 7 (0.4) 21 (1.1) 86 (4.4)
Renal transplant 711 8 (1.1) 0 (0.0) 8 (1.1) 14 (2.0)
Urologic 11,116 28 (0.3) 10 (0.1) 38 (0.3) 159 (1.4)
Vascular 6234 90 (1.4) 25 (0.4) 115 (1.8) 277 (4.4)
 Aortic-acute 196 21 (10.7) 7 (3.6) 28 (14.3) 57 (29.1)
 Aortic-elective 890 29 (3.3) 7 (0.8) 36 (4.0) 72 (8.1)
 Carotid endarterectomy 891 4 (0.4) 2 (0.2) 6 (0.7) 18 (2.0)
 Peripheral bypass 927 14 (1.5) 2 (0.2) 16 (1.7) 28 (3.0)
 Other vascular 3854 36 (0.9) 13 (0.3) 49 (1.3) 142 (3.7)
Other 9423 18 (0.2) 13 (0.1) 31 (0.3) 92 (1.0)
Any type 108,593 405 (0.4) 138 (0.1) 543 (0.5) 1877 (1.7)
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Table 5.2
Univariable relation among the Lee index, demographic and clinical characteristics, and perioperative 
cardiovascular death.
Number of 
procedures
Cardiovascular death Unadjusted odds ratio
(95% confidence interval)Number (%)
Adaptation of the Lee index score and its components (see Methods)
Adapted Lee index ≥3 969 35 (3.6) 11.0 (7.7-15.8)
2 3380 57 (1.7) 5.1 (3.8-6.7)
1 28,892 196 (0.7) 2.0 (1.7-2.4)
0 75,352 255 (0.3) 1
Type of surgery* High risk 29,426 224 (0.8) 1.9 (1.6-2.3)
Not high risk 79,167 319 (0.4) 1
History of ischemic heart 
disease
Yes 3588 77 (2.1) 4.9 (3.9-6.3)
No 105,005 466 (0.4) 1
History of heart failure Yes 1377 50 (3.6) 8.2 (6.1-11.0)
No 107,216 493 (0.5) 1
History of CVA Yes 500 11 (2.2) 4.6 (2.5-8.3)
No 108,093 532 (0.5) 1
Renal insufficiency Yes 1894 31 (1.6) 3.5 (2.4-5.0)
No 106,699 512 (0.5) 1
Diabetes mellitus Yes 2001 36 (1.8) 3.8 (2.7-5.4)
No 106,592 507 (0.5) 1
Detailed data on type of surgery
 Type of surgery† High risk 1078 63 (5.8) 73.6 (46.9-115)
Intermediate-high 
risk
40,985 371 (0.9) 10.8 (7.4-15.9)
Low-intermediate 
risk
33,275 81 (0.2) 2.9 (1.9-4.4)
Low risk 33,255 28 (0.1) 1
 Laparoscopic procedure Yes 15,318 24 (0.2) 0.3 (0.2-0.4)
No 93,275 519 (0.6) 1
 Emergency surgery Yes 774 47 (6.1) 14.0 (10.2-19.0)
No 107,819 496 (0.5) 1
Other potential risk determinants
 Age (years) ≥80 5314 77 (1.5) 23.0 (14.8-35.7)
70-80 12,619 165 (1.3) 20.7 (13.7-31.1)
60-70 15,742 146 (0.9) 14.6 (9.7-22.1)
50-60 15,675 91 (0.6) 9.1 (5.9-14.0)
40-50 16,987 37 (0.2) 3.4 (2.1-5.6)
<40 42,256 27 (0.1) 1
CVA = cerebrovascular accident. *According to the Lee index: high risk = intraperitoneal, intrathoracic, and suprainguinal 
vascular procedures; not high risk = other procedures. †According to the American Heart Association/American College 
of Cardiology classification: high risk = aortic; intermediate risk = abdominal; ear, nose, throat; neurologic; orthopedic; 
pulmonary; renal transplant; urologic; vascular, excluding aortic and carotid; low risk = breast; carotid; dental; endocrine; 
eye; gynecology; reconstructive. Within the intermediate risk group, patients undergoing orthopedic or urologic surgery 
had significantly lower risk than patients undergoing other types of surgery. Therefore, we labeled orthopedic and urologic 
procedures as low-intermediate risk, and the remaining procedures as intermediate-high risk.
Validation of the Lee risk index 83
(0.7%) who underwent emergency surgery had a significantly higher rate of cardiovascular death 
than did patients who underwent nonemergency surgery (6.1% vs. 0.5%; p <0.001).
In univariable analyses, the adapted Lee index and its individual components were associated with 
an increased risk of cardiovascular death (TABLE 5.2). The prospective C statistic for the prediction 
of cardiovascular mortality in this validation analysis was 0.63. The C statistic for this exploratory 
analysis was substantially higher in the subset of 66 530 low- to intermediate-risk surgical proce-
dures (including breast, carotid, dental, endocrine, eye, gynecology, orthopedic, reconstructive, and 
urologic surgery) than in the remaining 42 063 intermediate- to high-risk procedures (0.68 vs. 0.56). 
When more detailed information, including the type of surgery (defined as low, low-intermediate, 
intermediate-high, and high), whether it was laparoscopic or open, and whether it was emergent, 
was added to the Lee index, the retrospective C statistic was 0.79 (TABLE 5.3). If age were included, 
the C statistic rose further, to 0.85.
Table 5.3
Multivariable relation among the Lee index, type of surgery, age, and perioperative cardiovascular death, 
based on analyses of 108 593 subjects undergoing non-cardiac surgery.
Odds ratio (95% confidence interval)
Adapted Lee 
index only
Adapted Lee index 
and type of surgery
Adapted Lee index,
type of surgery and age
Model C statistic 0.63 0.79 0.85
Adapted Lee index* ≥3 11.0 (7.7-15.8)
2 5.1 (3.8-6.7)
1 2.0 (1.7-2.4)
0 1
Adapted Lee index, excluding 
type of surgery
≥3 9.2 (5.5-15.4) 6.4 (3.8-10.8)
2 5.6 (4.0-7.9) 4.0 (2.9-5.6)
1 2.3 (1.8-3.0) 1.7 (1.3-2.2)
0 1 1
Type of surgery† High risk 35.7 (22.1-57.6) 20.0 (12.3-32.5)
Intermediate-high risk 10.3 (7.0-15.2) 10.3 (7.0-15.1)
Low-intermediate risk 2.8 (1.8-4.3) 2.7 (1.7-4.1)
Low risk 1 1
Laparoscopic procedure Yes 0.3 (0.2-0.4) 0.3 (0.2-0.4)
No 1 1
Emergency surgery Yes 4.6 (3.2-6.5) 4.4 (3.1-6.4)
No 1 1
Age (years) ≥80 19.9 (12.8-31.1)
70-80 12.6 (8.3-19.0)
60-70 8.5 (5.6-12.9)
50-60 5.6 (3.6-8.7)
40-50 2.5 (1.5-4.1)
<40 1
*Index that assigns one point to each of the following characteristics: ischemic heart disease, history of heart failure, 
history of cerebrovascular disease, renal insufficiency, and diabetes mellitus. † According to the American Heart 
Association/American College of Cardiology classification: high risk = aortic; intermediate risk = abdominal; ear, nose, 
throat; neurologic; orthopedic; pulmonary; renal transplant; urologic; vascular, excluding aortic and carotid; low risk 
= breast; carotid; dental; endocrine; eye; gynecology; reconstructive. Within the intermediate risk group, patients 
undergoing orthopedic or urologic surgery had significantly lower risk than patients undergoing other types of surgery. 
Therefore, we labeled orthopedic and urologic procedures as low-intermediate risk, and the remaining procedures as 
intermediate-high risk.
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DISCuSSION
Cardiovascular mortality still is a major burden in patients undergoing non-cardiac surgery. In the 
investigated cohort, about 7 of every 1000 procedures in men and 3 of every 1000 procedures in 
women resulted in fatal in-hospital cardiovascular complications. In contrast, anesthesia-related mor-
tality occurs only in approximately 1 of 250 000 procedures16. Interestingly, patients who underwent 
postmortem examination were considerably more often classified as cardiovascular death than were 
patients in whom no such examination was performed, suggesting that the incidence and effect of 
cardiovascular complications after non-cardiac surgery may be underestimated in clinical practice.
The Lee index (or revised Goldman index) is considered the best currently available cardiac risk 
prediction index in non-cardiac surgery because it was developed on contemporary, prospectively 
gathered clinical data from unselected patients who underwent a wide spectrum of procedures and 
were followed systematically postoperatively, including standardized visits and cardiac biomarkers, 
for a range of clinically relevant cardiac outcomes17,18. In our study, the Lee index was adapted for 
an administrative database and its use extended to a different goal––the use of administrative data 
specifically to predict perioperative cardiovascular mortality. However, in agreement with another 
investigation19, our data also suggest that the Lee index is probably suboptimal for identifying patients 
with greater cardiac risk, perhaps because it excluded emergency operations and perhaps because 
the type of surgery, which is one of the main determinants of adverse cardiovascular outcome13, was 
considered in only 2 subtypes: high risk, including intraperitoneal, intrathoracic and suprainguinal 
vascular procedures; and all remaining nonlaparascopic procedures, mainly including orthopedic, 
abdominal, and other vascular procedures. We found that a more subtle classification, as suggested 
by the American Heart Association/American College of Cardiology guideline committee13, resulted, 
at least retrospectively, in a substantially better risk discrimination. We realize that the Lee index was 
developed for the prediction of prospectively detected “major cardiac complications” (which included 
myocardial infarction, cardiogenic pulmonary edema, cardiac arrest, and cardiac death) and not for 
the prediction of cardiovascular death only. It is unknown whether the C statistics would have been 
more favorable if we had used the same endpoint as Lee and colleagues, but some believe it may 
be easier to predict the incidence of death than to predict a broader range of clinical outcomes20. In 
addition, from the perspective of assessing quality of care using administrative databases, cardiovas-
cular mortality is certainly a relevant endpoint.
The American Heart Association/American College of Cardiology guidelines identify advanced age as 
a minor predictor of cardiovascular risk13. In our study, as in essentially every study of perioperative 
risk, cardiovascular mortality increased progressively with age3-11. Indeed, elderly patients might 
often have asymptomatic coronary disease, which places them at increased risk of perioperative 
cardiovascular complications. The key question has been whether age itself is an independent pre-
dictor or whether its importance is subsumed by its strong relation with other measurable evidence 
of the severity of disease or of comorbid conditions. Our finding of the major importance of age 
per se might be because our approach to assessing risk factors was by means of the medical his-
tory as coded according to the ICD-9 system and subsequently entered in an electronic database 
by administrative personnel based on written information provided by health-care professionals. 
These employees are specifically instructed to avoid inappropriate over-diagnosis; as a result, key 
medical conditions might have been overlooked, and, consequently, the relative contribution of 
these factors to cardiovascular death might have been underestimated, thereby also increasing the 
apparent independent contribution of age itself21. In addition, we restricted our analyses to patients 
who underwent surgery. No information was included from patients who were screened but who did 
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not undergo surgery because the risk was perceived as prohibitive. Obviously, exclusion of patients 
at risk of adverse cardiovascular outcome might have diluted estimates of relative risk.
The identification of patients at risk of perioperative cardiovascular complications has improved 
considerably in recent years. Beta-blockers reduce complication rates for some categories of patients, 
such as those undergoing major vascular surgery22-24, and statins may be useful as well25. By com-
parison, routine coronary revascularization is not beneficial26. The development and implementation 
of such strategies for the entire spectrum of surgical patients remains an important challenge for 
contemporary medicine27. In that regard, it is noteworthy that the incidence of fatal perioperative 
cardiovascular complications at our center did not decline during the 10-year study period.
Conclusion
This single center study, which involved over 100 000 subjects, demonstrated that perioperative car-
diovascular mortality is a major burden in patients undergoing non-cardiac surgery. Little progress 
has been achieved in reducing cardiovascular mortality during the years of the study. The adapted 
Lee index had an admirable performance to predict cardiovascular mortality, but its simple classifi-
cation of procedures as high risk versus not high risk seems suboptimal. Our analysis is limited by 
the fact that our data are derived from an administrative database, the retrospective nature of the 
data, the ICD-9 coding of clinical characteristics, and our evaluation of cardiovascular death rather 
than a broader range of clinical complications. Our approach seems most applicable to situations in 
which administrative data are to be used to assess outcomes and to compare outcomes in different 
hospitals or regions. Furthermore, prospective studies are warranted to confirm our findings.
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ABSTRACT
Background: The Lee-risk index (Lee-index) was developed to predict major adverse perioperative 
cardiac events (MACE). However, age is not included as a risk factor. The aim was to assess the value 
of the Lee-index in vascular surgery patients among different age categories.
Methods: Of 2 642 patients cardiovascular risk factors were noted to calculate the Lee-index. Patients 
were divided into four age categories; ≤ 55 (n = 396), 56–65 (n = 650), 66–75 (n = 1 058) and >75 years 
(n = 538). Outcome measures were postoperative MACE (cardiac death, MI, coronary revasculariza-
tion and heart failure). The performance of the Lee-index was determined using C-statistics within 
the four age groups.
Results: The incidence of MACE was 10.9%, for Lee-index 1, 2 and ≥ 3; 6%, 13% and 20%, respec-
tively. However, the prognostic value differed among age groups. The predictive value for MACE was 
highest among patients under 55 year (0.76 vs. 0.62 of patients aged > 75). The prediction of MACE 
improved in elderly (aged > 75) after adjusting the Lee-index with age, revised risk of operation (low, 
low-intermediate, high-intermediate and high-risk procedures) and hypertension (0.62 to 0.69).
Conclusion: The prognostic value of the Lee-index is reduced in elderly vascular surgery patients, 
adjustment with age, risk of surgical procedure, and hypertension improves the Lee-index signifi-
cantly.
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INTRODuCTION
Peripheral atherosclerotic disease (PAD) is becoming an increasingly important health issue in the 
Western society1-3. A clear increase of PAD is observed in elderly subjects. In The Rotterdam Study 
the prevalence of PAD increases from 6.6% in patients aged 55–59 years to 52% in patients aged 
>85 years4. As life expectancy improves, the prevalence of PAD is on the increase leading to 16 000 
hospital admissions annually in the Netherlands, 6% of all admissions due to cardiovascular diseases5. 
Postoperative outcome is related to the presence and extent of coronary artery disease as well as the 
regulation of risk factors for coronary artery disease such as diabetes mellitus, hyperlipidaemia, and 
hypertension1,2,4,6. Commonly, patients are screened prior to surgery using the Revised Cardiac Risk 
Index, which includes ischemic heart disease, heart failure, cerebrovascular disease, insulin depen-
dent diabetes mellitus, renal dysfunction, and high-risk surgery7. However, this risk index may have 
a potential limitation for preoperative cardiac risk assessment in vascular surgery patients as age is 
not included and only 21% of the original study population underwent vascular surgery. In this study 
we evaluated the prognostic value of the Revised Cardiac Risk Index and determined if the accuracy 
could be improved by the addition of different age categories and additional risk factors.
METhODS
Study design and patient selection
Between January 1993 and June 2006, 2 730 open non-cardiac vascular surgical procedures were 
performed in patients above 18 years old at Erasmus MC, Rotterdam, the Netherlands. Patients were 
divided into four categories according to their age: ≤ 55, 56–65, 66–75 and >75 years respectively. 
We excluded 88 procedures that were conducted within 30 days after the index procedure. The 
postoperative outcome of the remaining 2 642 procedures, performed in 2 298 different patients, 
was analyzed. Over the 13-year observation study, 250 patients had multiple surgical procedures. 
The procedure and not the patient was the unit of analysis because this approach is consistent with 
clinical practice, wherein the risk of perioperative complications is assessed in relation to a specific 
procedure. The Medical Ethics Committee of the Erasmus MC was informed about the study protocol, 
and per institutional practice no official approval was requested.
Revised Cardiac Risk Index factors
The Revised Cardiac Risk Index (Lee-index) assigns 1 point to each of the following 6 characteristics: 
high-risk surgery, ischemic heart disease, history of heart failure, cerebrovascular disease, renal insuf-
ficiency and insulin dependent diabetes mellitus. Ischemic heart disease was defined as a history 
of MI or positive stress test, current complaint of ischemic chest pain, or use of nitrate therapy, or Q 
waves on the electrocardiogram, but patients with a history of coronary artery bypass grafting (CABG) 
or percutaneous coronary intervention (PCI) were included only if they had current complaints of 
chest pain presumed to be due to ischemia; heart failure was defined as a history of heart failure, 
pulmonary edema, or paroxysmal nocturnal dyspnea, or a chest radiograph showing pulmonary 
vascular redistribution; renal insufficiency was a creatinine level > 177 umol/L; high-risk surgery as 
AAA, r-AAA and LLR procedures; and cerebrovascular disease was defined as a history of a stroke or 
transient ischemic attack. Notably, due to the high surgical risk of LLR, AAA and r-AAA surgery, by 
definition no Lee-index of 0 points was reported in these patients. This resulted in three categories 
according to the number of Lee risk index points: 1, 2 and ≥ 3.
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Other risk factors
Other baseline risk factors recorded of all patients were age, gender, hypertension (defined as systolic 
blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg and/or use of anti-hypertensive 
medication), chronic obstructive pulmonary disease (COPD) according to symptoms and pulmonary 
function tests (i.e. forced expiratory volume in 1 second <70% of maximal age and gender predictive 
value), body mass index, smoking status, hypercholesterolemia (total cholesterol of >5.2 mmol/L) 
and medication (including statins, diuretics, angiotensin-converting-enzyme inhibitors, calcium 
antagonists, nitrates, beta-blockers, aspirin and anti-coagulants). All prescription and over-the-
counter medications were noted on the day of admission.
Procedures
All patients underwent open vascular surgery, respectively: carotid endarterectomy (CEA), elective 
infrarenal abdominal aortic surgery (AAA), acute infrarenal AAA surgery (r-AAA) and lower limb arte-
rial reconstruction procedures (LLR).
Clinical follow-up and end points
Perioperative clinical information was retrieved from an electronic database of patients maintained 
in our hospital. From the municipal civil registries, we obtained the survival status. The follow-up was 
complete in 98.2%. The primary outcomes were major adverse cardiac event (MACE) and all-cause 
mortality, occurring within 30 days after surgery. The secondary outcome was all-cause mortality dur-
ing long-term follow-up. MACE within 30-days after surgery, was defined as cardiac death (which was 
defined as any death with a cardiac complication as the primary or secondary cause, including deaths 
following myocardial infarction, cardiac arrhythmia and heart failure), myocardial infarction or coro-
nary revascularization (PCI or CABG). Sudden death in a previously stable patient was considered as 
cardiac death. Myocardial infarction was defined as the presence of 2 out of the following 3 criteria: (1) 
typical chest-pain complaints, (2) electrocardiographic changes including acute ST elevation followed 
by appearance of Q waves or loss of R waves, or new left bundle branch block, or new persistent T wave 
inversion for at least 24 hours, or new ST segment depression which persists >24 hours, and (3) a posi-
tive troponin T, i.e. >0.10 ng/ml (>0.1 ug/L), or peak creatinine phosphokinase -MB >8% of an elevated 
total creatinine phosphokinase with characteristic rise and fall. Heart failure was defined according the 
New York Heart Association classification. In addition, the causes of death occurring within 30 days 
after surgery were grouped into three different categories: (1) cerebro-cardiovascular death (CCVD), (2) 
non-cerebrocardiovascular death (non-CCVD) and (3) unknown cause of death. Cerebro-cardiovascular 
death was defined as any death with a cerebro-cardiovascular complication as the primary or secondary 
cause and included deaths following myocardial infarction (MI), serious cardiac arrhythmias (defined 
as the presence of a sustained cardiac rhythm disturbance that required urgent medical intervention), 
congestive heart failure, stroke (cerebro vascular accident (CVA) or transient ischemic attack (TIA)), 
surgery-related fatal bleeding complications and others. Non-CCVD was defined as any death with a 
principal non-cerebro-cardiovascular cause, including infection, malignancy, respiratory insufficiency 
and others. The cause of death was ascertained by reviewing medical records, the computerized hospi-
tal database, autopsy reports, or by contacting the referring physician or general practitioner.
Statistical analysis
Continuous data are described as mean values and its standard deviation (± SD), and dichotomous 
data are described as percentage frequencies. The chi-square test was used for categorical variables 
and the analysis of variance (ANOVA) was used for continuous variables. Univariable logistic regres-
sion analysis was used to evaluate the relation between the Lee-index and MACE for each age 
category. Multivariable logistic analysis was performed to evaluate whether the predictive power 
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of the Lee-index could be improved by adding age, hypertension and more detailed information 
on the type of surgery (low risk (CEA), low-intermediate risk (LLR), high-intermediate risk (AAA) and 
high risk (r-AAA)). The performance of the risk model was determined by the C-statistics and its 
resulting area under the receiver operating characteristics (ROC) curve (AUC), which indicates how 
well a model rank orders patients with respect to their outcome (where 0.5 indicates no predictive 
value and 1.0 indicates perfect performance). Kaplan-Meier survival analysis was used to compare 
survival of patients, according to the three Lee-index categories. To test for differences between the 
resulting curves, the log-rank test was used. A p value of <0.05 was considered to be significant. All 
computations were performed with SPSS software version 12.0.1 (SPSS Inc., Chicago, Illinois, USA), 
running under Windows 2000 Professional.
RESuLTS
Patient characteristics
A total of 2 642 procedures were performed (21% CEA, 8% r-AAA, 34% AAA and 38% LLR). The mean 
age was 66 ± 11 years and 75% of the patients were men. Of these patients, 396 (15%) were ≤ 55, 
650 (25%) were 56–65, 1 058 (40%) were 66–75 and 538 (20%) were > 75 years. Men were 0.97 years 
older than were females (p=0.052). With increase of age, higher incidences of hypertension, COPD, 
ischemic heart disease and r-AAA and AAA surgery were observed (TABLE 6.1). No patients were 
reported with a Lee-index score of 0, as all patients with CEA had a positive history of cerebrovascular 
disease and/or presence of another risk factor used in the Lee risk index. The majority of patients had 
a score of 1 point (52%), followed by 30% and 18%, respectively 2 and ≥ 3 points (TABLE 6.2).
Primary end-point
A total of 287 (10.9%) patients had a major adverse cardiac event, for Lee-index 1, 2 and ≥ 3 respec-
tively 6.2%, 13.2% and 20.5%. Increasing rates of MACE were found with increased age, with a slight 
drop of incidences within patients aged >75 years. Within each age category, the Lee-index was sig-
nificantly associated with incidences of MACE. A correlation of all-cause mortality and Lee-index was 
found in all patients (p=0.03). However, no correlation of the Lee-index and all-cause mortality was 
found within each age category. Cerebro-cardiovascular events (116 (76%)) were the major cause of 
death which included: MI 19%, heart failure 10%, cardiac arrhythmia 10%, stroke 6%, fatal bleeding 
26% and others 5%.
The non-cerebro-cardiovascular (36 (24%)) events included: infection 14%, malignancy 0%, respira-
tory insufficient 6% and others 4%. No patient had an unknown cause of death. In total, 58 (39%) 
patients died because of cardiac complications within 30 days after surgery.
In univariate analysis, the Lee-index was associated with an increased risk of MACE as its individual 
components (TABLE 6.3). The prospective C-statistic for the prediction of MACE was 0.65. The pre-
dictive value of the Lee-index was significantly superior in patients aged ≤ 55 years compared to 
patients aged >75 years (area under the curve 0.76 vs. 0.62, p < 0.01). When more detailed informa-
tion, including type of surgery (low, low-intermediate, high-intermediate and high risk of surgery), 
age (≤ 55, age 56–65, age 66–75 and >75 years) and history of hypertension, was added to the model, 
the overall C-statistics improved to 0.71. Importantly, after the introduction of these additional risk 
factors no difference in the C-statistics was observed between each age category ≤ 55, age 56–65, 
age 66–75 and >75 years), respectively 0.71, 0.71, 0.69 and 0.69. The prediction of MACE in elderly 
patients improved from 0.62 to 0.69 (p = 0.02).
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Important differences in incidence of MACE were observed in relation to type of surgery. Overall 
incidences of MACE according to low-risk (CEA), low-intermediate (LLR), high-intermediate (AAA) and 
high-risk (r-AAA) surgery were 2.4%, 11.6%, 12.3% and 24.0%, respectively (p < 0.001) (FIGURE 6.1). 
Within each type of surgery, the Lee-index was significantly associated with risk of MACE.
When we perform our analysis applied only to patients having a single procedure (n = 2 298, 66 ± 11 
years, 75% were men), our results remained the same. For example, incidences of hypertension were 
38%, 43%, 46% and 47% for age category ≤ 55, 56–65, 66–75 and > 75 years respectively (p = 0.03). 
The prospective C-statistic for the prediction of MACE was also 0.65 (0.76, 0.66, 0.64 and 0.62 for each 
age category (≤ 55, age 56–65, age 66–75 and > 75 years)). After the introduction of our additional 
risk factors no difference in the C-statistics was observed between each age category, respectively 
0.74, 0.73, 0.71 and 0.71. The multivariate analysis showed the same results as presented in TABLE 6.3. 
Because of these findings, we concluded that the influence of patients with multiple procedures on 
the overall results does not have an important impact on our results.
Table 6.1 Baseline characteristics of all patients undergoing major vascular surgery, grouped into four age categories.
All
2 642 
(100%)
Age ≤ 55
396 (15%)
Age 56 - 65
650 (25%)
Age 66 - 75
1 058 (40%)
Age > 75
538 (20%)
P-value
Demographics
 Mean age (± SD) 66 (± 11) 47 (± 8) 61 (± 3) 70 (± 3) 79 (± 4) <0.001
 Male (%) 75 68 79 77 74 <0.001
Revised Cardiac Risk Index factors (%)
 Ischemic heart disease 30 25 31 29 32 0.05
 Heart failure 5 6 5 5 7 0.5
 High-risk surgery 79 79 77 77 87 <0.001
  Abdominal aortic surgery 34 30 32 36 36 0.06
  Acute aortic surgery 8 3 5 9 13 <0.001
  Lower limb reconstruction 37 47 40 32 39 <0.001
 Renal insufficiency 6 7 5 6 5 0.4
 Insulin dependent diabetes mellitus 15 17 12 14 17 0.08
 Cerebrovascular disease 31 27 34 34 25 <0.001
Other risk factors (%)
 COPD* 18 11 15 21 23 <0.001
 Current smoker 24 25 27 23 22 0.2
 Hypercholesterolemia 18 25 19 16 13 <0.001
 Body mass index (± SD) 25.1 (± 5) 25.4 (± 5) 25.3 (± 6) 24.9 (± 4) 24.7 (± 3) 0.02
 Hypertension 46 39 44 47 48 0.02
Medication use (%)
 Statins 26 31 31 26 16 <0.001
 Diuretics 18 13 15 19 23 <0.001
 ACE-inhibitorsŦ 31 28 34 31 33 0.2
 Calcium antagonists 34 33 33 35 31 0.4
 Nitrates 19 15 19 19 21 0.2
 Beta-blockers 33 31 35 35 31 0.3
 Aspirin 40 37 40 42 40 0.3
 Anti-coagulation 20 18 22 20 18 0.4
COPD= chronic obstructive pulmonary disease; ACE-inhibitors= angiotensin-converting-enzyme inhibitors
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Table 6.2
Incidences of major adverse cardiac events and all-cause mortality, according to the Revised Cardiac Risk 
score.
All Lee-index 1 Lee-index 2 Lee-index ≥3 P-value AUC AUC*
All
Incidences – no. (%) 2 642 (100) 1 371 (52) 802 (30) 469 (18)
All-cause death – no. (%) 152 (5.8) 63 (4.6) 55 (6.9) 34 (7.2) 0.03
MACE – no. (%) 287 (10.9) 85 (6.2) 106 (13.2) 96 (20.5) < 0.001 0.65 0.71
Age ≤ 55
Incidences – no. (%) 396 (100) 234 (59) 94 (24) 68 (17)
All-cause death – no. (%) 10 (2.5) 5 (2.1) 3 (3.2) 2 (2.9) 0.84
MACE – no. (%) 17 (4.3) 3 (1.3) 5 (5.3) 9 (13.2) < 0.001 0.76 0.71
Age 56 – 65
Incidences – no. (%) 650 (100) 346 (53) 200 (31) 104 (16)
All-cause death – no. (%) 22 (3.4) 10 (2.9) 7 (3.5) 5 (4.8) 0.63
MACE – no. (%) 60 (9.2) 21 (6.1) 17 (8.5) 22 (21.2) < 0.001 0.64 0.71
Age 66 – 75
Incidences – no. (%) 1 058 (100) 543 (51) 335 (32) 180 (17)
All-cause death – no. (%) 68 (6.4) 30 (5.5) 23 (6.9) 15 (8.3) 0.38
MACE – no. (%) 144 (13.6) 43 (7.9) 59 (17.3) 43 (23.9) <0.001 0.64 0.69
Age > 75
Incidences – no. (%) 538 (100) 248 (46) 173 (32) 117 (22)
All-cause death – no. (%) 52 (9.7) 18 (7.3) 22 (12.7) 12 (10.3) 0.17
MACE – no. (%) 66 (12.3) 18 (7.3) 26 (15.0) 22 (18.8) 0.003 0.62 0.69
AUC = Area Under the Curve; MACE = major adverse cardiac event; * Adjusted for type of surgery (low, low-intermediate, 
high-intermediate and high risk of surgery), age (≤ 55, 56 – 65, 66 – 75 and > 75 years) and history of hypertension
Table 6.3 Unadjusted and adjusted predictors of estimate risk of major adverse cardiac events.
Unadjusted HR, (95% CI) Adjusted HR*, (95% CI)
Lee-index 1 (reference) 1.0 1.0
Lee-index 2 2.30 (1.71 – 3.11) 1.94 (1.37 – 2.73)
Lee-index ≥ 3 3.89 (2.85 – 5.33) 2.92 (1.92 – 4.44)
 High-risk surgery 6.17 (3.51 – 10.85) 6.97 (3.68 – 13.22)
 Diabetes mellitus 1.84 (1.36 – 2.48) 1.51 (1.11 – 2.06)
 Cerebrovascular disease 1.76 (1.26 – 2.45) 1.53 (1.09 – 2.14)
 Ischemic heart disease 2.31 (1.80 – 2.97) 1.70 (1.30 – 2.22)
 Heart failure 2.43 (1.60 – 3.68) 1.31 (0.84 – 2.06)
 Renal insufficiency 2.24 (1.64 – 3.05) 1.71 (1.24 – 2.36)
Age ≤ 55 years (reference) 1.0 1.0
Age 56 – 65 years 2.27 (1.30 – 3.94) 2.44 (1.34 – 4.42)
Age 66 – 75 years 3.51 (2.10 – 5.89) 3.49 (1.99 – 6.10)
Age > 75 years 3.11 (1.80 – 5.40) 2.56 (1.41 – 4.65)
Low-risk surgery (reference) 1.0 1.0
Low-intermediate risk 5.36 (2.99 – 9.60) 4.04 (2.17 – 7.54)
High-intermediate risk 5.76 (3.21 – 10.34) 4.14 (2.23 – 7.68)
High-risk 12.95 (6.84 – 24.52) 10.45 (5.22 – 20.95)
History of hypertension 2.15 (1.67 – 2.77) 1.70 (1.25 – 2.31)
HR= hazard ration; CI= confidence interval; *Adjusted for the four age categories (≤ 55, 56-65, 66-75 and > 75 years), risk 
of surgery (low, low-intermediate, high-intermediate and high risk), hypertension, year of operation, chronic obstructive 
pulmonary dysfunction, hypercholesterolemia, smoking status, body mass index, gender and cardiovascular medication
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Secondary end-point
Although the Lee-index was originally developed to predict perioperative cardiac complications, a 
clear association was found between the Lee-index and all-cause mortality during follow-up (FIGURE 
6.2). A total of 1 454 (55%) patients died during a mean period of 6.4 ± 3.9 years. Annual mortality 
rates of patients with a Lee-index score of 1, 2 and ≥ 3 were 5.2%/year, 6.4%/year and 7.3%/year 
respectively (p < 0.001). In multivariate analysis, adjusting for the four age categories, risk of surgery 
(low, low-intermediate, high-intermediate and high risk), year of operation, chronic obstructive 
pulmonary dysfunction, hypercholesterolemia, smoking status, body mass index, gender, hyperten-
sion and cardiovascular medication, the risk of all-cause mortality was 1.45 (95% CI: 1.28–1.65) for 
Lee-index 2 and 1.90 (95% CI: 1.63–2.22) for Lee-index ≥ 3, compared with Lee-index 1. When analysis 
was performed for patients with a single procedure, the risk of all-cause mortality was 2.01 (95% CI: 
1.37–2.94) for Lee-index 2 and 3.11 (95% CI: 1.94–4.97) for Lee-index ≥ 3, compared to Lee-index 1.
DISCuSSION
The main finding of our study is that the prognostic value of the Revised Cardiac Risk Index (Lee-
index) is reduced in the very elderly patients (>75 years) undergoing vascular surgery. The Lee-index 
was introduced to assess perioperative cardiac risk among a large number of patients. Risk factors 
included are high-risk surgery, ischemic heart disease, history of heart failure, cerebrovascular disease, 
renal insufficiency and insulin dependent diabetes mellitus. Importantly, age was not included in the 
index. In addition, only a low number of vascular surgery patients were included. Our study showed 
that if additional information was added to the Lee-index (e.g. age, a more detailed classification 
of type of vascular surgery and history of hypertension), the accuracy of the Lee-index to predict 
postoperative MACE improves significantly in vascular surgery patients, among the entire strata of 
age.
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Figure 6.1 Incidences of major cardiac events, according to type of operation and the Revised Cardiac Risk score.
MACE = major adverse cardiac events; r-AAA = acute infrarenal AAA surgery; AAA = elective infrarenal 
abdominal aortic surgery; LLR = lower limb arterial reconstruction procedures; CEA = carotid 
endarterectomy, *Lee-index that assigns one point to each of the following characteristics: ischemic 
heart disease, history of heart failure, high-risk surgery, history of cerebrovascular disease, renal 
insufficiency and diabetes mellitus.
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The Lee-index is a modification of the original Goldman risk index8, developed in the 1990s and 
validated in numerous clinical studies and is currently considered the best available risk model. 
Although the Lee-index was developed using clinical data of 4 315 consecutive patients undergoing 
non-cardiac surgery, the model has shortcomings for vascular surgery patients. Of all patients, only 
21% underwent vascular surgery and all procedures were considered as high-risk. However, postop-
erative morbidity and mortality varied considerably among different vascular surgical procedures9-11. 
In order to improve the predictive value of the Lee-index, we specified the type of vascular surgery 
into four categories; low, low-intermediate, high-intermediate and high-risk.
However, the main limitation of the Lee-index is that age is not included. The number of patients 
referred for vascular surgery is increasing with a substantial number of septo- and octogenarians. The 
average age of AAA surgery increased from 69 to 72 years during 1980–200012. In addition, this aging 
population presents with complex co-morbidity associated with increased postoperative mortality 
rates.
Several risk indices have been developed to stratify vascular surgery patients based on age and 
clinical cardiac risk factors. In 1994, Samy et al. developed a scoring system in 500 patients scheduled 
for abdominal aortic aneurysm surgery for the prediction of postoperative mortality; the Glasgow 
aneurysm score13. This score included myocardial disease, cerebrovascular disease, renal dysfunction 
and age as a continuous variable as risk factors. Age was an independent risk factor for postoperative 
mortality (p = 0.02). Steyerberg et al. constructed the Leiden Risk Model in 246 patients undergoing 
abdominal aortic aneurysm surgery and included age per decade (<60, 60–70 and >70 years) as a 
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Figure 6.2 All cause long-term mortality in 2,642 patients who underwent major vascular surgery, according to 
the Revised Cardiac Risk score.
Lee-index that assigns one point to each of the following characteristics: ischemic heart disease, 
history of heart failure, high-risk surgery, history of cerebrovascular disease, renal insufficiency and 
diabetes mellitus.
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risk factor14. Age had only a moderate predictive value for all-cause perioperative mortality (OR 1.9; 
95% CI: 0.9–4.2). In addition, L’Italien et al. developed a risk model among 1 081 patients undergoing 
different vascular surgical procedures, with an overall predictive value for cardiac death and non-fatal 
myocardial infarction of 0.74 (C-statistic)15. They included advanced age (>70 years) as a dichotomous 
risk factor. The limitations of these studies are the low number of patients included, none of the stud-
ies had MACE as their end-point and the focus is predominantly on aortic surgery.
Preoperative cardiovascular risk stratification has been an area of intense interest for identifying 
patients at higher cardiac risk. Patients classified as high risk can be refrained for surgery or should be 
considered to undergo less invasive surgery (like endovascular procedures). Additional cardio protec-
tive therapy in elderly like beta-blockers and statins16-18 has improved in recent years. In addition to 
the immediate postoperative outcome, prognostic indices should be considered to assess long-term 
prognosis, as patients should live long enough to enjoy the benefits of surgery. As shown in the 
follow-up of patients undergoing major vascular surgery with different cardiac risk index scores, 
annual mortality rates increased by each risk factor added, ranging from 5.2%/year in patients with 
1 risk factor, to 6.4%/year and 7.3%/year for 2 and ≥ 3 risk factors respectively. This indicates that 
the prognosis is related to underlying cardiovascular disease. Postoperative surveillance of patients 
among the high-risk scores with aggressive anti-ischemic therapy is indicated to improve long-term 
outcome.
A major limitation of our study is the retrospective analysis of prospectively collected data. Changes 
in the perioperative management have evolved markedly over time and were not taken into account 
in our analysis. These include multiple factors ranging from preoperative management, such as drug 
therapy, anesthesiological and surgical techniques to intensive post-surgical care management. We 
tried to adjust for this confounding by adding the year of operation to our multivariate analysis.
In conclusion, this revision of the Lee-index, now including age, risk of surgery and hypertension, 
clearly stratifies vascular surgery patients into low, intermediate and high risk. In addition, this model 
provides long-term prognostic value.
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Preoperative cardiac testing 101
INTRODuCTION
Patients undergoing non-cardiac vascular surgery are at significant risk of perioperative cardiac com-
plications1,2. Though recent developments in anesthesiological and surgical techniques, e.g. loco-
regional anesthesia and endovascular treatment modalities, have improved postoperative cardiac 
outcome considerably, perioperative cardiac complications remain a significant problem.
Myocardial infarction (MI) accounts for 10% to 40% of perioperative fatalities, and is considered to be 
the major determinant of postoperative mortality in non-cardiac vascular surgery3-5. This increased 
risk of perioperative cardiac complications is a function of both the patient population at risk and 
the surgical procedure. Importantly, non-cardiac vascular surgery patients frequently have underly-
ing symptomatic or asymptomatic coronary artery disease (CAD). A landmark study by Hertzer et 
al showed that 61% of 1000 patients undergoing non-cardiac vascular surgery had at least one 
significant coronary artery stenosis (≥50%)6.
Patients for vascular surgery should have an extensive preoperative workup for perioperative car-
diovascular risk. The primary goal of treatment is to reduce cardiovascular complications around the 
vascular surgical procedure. Evidently, the long-term cardiovascular event risk will also decrease7.
This review will describe the current status of preoperative workup for patients undergoing non-
cardiac vascular surgery, including noninvasive cardiac testing for myocardial ischemia, a major 
determinant of perioperative outcome.
PERIOPERATIVE MyOCARDIAL INFARCTION
Myocardial infarction is known to be the major cause of morbidity and mortality in non-cardiac 
vascular surgery patients. The highest incidence of perioperative MI (PMI) is within the first 3 days 
after surgery (± 5%)2. The prevalence of acute coronary syndrome with symptomatic or asymptom-
atic perioperative myocardial ischemia assessed by serum troponin I or T in major vascular surgery 
patients is even 15% to 25%8-9.
The pathophysiology of PMI is not entirely clear compared to MIs occurring in the nonoperative set-
ting. Coronary plaque rupture leading to occlusive coronary thrombosis is suggested as an important 
causal mechanism, like in MIs occurring in the nonoperative setting. Surgery itself is a significant 
stress factor leading to an increased incidence of plaque rupture. Factors provoking physiologic 
stress during surgery include anesthetic agents, response to surgically induced hypotension, anemia, 
and postoperative pain. Two retrospective studies investigated the coronary pathology of fatal PMI. 
Dawood et al.10 performed histopathologic analyses of coronary arteries in 42 patients with a fatal 
PMI within the first 30 days after surgery. Evidence of plaque rupture was found in only 55% of the 
patients. In more than half of the patients, the investigators were unsuccessful at predicting the site 
of infarction based on the severity of the underlying coronary artery stenosis. These findings were 
confirmed by Cohen and Aretz, who analyzed the coronary pathology of 26 patients with PMI11. In 
only 12 of these patients (46%) plaque rupture was identified as the causative mechanism of PMI.
Perioperative MI may also be caused by a sustained myocardial oxygen supply/demand imbalance 
due to prolonged hemodynamic stress. Surgery-related factors such as increased heart rate, elevated 
blood pressure, pain, and the use of sympathomimetic drugs may further increase myocardial oxygen 
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demand. In addition, surgery may cause a decrease in oxygen supply as the result of hypotension, 
vasospasm, anemia, and hypoxia.
Plaque rupture and sustained myocardial oxygen supply/demand imbalance probably contribute 
equally to the occurrence of PMI. As already noted, the location of a plaque rupture is impossible to 
predict with commonly used techniques. However, the extent of significant coronary atherosclerosis 
can be defined with cardiac stress testing. These two pathophysiological mechanisms imply that 
multiple strategies are required to reduce perioperative cardiac risk. In this respect, beta-blockers 
were suggested to prevent MI by reducing the mechanical and hemodynamic stress on vulnerable 
plaques, and by preventing prolonged, stress-induced ischemia12.
CARDIAC RISk STRATIFICATION
Adequate preoperative cardiac risk assessment is essential for identifying high-risk patients for peri-
operative cardiac events. Several risk indices were developed to stratify vascular surgical patients, 
based on clinical cardiac risk factors. The cardiac risk index of Goldman et al.13 in 1977 was the first 
multifactorial model specifically for perioperative cardiac complications to be widely used. This risk 
index was developed in a non-cardiac surgical population. The authors identified nine independent 
risk factors correlated with postoperative serious or fatal cardiac complications: (1) preoperative 
third heart sound or jugular venous distention; (2) MI in the preceding 6 months; (3) >5 premature 
ventricular contractions per minute documented at any time before operation; (4) rhythms other 
than sinus rhythm or the presence of premature atrial contractions on preoperative electrocardio-
gram (ECG); (5) age >70 years; (6) an intraperitoneal, intrathoracic, or aortic operation; (7) emergency 
operation; (8) important valvular aortic stenosis; and (9) poor general medical condition. This index 
was modified by Detsky et al. in 198614, who added the presence of angina and a remote history 
of MI to the original model of Goldman et al.13 They used a Bayesian approach involving pretest 
probabilities, and presented the modified cardiac risk index in a simple normogram.
The Glasgow aneurysm score, described in 1994, was one of the first cardiac risk scores only intended 
for vascular surgical procedures15. In a retrospective study of 500 randomly chosen patients sched-
uled for open abdominal aortic aneurysm repair, potential preoperative risk factors were related to 
postoperative in-hospital mortality. One year later, the Leiden Risk Model for perioperative mortality 
in patients with an abdominal aortic aneurysm was developed by Steyerberg et al.16 This clinical pre-
diction rule was based on several risk factors obtained from the literature, and validated in a cohort 
of 246 patients undergoing open abdominal aortic aneurysm repair.
In 1996, L’Italien et al. developed and validated a Bayesian model for preoperative cardiac risk assess-
ment in a total of 1081 consecutive patients undergoing elective major vascular surgery17. This study 
had a combined endpoint of nonfatal MI or cardiac death. Using 567 patients as a derivation cohort, 
the following risk factors were identified as predictors of adverse postoperative outcome: myocar-
dial infarction, congestive heart failure, angina pectoris, prior coronary revascularization, diabetes 
mellitus, and age >70 years. Importantly, the validation cohort (514 patients) exhibited a prognostic 
accuracy of 74%. Patients classified as low-risk, intermediate-risk, and high-risk had cardiac event 
rates of 3%, 8%, and 18%, respectively.
In 1999, Lee et al.18 developed the largest and currently most widely used model of risk assessment, 
the Revised Cardiac Risk Index. This index identifies six predictors of major cardiac complications: (1) 
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high-risk type of surgery, (2) history of ischemic heart disease, (3) history of congestive heart failure, 
(4) history of cerebrovascular disease, (5) preoperative treatment with insulin, and (6) preoperative 
serum creatinine >2.0 mg/dL. Based on the presence of none, 1, 2, or ≥3 predictors, the rate of major 
cardiac complications in the validation cohort (n = 1422) was estimated to be 0.4%, 0.9%, 7%, and 
11%, respectively.
The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo (DECREASE) I Trial identi-
fied comparable independent clinical risk factors associated with major vascular surgery: a history of 
myocardial infarction, angina, congestive heart failure, diabetes, renal dysfunction, cerebrovascular 
events, and age >70 years19. Recently, Kertai et al. developed a Bayesian model for the prediction of 
all-cause perioperative mortality in 1537 patients undergoing all types of open vascular surgery20. 
Risk factors associated with postoperative all-cause death included ischemic heart disease, con-
gestive heart failure, cerebrovascular events, hypertension, renal dysfunction, chronic pulmonary 
disease, and type of vascular surgery, i.e. ruptured aneurysm abdominal aorta (AAA), elective AAA, 
lower extremity, and carotid vascular surgery. The final logistic regression model with nine indepen-
dent predictors (including beta-blocker and statin use) of perioperative mortality was used to create 
a variable-weight index, the customized probability index, where scores were assigned based on 
parameter estimates of individual predictors. The sum of scores of surgical risk (0-46 points), medi-
cal history (0-67 points), and cardioprotective medication (statins -10 points and beta-blockers -15 
points) was calculated for an overall cardiac risk.
NONINVASIVE TESTINg
Once the assessment of risk factors indicates an increased cardiac perioperative risk, or if there is a 
suspicion of CAD upon examination, further cardiac testing is warranted. According to the current 
guidelines of the American College of Cardiology/American Heart Association21, preoperative car-
diac exercise or pharmacologic stress testing is recommended for (1) patients with an intermediate 
pretest probability of CAD, (2) patients undergoing initial evaluation for suspected or proven CAD, 
(3) subjects with a significant change in clinical status, (4) demonstration of proof of myocardial 
ischemia before coronary revascularization, (5) evaluation of adequacy of medical treatment, and (6) 
prognostic assessment after an acute coronary syndrome.
One of the main issues in preoperative cardiac risk assessment is to identify those patients who 
should undergo additional stress testing before surgery. The randomized, multicenter DECREASE II 
Study assessed the value of preoperative cardiac testing in intermediate-risk patients receiving beta-
blocker therapy with tight heart-rate control22. In total, 1476 vascular surgical patients were divided 
into three risk groups based on the risk score of Boersma et al.19 All 770 intermediate-risk patients 
were randomly assigned to preoperative cardiac stress-testing or no testing. Importantly, all patients 
in the DECREASE II Study received beta-blocker therapy, irrespective of stress-test results, aiming at 
tight heart-rate control, i.e. a heart rate of 60 to 65 beats per minute. This study demonstrated no 
differences in cardiac death and MI at 30 days between patients assigned to no testing versus cardiac 
stress testing (1.8% versus 2.3%; odds ratio [OR], 0.78; 95% confidence interval [CI], 0.28 to 2.1). Also, 
2-year outcomes were comparable in intermediate-risk patients with and without testing, i.e. 4.3% 
versus 3.1%, respectively. These results indicate that intermediate-risk patients undergoing major 
vascular surgery are at a relatively low perioperative risk and do not benefit from preoperative cardiac 
testing when receiving beta-blocker therapy with tight heart-rate control.
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For those patients who require cardiac testing, several noninvasive and physiological (and nonphysi-
ological) stress tests are available for the evaluation of perioperative risk. Nonphysiological stress 
tests are especially recommended to detect preoperative myocardial ischemia in asymptomatic 
vascular surgery patients.
Rest Electrocardiography
Different studies associated abnormal ECG findings with perioperative cardiac complications13,14,23. 
In a large prospective study by Lee et al.18 involving 4315 patients undergoing major non-cardiac sur-
gery, a history of ischemic heart disease was one of the six independent predictors of major cardiac 
complications. Pathological Q-waves, as an electrocardiographic sign of MI in the past, were found 
in 17% of patients, with a 2.4-fold increased risk of perioperative events. A recent retrospective study 
confirmed the prognostic value of routine preoperative electrocardiography in 22,457 non-cardiac 
operations24. Patients with abnormal ECG findings had a higher incidence of 30-day cardiovascular 
death compared with patients with a normal ECG (1.8% versus 0.3%; adjusted OR, 3.4; 95% CI, 2.4 
to 4.5). In addition, it was demonstrated that a preoperative ECG is also predictive for long-term 
outcome, independent of clinical findings and perioperative ischemia, in CAD patients undergoing 
major non-cardiac surgery25.
ST-segment holter
The use of ambulant 24-hour ST-segment registration for evaluation of perioperative cardiac risk was 
first described by Raby et al.26 They reported a sensitivity of 75% and a specificity of 83% for the 
prediction of a combined endpoint of cardiac death and nonfatal MI. A large meta-analysis showed 
lower values, comprising eight studies with a total of 893 patients, with a weighted sensitivity of 52% 
(95% CI, 21% to 84%) and a specificity of 70% (95% CI, 57% to 83%)27. The advantages of ST-segment 
Holter include its low cost and wide availability.
Exercise Electrocardiogram
The most commonly used physiologic stress test for detecting myocardial ischemia uses a treadmill 
or cycle ergometer. Among its advantages, this test provides an estimate of functional capacity, 
and hemodynamic response, and detects myocardial ischemia through ST-segment changes. The 
accuracy of an exercise ECG varies widely among studies. A meta-analysis by Kertai et al.27 for the 
detection of myocardial ischemia with treadmill testing in vascular surgery patients showed a rather 
low sensitivity (74%; 95% CI, 60% to 88%) and specificity (69%; 95% CI, 60% to 78%), comparable 
to daily clinical practice. However, important limitations in patients with peripheral vascular disease 
involve their frequently limited exercise capacity. Furthermore, preexisting ST-segment deviations, 
especially in the precordial leads V5 and V6 at the rest ECG, make a reliable ST-segment analysis more 
difficult28.
Stress Echocardiography
Because most patients with peripheral vascular disease are unable to exercise maximally, stress 
echocardiography with pharmacologic stressors (such as dobutamine) is a good alternative. 
Although vasodilators (e.g., dipyridamole or adenosine) may have advantages for the assessment of 
myocardial perfusion, dobutamine is the preferred pharmacological stressor when the test is based 
on an assessment of regional wall-motion abnormalities29. Dobutamine is a synthetic catecholamine 
with predominantly β1-receptor-stimulating properties, resulting in a strong positive inotropic effect 
and modest chronotropic effect on the heart. During the stress test, dobutamine is intravenously 
administered. A graded dobutamine infusion starting at 5 μg/kg/min, and increasing at 3-minute 
intervals to 10, 20, 30, and 40 μg/kg/min, is the standard for dobutamine stress echocardiography 
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(DSE). During dobutamine infusion, contractility and heart rate increase, leading to increased myo-
cardial oxygen demand. Myocardial ischemia leading to systolic contractile dysfunction, detectable 
by echocardiography, occurs in regions supplied by hemodynamically significant stenotic coronary 
arteries.
Tissue harmonic imaging is advised for stress echocardiography. This special imaging setting reduces 
near-field artifacts, improves resolution, enhances myocardial signals, and is superior to fundamental 
imaging for endocardial border visualization. The improvement in endocardial visualization is further 
enhanced by the use of contrast agents for left-ventricular (LV) opacification. Contrast agents increase 
the number of interpretable LV wall segments. These recent developments exhibit decreased inter-
observer variability, and have improved the sensitivity of stress echocardiography30.
Many reports demonstrated that DSE predicts perioperative events in patients undergoing vascular 
surgery31-34. The negative predictive value of dobutamine stress tests is high, although the positive 
predictive value is much lower.
Kertai et al. reported a weighted sensitivity of 85% (95% CI, 74% to 97%) and a specificity of 70% (95% 
CI, 62% to 69%) for DSE in 850 patients from eight studies.27 A recent meta-analysis by Beattie et al 
analyzed the predictive value of pharmacological stress testing compared with myocardial perfu-
sion scintigraphy35. This report included 25 studies (3373 patients) of mainly dobutamine as well as 
dipyridamole stress echocardiography. The likelihood ratio of a perioperative event with a positive 
stress echocardiography was 4.09 (95% CI, 3.21 to 6.56).
Myocardial Perfusion Scintigraphy
Myocardial perfusion scintigraphy (MPS) is a widely used technique in the preoperative risk assess-
ment of patients undergoing vascular surgery. The technique involves intravenous administration 
of a small quantity of a radioactive tracer. The detection of CAD is based on a difference in blood-
flow distribution through the LV myocardium. These differences in perfusion can be explained by 
insufficient coronary blood flow based on coronary stenosis. Nowadays, technetium-99m-labeled 
radiopharmaceutical is the most widely used tracer. Myocardial perfusion scintigraphy is used in 
combination with exercise or pharmacologic stress testing to diagnose the presence of CAD. If there 
is a decrease or loss in regional perfusion after maximal vasodilatation with, for example, adenosine, 
as seen in hemodynamically significant CAD or in transmural MI, a reduced radiopharmaceutical 
signal is observed. Stress and rest MPS are compared for reversible abnormalities. A positive MPS is 
associated with an increased risk of perioperative and postoperative cardiac complications.
This method of noninvasive testing has been extensively studied, and was included in several meta-
analyses27,35-37. Boucher et al. were among the first to report on using MPS for preoperative cardiac risk 
assessment36. They performed preoperative dipyridamole-thallium imaging in 48 patients scheduled 
for peripheral vascular surgery. Half of the patients with thallium redistribution had cardiac events, 
whereas no events occurred in the 32 patients with a normal scan or with nonreversible defects only 
(p < 0.001).
Studies indicate that MPS is highly sensitive for the prediction of cardiac complications, but its speci-
ficity was reported as less satisfactory. A meta-analysis by Etchells et al.37 investigated the prognostic 
value of semiquantitative dipyridamole MPS for perioperative cardiac risk in patients undergoing 
non-cardiac vascular surgery. They included nine studies, involving a total of 1179 vascular surgery 
patients, with a 7% cardiac complication rate. One of the most important findings in this study was 
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that reversible ischemia in <20% of the myocardial segments did not change the likelihood of peri-
operative complications. Patients with more extensive reversible defects were at increased risk: 20 
to 29% reversibility (likelihood ratio [LR] 1.6; 95% CI 1.0 to 2.6), 30 to 39% reversibility (LR 2.9; 95% CI 
1.6 to 5.1), 20 to 9% reversibility (LR 1.6; 95% CI 1.0 to 2.6), 40% to 49% reversibility (LR 2.9; 95% CI 1.4 
to 6.2) and ≥50% or more reversibility (LR 11; 95% CI 5.8 to 20). These reversible defects in >20% of 
myocardial segments were only seen in 23% of all patients.
Another meta-analysis which assessed the prognostic value of six diagnostic tests reported a sen-
sitivity of 83% (95% CI, 77% to 89%) and a much lower specificity of 47% (95% CI, 41% to 57%) for 
MPS27. More recently, Beattie et al.35 performed a meta-analytic comparison, including in total 39 
thallium-imaging studies involving vascular surgery patients were included, and resulted in a sum-
mary likelihood ratio of 1.83 (95% CI, 1.57 to 2.13).
Which Test to Choose?
There is no large direct comparison of these techniques in perioperative risk assessment in the same 
patient population. However, several meta-analyses compared different techniques with respect 
to sensitivity and specificity. An early comparison of dipyridamole perfusion imaging and DSE was 
performed by Shaw et al.34 The recent meta-analysis by Kertai et al. compared six different diagnostic 
tests for diagnostic accuracy to predict perioperative cardiac risk in patients undergoing major vascu-
lar surgery27. Eventually, 58 studies met the inclusion criteria, with a total of 8119 patients. A positive 
trend in favor of DSE for better diagnosis compared with other tests was indicated. However, this was 
only statistically significant compared with MPS. Beattie et al. conducted a meta-analysis of 68 studies 
comparing thallium MPS with stress echocardiography in 10,049 non-cardiac surgery patients35. The 
authors concluded that stress echocardiography was preferable for predicting postoperative events 
because of its better negative predicative characteristics.
Nevertheless, because the tests have comparable accuracy, there is no definite answer to the question 
of which test to choose. The choice of test should be based on the center’s experience and short-term 
availability. Accurate assessment of the ischemic burden is important in predicting perioperative and 
postoperative risk.
PERIOPERATIVE MANAgEMENT
In general, two strategies have been used in an attempt to reduce the incidence of PMIs and other 
cardiac complications: preoperative coronary revascularization, and prophylactic pharmacological 
treatment. In recent years, more attention has been focused on the role of pharmacological treat-
ment, whereas controversy continues over the appropriate management of patients diagnosed 
preoperatively with significant coronary artery disease. With respect to prophylactic coronary revas-
cularization, American College of Cardiology/American Heart Association guidelines recommend 
revascularization only for subgroups of high-risk patients with unstable cardiac symptoms or with 
likely long-term benefits of coronary artery revascularization21. However, these current guideline rec-
ommendations are based on studies not designed to answer the research question of prophylactic 
revascularization38,39. Recently, the randomized Coronary Artery Revascularization Prophylaxis (CARP) 
Trial demonstrated that there is no reduction in the number of perioperative or postoperative MIs, 
deaths, lengths of hospital stay, or improved long-term outcomes in patients who undergo preopera-
tive coronary revascularization compared with patients who receive optimized medical therapy40. 
Yet it must be noted that the majority of patients in the CARP Trial had only one-vessel or two-vessel 
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disease, with preserved LV function. Optimal preoperative medical treatment, especially with tight 
heart rate control, is essential for decreasing perioperative risk. The aim of the recent randomized 
pilot study DECREASE V was to assess the feasibility of prophylactic coronary revascularization in 
patients with preoperative, extensive, stress-induced ischemia41. Patients with ≥3 risk factors, and 
who had extensive stress-induced ischemia using DSE, were randomly assigned to prophylactic 
revascularization or pharmaceutical treatment. Revascularization did not improve 30-day or 1-year 
outcomes. The incidence of the composite endpoint of all-cause 30-day mortality and MI for patients 
with preoperative revascularization or medical treatment was 43% versus 33%, respectively (OR, 1.4; 
95% CI, 0.7 to 2.8) and at 1 year, 49% versus 44% (OR, 1.2; 95% CI, 0.7 to 2.3).
These findings of both CARP and DECREASE V support the current guidelines of the American College 
of Cardiology and American Heart Association for perioperative management in high-risk patients, to 
reserve revascularization only for cardiac unstable patients. In high-risk patients scheduled for major 
non-cardiac vascular surgery, prophylactic revascularization might be switched to postoperative 
revascularization, preventing the delay of surgery.
It must be noted that preoperative revascularization can even be harmful for the patient because 
of periprocedural complications during revascularization and postponement of the non-cardiac 
procedure. Importantly, the cumulative risk of prophylactic coronary revascularization and non-
cardiac surgery needs to be weighed against the risk of non-cardiac surgery alone and the immediate 
benefits of prophylactic coronary revascularization.
Besides coronary revascularization, an extensive preoperative cardiac evaluation with noninvasive 
cardiac testing might improve outcomes by inducing optimal medical management in the periopera-
tive periods. Perioperative beta-blockers and statins have, in this respect, shown a significant benefit 
in decreasing perioperative cardiac mortality and morbidity42-46. Because of the increasing evidence 
of the beneficial effects of beta-blockers in the perioperative period, the guidelines on perioperative 
beta-blocker therapy were recently updated47.
CONCLuSIONS
Preoperative risk assessment with a noninvasive stress test (MPS or DSE) is necessary only in high-risk 
patients without unnecessary delay for vascular surgery. High-risk patients can easily be selected 
through the risk score index. Prophylactic revascularization should only be performed in those with 
unstable coronary artery disease. The optimal perioperative medical treatment, especially tight 
heart-rate control, is essential for decreasing perioperative and postoperative cardiac risk.
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ABSTRACT
Background: Treatment guidelines of the American College of Cardiology/American Heart Associa-
tion recommend cardiac testing in these patients to identify subjects at increased risk. This policy 
delays surgery, even though test results might be redundant and beta-blockers with tight heart rate 
(HR) control provide sufficient myocardial protection. Furthermore, the benefit of revascularization 
in high-risk patients is ill-defined. The purpose of this study was to assess the value of preoperative 
cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight HR control 
scheduled for major vascular surgery.
Methods: All 1,476 screened patients were stratified into low-risk (0 risk factors), intermediate-risk 
(1 to 2 risk factors), and high-risk (≥ 3 risk factors). All patients received beta-blockers. The 770 
intermediate-risk patients were randomly assigned to cardiac stress-testing (n = 386) or no testing. 
Test results influenced management. In patients with ischemia, physicians aimed to control HR below 
the ischemic threshold. Those with extensive stress-induced ischemia were considered for revascu-
larization. The primary end point was cardiac death or myocardial infarction at 30-days after surgery.
Results: Testing showed no ischemia in 287 patients (74%); limited ischemia in 65 patients (17%), and 
extensive ischemia in 34 patients (8.8%). Of 34 patients with extensive ischemia, revascularization 
before surgery was feasible in 12 patients (35%). Patients assigned to no testing had similar incidence 
of the primary endpoint as those assigned to testing (1.8% vs. 2.3%; odds ratio [OR] 0.78; 95% con-
fidence interval [CI] 0.28 to 2.1; p = 0.62). The strategy of no testing brought surgery almost 3 weeks 
forward. Regardless of allocated strategy, patients with a HR <65 beats/min had lower risk than the 
remaining patients (1.3% vs. 5.2%; OR 0.24; 95% CI 0.09 to 0.66; p = 0.003).
Conclusions: Cardiac testing can safely be omitted in intermediate-risk patients, provided that beta-
blockers aiming at tight HR control are prescribed.
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INTRODuCTION
According to the guidelines of the American College of Cardiology /American Heart Association ( 
ACC/AHA), all patients scheduled for major vascular surgery who have clinical features associated 
with increased cardiac risk should undergo noninvasive cardiac stress-testing1. Perioperative beta-
blocker therapy is recommended for patients with inducible ischemia undergoing major vascular 
surgery. The guidelines also recommend coronary angiography for patients with high-risk noninva-
sive test results and myocardial revascularization in patients with prognostic high-risk anatomy in 
whom long-term outcome is likely to be improved. However, noninvasive testing might delay surgery 
and run the risk of aortic aneurysmal rupture or exacerbation of critical limb ischemia. Furthermore, 
a recent randomized, controlled trial of preoperative myocardial revascularization in vascular surgery 
patients showed no improvement in perioperative or long-term outcome associated with prophylac-
tic revascularization2.
In a previous retrospective observational study of 1,351 patients undergoing major vascular surgery, 
we found that counting clinical risk factors effectively stratified vascular surgery patients into low-risk 
(0 risk factors), intermediate-risk (1 to 2 risk factors), and high-risk (≥ 3 risk factors) categories3. Among 
patients receiving beta-blockers, perioperative cardiac event rates were 0% and 0.9% in low- and 
intermediate-risk patients, respectively. Of all intermediate-risk patients studied, only a minority (2%) 
experienced extensive stress-induced myocardial ischemia3. These data do not support the routine 
use of preoperative noninvasive testing in intermediate-risk patients, who constitute more than 50% 
of the major vascular surgery population, provided that perioperative beta-blockade is employed.
We therefore undertook the second multi-center DECREASE-II (Dutch Echocardiographic Cardiac 
Risk Evaluation) study to prospectively assess the value of cardiac testing according to the ACC/AHA 
guidelines in intermediate-risk patients receiving beta-blocker therapy with tight heart rate (HR) 
control scheduled for major vascular surgery.
METhODS
Study protocol
Between 2000 and 2005, we enrolled 1,476 patients undergoing elective open abdominal aortic or 
infrainguinal arterial reconstruction at 5 participating centers. Patients were screened for the follow-
ing cardiac risk factors: age over 70 years, angina pectoris, prior myocardial infarction (MI) on the basis 
of history or a finding of pathologic Q waves on electrocardiography, compensated congestive heart 
failure or a history of congestive heart failure, drug therapy for diabetes mellitus, renal dysfunction 
(serum creatinine >160 μmol/l), and prior stroke or transient ischemic attack.
On the basis of previous study results, patients were divided into 3 groups: 0 risk factors (low-risk), 1 
or 2 risk factors (intermediate-risk), ≥ 3 risk factors (high-risk)3. Low-risk patients were referred for sur-
gery with beta-blocker therapy without additional testing. Intermediate-risk patients were randomly 
(1:1) assigned to preoperative cardiac stress-testing or no testing. Cardiac testing was performed by 
dobutamine echocardiography or dobutamine or dipyridamole perfusion scintigraphy, as previously 
described4,5. Test results were scored by the extent of stress-induced ischemia with a 16-segment 
model in dobutamine echocardiography and a 6-wall model in stress perfusion scintigraphy. In 
addition during dobutamine echocardiography, the HR at which ischemia occurred (i.e. ischemic HR 
threshold) was noted. Limited ischemia was defined by the presence of 1 to 4 ischemic segments 
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or 1 to 2 ischemic walls, whereas extensive ischemia was defined by ≥ 5 ischemic segments or ≥ 3 
ischemic walls. Patients without ischemia as well as those with limited ischemia were referred for 
surgery with beta-blocker therapy. In patients with extensive ischemia, test results were discussed 
with the treating physicians and only in those patients in whom the index surgical procedure could 
be delayed was coronary angiography performed and revascularization considered after the angiog-
raphy data were obtained. The type of coronary revascularization, bypass surgery or percutaneous 
coronary intervention, was decided by the treating physicians on the basis of coronary anatomy and 
the possible delay of the index surgical procedure. High-risk patients were referred for additional 
cardiac testing. All patients provided written informed consent, and the study was approved by the 
Erasmus Medical Center medical ethics committee and local research ethics committees.
Beta-blocker therapy
Perioperative beta-blocker therapy was installed in all patients. Patients receiving chronic beta-
blocker therapy continued their medication. Patients without beta-blockers started with bisoprolol 
2.5 mg once/day at the screening visit. Beta-blocker dose was adjusted in all patients at admission 
to the hospital and on the day before surgery to achieve a resting HR of 60 to 65 beats/min. The 
same dose of beta-blockers was continued postoperatively except in patients who were unable to 
take medication orally or by nasogastric tube postoperatively. In these patients, the HR was moni-
tored continuously in the intensive care unit or hourly at the ward, and intravenous metoprolol was 
administered at a dose sufficient to keep the HR between 60 and 65 beats/min. The HR and blood 
pressure were measured immediately before each scheduled dose of beta-blockers. Beta-blockers 
were withheld if the HR was under 50 beats/min or the systolic blood pressure was under 100 mmHg. 
After discharge, patients continued beta-blocker therapy and dose adjustments were carried out 
during outpatient visits to achieve a resting HR of 60 to 65 beats/min.
Perioperative management
Anesthetic management, monitoring, surgical technique, and other aspects of perioperative 
management were at the discretion of the attending physician. Results of preoperative testing and 
coronary revascularization were discussed with the attending physicians. In patients with limited or 
extensive ischemia, HR and hemodynamic management during surgery was implemented to control 
HR below the ischemic threshold and otherwise below 65 beats/min. Anticoagulant and antiplatelet 
therapy were continued for a period of at least 4 weeks after percutaneous coronary intervention 
and continued during surgery. Intraoperative ischemia was treated at the discretion of attending 
physicians, and additional beta-blockers were permitted.
End point definition
All patients were monitored for cardiac events during hospital stay after surgery. Twelve-lead 
electrocardiography and serum troponin-T level was determined 1, 3, 7, and 30 days after surgery. 
Additional tests were performed at the discretion of the attending physician. Outpatient follow-up 
was performed at 30 days if a patient had been discharged from the hospital. At the outpatient 
clinic all patients were screened at 3-month intervals for cardiac events by clinical history, troponin-T 
measurements, and 12-lead electrocardiography recording. All data were collected by the participat-
ing centers and evaluated in a blinded fashion by members of the adverse-events committee. The 
median follow-up was 2.0 years (25th and 75th percentile: 0.8 and 3.1, respectively).
The primary end point was a composite of cardiac death and nonfatal MI at 30 days after surgery. Car-
diac death was defined as a death caused by acute MI, significant cardiac arrhythmias, or refractory 
congestive heart failure or as a death occurring suddenly without another explanation. A nonfatal MI 
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was defined by both a positive troponin-T level and a finding of new Q waves lasting more than 0.03 s 
on the electrocardiogram. We also report the incidence of the composite end point during long-term 
follow-up. A nonfatal MI during follow-up was defined by new Q waves lasting more than 0.03 s on 
the electrocardiogram with or without positive troponin-T level.
Sample size
The primary objective of this trial was to demonstrate that the strategy of no testing is non-inferior 
to the strategy of cardiac testing in intermediate-risk patients. In a previous study we noted a 5% 
incidence of perioperative cardiac death or nonfatal MI in intermediate-risk patients3. We judged that 
the strategy of no testing is non-inferior to testing if the difference in primary end point is not more 
than 4%. On the basis of these assumptions, a total of 734 patients are needed to demonstrate non-
inferiority with an alpha level of 5% and a power of 80%.
Statistical analysis
Continuous data are presented as median values and corresponding 25th and 75th percentiles, 
whereas dichotomous data are presented as percentages. Differences in clinical and surgical charac-
teristics between patients allocated to no testing or testing were evaluated by chi-square tests. Dif-
ferences in the incidence of the primary end point were evaluated by a chi-square test. The incidence 
of cardiac events over time was further examined by the Kaplan-Meier method, whereas a log-rank 
test was applied to evaluate differences between the allocated treatment strategies. Analyses were 
performed according to the intention to treat principle. All statistical tests were 2-sided and a p value 
< 0.05 was considered significant.
Cardiac risk factors
Yes
No Mild Extensive
Myocardial ischemia
YesNo
Revascularization
287 65 22 12
No
384
0 > 3
354 352
1 or 2
Testing (randomisation)
Figure 8.1 Flow chart of the study.
Cardiac risk factors included: age over 70 years, angina pectoris, prior myocardial infarction on the 
basis of history or a finding of pathologic Q waves on electrocardiography, compensated congestive 
heart failure or a history of congestive heart failure, current treatment for diabetes mellitus, renal 
dysfunction (serum creatinine >160 μmol/l), and prior stroke or transient ischemic attack. Patients with 
1 or 2 cardiac risk factors were randomly (1:1) assigned to cardiac testing or no testing. Test results were 
classified as no ischemia, limited ischemia, and extensive ischemia. Patients with extensive ischemia 
were considered for coronary revascularization.
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RESuLTS
Characteristics of patients
A total of 1,476 patients were enrolled and screened for cardiac risk factors, and 354 patients (24%), 
770 patients (52%), and 352 patients (23%) were classified as low-, intermediate- and high-risk, 
respectively (FIGURE 8.1). A total of 386 intermediate-risk patients were assigned to cardiac testing 
and 384 patients were assigned to no testing. There were no differences in the presence of ischemic 
heart disease (i.e., previous MI and angina pectoris) between the 2 groups (TABLE 8.1). Testing showed 
no ischemia in 287 patients (74%); limited ischemia in 65 patients (17%), and extensive ischemia in 
34 patients (8.8%). No serious side effects occurred during stress-testing. Stress-induced ischemia 
during dobutamine echocardiography was noted in 90 patients. The median HR at which ischemia 
occurred was 112 beats/min (range 92 to 120 beats/min). Of 34 patients with extensive stress-induced 
ischemia, revascularization before surgery was considered feasible by the treating physicians in 12 
patients (35%), percutaneous intervention in 10 patients, and bypass surgery in 2 patients. Coronary 
angiography showed 2-vessel disease in 5 patients (42%) and 3-vessel disease in 6 patients (50%). 
Complete revascularization was achieved in 6 patients (50%).
The median duration of screening to operation was 53 days (range 13 to 121 days) in patients assigned 
to testing and 34 days (range 7 to 88 days) in the no-testing group (p < 0.001). The HR decreased from 
a median of 70 beats/min at the screening visit to 60 beats/min before operation and was similar in 
both groups (FIGURE 8.2).
Perioperative cardiac events
The incidence of the 30-day end point in low-, intermediate-, and high-risk patients was 0.3%, 2.2%, 
and 8.5%, respectively (p < 0.001) (TABLE 8.2). No difference in 30-day outcome was observed in 
Table 8.1 Baseline characteristics.
Patients with 1 or 2 cardiac risk factors*
All Patients Testing No Testing
No. of patients 1,467 386 384
Age (yrs) 67.0 (59.5, 73.8) 67.3 (60.9, 73.9) 68.0 (60.9, 73.5)
Men (%) 73.3 77.5 72.1
History of diabetes (%) 21.8 22.3 21.9
History of angina pectoris (%) 55.1 67.6 63.8
History of myocardial infarction (%) 27.0 18.7 15.9
History of congestive heart failure (%) 11.5 3.9 3.7
History of cerebrovascular accident (%) 19.1 16.1 16.7
History of renal failure (%) 8.5 4.9 6.0
Statin use (%) 42.1 42.8 42.2
ACE inhibitor use (%) 32.6 31.6 33.1
Aspirin use (%) 45.3 47.2 44.5
Type of surgery
 Thoraco-abdominal (%) 4.9 5.2 4.4
 Tube graft (%) 12.6 15.0 10.7
 Bifurcated graft (%) 38.1 38.9 34.1
 Femoro-popliteal (%) 44.4 40.9 50.8
ACE = angiotensin-converting enzyme. *Cardiac risk factors include: age ≥70 yrs, angina pectoris, myocardial infarction, 
congestive heart failure, cerebrovascular accident, diabetes mellitus, and renal failure3.
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intermediate-risk patients with and without testing, (2.3% vs. 1.8%; odds ratio [OR] 0.78, 95% confi-
dence interval [CI] 0.28 to 2.1) (TABLE 8.2). The upper limit of the 95% CI of the absolute risk difference 
in favor of cardiac testing was 1.2%, indicating non-inferiority of the no-testing strategy according 
to our pre-specified criteria. The incidence of the primary end point in patients without, limited, and 
extensive ischemia was 0%, 6.2%, and 14.7%, respectively (p < 0.001). In intermediate-risk patients 
with extensive ischemia, revascularization did not improve 30-day outcome (25.0% vs. 9.1% events; 
OR 3.3, 95% CI 0.5 to 24; p = 0.32). One patient died after successful revascularization before surgery 
because of a ruptured aortic aneurysm.
Screening Admission Surgery Screening Admission Surgery
H
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rt
ra
te
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)
Testing No testing
median
50
60
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90
1st quartile
3rd quartile
Mean-SD
Mean+SD
Figure 8.2 Heart rate at the screening visit, at the day of hospital admission, and immediately before surgery in 
patients allocated to cardiac testing (left) or no testing (right).
Heart rate values are presented as beats/min (bpm).
Table 8.2 Patient outcome at 30 days after surgery.
No. of 
Pa-
tients
All-
Cause
Death 
(%)
p-
value
Cardio-
vascular 
Death 
(%)
p-
value
MI (%) Cardio-
vascular 
Death or 
MI (%)
Odds Ratio 
(95% CI)
p-
value
All patients 1,476 51 (3.5) 27 (1.8) 39 (2.6) 48 (3.3)
Cardiac risk factors 0.002 <0.001 <0.001
 0 354 6 (1.7) 1 (0.3) 0 (0) 1 (0.3) 1
 1 or 2 770 23 (3.0) 8 (1.0) 13 (1.7) 17 (2.2) 8.0 (1.1, 161)
 ≥3 352 22 (6.3) 18 (5.1) 26 (7.4) 30 (8.5) 33 (4.8, ∞)
Patients with 1 or 2 cardiac risk factors 0.14 0.29 0.62
 Allocated to testing 386 15 (3.9) 6 (1.6) 7 (1.8) 9 (2.3) 1
 Allocated to no testing 384 8 (2.1) 2 (0.5) 5 (1.3) 7 (1.8) 0.78 (0.28, 2.1)
Patients with 1 or 2 cardiac risk factors 
allocated to testing
<0.001 <0.001 <0.001
 No ischemia 287 6 (2.1) 0 (0) 0 (0) 0 (0) 1
 1–4 ischemic segments 65 3 (4.6) 2 (3.1) 4 (6.2) 4 (6.2) 42 (2.2, ∞)*
 ≥5 ischemic segments 34 6 (17.7) 4 (11.8) 3 (8.8) 5 (14.7) 107 (5.8, ∞)*
CI = confidence interval; MI = myocardial infarction. These estimators use a correction of 0.5 in the cell that contains a zero.
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Late cardiac events
The incidence of the 3-year end point in low-, intermediate-, and high-risk patients was 0.7%, 3.7%, 
and 14.8%, respectively. No difference in 2-year outcome was observed in intermediate-risk patients 
with and without testing (4.3% vs. 3.1%; p = 0.30) (FIGURE 8.3).
hR control
The incidence of the 30-day end point showed a significant correlation with HR control. The study 
aimed at a HR between 60 and 65 beats/min before surgery, and the median HR was 60 beats/min. 
The HR was below 50 beats/min in 1.7% of the intermediate-risk patients and more than 65 beats/
min in 16.5% (no difference between allocated groups). Patients with a HR <65 beats/min had lower 
incidence of the primary end point than the remaining patients (1.3% vs. 5.2%; OR 0.24, 95% CI 0.09 
to 0.66; p = 0.003). The incidence of the primary end point increased by a factor 1.5 (95% CI 1.1 to 2.0; 
p = 0.006) for each 5 beats/min heart-rate increase (FIGURE 8.4).
DISCuSSION
In this randomized, multicenter study, we found that cardiac testing of intermediate-risk patients 
before major vascular surgery, as recommended by the guidelines of the ACC/AHA, provided no 
benefit in patients receiving beta-blocker therapy with tight HR control1. Cardiac test results influ-
enced patients’ management. The treating physicians were aware of the presence of stress-induced 
myocardial ischemia as well as the HR at which ischemia occurred (i.e. ischemic threshold). Physicians 
were encouraged to control HR below the ischemic threshold. Furthermore, in a selected number 
of patients with extensive stress-induced ischemia, preoperative coronary revascularization was 
performed. According to the present guidelines, this is thought to be the optimal strategy. However, 
1 2 30 1 2 30
No risk factors 
1 or 2 risk factors
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Figure 8.3 Incidence of cardiac death or myocardial infarction (MI) during 3-year follow-up according to the 
number of cardiac risk factors (left) and allocated strategy in patients with 1 or 2 cardiac risk factors 
only (right).
The incidence of cardiac death or MI was associated with the number of cardiac risk factors at 
screening (log-rank p < 0.001). There was no significant difference in the long-term incidence of cardiac 
events between patients allocated to cardiac testing or no testing (log-rank p = 0.30).
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interestingly, compared with the no-testing population, a reverse trend in perioperative outcome 
was observed. An absolute increase in perioperative cardiac death or MI of more than 1.2% in patients 
assigned to no testing can be excluded with 95% certainty. Importantly, the strategy of no testing 
brought the operation almost 3 weeks forward.
Although testing identified a minority of intermediate-risk patients with an increased risk of periop-
erative cardiac death or MI, we considered the overall cardiac event rate of 2.2% in this population as 
sufficiently low to preclude testing.
Preoperative risk stratification with simple clinical cardiac risk markers effectively identified patients 
at low-, intermediate-, and high-risk with a perioperative cardiac event rate of 0.3%, 2.2%, and 8.5%, 
respectively. The absence of the aforementioned cardiac risk factors identified a population of truly 
low risk, even in the presence of peripheral atherosclerotic disease. During long-term follow-up a 
similar trend was observed; the incidence of late cardiac death and MI in low-, intermediate-, and 
high-risk patients was 0.7%, 3.7%, and 14.8%, respectively (p < 0.001).
Beta-blocker therapy has become an essential part of the medical treatment of patients with acute 
coronary syndromes, also a major cause of perioperative adverse outcome. Two randomized trials 
showed that perioperative beta-blocker therapy was associated with an improved outcome in high-
risk surgical patients6,7. A recent large retrospective observational study, evaluating the effect from 
663,635 surgical procedures confirmed the benefit of beta-blocker in those with increased risk8. 
These promising results were questioned by a recent meta-analysis of 8 randomized clinical trials 
evaluating a total number of 1,152 patients. This meta-analysis showed only a nominal statistically 
significant effect of beta-blockers for the composite end point of 30-day cardiovascular mortality, 
nonfatal MI, and nonfatal cardiac arrest (relative risk 0.44; 95% CI 0.20 to 0.97)9. Two more recently 
completed studies failed to show a favorable effect of beta-blockers. In the POBBLE (Perioperative 
Beta-Blockade) trial metoprolol failed to improve 30-day cardiovascular outcome in 97 low-risk 
0%
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Heart rate before surgery (bpm)
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Figure 8.4 Cumulative distribution of the heart rate before surgery (left) and the relation between heart rate and 
perioperative cardiovascular events (right).
For this analysis we included patients with 1 to 2 risk factors. The hazard ratio was adjusted for clinical 
risk factors. bpm = beats/min.
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vascular surgery patients; those with a history of ischemic heart disease were excluded10. The DIPOM 
(Diabetic Postoperative Mortality and Morbidity) trial, involving 921 patients with diabetes undergo-
ing non-cardiac surgery, failed to show that metoprolol significantly reduced the risk of death and 
cardiac complications after a median follow-up of 18 months11.
A potential factor that might explain these conflicting study outcomes is a difference in dosing and HR 
control. Beta-blockers reduce HR and myocardial contractility and, subsequently, myocardial oxygen 
demand. To exert the optimal beneficial effect, dose adjustments for HR control are important. In a 
small randomized study, the HR threshold at which ischemia occurred was assessed with ambulatory 
electrocardiographic monitoring in 26 patients12. These patients were randomized to either tight 
HR control (i.e. 20% less than the ischemic threshold but >60 beats/min) or normal, non-adjusted 
beta-blocker therapy. Tight HR control was associated with a significant reduction of perioperative 
ischemia in 7.7% versus 92%. We confirmed these findings, because tight HR control was clearly asso-
ciated with an improved outcome. We believe that for a proper interpretation of the perioperative 
cardiac protective effect of beta-blockers, the effect on HR control needs to be taken into account. 
This might be a potential limitation for clinical trials using a study design with blinded randomization 
and fixed beta-blocker doses.
Study limitations
The assessment of the HR at which ischemia occurred during stress-testing was only feasible in 
patients evaluated by dobutamine echocardiography. In patients evaluated by nuclear imaging only, 
the presence and extent of ischemia could be assessed. The effect of coronary revascularization in 
intermediate-risk patients with extensive stress-induced ischemia cannot be assessed, owing to the 
insufficient number of patients studied.
Conclusions
In conclusion, we found that 30-day and long-term cardiac death and MI rate in intermediate-risk 
patients undergoing abdominal aortic or infrainguinal arterial reconstruction surgery was sufficiently 
low to preclude preoperative testing for coronary artery disease.
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ABSTRACT
Background: Abdominal aortic aneurysm (AAA) size and growth has been found to be associated 
with local generation of inflammation markers such as interleukin-6. Inflammation also seems to play 
a pivotal role in perioperative adverse cardiac events. We hypothesized that patients with a large AAA 
are at increased risk for cardiac events.
Methods: Consecutive patients who underwent a CTA scan prior to open elective infrarenal AAA 
repair between March 2000 and December 2005 at 3 hospitals were analyzed. All patients were 
screened for clinical risk factors (age, gender, angina pectoris, myocardial infarction, heart failure, 
diabetes, stroke, renal failure, chronic obstructive pulmonary disease), and cardioprotective medica-
tion. Postoperatively data on troponin release, CK/CK-MB, and ECG were routinely collected. The main 
outcome measure was the combined endpoint of 30-day cardiovascular death and non-fatal MI. 
Multivariate Cox regression analysis was used to evaluate the influence of AAA size on postoperative 
cardiac outcome.
Results: A total of 500 patients were included in this study. Their mean age was 70 ± 9.3 years, and 
431 (86%) were male. Thirty-one (6.2%) patients suffered from perioperative cardiovascular compli-
cations, including 15 (3.0%) cardiovascular deaths and 16 (3.2%) nonfatal MIs. After correction for 
other risk factors, including age, Revised Cardiac Risk Index, medication use, duration of surgery, 
and intraoperative blood loss, AAA size was independently associated with perioperative nonfatal 
MI and cardiovascular death (3.2% increase in risk for each millimeter added, 95% CI 1.1% to 6.2%, 
p=0.007).
Conclusion: A larger AAA size is independently associated with an increased incidence of periopera-
tive cardiovascular complications after elective infrarenal AAA repair.
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INTRODuCTION
Abdominal aortic aneurysm (AAA) occurs frequently in the elderly population, i.e. a prevalence of 
5-7% in males between 65 and 74 years, increasing to over 10% in males over 74 years of age1-3. The 
overall mortality from ruptured AAA remains high, i.e. up to 75%, and preventive elective repair of 
large AAAs appears to be the best option4. However, perioperative cardiac complications of elective 
AAA repair remain a significant problem despite recent perioperative advancements such as cardio-
protective medication and improved anesthesiological and surgical care5,6.
The pathophysiology of these perioperative adverse cardiac events is not entirely clear. Coronary 
plaque instability because of inflammation leading to thrombosis and myocardial infarction is a 
major cause of perioperative cardiac events similar to myocardial infarctions occurring in the non-
operative setting7. At least two studies evaluating the pathophysiology of perioperative MI using 
non-invasive tests, coronary angiography, and autopsy results showed that coronary plaque rupture 
and thrombus formation occurred in around 50% of all fatal cases, while a sustained mismatch of 
oxygen supply and demand was responsible for the remaining half8,9.
It has been shown that AAAs might be an important source of circulating inflammatory markers, e.g. 
Interleukin-6 (IL-6), serum amyloid A, C-reactive protein, and high sensitive C-reactive protein. These 
inflammatory markers are also positively related to the abdominal aortic size10-13. As was recently 
shown the concentration of inflammatory markers such as IL-6 and high sensitive C-reactive protein is 
predictive for adverse cardiac events in patients with peripheral arterial disease14. Furthermore it has 
also been shown by Brady et al. that AAA size is predictive for long-term cardiovascular mortality15.
Since AAA size and growth seems to be related to the concentration of circulating (pro-) inflammatory 
markers and to long-term cardiac outcome we hypothesized that patients with a large AAA might be 
more prone to adverse perioperative cardiac events after AAA repair than patients with small AAAs. 
To evaluate this hypothesis we conducted the present study.
METhODS
Patient population
The study population was composed of patients who underwent a CTA scan prior to elective open 
infrarenal abdominal aortic aneurysm repair between January 2000 and January 2005 at one of 
three hospitals, i.e. Erasmus University Medical Center in Rotterdam, Albert Schweitzer Hospital in 
Dordrecht, and Reinier de Graaf Hospital in Delft, the Netherlands. Patients were retrospectively 
identified by screening of surgical medical charts. A CTA scan of the AAA prior to surgical repair to 
measure the maximum diameter of the AAA was required to be included in this analysis. All CTA 
scans were scored, including maximum diameter, by the attending radiologist. In a weekly meeting 
of radiologists and vascular surgeons the measurements of the AAAs were reviewed and if necessary 
adjusted after consensus was reached. To obtain a more homogenous study population patients 
with an inflammatory or mycotic aneurysm were excluded from analysis. All operation reports were 
screened to make sure only patients requiring infrarenal aortic cross clamping were included in the 
analysis. The study was approved by the Medical Ethics Committee of the Erasmus Medical Center.
Ch
ap
te
r 9
126
Perioperative cardiac risk assessment
All patients were screened for cardiac risk factors, including age, hypertension (i.e. medical therapy 
to control hypertension), history of or presence of angina pectoris, previous myocardial infarction, 
heart failure, stroke, renal failure (i.e. a serum creatinine of >2.0 mg/dL), diabetes mellitus. Smoking 
status (never, current, or former) and the presence of chronic obstructive pulmonary disease (COPD) 
was noted as well. A patient was classified as having COPD at the preoperative screening visit 
according to symptoms and pulmonary function test (i.e. FEV1 <70% of maximal age and gender 
predictive value). Heart failure was scored according to the notes of the preoperative screening 
visits as well. All prescription and over-the-counter medications were noted on the day of admission 
and were classified as follows: statins, beta-blockers, platelet aggregation inhibitors, angiotensin 
converting enzyme inhibitors, calcium channel blockers, diuretics, and nitrates. Patients unable 
to take medication orally perioperatively were switched to intravenous formula. If no intravenous 
formula was available, i.e. statins and angiotensin converting enzyme inhibitors, oral medication 
was restarted as soon as possible after surgery. In all patients duration of surgery and intraoperative 
blood loss were noted.
Outcome
The main outcome measure was the combined endpoint of 30-day cardiovascular death and non-
fatal myocardial infarction. Secondary, 30-day all-cause mortality was analyzed. Cardiovascular death 
was defined as any death with a cardiovascular cause, including those deaths following a cardiac 
procedure, cardiac arrest, myocardial infarction, pulmonary embolus, stroke, or sudden deaths not 
ascribed to other causes. Myocardial infarction was defined as the presence of 2 out of the follow-
ing 3 criteria: (1) Characteristic ischemic symptoms lasting > 20 minutes, (2) electrocardiographic 
changes including acute ST elevation followed by appearance of Q waves or loss of R waves, or new 
left bundle branch block, or new persistent T wave inversion for at least 24 hours, or new ST segment 
depression which persists > 24 hours, and (3) a positive troponin T, i.e. >0.10 ng/ml, or peak creatinine 
phosphokinase -MB >8% of an elevated total creatinine phosphokinase with characteristic rise and 
fall16. To assess cardiac complications during the postoperative period blood and plasma samples 
for cardiac troponin T, creatinine phosphokinase levels, creatinine phosphokinase -MB levels, and 
electrocardiography were collected.
Statistical analysis
Continuous variables were described as mean value (range), and categorical variables as percent 
frequencies. Linear regression analysis was used to explore the relation between aneurysm size and 
duration of surgery and blood loss. Kaplan-Meier survival curves were constructed to assess periop-
erative cardiovascular event-free and overall survival. The association of AAA size, cardiovascular risk 
factors and medication use with perioperative cardiovascular complications and all-cause death was 
assessed via multivariate Cox regression analysis. All covariables associated with perioperative cardiac 
complications or all-cause mortality (p < 0.20 in univariate analysis) were included in the multivariate 
model. The number of outcome events in the study was limited. Therefore, to avoid overfitting, and to 
enable assessment of the relation between clinical risk factors and the perioperative composite end-
point, we used the Revised Cardiac Risk Index16. The Revised Cardiac Risk Index identifies 6 predictors 
(high-risk surgery, ischemic heart disease, congestive heart failure, cerebrovascular disease, insulin 
dependent diabetes mellitus, and renal failure) of major cardiac complications. Based on the pres-
ence of 0, 1, 2, or 3 or more of these predictors, the rate of major cardiac complications was estimated 
to be 0.4%, 0.9%, 7%, and 11%, respectively in the original study by Lee et al. resulting in an excellent 
area under the curve (AUC) of 0.81. Receiver operating characteristic curve analysis was performed to 
calculate AUC values. The performance of risk models can be determined by the AUC, which indicates 
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how well a model rank orders patients with respect to their outcomes, where 0.5 indicates no predic-
tive value and 1.0 indicates perfect performance17. The limit of statistical significance was set at p 
= 0.05 (two sided). All analysis was performed using the statistical software SPSS for Windows 12.1 
(SPSS Inc., Chicago, Illinois, USA).
RESuLTS
Patient characteristics
A total of 500 patients with an infrarenal AAA were included in the study. The majority of patients 
were males (86%) and the mean age was 70 ± 9.3 years. The overall median maximum AAA diameter 
was 56 mm (range 42 to 110 mm). According to the Revised Cardiac Risk index classification almost 
half of the patients (41%) had 1 risk factor, i.e. high-risk type of surgery, whereas respectively 33% 
and 26% had 2, and 3 or more risk factors. Baseline clinical characteristics and medication use are 
presented in TABLE 9.1. The median duration of surgery was 216 minutes and median blood loss 
Table 9.1
Baseline characteristics, surgery, and medication use during hospitalization of all patients and in patients 
with or without perioperative events.
All patients
(N=500)
Patients without events
(N=469)
Patients with events
(N=31)
Men – no. (%) 431 (86) 404 (86) 27 (87)
Age – mean (SD) 70 (9.3) 70.3 (60 – 89) 73.5 (64 – 89)
Median AAA size – mm (range) 56 (42 – 110) 56 (42 – 110) 66 (47 – 95)
Median duration of surgery – min (range) 216 (120 – 535) 216 (120 – 500) 210 (140 – 535)
Median blood loss – ml (range) 2100 (400 –18000) 2100 (400 – 18000) 3100 (2000 - 6500)
Previous Angina Pectoris – no. (%) 110 (22) 101 (22) 9 (29)
Previous myocardial infarction – no. (%) 163 (33) 150 (32) 13 (42)
Previous heart failure – no. (%) 26 (5) 24 (5) 2 (7)
CVA or TIA – no. (%) 77 (15) 72 (15) 5 (16)
Diabetes Mellitus – no. (%) 48 (10) 45 (10) 3 (10)
Renal failure – no. (%) 28 (6) 24 (5) 4 (13)
Systemic hypertension – no. (%) 207 (42) 197 (43) 10 (33)
COPD – no. (%) 127 (25) 115 (25) 12 (39)
Revised Cardiac Risk Index
 1 risk factor – no. (%) 203 (41) 195 (42) 8 (26)
 2 risk factors – no. (%) 165 (33) 154 (33) 11 (36)
 3 or more risk factors – no. (%) 132 (26) 120 (26) 12 (39)
Platelet aggregation inhibitors – no. (%) 178 (36) 170 (36) 8 (26)
ACE-inhibitors – no. (%) 152 (31) 144 (31) 8 (26)
Diuretics – no. (%) 84 (17) 80 (17) 4 (13)
Nitrates – no. (%) 66 (13) 60 (13) 6 (19)
Beta-blockers – no. (%) 364 (73) 349 (74) 15 (48)
Statins – no. (%) 202 (40) 196 (42) 6 (19)
Calcium-antagonists – no. (%) 157 (31) 147 (32) 10 (32)
MI = myocardial infarction; CVA = Cerebrovascular event; TIA = transient ischemic attack; COPD = chronic obstructive 
pulmonary disease; ACE = angiotensin-converting enzyme
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during surgery was 2100 ml. Neither duration of surgery (p = 0.78) nor blood loss during surgery (p = 
0.13) was related to AAA size.
Perioperative cardiovascular outcome
Perioperative cardiac events occurred in 31 (6.2%) patients. These events included cardiovascular 
death (n=15) and non-fatal MI (n=16). In univariate analysis age, AAA diameter, and Revised Cardiac 
Risk Index were associated with worse outcome, whereas beta-blocker therapy and statin therapy 
were both associated with a reduced incidence of perioperative adverse cardiac events (TABLE 9.2). 
In multivariate analysis AAA size was associated with an increased incidence of perioperative cardiac 
events (3.4% increase in risk for each millimeter added, 95% CI 1.1 % - 6.2%, p = 0.007). Furthermore 
age and a higher score of the Revised Cardiac Risk Index were associated with an increased risk of 
perioperative cardiac events (TABLE 9.2). ROC analysis showed an area-under-the-curve (AUC) of 0.60 
for the Revised Cardiac Risk Index alone, but this AUC improved to 0.69 if AAA size was added to 
the model (p = 0.001). If age was added to the model as well, the AUC further improved to 0.75 (p 
= 0.003). Beta-blocker therapy and statin therapy on the other hand were both associated with a 
reduced incidence of perioperative cardiac events in multivariate analysis (Hazard ratio 0.31, 95% CI 
0.15-0.63, and Hazard ratio 0.40, 95% CI 0.16–0.95 respectively).
Table 9.2 Perioperative cardiac death and nonfatal myocardial infarction.
Univariate analysis Multivariate analysis
OR 95% CI P-value adjusted OR 95% CI P-value
Men 1.09 0.38 – 3.12 0.87
Age (per year increase) 1.09 1.04 – 1.14 0.001 1.07 1.02 – 1.12 0.01
AAA diameter (per mm increase) 1.04 1.02 – 1.06 0.001 1.03 1.01 – 1.06 0.007
Intraoperative blood loss (per 500 ml 
increase)
1.06 0.92 – 1.22 0.41
Duration of surgery (per 10 minutes 
increase)
1.02 0.97 – 1.07 0.43
Systemic hypertension 0.68 0.32 – 1.46 0.68
Chronic obstructive pulmonary 
disease
1.91 0.93 – 3.93 0.08 1.81 0.85 – 3.89 0.13
Revised Cardiac Risk Index
 1 risk factor 1 1
 2 risk factors 1.73 0.70 - 4.30 0.24 2.30 0.92 - 5.76 0.07
 3 or more risk factors 2.35 0.96 – 5.75 0.06 3.55 1.40 – 8.99 0.008
Medication use
 Platelet aggregation inhibitors 0.62 0.28 – 1.40 0.25
 ACE-inhibitors 0.79 0.36 – 1.78 0.58
 Diuretics 0.73 0.26 – 2.10 0.56
 Nitrates 1.58 0.65 – 3.86 0.31
 Beta-blockers 0.34 0.17 – 0.69 0.003 0.31 0.15 – 0.63 0.01
 Statins 0.35 0.14 – 0.85 0.02 0.40 0.16 – 0.95 0.04
 Calcium-antagonists 1.04 0.49 - 2.20 0.92
AAA = abdominal aortic aneurysm; COPD = chronic obstructive pulmonary disease; ACE = angiotensin converting enzyme; 
Odds ratio (OR), 95% confidence intervals (CI) and p-values in univariate analysis by means of the Log-rank test and 
multivariate analysis by means of Cox regression analysis
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Perioperative all-cause mortality
In total 29 (5.8%) patients died during the first 30 days after AAA repair. Of these 15 (52%) were caused 
by cardiovascular complications, 4 (14%) by respiratory complications, 6 (21%) by multi-organ failure, 
and 4 (14%) by other complications. The results of univariate analysis are shown in TABLE 9.3. The size 
of AAA was not significantly associated with perioperative all-cause death (p = 0.08) in univariate 
analysis. In multivariate analysis (TABLE 9.3) AAA size was also not associated with an increase or 
reduction in perioperative all-cause mortality (adjusted Odds ratio for every mm increase in size 1.02, 
95% CI 0.98–1.05, p = 0.35). Two or more clinical risk factors and increased age were associated with 
an increased incidence of 30-day mortality in multivariate analysis. Beta-blocker therapy and statin 
therapy on the other hand were associated an approximate 4-fold relative risk reduction (TABLE 9.3).
DISCuSSION
This study showed an association between AAA size and perioperative cardiovascular complications 
after elective infrarenal AAA repair irrespective of other known factors influencing perioperative 
cardiovascular outcome. This study also showed a beneficial effect of both statin therapy and beta-
blocker therapy in patients undergoing open AAA repair.
Table 9.3 Perioperative all-cause mortality.
Univariate analysis Multivariate analysis
OR 95% CI P-value adjusted 
OR
95% CI P-value
Men 1.39 0.42 – 4.58 0.59
Age (per year increase) 1.10 1.04 – 1.15 0.001 1.09 1.03 – 1.15 0.005
AAA diameter (per mm increase) 1.02 0.99 – 1.05 0.08 1.02 0.98 – 1.05 0.35
Intraoperative blood loss (per 500 ml 
increase)
1.14 1.01 – 1.28 0.04 1.07 1.01 – 1.17 0.04
Duration of surgery (per 10 minutes 
increase)
1.02 0.97 – 1.08 0.39
Systemic hypertension 1.51 0.71 – 3.21 0.28
Chronic obstructive pulmonary disease 1.83 0.86 – 3.87 0.12 1.50 0.63 – 3.58 0.36
Revised Cardiac Risk Index
 1 risk factor 1 1
 2 risk factors 2.79 0.97 – 8.02 0.06 3.28 1.11 – 9.72 0.03
 3 or more risk factors 4.16 1.48 – 11.66 0.007 4.88 1.62 – 14.67 0.005
Medication use
 Platelet aggregation inhibitors 0.82 0.37 – 1.79 0.61
 ACE-inhibitors 0.73 0.31 – 1.70 0.46
 Diuretics 1.96 0.87 – 4.43 0.11 2.10 0.79 – 5.61 0.14
 Nitrates 1.06 0.37 – 3.04 0.91
 Beta-blockers 0.29 0.14 – 0.61 0.001 0.21 0.10 – 0.45 <0.001
 Statins 0.30 0.12 – 0.79 0.02 0.26 0.11 – 0.76 0.01
 Calcium-antagonists 2.08 1.01 – 4.32 0.05 2.10 0.89 – 4.82 0.09
AAA = abdominal aortic aneurysm; COPD = chronic obstructive pulmonary disease; ACE = angiotensin converting enzyme; 
Odds ratio (OR), 95% confidence intervals (CI) and p-values in univariate analysis by means of the Log-rank test and 
multivariate analysis by means of Cox regression analysis
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The overall 30-day mortality rate of 5.8% is in line with other studies on open infrarenal AAA repair18. 
As has been reported in previous studies approximately half of all perioperative deaths after AAA 
repair are attributable to cardiovascular complications, an observation that was confirmed in our 
study. The 6.2% perioperative overall cardiac event rate of our study emphasizes the high cardiac risk 
for patients undergoing vascular surgery. This high cardiac risk is explained by the high prevalence of 
(a-) symptomatic coronary artery disease in AAA patients. As was shown by Hertzer et al. in a study 
involving 1000 vascular surgical patients undergoing coronary angiography, over 60% of patients 
with an AAA have some form of coronary artery disease19. As these lesions may cause a myocardial 
supply / demand imbalance due to prolonged tachycardia and increased myocardial contractility20, 
they are thought to be responsible for approximately half of all postoperative myocardial infarctions. 
This hypothesis has been confirmed in at least two studies using non-invasive tests, coronary angiog-
raphy, and autopsy results8,9. The other 50% of myocardial infarctions might be caused by sudden 
rupture of so-called vulnerable coronary plaques. Surgery imposes extra myocardial workload, result-
ing in mechanical stress, stress-induced inflammation and possibly spasms. This can cause vulner-
able plaques to become unstable, leading to the cascade of plaque rupture, thrombus formation, 
myocardial ischemia, myocardial infarction, and eventually death. Naghavi and colleagues, in their 
extensive review on vulnerable plaques, reported that inflammation is one of the major criteria in 
the definition of vulnerable plaques7,21. It is generally well accepted that inflammation is of imminent 
importance in the whole process. Therefore, most research has been focused on inflammation of 
coronary plaques as the ultimate trigger for vulnerable plaque rupture. This interest in inflammatory 
components has been justified in several population-based studies in which a positive relationship 
between inflammation markers and the occurrence of cardiovascular events was found22.
In recent studies the presence of an abdominal aortic aneurysm was found to be positively related 
to circulating inflammatory markers. These inflammatory markers include IL-1 beta, IL-6, TNF-alpha, 
IFN-gamma, CRP, and high-sensitive CRP10-13,23. Importantly, both Jones et al. and Rhode et al. found 
a positive correlation between circulating IL-6 levels and AAA size10. Vainas et al. found a similar 
correlation between high-sensitive CRP and AAA size. Importantly, they also found CRP mRNA in 
AAA tissue11. Based on these observations it might be hypothesized that aneurysmal tissue produces 
inflammatory markers. In other words, patients with an AAA have a higher level of circulating inflam-
matory markers, and patients with a large AAA have a higher level of circulating inflammatory mark-
ers than patients with small AAAs. However, a different hypothesis might also be true; patients with 
an elevated inflammatory status may be more prone to AAA development and growth than patients 
with a normal inflammatory status. Subsequently patients with an elevated inflammatory status have 
a faster growing, larger AAA. Which hypothesis is true remains unknown and further research in this 
area is required.
In large prospective population based studies it was shown that circulating levels of high-sensitive 
C-reactive protein and IL-6 are related to long-term cardiac outcome. In a study by Ridker et al. IL-6 
was a good predictor for myocardial infarction during a 6-year follow-up in 440 patients24. Also 
elevated high-sensitive C-reactive protein levels nowadays, supported by several clinical studies, are 
considered to be associated with long-term adverse cardiac events.
Since patients with large AAAs seem to have an elevated inflammatory status compared to patients 
with small AAAs it might be hypothesized that patients with a large AAA are more prone to vulnerable 
plaque rupture than patients with a small AAA (FIGURE 9.1). This hypothesis was confirmed by Brady 
et al. in a group of 2305 patients; AAA size was associated with a 34% increased risk for cardiovascular 
long-term mortality for every 0.8 cm added to AAA size15.
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The outcome of the UK Small Aneurysm Trial did not show a relation between AAA size and periop-
erative all-cause 30-day mortality25. Our study confirmed this observation. No association between 
AAA size and perioperative all-cause mortality was found. Unfortunately the UK Small Aneurysm Trial 
did not reported on cardiac death. It would be interesting to evaluate recent prospective trials on 
infrarenal abdominal aneurysm repair such as the UK Small Aneurysm Trial, the DREAM trial26 and 
EVAR-1 trial27 for the relationship between AAA size and postoperative cardiac outcome.
This study has several limitations due to its retrospective nature. Autopsy was performed in only a 
minority of patients that died and thus misclassification of cause of death might have occurred. Also, 
there was no prespecified protocol for the measurement of the maximum abdominal aortic diameter 
and the measurement of this diameter was done on the basis of institutional common practice. 
Furthermore no information on the inflammatory state of our study population, e.g. IL-6 and hsCRP 
levels, was available.
In conclusion, this study shows a clear association between AAA size and postoperative cardiac 
outcome, irrespective of other known risk factors. Future studies on the influence of AAA size on 
perioperative outcome should, if possible, also include the patients’ inflammatory status.
Production of inflammatory 
markers in AAA wall
Infiltration of coronary plaque
Rupture of coronary plaque
Myocardial infarction
Figure 9.1 From abdominal aortic aneurysm (AAA) to myocardial infarction in patients undergoing AAA repair.
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ABSTRACT
Objective: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is secreted by the heart in response 
to ventricular wall stress and has prognostic value in patients with heart failure, coronary artery dis-
ease and heart valve abnormalities. Postoperative and long-term outcome is also related to these risk 
factors. This study was conducted to assess the additional prognostic value of NT-proBNP levels as a 
simple objective risk marker for postoperative cardiac events among vascular surgery patients.
Methods: In 400 vascular surgery patients a detailed cardiac history (angina, myocardial infarction, 
age > 70 years, diabetes, renal failure, stroke, heart failure), resting echocardiography and NT-proBNP 
levels were obtained. Postoperative troponin-T and ECG were obtained on day 1, 3, 7, 30 and 
whenever clinically indicated. Patients were followed every 6 months at the outpatient clinic. Study 
endpoints were perioperative cardiac events, i.e. composite of cardiac death, myocardial infarction, 
and troponin release, and long-term all-cause mortality. Multivariable regression analyses were used 
to assess the additional value of NT-proBNP, and the optimal cut-off value was assessed by ROC curve 
analysis.
Results: Postoperative troponin T release occurred in 79 (20%) patients. Using cardiac risk factors only, 
patients were classified as low (0 risk factors), intermediate (1-2) and high (≥ 3) cardiac risk (event rate 
7%, 15%, and 37% respectively). Median NT-proBNP level was 206 pg/ml (interquartile range 80-548). 
The risk of postoperative cardiac events was augmented with increasing NT-proBNP, irrespective of 
underlying cardiac risk factors and type of vascular surgery. In addition to cardiac risk factors only 
(C-index 0.66) or cardiac risk factors and site and type of surgery (C-index 0.81), NT-proBNP was an 
excellent tool for further risk stratification (C-index 0.86) with an optimal cut-off value of 350 pg/ml. 
In multivariate analysis NT-proBNP > 350 pg/ml remained significantly associated with periopera-
tive cardiac events (OR 4.7, 95% CI 2.1-10.5, p < 0.001). NT-proBNP > 350 pg/ml was also associated 
with an independent 1.9-fold (95% CI 1.1-3.2) increased risk for long-term mortality during a median 
follow-up of 2.4 years.
Conclusion: NT-proBNP is an independent prognostic marker for postoperative cardiac events and 
long-term mortality in patients undergoing different types of vascular surgery and might be used for 
preoperative cardiac risk stratification.
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INTRODuCTION
Cardiovascular complications are a major cause for morbidity and mortality in patients undergoing 
non-cardiac vascular surgery. The incidence of perioperative myocardial infarction in major non-
cardiac vascular surgery is around 4 to 5% and the prevalence of symptomatic or asymptomatic 
perioperative myocardial damage as assessed by serum troponin I or serum troponin T is even 15 to 
25%1,2. Also long-term outcome of vascular patients after surgery is severely compromised by their 
cardiac status. As was recently shown, cardiovascular deaths account for up to 50% of long-term 
mortality in this group of patients3.
Identification of patients at increased cardiac risk is of critical importance. In a previous observational 
study of 1,351 patients undergoing major vascular surgery, we found that counting clinical risk factors 
effectively stratified vascular surgery patients into low-risk (0 risk factors), intermediate-risk (1 to 2 
risk factors), and high-risk (≥ 3 risk factors) categories4. In vascular surgery patients clinical evaluation 
alone may underestimate cardiac risk as symptoms of coronary artery disease might be obscured by 
peripheral arterial disease symptoms such as intermittent claudication. As was shown cardiac stress 
testing significantly improves preoperative risk stratification in vascular surgical patients4. However, 
cardiac stress testing is costly, requires highly trained personnel and is time consuming.
Recently, it has been suggested that N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) might 
be a useful laboratory measurement to improve preoperative cardiac risk stratification in addition 
to clinical evaluation5-7. This laboratory measurement is simple, avoids the extra costs and time 
of cardiac stress testing and is easy to interpret. Previously, several studies at our institution were 
performed evaluating the predictive value of NT-proBNP. However, the studied groups were relatively 
small and the maximum median follow-up was only 14 months. Therefore, the aim of the current 
study was to evaluate the usefulness of NT-pro-BNP in risk stratification, for both perioperative and 
long term outcome, of an unselected group of patients undergoing non-cardiac vascular surgery.
METhODS
Patients
The study population consisted of 400 patients undergoing elective surgery during the period 
January 2005 to November 2006. Patients undergoing abdominal aortic aneurysm repair, peripheral 
bypass surgery and carotid surgery were included in the analysis. These patients were identified in a 
prospectively maintained database of all patients undergoing vascular surgery at this institution. The 
study was approved by the Medical Ethics Committee of Erasmus MC.
Prior to surgery, a detailed cardiac history was obtained and patients were screened for hypertension 
(blood pressure >140/90 mmHg, or medical therapy to control hypertension), diabetes mellitus (fast-
ing glucose level >7.0 mmol/L, or medication to control diabetes), and renal failure (serum creatinine 
level ≥ 2.0 mg/dL). The presence of coronary artery disease was indicated by a previous myocardial 
infarction, previous coronary intervention, or present stable angina pectoris. Other cardiovascular risk 
factors scored in all patients included a history of CVA or TIA, age over 70 years, chronic heart failure, 
and chronic obstructive pulmonary disease (defined as a FEV1 < 70% of age and gender predictive 
value or medication use).
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At our institution troponin T levels are routinely measured in patients undergoing major vascular 
surgery on postoperative day 1, 3, 7, 30 and whenever clinically indicated by ECG changes, consistent 
with myocardial ischemia or infarction. Routinely ECGs were recorded preoperatively and on day 1, 3, 
7, and 30 after surgery. Troponin T level was measured using a whole blood rapid test (TropT version 
2, Roche Diagnostics, Mannheim, Germany).
Measurement of plasma NT–pro-BNP
A median of 27 days (interquartile range 3–83 days) prior to the surgical procedure NT-proBNP level 
was measured. The samples were centrifuged, and plasma was frozen at −80°C until assay. NT–pro-BNP 
was measured with an electrochemoluminescence immunoassay kit (Elecsys 2010, Roche Diagnos-
tics GmbH, Mannheim, Germany). The method is a “sandwich”-type quantitative immunoassay based 
on polyclonal antibodies against epitopes in the N-terminal part of pro-BNP. The lower detection 
limit was 5 pg/ml. Intra-assay coefficients of variance at 271 and 6,436 pg/ml were 1.9% and 0.9%, 
respectively. Assays were performed by a laboratory technician blinded to the patients’ clinical data.
Outcome measures
Perioperative endpoints were myocardial damage, defined by elevated troponin T levels, non-fatal 
myocardial infarction and cardiovascular death within 30 days after surgery. The long-term endpoint 
was all-cause mortality. Myocardial infarction was defined as the presence of 2 out of the follow-
ing 3 criteria: (1) Characteristic ischemic symptoms lasting > 20 minutes, (2) electrocardiographic 
changes including acute ST elevation followed by appearance of Q waves or loss of R waves, or 
new left bundle branch block, or new persistent T wave inversion for at least 24 hours, or new ST 
segment depression which persists > 24 hours, and (3) a positive troponin T, i.e. >0.10 ng/ml, or 
peak CK-MB >8% of an elevated total creatinine phosphokinase with characteristic rise and fall8. 
Cardiovascular death was defined as any death with a cardiovascular cause, including those deaths 
following a cardiac procedure, cardiac arrest, myocardial infarction, pulmonary embolus, stroke, or 
sudden deaths not ascribed to other causes. Survival status was ascertained by contacting the civil 
service registry.
Statistical analysis
Continuous data with a normal distribution are expressed as means and were compared using 
Student’s t test. Continuous data with a significant skewed distribution are expressed as medians 
and were compared using the Mann-Whitney U-statistic test. Categorical data are presented as per-
centage frequencies, and differences between proportions were compared using the chi-square test. 
Univariate logistic regression analysis was used to evaluate the association of baseline characteristics 
and NT–pro-BNP values with postoperative outcome. Furthermore, the association of cardiovas-
cular risk factors, site and type of surgery and NT-proBNP levels with perioperative cardiovascular 
complications and all-cause death as well as long-term mortality was assessed via multivariate Cox 
regression analysis including interaction terms. All covariables associated with perioperative cardiac 
complications or all-cause mortality (p < 0.20 in univariate analysis) were included in the multivariate 
model. The number of outcome events in the study was limited. Therefore, to avoid overfitting, and to 
enable assessment of the relation between clinical risk factors and the perioperative and long-term 
endpoint, we used the cardiac risk score as described by Boersma et al.4 This cardiac risk score identi-
fies 7 predictors (age > 70 years, history of myocardial infarction, congestive heart failure, angina 
pectoris, cerebrovascular disease, diabetes mellitus, and renal failure) of major cardiac complications. 
Based on these risk factors patients can be categorized as low risk (no risk factors), intermediate risk 
(1 or 2 risk factors) and high risk (≥ 3 risk factors). Receiver operating characteristic curve analysis was 
performed to calculate AUC values and the optimal NT-proBNP cut-off value for both perioperative 
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cardiac events and long-term mortality. The performance of risk models can be determined by the 
AUC, which indicates how well a model rank orders patients with respect to their outcomes, where 
0.5 indicates no predictive value and 1.0 indicates perfect performance. The limit of statistical signifi-
cance was set at p = 0.05 (two-sided). All analysis was performed using the statistical software SPSS 
for Windows 12.1 (SPSS Inc., Chicago, Illinois, USA).
RESuLTS
Patient characteristics
A total of 400 patients undergoing abdominal aortic aneurysm repair (n=159), lower limb arterial 
reconstructions (n=130) or carotid artery surgery (n=111) were included in the study. Endovascular 
procedures comprised 30% of the studied surgical procedures; 68 endovascular aneurysm repair and 
52 carotid artery stenting. The majority of patients were males (76%) and the mean age was 67.5 ± 
10.6 years. According to cardiac risk score by Boersma et al. 14% of patients had low cardiac risk, 60% 
intermediate cardiac risk and 26% high cardiac risk. Baseline clinical characteristics are presented in 
TABLE 10.1.
The median NT-proBNP level was 206 pg/ml, interquartile range 80–548 pg/ml. Median levels of NT-
proBNP increased with preoperative cardiac risk according to clinical risk factors4; low risk 95 pg/ml, 
Table 10.1 Baseline characteristics.
All patients (N =400)
Men – no. (%) 305 (76)
Age – mean ± SD 67.5 ± 11
Risk factors
 Previous angina pectoris – no. (%) 101 (25)
 Previous myocardial infarction – no. (%) 118 (30)
 Previous heart failure – no. (%) 18 (5)
 Previous CABG or PTCA – no. (%) 91 (23)
 CVA or TIA – no. (%) 156 (9)
 Diabetes Mellitus – no. (%) 88 (23)
 Renal failure – no. (%) 33 (8)
 Systemic hypertension – no. (%) 189 (47)
 COPD – no. (%) 140 (35)
Clinical cardiac risk
 Low – no. (%) 54 (14)
 Intermediate – no. (%) 241 (60)
 High – no. (%) 105 (26)
Site of surgery
 Carotid artery – no. (%) 111 (28)
 Abdominal aortic – no. (%) 159 (40)
 Lower extremity  – no. (%) 130 (32)
Type of surgery
 Endovascular treatment – no. (%) 120 (30)
 Open surgery – no. (%) 280 (70)
CABG = coronary artery bypass graft; PTCA = percutaneous transluminal coronary angioplasty; CVA = cerebrovascular 
accident; TIA = transient ischemic attack; COPD = chronic obstructive pulmonary disease
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intermediate risk 184 pg/ml, and high risk 440 pg/ml. Patients undergoing aortic aneurysm repair or 
lower extremity arterial reconstructions had a significantly higher median NT-proBNP level compared 
to patients scheduled for carotid artery surgery; respectively 226 pg/ml, 283 pg/ml, and 119 pg/ml. 
Other variables associated with NT-proBNP are shown in TABLE 10.2.
Perioperative outcome
A total of 79 patients (20%) experienced troponin release, indicative for myocardial ischemia. Of 
these 19 (5%) patients had also either ischemic symptoms or ECG changes suggestive for infarction 
and were thus classified as patients with myocardial infarction. At total of 12 (3.0%) patients died 
within 30 days after surgery of which 8 (2.0%) died due to a cardiovascular cause.
Patients undergoing aortic aneurysm repair or lower extremity arterial revascularization had a sig-
nificantly higher incidence of myocardial damage as compared to patients undergoing carotid artery 
surgery (30%, 21% and 4% respectively, p < 0.001). Also preoperative risk score based on clinical risk 
factors alone was a good predictor for postoperative myocardial damage; the incidence of myocardial 
ischemia was 7% for patients deemed to be at low risk, 15% for patients at intermediate risk, and 37% 
for patients at high risk (p < 0.001).  Tertiles of NT-proBNP were also strong predictors of perioperative 
events, in particular patients in the highest tertile had a high risk for perioperative events; lowest 
tertile 6%, intermediate tertile 12% and highest tertile 42% (p < 0.001) (FIGURE 10.1A and 10.1B). 
Other univariate predictors of perioperative cardiac events are shown in TABLE 10.3.
Using ROC curve analysis an optimal cut-off value for NT-proBNP for the prediction of perioperative 
cardiac events was established, i.e. 350 pg/ml (FIGURE 10.2). Using this cut-off value, in univariate 
Table 10.2 Association between risk factors and median NT-proBNP levels (pg/ml).
yes No P-value
Men 204 213 0.49
Age (per year increase) 0.18
Risk factors
 Previous angina pectoris 326 170 0.04
 Previous myocardial infarction 329 162 0.006
 Previous heart failure 1064 192 <0.001
 CVA or TIA 182 210 0.17
 Diabetes Mellitus 211 198 0.27
 Renal failure 1484 180 <0.001
Clinical cardiac risk
 Low 95 Reference
 Intermediate 184 0.11
 High 440 0.01
Site of surgery
 Carotid artery 119 Reference
 Abdominal aortic 226 0.09
 Lower extremity 283 0.004
Type of surgery
 Endovascular treatment 188 0.71
 Open surgery 213
CABG = coronary artery bypass graft; PTCA = percutaneous transluminal coronary angioplasty; CVA = cerebrovascular 
accident; TIA = transient ischemic attack; COPD = chronic obstructive pulmonary disease
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analysis patients with levels of NT-proBNP above this value were at 7-fold increased risk for periopera-
tive cardiac events (95% CI 4.0–12.3) (FIGURE 10.3). Also in multivariate analysis, using interaction 
terms and adjusting for clinical cardiac risk factors, site and type of surgery, patients with a NT-proBNP 
level > 350 pg/ml were at a significant 4.7 fold increased risk (95% CI 2.1–10.5, p<0.001). Importantly, 
also when adding the different clinical risk factors separately in the multivariate model, i.e. not as a 
clinical risk index, an elevated NT-proBNP remained independently associated with an increased risk 
for perioperative myocardial damage (adjusted OR 5.8; 95% CI 2.9–11.8).
Table 10.3 Predictors of perioperative cardiac damage.
univariate Multivariate
OR 95% CI P-value OR 95% CI P-value
Clinical risk score
 Low cardiac risk 1 - 1 -
 Intermediate cardiac risk 3.2 0.95 – 10.8 0.06 4.5 0.94 – 21.7 0.06
 High cardiac risk 7.0 2.32 – 20.9 0.001 14.9 2.9 – 34.3 <0.001
Site of surgery
 Carotid 1 - 1 -
 Lower extremity 7.5 2.53 – 22.3 <0.001 4.3 1.1 – 17.4 0.04
 Abdominal aortic 10.9 3.80 – 31.5 <0.001 12.8 3.4 – 48.0 <0.001
Type of surgery
 Open 1 - 1 -
 Endovascular 0.3 0.12 – 0.52 <0.001 0.11 0.04 – 0.30 <0.001
NT-proBNP
 ≤ 350 pg/l 1 - 1 -
 > 350 pg/l 7.0 3.97 – 12.3 <0.001 4.7 2.1 – 10.5 <0.001
Male 2.1 1.04 – 4.13 0.04 1.65 0.57 – 4.8 0.36
COPD 2.8 1.62 – 4.56 <0.001 1.4 0.60 – 3.4 0.42
Odds ratio (OR), 95% confidence intervals (CI) and p-values in univariate analysis by means of the Log-rank test and 
multivariate analysis by means of logistic regression analysis; COPD = Chronic Obstructive Pulmonary Disease
0
10
20
30
40
50
M
yo
ca
rd
ia
l i
sc
he
m
ia
 (%
)
Lo
we
st 
  M
idd
le  
Hig
he
st
NT
-pr
o-B
NP
 (te
rtil
es)
Aortic Lower extremity Carotid
Site of surgery
Figure 10.1a Preoperative N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in tertiles and the relation 
with site of surgery and perioperative myocardial damage.
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ROC analysis showed an area-under-the-curve (AUC) of 0.66 for the clinical cardiac risk score alone, 
but this AUC improved to 0.81 if site and type of surgery were added to the model. If NT-proBNP 
(cut-off 350 pg/ml) was added to the model as well, the AUC further improved to 0.86.
Long-term survival
During a median follow-up of 29 months (interquartile range 20–36 months) 58 patients died. In 
univariate analysis patients considered to be at low risk according to the risk score by Boersma indeed 
had a better survival compared to those at intermediate or high risk (HR 4.4, 95% CI 1.1–18.2, and HR 
7.8, 95% CI 1.9–32.9 respectively, TABLE 10.4). Also, patients undergoing carotid artery procedures 
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Figure 10.1b Preoperative NT-proBNP levels in tertiles and the relation with clinical cardiac risk and perioperative 
myocardial damage.
NT-proBNP tertiles in pg/mL: Lowest, 5-119; middle, 122-383; highest, >383.
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Figure 10.2 Assessment of the optimal cutoff value 
(i.e. 350 pg/mL) of N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) for the 
prediction of perioperative myocardial 
damage.
Figure 10.3 Value of N-terminal pro-B-type natriuretic 
peptide (NT-proBNP), divided in low (<350 
pg/mL, light bars) and high (>350 pg/mL, 
dark bars), for perioperative cardiac risk 
assessment in addition to a clinical cardiac 
risk score.
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were at 4-6 fold lower risk compared to patients who underwent abdominal aortic or peripheral 
bypass surgery.
Similar to the perioperative setting, using ROC curve analysis an optimal cut-off value for NT-proBNP 
for the prediction of long-term survival was established. Interestingly the optimal value was similar to 
that in the perioperative setting, i.e. 350 pg/ml. Using this cut-off value, in univariate analysis patients 
with levels of NT-proBNP above this value were at 3-fold increased risk for long-term mortality (95% 
CI 1.9–5.3). Also in multivariate analysis, adjusting for clinical risk factors, site and type of surgery 
patients with a NT-proBNP level > 350 pg/ml were at a significant 1.9 fold increased risk (95% CI 
1.1–3.2) for all-cause mortality.
DISCuSSION
The current study shows that NT-proBNP is a highly promising tool for perioperative and long-term 
cardiac risk stratification in patients undergoing vascular surgery.
The reasons why NT-proBNP seems to be so effective in perioperative risk stratification are multifac-
torial and are related to the cause of NT-proBNP release. Previous studies revealed that ventricular 
wall stress modulates BNP gene expression in cardiomyocytes9. Factors that induce ventricular wall 
stress are numerous and several are known to be related to outcome in patients undergoing vascular 
surgery. In cardiology literature NT-proBNP had emerged as an independent predictor of clinical out-
come in patients with heart failure10-12. Several studies have shown that heart failure also is a strong 
predictor for both perioperative and long-term cardiac outcome in patients scheduled for vascular 
surgery4,13. Another important factor related to both NT-proBNP level and postoperative outcome 
Table 10.4 Predictors of long-term mortality.
univariate Multivariate
hR 95% CI P-value hR 95% CI P-value
Clinical risk score
 Low cardiac risk 1 - 1 -
 Intermediate cardiac risk 4.4 1.05 – 18.2 0.042 5.0 1.2 – 21.1 0.03
 High cardiac risk 7.8 1.85 – 32.8 0.005 7.8 1.8 – 34.5 0.007
Site of surgery
 Carotid 1 - 1 -
 Lower extremity 7.0 2.48 – 19.8 <0.001 6.7 2.2 – 19.8 0.001
 Abdominal aortic 4.7 1.66 – 13.5 0.004 4.4 1.5 -12.5 0.007
Type of surgery
 Open 1 - 1 -
 Endovascular 0.6 0.34 – 1.1 0.09 0.8 0.4 – 1.6 0.58
NT-proBNP
 ≤ 350 pg/l 1 - 1 -
 > 350 pg/l 3.2 1.93 – 5.3 <0.001 1.9 1.1 – 3.2 0.02
Male 1.68 0.85 – 3.3 0.13 1.6 0.8 – 3.2 0.17
Hypertension 0.91 0.56 – 1.5 0.71
COPD 1.33 0.81 – 2.2 0.26
Hazard ratio (HR), 95% confidence intervals (CI) and p-values in univariate analysis by means of the Log-rank test and 
multivariate analysis by means of Cox regression analysis; COPD = Chronic Obstructive Pulmonary Disease
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is the presence of coronary artery disease detected during non-invasive stress testing. Importantly 
there is a close correlation between the level of NT-proBNP and the presence and extent of stress 
inducible myocardial ischemia non-invasive stress testing. In the PROMPT- TIMI 35 study Sabatine 
et al. described a population of 112 patients undergoing nuclear perfusion imaging14. In patients 
with mild or moderate stress inducible myocardial ischemia median levels of NT-proBNP were higher 
compared to patients without stress inducible myocardial ischemia (158 an 302 pg/ml versus 109 
pg/ml respectively). Since stress inducible myocardial ischemia is a strong predictor of postoperative 
cardiac events it is not surprising that in the present study patients with high NT-proBNP were at 
increased risk for perioperative events.
Besides heart failure and myocardial ischemia there are several other factors, both cardiac and non-
cardiac, that might influence NT-proBNP levels and postoperative outcome such as aortic valve steno-
sis, renal dysfunction, left ventricular hypertrophy, pulmonary hypertension, COPD and BMI15,16.
The results of the registry of the DECREASE I trial showed that non-invasive stress testing indeed has 
important additional prognostic implications on top of clinical cardiac risk factors only in patients 
undergoing vascular surgery4. However, as shown in the randomized DECREASE II trial, in patients on 
tight heart rate control preoperative non-invasive stress testing in patients at intermediate cardiac risk, 
i.e. 1 or 2 clinical risk factors, has no additional value and postpones the surgical procedure unneces-
sary17. However, also in patients with 1 or 2 risk factors only, there is a small group of approximately 
10% with extensive stress inducible myocardial ischemia with severe prognostic implications17. 
Though not cost-effective to detect these patients with non-invasive stress testing, a relative simple 
and cheap NT-proBNP measurement might guide us to this small, but very high-risk, proportion of 
patients. On the other hand in patients deemed to be at high cardiac risk based on clinical risk fac-
tors, i.e. ≥ 3 risk factors, approximately 60% does not have stress inducible myocardial ischemia4. 
Theoretically these patients undergo unnecessary extensive cardiac evaluation. The current study 
showed that NT-proBNP levels, divided in low (< 350 pg/ml) and high (> 350 pg/ml), effectively strati-
fies patients into low and high risk independent of the clinical cardiac risk score. Hence NT-proBNP 
might be useful as an initial screening tool to identify those that require more extensive preoperative 
cardiac work-up.
The findings of the current study are in line with previous studies at other institutions. Yeh et al. 
reported on a group of 190 patients undergoing elective non-cardiac surgery requiring general anes-
thesia. They found an optimal cut-off value of 450 pg/ml for adverse perioperative cardiac events. 
Several other studies have been performed using BNP instead of NT-proBNP. Importantly the results 
also consistently showed a predictive value of BNP similar to the studies with NT-proBNP5,6,18. In the 
present study it was confirmed that not only in relatively high risk patients undergoing high risk 
vascular surgery NT-proBNP might be a useful screening tool but also in a general population of 
vascular surgery patients undergoing all types of vascular procedures.
In this respect it is noteworthy that among patients scheduled for carotid artery surgery only those 
with a NT-proBNP above 350 pg/ml experienced cardiac troponin T release, suggestive for myocar-
dial necrosis. In general carotid procedures are associated with a substantial lower cardiac risk as 
compared to lower extremity arterial reconstructions and AAA repair. Therefore noninvasive stress 
testing in this group of patients is usually not performed. However with the short-term results of the 
SAPPHIRE trial19 in mind, identification of patients at increased cardiac risk is preferable, also in this 
patient population, to make a balanced decision to treat patients either with carotid endarterectomy 
or carotid stenting. NT-proBNP might be useful for the identification of these patients.
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It should be noted that the current available studies on the use of NT-proBNP are relatively small 
and the potential pitfalls of NT-proBNP, such as the influence of renal function, COPD and BMI must 
be clarified. Recently we described the impact of renal function on the usefulness of NT-proBNP. In 
particular in patients with severe renal dysfunction, i.e. GFR < 30 ml/min, the reliability of NT-proBNP 
as a screening marker was questioned20.
Furthermore, the positive finding in this study in favor of NT-proBNP as a preoperative risk marker 
should not be overestimated. One must realize that NT-proBNP covers only parts of the pathways 
of perioperative myocardial infarctions. Although the pathophysiology of perioperative myocardial 
infarction is not entirely clear, plaque rupture, leading to thrombus formation and subsequent 
vessel occlusion, is implicated in a similar manner to that causing MI in the non-operative setting. 
Autopsies have shown that coronary plaque rupture and thrombus formation occur in 50% of all fatal 
MIs, whereas a sustained oxygen supply-demand mismatch is responsible for the other half. Due to 
the nature of the release of this peptide it might be expected that it will only cover the mechanism 
of sustained myocardial oxygen demand-supply mismatch adequately. This is also reflected by the 
sensitivity and specificity of approximately 80% found in the current study. The finding that despite 
these limitations NT-proBNP still seems to be a good cardiac risk marker might be explained by the 
presence of both significant stenotic and unstable non-significant stenotic lesions in a diffusely 
diseased coronary tree.
In conclusion, NT-proBNP is a promising marker in the setting of preoperative cardiac risk stratifica-
tion. An elevated NT-proBNP should be seen as an alert for a possible increased risk for perioperative 
events and should trigger the treating physician to find the cause responsible for this elevation. 
Though the initial results of NT-proBNP as a screening tool for perioperative and long-term cardiac 
risk assessment in patients undergoing vascular surgery are promising further, larger studies are 
required to establish the usefulness and limitations more precisely. One of the ongoing studies in 
this respect is the DECREASE VI study (ISRCTN 48518771) in which 1800 patients will participate and 
is scheduled to be completed in 2010.
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INTRODuCTION
About 3.8% of the population of the Netherlands will undergo non-cardiac surgery annually1. Patients 
undergoing major non-cardiac surgery are at significant risk of cardiovascular morbidity and mortal-
ity. Although the perioperative event rate has declined over the past 30 years, 30-day cardiovascular 
mortality in major non-cardiac surgery remains as high as 3% to 6%2,3. Myocardial infarction (MI) is 
the most frequent fatal complication in this respect, accounting for 10-40% of postoperative fatali-
ties4,5. Although the understanding of the pathophysiology is not entirely clear, evidence exists that 
coronary plaque rupture, which leads to thrombus formation and subsequent vessel occlusion, is 
the predominant causative mechanism behind such complications, similar to MIs occurring in the 
nonoperative setting6-9. However, a MI may also be induced by perioperative myocardial oxygen 
demand / supply mismatch10. Factors involved include surgical stress, tachycardia, hypertension, and 
pain. It should be noticed that these factors might also be directly involved in the process of coronary 
plaque instability and subsequent rupture. The incidence of vasospasm, anemia, and hypoxia may 
worsen these conditions further.
Plaque instability and oxygen demand / supply mismatch leading to myocardial infarction might be 
positively influenced by drugs acting on these mechanisms. To assess the effect of pharmaceutical 
strategies (beta-blockers, statins or both) to prevent perioperative cardiac complications, a large 
prospective, randomized trial has been set up: the DECREASE-IV study.
Preoperative cardiovascular risk assessment
Numerous investigators have described the relationship between patient characteristics and the risk 
of adverse cardiovascular outcome10-17. The multivariable cardiovascular risk indices developed by 
Goldman, Detsky and Eagle are most frequently quoted in perioperative care management10,14,17. 
Nowadays, the clinical importance of perioperative cardiovascular complications is well recognized. 
However, most studies evaluating cardiovascular risk in a general surgical population date from the 
1970s and 1980s. These classical investigations of unselected surgical patients are based on relatively 
small samples (the largest series, from 1987, consists of 2,609 patients) and a few outcome events12,17. 
Consequently, important risk factors may have been missed, due to a lack of statistical power. More 
recent studies have focused mainly on patients undergoing specific types of surgery, such as thoracic, 
orthopedic, or vascular15,18,19. Furthermore, there have been significant advances in perioperative 
care in the last decades. For instance, the identification of patients at risk using perfusion scintigraphy 
or stress echo has become widely available. The impact of these developments on the incidence and 
lethality of cardiovascular complications and the predictive value of established cardiac risk factors 
is yet unknown.
Implications of perioperative cardiovascular risk reduction
Perioperative cardiovascular risk reduction could potentially save many lives. In the Netherlands with 
16 million inhabitants for example, every year approximately 800.000 non-cardiac surgical proce-
dures are performed. In the last decade the number of postoperative deaths in the Netherlands was 
stable at around 15,200 annually1. Considering that approximately one third of postoperative fatali-
ties are ascribed to cardiac complications, yearly 5,000 surgical patients die of perioperative cardiac 
complications in the Netherlands. Hence, a 10% reduction in perioperative cardiac mortality will save 
approximately 500 lives annually (FIGURE 11.1).
However, studies that successfully aimed at cardiovascular risk identification were not succeeded by 
trials that focused at systematic risk reduction. Hence, effective cardioprotective treatment strategies 
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remain undefined for substantial portions of the non-cardiac surgery population. Especially, the 
optimal cardiovascular risk reduction strategy in patients with moderate to high risk (i.e. risk of 
cardiovascular mortality more than 1%) is yet unknown. Ideally, cardiac risk factors should identify 
those patients who experience an increased risk of perioperative myocardial ischemia. In previous 
studies15,19-22, it is suggested that for patients at low or intermediate risk (i.e. two or less risk fac-
tors), effective systemic pharmacological protection reduces perioperative cardiovascular risk to an 
acceptable level. Patients at high risk should undergo exercise or pharmacological testing to exclude 
extensive myocardial ischemia. If a patient at high risk has no or only mild ischemia during stress 
testing, pharmacological protection is probably sufficient. On the other hand, patients with exces-
sive myocardial ischemia suggestive of left main or three-vessel disease should probably undergo 
coronary revascularization before being operated.
Perioperative risk reduction by beta-blockers
Beta-blockers form a class of agents with great cardioprotective potential. Beta-blockers will decrease 
myocardial oxygen demand by reduction of heart rate and myocardial contractility23,24. Furthermore, 
beta-blockers reduce the adrenergic activity, which results in reduced levels of free fatty acid, thus 
causing a shift in the myocardial metabolism towards glucose uptake25.
Several studies addressed the relation between beta-blocker use and perioperative myocardial 
ischemia. Stone and co-authors studied the effect of low-dose beta-blockers (labetolol, atenolol, or 
oxprenolol) in 128 hypertensive patients undergoing non-cardiac surgery26. Patients who received 
beta-blockers had a lower incidence of myocardial ischemia, as diagnosed using continuous 12-lead 
ECG monitoring, than patients without beta-blocker treatment (2.2% versus 28.0% events; p-value 
<0.001). Wallace and co-authors confirmed these findings in a data set of 200 patients who either 
had established CAD, or had increased risk of CAD, according to clinical characteristics and age27. The 
incidence of myocardial ischemia was significantly lower among patients randomized to atenolol as 
compared to placebo (24% versus 39% events; p-value 0.03).
Mangano and co-authors conducted the first randomized controlled study evaluating the cardiopro-
tective effect of beta-blockers in patients undergoing non-cardiac surgery28. Two hundred patients 
undergoing vascular surgery were randomized to atenolol treatment or placebo. No difference 
was observed in perioperative mortality between the two treatment arms. However, atenolol was 
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Figure 11.1 Lives saved per year in the Netherlands by reducing the perioperative cardiac risk.
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associated with significant lower mortality during two-year follow-up. The lack of a perioperative 
cardioprotective effect of atenolol in this study was probably related to the fact that unselected, low 
risk patients were included. The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress 
Echo (DECREASE-I) study29, clearly demonstrated a cardioprotective effect of bisoprolol, a selective 
beta-blocker, in high-risk patients undergoing major vascular surgery. Bisoprolol was associated with 
a significant reduction in composite endpoint of cardiovascular death and myocardial infarction dur-
ing the 30-day perioperative phase (3.3% versus 34.0% events; p-value <0.01).
Although the results are promising, the use of beta-blockers in patients at risk for CAD is not yet 
common practice. In a recent study, Schmidt et al. showed that in 158 patients undergoing major 
non-cardiac surgery only 27% of eligible patients did receive beta-blockers30. Similar results were 
shown in a survey of Canadian anesthesiologists31.
Perioperative risk reduction by statins
Several investigations have demonstrated that 3-hydroxy-3-methylglutaril coenzyme A reductase 
inhibitors (statins) have favorable actions on atherosclerosis and vascular properties that go beyond 
those attributed to cholesterol lowering32-34. Statins may attenuate coronary artery plaque inflamma-
tion, induce plaque stability in addition to antithrombogenic, antiproliferative and leukocyte-adhe-
sion inhibiting effects 32,35-42. Due to these properties, statins may help stabilize vulnerable coronary 
plaques, thereby prevent plaque rupture with subsequent myocardial ischemia and myocardial 
damage. In a recently conducted case-control study, Poldermans et al. demonstrated that statin use 
among patients undergoing major vascular surgery was associated with a four-fold risk reduction in 
perioperative all-cause mortality (multivariably adjusted odds ratio 0.22 and 95% confidence interval 
0.10 to 0.47)43. This result was consistent in subgroups of patients according to the type of surgery, 
cardiovascular risk factors, and beta-blocker use. Similarly, Durazzo et al., reported a 68% reduction in 
the incidence of adverse cardiovascular events during 6-months follow-up among vascular surgery 
patients who were randomly assigned to atorvastatin compared with placebo (8.3% versus 26.0% 
events; p-value <0.01)44. Recently Lindenauer et al. confirmed these results in another retrospective 
study. In a study of 780,591 patients undergoing major non-cardiac surgery 9.9% of patients were on 
statin therapy45. Statin therapy was associated with a risk reduction of postoperative death of 40%.
ThE DECREASE-IV TRIAL
Study population
Patients who are (1) aged 40 years or older, (2) scheduled for elective non-cardiac surgery and (3) 
have an estimated risk for cardiovascular death of more than 1%, will be enrolled in the DECREASE-IV 
trial. Exclusion criteria for this trial are: the use of beta-blockers; a contraindication for beta-blocker 
use; the use of statins prior to randomization; a contraindication for statin use; unstable coronary 
heart disease, evidence of 3-vessel disease or left main disease; elevated cholesterol according to 
the national cholesterol consensus; emergency surgery; inability or unwillingness to provide written 
informed consent; and previous participation in this same trial.
Study objectives
The general objective of the DECREASE-IV trial is to assess the clinical efficacy of beta-blocker therapy, 
statin therapy and combination therapy with beta-blockers and statins in patients undergoing major 
non-cardiac surgery.
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Study design
The overall study design of the DECREASE-IV trial is shown in the flowchart (FIGURE 11.2). During 
a period of 4 years all patients planned for elective surgery at Erasmus Medical Centre Rotterdam 
will be screened at the preoperative screening visit according to a newly developed cardiovascular 
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Contraindication for beta-blocker use?
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Figure 11.2 Flowchart of the DECREASE-IV trial.
ASAT, Aspartate transaminase; ALAT, alanine aminotransferase; ULN, upper Limit of Normal.*Boersma 
et al.46 †Liver enzymes; ‡Heart enzymes.
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risk-evaluation scheme46. A computerized version of this scheme will be applied, which enables an 
automated check on all in- and exclusion criteria. According to the outcome of the risk-evaluation 
scheme, patients with a chance of more than 2% on perioperative cardiovascular death will undergo 
further cardiac evaluation, including ECG and/or stress myocardial testing. Patients with extensive 
myocardial ischemia are excluded. Participants will then be randomized according to an open-label, 
factorial design between (1) beta-blocker therapy (bisoprolol), (2) statin (fluvastatin), (3) combination 
of beta-blockers and statins (bisoprolol and fluvastatin) and (4) neither beta-blockers nor statins 
(control group). Study medication is started within 0-30 days prior to surgery and will be continued 
until 30 days after surgery.
The starting dose of bisoprolol is 2.5 mg orally per day, if resting heart rate >50 bpm. During hospi-
talization the resting heart rate will be evaluated on a daily basis and the bisoprolol regimen might 
be modified +/- 1.25 or 2.5 mg per day, i.e. dosages of 1.25, 2.5, 3.75, 5.0, 7.5 and 10 mg, in order 
to obtain a target heart rate of 50-70 bpm. Patients who are not able to take bisoprolol orally in 
the perioperative period will receive IV metoprolol until the patient is able to switch back to oral 
medication. Bisoprolol administration will be temporarily stopped if resting heart rate is < 50 bpm 
or systolic blood pressure is < 100 mmHg, or a patient is suspected to be in congestive heart failure, 
bronchospasm or develops first degree AV-block with a PR interval > 0.30 seconds or second or third 
degree of AV block.
Patients assigned to the statin or combined group will start with fluvastatin 80 XL daily tablets before 
surgery. To avoid problems with statin intake and low plasma levels shortly after the operation, the 
“slow-release” statin Fluvastatin 80 XL has been chosen. Patients not able to take fluvastatin orally will 
take fluvastatin medication by naso-gastric tube. If oral or naso-gastric administration is impossible, 
fluvastatin medication is skipped, as no IV formulations of statins are available.
To assess perioperative cardiac events, an ECG will be made at days 1, 3 and 7 postoperatively. On 
these same days blood samples will be taken to assess heart- and liver enzymes. Patients will be 
evaluated at follow-up visits 30 days and 1 year after surgery.
The primary efficacy objective is to determine the impact of perioperative administration of 
bisoprolol, fluvastatin and their combination on the incidence of 30-day cardiovascular events, i.e. 
the composite of cardiac death, and non fatal MI (TABLE 11.1), in moderate and high risk patients 
undergoing non-cardiac surgery. MI is based on the definition of the consensus document of The 
Joint European Society of Cardiology/American College of Cardiology committee for the redefinition 
Table 11.1 Definitions of primary end points.
Cardiovascular death Any death with a cardiovascular cause, including those deaths following a cardiac 
procedure, cardiac arrest, myocardial infarction, pulmonary embolus, stroke, 
hemorrhage, or deaths due to unknown causes.
Non fatal myocardial infarction Requires 2 of the following:
(1) Characteristic ischemic symptoms (i.e. chest pain, shortness of breath, etc) lasting 
longer than 20 minutes;
(2) ECG changes including acute ST elevation followed by appearance of Q waves 
or loss of R waves, or new left bundle branch block, or new persistent T wave 
inversion for at least 24 hours, or new ST segment depression which persists for at 
least 24 hours;
(3) A positive troponin, i.e. >0.10 ng/ml, or peak CK-MB ≥8% of an elevated total CK 
with characteristic rise and fall.
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of myocardial infarction47. Secondary efficacy objectives of the DECREASE-IV study are to determine 
the impact of perioperative administration of bisoprolol and/or fluvastatin on (1) the incidence of 
total mortality, cardiovascular death, and nonfatal myocardial infarction during 1 year follow-up; (2) 
the length of hospital stay, and length of ICU/CCU stay; (3) the 30-day incidence of clinically signifi-
cant cardiac arrhythmias and heart failure and the need for coronary revascularization procedures. 
Furthermore, the DECREASE-IV trial has five safety objectives, namely to determine the impact of the 
different treatments on: (1) the 30-day congestive heart failure; (2) the 30-day incidence of clinically 
significant bradycardia; (3) the 30-day incidence of clinically significant hypotension; (4) the 30-day 
incidence of clinically significant liver dysfunction and (5) the occurrence of myopathy.
Data analysis
The incidence of the primary outcome, 30-day cardiovascular events, in the control group is estimated 
to be 6.0%. A 30% relative risk reduction (odds ratio 0.7) associated with bisoprolol therapy as well as 
with fluvastatin therapy is anticipated. The combination of bisoprolol and fluvastatin is supposed to 
result in a 50% relative risk reduction (odds ratio 0.7*0.7=0.49) as compared to control therapy.
Based on these assumptions a sample size of 6 000 patients, with 1 500 patients in each group, is 
needed to detect the anticipated risk reduction of 30% with a power of 81%, α=0.05 (two-sided). The 
power will be 97% to detect the anticipated 50% risk reduction associated with combination therapy. 
The intention to treat principle will guide all analyses. Time-to-the first occurrence of one of the com-
ponents of the primary efficacy endpoint will be presented using the Kaplan-Meier estimator. The 
rate of occurrence of the primary endpoint between the randomized groups will be compared using 
the log-rank statistics. Employing the Cox proportional hazards model, the hazard ratio and its associ-
ated 95% confidence interval, will derive treatment effect. Univariable and multivariable analysis will 
be conducted. Secondary endpoints will be tabulated by treatment group. The rate of occurrence 
of each secondary endpoint will be compared using log-rank statistics. Length of hospital stay and 
length of IC/CCU stay will be compared using one-way analysis if variance or a non-parametric test. 
Multivariable Cox proportional hazards regression analyses will be performed to evaluate differential 
treatment effects with regard to subgroups (e.g. age, gender, duration of statin treatment, heart rate). 
Safety outcomes will be compared using the log-rank statistic.
The DECREASE-IV trial was designed as an investigator-initiated protocol from the clinical epidemiol-
ogy unit of the department of cardiology at the Erasmus Medical Centre Rotterdam, the Netherlands. 
An independent Endpoint Adjudication Committee will meet on a monthly basis to review all patients 
that are operated during that month. An independent 4-member Data and Safety Monitoring Board 
has been established and will review unblinded safety data four times yearly and will advise the 
Steering Committee on continuation or termination of the trial in relation to safety aspects.
What will the DECREASE-IV trial teach us?
The DECREASE-IV trial has been designed to teach us critical new insights in the best pharmaceutical 
prevention of perioperative cardiovascular complications in surgical patients. This issue is of sig-
nificant importance since cardiovascular complications are the main cause of death among patients 
undergoing non-cardiac surgery, accounting for an approximate death rate of 3-6% in moderate 
and high-risk patients. Apart from mortality, cardiovascular caused perioperative complications 
necessitate a prolonged hospital stay in a substantial number of patients. As a consequence, a posi-
tive finding of the DECREASE-IV trial will have a major beneficial effect on perioperative mortality, 
morbidity and costs. It would provide us a clear indication for the routine use of statins, beta-blockers 
or a combination of both in the perioperative period.
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ABSTRACT
Background: Beta-blockers and statins reduce perioperative cardiac events in high-risk patients 
undergoing vascular surgery by restoring the myocardial oxygen supply/demand balance and/or 
stabilizing coronary plaques. However their effects in intermediate risk patients remained ill-defined. 
This study evaluated the effectiveness and safety of beta-blockers and statins for the prevention of 
perioperative cardiovascular events in intermediate-risk patients undergoing non-cardiovascular 
surgery.
Methods: Prior to surgery (median 34 days), 1066 patients were assigned to bisoprolol, fluvastatin, 
combination treatment or control therapy. Intermediate-risk patients were defined by an estimated 
risk of perioperative cardiac death and myocardial infarction (MI) of 1-6%, using clinical data and type 
of surgery. Starting dose of bisoprolol was 2.5 mg daily, titrated to a perioperative heart rate of 50-70 
beats per minute. Fluvastatin was prescribed in a fixed dose of 80 mg. The primary endpoint was the 
composite of 30-day cardiac death and MI.
Results: Patients randomized to bisoprolol (N=533) had a lower incidence of the endpoint than those 
randomized to bisoprolol-control (2.1% vs. 6.0% events; HR 0.34; 95% CI: 0.17-0.67; p=0.002). Patients 
randomized to fluvastatin experienced a lower incidence of the endpoint than those randomized to 
fluvastatin-control therapy (3.2% vs. 4.9% events; HR 0.65; 95% CI 0.35-1.10), but statistical signifi-
cance was not reached (p=0.17).
Conclusion: Bisoprolol was associated with a significant reduction of 30-day cardiac complications, 
while fluvastatin showed a trend for improved outcome.
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INTRODuCTION
Annually approximately 40 million people in the European Union undergo non-cardiac surgery. 
Cardiac events are a major cause of perioperative morbidity and mortality in these patients, resulting 
in a mortality rate of 1%1. A myocardial infarction (MI) accounts for 10-40% of postoperative fatali-
ties2. Both beta-blockers and statins reduce perioperative cardiac events in high-risk patients3-6. The 
pathophysiology of a fatal MI is complex. It can be related to myocardial oxygen demand/supply 
mismatch, due to perioperative surgical stress, tachycardia, hypertension, and pain7. Alternatively, 
coronary plaque instability and subsequent rupture may lead to infarction8. Drugs that influence 
plaque stability and myocardial oxygen balance may influence the incidence and severity of periop-
erative MI. Beta-blockers improve myocardial oxygenation by decreasing heart rate and myocardial 
contractility9. Additionally, by reducing mechanical and shear stresses, beta-blockers may also pro-
mote coronary plaque stability. Additionally, beta-blockers might have anti-inflammatory effects10. 
Statins aim at coronary plaque stabilization by decreasing lipids, lipid oxidation, inflammation, matrix 
metalloproteinase and cell death, and increasing tissue inhibitor of metalloproteinase and collagen11. 
Both therapies have been associated with improved outcome in high-risk surgery. However, the vast 
majority of patients scheduled for surgery are at low- and intermediate-risk. In this population, the 
effect of perioperative beta-blockers and statins remains undefined. Our primary goal was to assess 
the effectiveness and safety of beta-blockers, statins and their combination, on the incidence of peri-
operative cardiac death and myocardial infarction in intermediate-risk surgical patients undergoing 
non-cardiovascular surgery.
METhODS
The DECREASE-IV study was a prospective, open-label, multicenter, randomized, controlled trial and 
was done in accordance with the Declaration of Helsinki. The protocol was approved by all hospital 
ethics committees. All patients gave written informed consent.
Study population
The design of DECREASE-IV has been published previously and is registered under number 
ISRCTN4763749712. Briefly, patients aged ≥ 40 years, who were scheduled for elective non-cardio-
vascular surgery and had an estimated risk for a perioperative cardiovascular event between 1 and 
6% were eligible. The risk-estimation was based on clinical characteristics and an electrocardiogram 
(ECG)1. Exclusion criteria for enrolment were: the use of or a contraindication for beta-blocker or 
statin use; emergency surgery; inability to provide written informed consent; and previous participa-
tion in this trial. The exclusion of patients on beta-blocker or statin therapy was based on ethical 
considerations, being unable to withhold the use of these medications in the presence of an existing 
indication.
Treatment
A 2x2 factorial study design was used13. After signing informed consent, patients were randomized 
on a 1:1 ratio to receive beta-blocker therapy (bisoprolol, Merck KGaA, Darmstadt, Germany) or beta-
blocker control. Patients were also randomized on a 1:1 ratio to receive statin therapy (fluvastatin XL, 
Novartis, Basel, Switzerland) or statin control. Hence, there were 4 treatment groups: bisoprolol alone, 
fluvastatin alone, both, or neither (double control). Randomization was applied by using a computer 
algorithm, and was stratified according to hospital. Study medication was started immediately after 
randomization, median 34 days prior to surgery, and continued until 30 days after surgery.
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The starting dose of bisoprolol was 2.5 mg orally per day, if resting heart rate was >50 bpm. During 
hospitalization, resting heart rate was evaluated on a daily basis and drug dose was modified with 
steps of 1.25 or 2.5 mg per day, up to a maximum dose of 10 mg, aiming at a heart rate of 50-70 bpm. 
The use of an open-label design was therefore necessary in order to titrate the bisoprolol dose to the 
therapeutic heart rate. Patients unable to take bisoprolol orally received intravenous metoprolol until 
the patient was able to switch back to oral medication. Bisoprolol administration was temporarily 
withheld if any of the following developed: resting heart rate <50 bpm; systolic blood pressure <100 
mmHg; heart failure; bronchospasm; PR interval >0.30 s; second or third degree AV block. Fluvastatin 
was prescribed in a fixed daily dose of 80 mg. The “slow-release” statin fluvastatin 80 XL was chosen, to 
overcome problems in those patients who could not take statins early after surgery orally. If patients 
used nasogastric feeding, standard fluvastatin therapy was administered. Perioperatively, patient 
treatment was left to the attending physician’s discretion as needed, with no restrictions imposed.
Endpoints
The primary efficacy endpoint was a composite of cardiac death and non-fatal MI until 30-days after 
surgery. MI was defined on the basis of cardiac troponins and ECG-measurements, which were sys-
tematically collected on days 1, 3 and 7 postoperatively and whenever clinically indicated. Nonfatal 
MI required any two of the following: (1) characteristic ischemic symptoms lasting > 20 minutes; (2) 
ECG changes including acute ST elevation followed by appearance of Q waves or loss of R waves, 
or new left bundle branch block, or new persistent T wave inversion for at least 24 hours, or new ST 
segment depression which persists for at least 24 hours; (3) a positive troponin T measurement with 
characteristic rise and fall14. All deaths were classified as either cardiovascular or non-cardiovascular. 
Cardiovascular death is defined as any death with a cardiovascular complication as the primary or 
secondary cause, and includes deaths following myocardial infarction, cardiac arrhythmia, resus-
citation, heart failure, or stroke. Non-cardiovascular death is defined as any death with a primary 
non-cardiovascular cause, including surgery-related bleeding complications, cancer, trauma and 
infection. Sudden death in a previously stable patient is considered as cardiovascular15.
Secondary efficacy endpoints included all-cause mortality, cardiac arrhythmias, acute heart failure, 
and coronary revascularization.
Safety endpoints included stroke, clinically significant bradycardia and hypotension, clinically signifi-
cant liver dysfunction, i.e. ALAT > 3 times upper limit of normal, CK level more than 10 times upper 
limit of normal, myopathy, and rhabdomyolysis. All endpoints that occurred since randomization 
until 30 days after surgery were counted.
Sample size calculation
The incidence of the primary efficacy endpoint in patients randomized to double control was esti-
mated at 6.0%. We anticipated a 30% relative risk reduction (odds ratio 0.7) associated with bisoprolol 
as well as fluvastatin therapy. The combination of bisoprolol and fluvastatin was anticipated to result 
in a 50% relative risk reduction (odds ratio 0.7*0.7=0.49), compared to double control therapy. A total 
of 6000 patients are needed (1500 per group) to detect the anticipated risk reduction with a power 
of 81% and a two-sided α of 5%.
In the participating hospitals a total of 10,000 patients undergo elective non-cardiovascular surgery 
annually. We had anticipated that 2,000 of them would be eligible and provide informed consent, so 
that patient enrolment would be completed within 3 years. Actual enrolment started in July 2004 and 
ended in February 2008. The study was terminated early because of slow patient recruitment. During 
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the study period, roughly 45,000 patients were screened, of whom 6,460 met the inclusion criteria. 
However, 78% of these otherwise eligible patients were receiving beta-blocker or statin therapy, 
instead of the anticipated 20%. Of the remaining patients, 355 did not provide informed consent or 
had previously participated in the study, leaving 1066 patients to be included.
Data analysis
The time to the first occurrence of the primary efficacy endpoint was determined according to 
the Kaplan-Meier method, and differences between allocated groups were evaluated by log-rank 
statistics. The Cox proportional hazards (PH) model was applied to obtain treatment effects on the 
primary efficacy endpoint, which are presented as hazard ratio’s (HR) and 95% confidence intervals 
(CI). Cox PH models including interaction terms were applied to evaluate the effects of bisoprolol and 
fluvastatin treatment in each other’s presence or absence. Analyses of other endpoints were based on 
contingency tables and chi-square tests. All analyses were performed according to the intention-to-
treat principle. All statistical tests were 2-sided, and a p-value <0.05 was considered significant.
RESuLTS
Patients
A total of 264 patients were randomized to bisoprolol therapy, 265 to fluvastatin therapy, 269 to 
combination therapy and 268 patients to double control therapy. Patient characteristics are pre-
sented in TABLES 12.1 and 12.2. The key characteristics were as follows: median age 64 years; 60% 
male; 11% diabetes mellitus; 6% angina pectoris; 5% prior MI; 4% prior stroke. Most common types of 
surgery were general (39%), urological (19%), orthopedic (16%), and ear-nose-throat (12%). General 
anesthesia was used in 94%, and 91% of patients were in American Society of Anesthesiologists (ASA) 
class 1 or 2. The treatment groups did not differ with respect to baseline or operative characteristics 
(TABLES 12.1 and 12.2).
Outcome
The median time between starting medication and surgery was 34 (21-53) days, with no differences 
between treatment groups (TABLE 12.3). Two patients died from non-cardiac complications while 
awaiting surgery. Twenty-four patients died within 30 days after surgery. Five patients suffered 
cardiac death and 38 patients had nonfatal MI within 30 days. Thus, 43 (4.0%) patients reached the 
primary efficacy endpoint of cardiac death or nonfatal MI (TABLE 12.3). Time-to-event curves for the 
primary end point, by treatment group, are presented in FIGURE 12.1. The incidence of the primary 
outcome differed significantly between allocated groups, being lowest in the patients randomized to 
bisoprolol alone (1.9%) and highest in the patients randomized to double control (7.8%).
Comparison of the 533 patients allocated to bisoprolol therapy with the 533 patients allocated to 
bisoprolol-control therapy
Baseline heart rate was similar in patients randomized to bisoprolol and the patients randomized 
to bisoprolol-control, but preoperative heart rate was significantly lower in patients randomized to 
bisoprolol (TABLE 12.2), indicating adequate drug compliance. On the day of surgery, the bisoprolol 
dose was 2.5 mg in 99% of patients and 5.0 mg in 1%. All patients allocated to bisoprolol had a heart 
rate of < 70 beats per minute prior to surgery. A total of 11 (event rate according to the Kaplan-
Meier method 2.1%) patients allocated to bisoprolol therapy reached the primary efficacy endpoint, 
compared to 32 (6.0%) allocated to bisoprolol-control (FIGURE 12.2). Hence, bisoprolol therapy was 
associated with a 67% relative reduction in the incidence of cardiac death or MI (HR 0.34; 95% CI: 
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0.17-0.67; p = 0.002). There was no evidence of heterogeneity in the beneficial effect of bisoprolol 
between patients randomized to fluvastatin versus fluvastatin-control (p-value associated with the 
interaction term 0.26).
Ischemic stroke occurred in 7 (0.7%) patients, of which 4 (0.8%) were randomized to bisoprolol and 
3 (0.6%) to bisoprolol-control (p = 0.68). In total, 3 (0.6%) patients randomized to bisoprolol reached 
one other beta-blocker-related safety endpoint (heart failure clinically significant bradycardia or 
hypotension), compared to 2 (0.4%) patients randomized to bisoprolol-control (p = 0.65).
Table 12.1 Baseline characteristics, medication use and preoperative 12-lead ECG findings per treatment group.
Total
(N=1066)
Bisoprolol 
only
(N=264)
Fluvastatin 
only
(N=265)
Combination 
therapy
(N=269)
Double 
control
(N=268)
Baseline characteristics
 Male gender – no. (%) 639 (60.0) 160 (60.8) 163 (61.5) 163 (60.8) 153 (57.1)
 Age, years (*IQR) 65.4 (57,74) 66.8 (58,74) 65.4 (59,73) 63.8 (56,74) 65.6 (57,74)
 Diabetes Mellitus – no. (%) 115 (10.8) 29 (11.0) 32 (12.1) 30 (11.2) 24 (9.0)
 Angina Pectoris – no. (%) 55 (5.6) 11 (4.2) 15 (5.7) 14 (5.2) 15 (5.6)
 Myocardial infarction – no. (%) 54 (5.1) 16 (6.1) 16 (6.0) 13 (4.8) 9 (3.4)
 Chronic heart failure – no. (%) 8 (0.8) 3 (1.1) 3 (1.1) 2 (0.7) 0
 Stroke – no. (%) 46 (4.3) 11 (4.2) 10 (3.8) 13 (4.8) 12 (4.5)
 Renal failure – no. (%) 11 (1.0) 2 (0.8) 3 (1.1) 2 (0.7) 4 (1.5)
Medication use
 Diuretics – no. (%) 102 (9.6) 24 (9.1) 20 (7.6) 29 (10.8) 29 (10.8)
 Aspirin – no. (%) 102 (9.6) 26 (9.6) 27 (10.2) 25 (9.3) 24 (9.0)
 Calcium antagonists – no. (%) 34 (3.2) 8 (3.0) 7 (2.6) 11 (4.1) 8 (3.0)
 ACE inhibitors – no. (%) 96 (9.0) 23 (8.7) 26 (9.8) 23 (8.6) 24 (9.0)
 Angiotensin II inhibitors – no. (%) 58 (5.4) 11 (4.2) 16 (6.0) 15 (5.6) 16 (6.0)
 Anticoagulants – no. (%) 48 (4.5) 11 (4.2) 16 (6.0) 12 (4.5) 9 (3.4)
 Antiarrythmics – no. (%) 9 (0.8) 1 (0.4) 2 (0.8) 4 (1.5) 2 (0.8)
 Nitrates – no. (%) 11 (1.0) 1 (0.4) 4 (1.5) 2 (0.7) 4 (1.5)
 Digoxin – no. (%) 15 (1.4) 3 (1.1) 6 (2.3) 1 (0.4) 5 (1.9)
 Oral antidiabetics – no. (%) 78 (7.3) 21 (8.0) 19 (7.2) 20 (7.4) 18 (6.7)
 Insulin – no. (%) 48 (4.5) 7 (2.7) 18 (6.8) 11 (4.1) 12 (4.5)
 Glucocorticoids – no. (%) 88 (8.3) 18 (6.8) 19 (7.2) 31 (11.5) 20 (7.5)
Preoperative 12-lead ECG findings
 Abnormal ECG – no. (%) 487 (45.7) 122 (46.2) 122 (46.0) 124 (46.1) 119 (44.4)
 Atrial fibrillation – no. (%) 15 (1.4) 4 (1.5) 5 (1.9) 3 (1.1) 3 (1.1)
 Right bundle branch block – no. (%) 90 (8.4) 18 (6.8) 21 (7.9) 20 (7.4) 31 (11.6)
 Left bundle branch block – no. (%) 74 (6.9) 18 (6.8) 19 (7.2) 22 (8.2) 15 (5.6)
 Q-waves – no. (%) 103 (9.7) 22 (8.3) 32 (12.1) 27 (10.0) 22 (8.2)
 Left ventricle hypertrophy – no. (%) 83 (7.8) 24 (9.1) 21 (7.9) 22 (8.2) 16 (6.0)
 Right ventricle hypertrophy – no. (%) 1 (0.1) 1 (0.4) 0 0 0
 Preventricular contractions – no. (%) 78 (7.3) 20 (7.6) 24 (9.1) 23 (8.6) 11 (4.1)
*IQR = interquartile range
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Table 12.2 Surgery details per treatment group.
Total
(N=1066)
Bisoprolol only
(N=264)
Fluvastatin only
(N=265)
Combination 
therapy
(N=269)
Double control
(N=268)
Anesthesia
 General – no. (%) 1001 (93.9) 249 (94.3) 246 (92.8) 253 (94.1) 253 (94.4)
 Spinal – no. (%) 29 (2.7) 8 (3.0) 7 (2.6) 7 (2.6) 7 (2.6)
 Local – no. (%) 36 (3.4) 7 (2.7) 12 (4.8) 9 (3.3) 8 (3.0)
Specialism
 General surgery – no. (%) 415 (38.9) 97 (36.9) 96 (36.2) 106 (39.4) 116 (43.3)
 Urology – no. (%) 205 (19.3) 58 (22.1) 53 (20.0) 46 (17.1) 48 (17.9)
 Orthopedics – no. (%) 174 (16.3) 50 (19.0) 43 (16.2) 48 (17.8) 33 (12.3)
 Ear-nose-throat – no. (%) 133 (12.4) 30 (11.4) 30 (11.3) 35 (13.0) 38 (14.2)
 Gynaecology – no. (%) 53 (5.0) 8 (3.0) 13 (4.9) 17 (6.2) 15 (5.6)
 Plastic surgery – no. (%) 55 (5.1) 12 (4.6) 22 (8.3) 9 (3.4) 12 (4.5)
 Dental surgery – no. (%) 10 (0.9) 1 (0.4) 4 (1.5) 2 (0.7) 3 (1.1)
 Ophthalmology – no. (%) 10 (0.9) 4 (1.5) 3 (1.1) 1 (0.4) 2 (0.8)
 Other – no. (%) 10 (0.9) 3 (1.1) 1 (0.4) 5 (1.9) 1 (0.4)
*ASA score
 1 – no. (%) 392 (36.8) 95 (36.0) 96 (36.2) 105 (39.0) 96 (35.8)
 2 – no. (%) 573 (53.8) 144 (54.6) 140 (52.8) 140 (52.0) 149 (55.6)
 3 – no. (%) 101 (9.5) 25 (9.5) 29 (11.0) 24 (8.9) 23 (8.6)
*ASA = American Society of Anesthesiologists
Table 12.3 Treatment information, primary and secondary study end points per treatment group.
Variable Total
(N=1066)
Bisoprolol 
only
(N=264)
Fluvastatin 
only
(N=265)
Combination 
therapy
(N=269)
Double 
control
(N=268)
p-value
Treatment information
 Time to surgery, days (IQR*) 34 (21,53) 34.5 (22,52) 36 (22,56) 35 (20,52) 34 (20,53) 0.88
 Heart rate at screening, bpm (IQR) 77 (70,85) 76.5 (71,84) 77 (68,85) 77 (72,85) 77 (67,87) 0.60
 Heart rate preoperative, bpm (IQR) 68 (62,76) 64 (60,68) 78 (68,84) 65 (62,68) 76 (68,84) <0.001
 Heart rate difference, bpm (IQR) -8 (-14,0) -12 (-21,-7) 0 (-7,6) -12 (-19,-8) 0 (-8,6) <0.001
Primary end points
 Cardiac death or MI (%)† 43 (4.0) 5 (1.9) 11 (4.1) 6 (2.2) 21 (7.8) 0.001
 Myocardial infarction (%) 38 (3.6) 5 (1.9) 9 (3.4) 6 (2.2) 18 (6.7) 0.01
 30-day total mortality (%) 26 (2.4) 3 (1.1) 7 (2.6) 7 (2.6) 9 (3.4) 0.41
  Cardiac (%) 5 (0.5) 0 2 (0.8) 0 3 (1.1) 0.15
  Sepsis (%) 11 (1.0) 3 (1.1) 2 (0.8) 4 (1.5) 2 (0.7) 0.80
  Other (%) 10 (0.9) 0 3 (1.1) 3 (1.1) 4 (1.5) 0.31
Secondary end points
 Hospital stay, days (IQR) 8 (5,15) 8.5 (5,14) 8 (5,15) 8 (5,14) 9 (5,15) 0.71
‡ICU admittance (%) 213 (20.0) 53 (20.1) 52 (19.6) 50 (18.6) 58 (21.6) 0.85
‡ICU stay, days (IQR) 2 (1,6) 2 (2,5) 3 (1,11) 2 (1,4) 2 (1,4) 0.68
 Arrhythmia (%) 9 (0.8) 2 (0.8) 3 (1.1) 1 (0.4) 3 (1.1) 0.74
 Heart failure (%) 3 (0.3) 1 (0.4) 1 (0.4) 0 1 (0.4) 0.79
 Revascularization (%) 1 (0.1) 0 1 (0.4) 0 0 0.39
* IQR = interquartile range, † MI = myocardial infarction, ‡ ICU = intensive care unit
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Comparison of the 534 patients allocated to fluvastatin therapy with the 532 patients allocated to 
fluvastatin-control therapy
A total of 17 (event rate according to the Kaplan-Meier method 3.2%) patients allocated to fluvastatin 
therapy reached the primary endpoint, compared to 26 (4.9%) allocated to therapy without fluvas-
tatin (FIGURE 12.2). Hence, a reduction in the incidence of the primary endpoint was observed in 
favor of fluvastatin therapy, but statistical significance was not reached (HR: 0.65; 95% CI: 0.35-1.20; 
p = 0.17).
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Figure 12.1 Incidence of primary study end point by treatment group.
0%
2%
4%
6%
8%
0 7 14 21 28
Days after surgery
BBL vs. BBL-control
0%
2%
4%
6%
8%
0 7 14 21 28
Days after surgery
Statin vs. statin-control
P-value 0.002 P-value 0.17
Bisoprolol control
Bisoprolol 
C
ar
di
ac
 d
ea
th
 o
r n
on
fa
ta
l m
yo
ca
rd
ia
l i
nf
ar
ct
io
n
C
ar
di
ac
 d
ea
th
 o
r n
on
fa
ta
l m
yo
ca
rd
ia
l i
nf
ar
ct
io
n
Fluvastatin control
Fluvastatin
0%
2%
4%
6%
8%
0 7 14 21 28
Days after surgery
BBL vs. BBL-control
0%
2%
4%
6%
8%
0 7 14 21 28
Days after surgery
Statin vs. statin-control
P-value 0.002 P-value 0.17
Bisoprolol control
Bisoprolol 
C
ar
di
ac
 d
ea
th
 o
r n
on
fa
ta
l m
yo
ca
rd
ia
l i
nf
ar
ct
io
n
C
ar
di
ac
 d
ea
th
 o
r n
on
fa
ta
l m
yo
ca
rd
ia
l i
nf
ar
ct
io
n
Fluvastatin control
Fluvastatin
Figure 12.2 Incidence of primary study end point for each individual treatment vs. control.
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A stroke occurred in 3 (0.6%) patients who were randomized to fluvastatin therapy and in 4 (0.7%) 
patients randomized to fluvastatin-control (p = 0.71). In total, 8 (1.5%) patients randomized to fluvas-
tatin therapy had clinically significant liver dysfunction compared to 11 (2.1%) on fluvastatin-control 
therapy (p = 0.48). No patient experienced myopathy or rhabdomyolysis.
DISCuSSION
The DECREASE-IV study shows that treatment with bisoprolol, titrated to a perioperative heart rate of 
50-70 beats per minute and initiated at a median of 34 days prior to surgery, resulted in a significant 
reduction of perioperative cardiovascular complications, particularly MI. Only 26 patients need to 
receive bisoprolol prophylaxis to prevent one perioperative cardiac event. This study was not able to 
demonstrate a significant reduction in cardiovascular complications by fluvastatin therapy. However, 
we appreciate that – due to its early termination – DECREASE-IV lacked statistical power to reveal 
clinically relevant differences in this respect. Slow enrolment occurred due to the fact that 78% of the 
patients who met the inclusion criteria were on beta-blocker and/or statin therapy, as opposed to the 
estimated 10% of patients receiving beta-blocker and 10% receiving statin therapy.
Beta-blocker therapy for perioperative cardiac risk reduction
Although widely prescribed, there is still considerable debate about the protective effect of beta-
blockers, with several studies showing a benefit of perioperative beta-blocker treatment2-4, while 
others found no cardioprotective effect16-18. The POISE study showed, similar to DECREASE-IV, that 
beta-blocker therapy reduced the risk of MI but increased the incidence of stroke and overall mor-
tality, a finding that was not confirmed in DECREASE-IV19. There are two major design differences 
between DECREASE-IV and POISE that may explain the differential findings: dose titration and timing 
of therapy.
It is well-known that initiation time and dose titration influence the effectiveness of perioperative 
beta-blocker therapy. The effects of acute beta-blockade include a reduction of myocardial oxygen 
demand. However, a beneficial effect of beta-blockade on coronary plaque stability, related to sus-
tained mechanical and anti-inflammatory effects, might require weeks to develop. Prolonged beta-
blockade has been shown to decrease the level of inflammatory cytokines both in the myocardium 
and the systemic circulation10,20,21, as well as decreasing the progression of coronary atherosclero-
sis22. Additionally, it seems crucial to continue beta-blockers postoperatively. It has been shown that 
withdrawal of beta-blocker therapy early after surgery was associated with a 2.7-fold increased risk of 
1-year mortality compared to patients not using beta-blockers23.
In addition to initiation time, dose adjustment for heart rate control is important in beta-blocker 
therapy24. Accordingly, the new ACC/AHA guidelines on perioperative care strongly recommend 
achieving and maintaining a heart rate of 60-65 beats per minute25. The POISE trial initiated meto-
prolol treatment just before surgery and the maximum recommended therapeutic dose (MRTD) 
could be achieved within the first day of treatment19. In contrast, the DECREASE studies employed 
a relatively low bisoprolol dose (12.5% of MRTD) that was carefully titrated during approximately 
30 days12,26. Notably, the POISE trial observed a 1% incidence of stroke in the group randomized to 
metoprolol compared to 0.5% in the control group. In comparison the incidence of stroke was 0.4% 
in the DECREASE studies, with no difference between groups.
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The outcome of these studies suggest that two different treatment protocols applying beta-blockers 
are effective in reducing perioperative cardiac complications; one prescribing a high dose imme-
diately prior to surgery, the other a dose titration approach over a prolonged period. However, the 
cardioprotective effect of the high dose regimen comes at the cost of an increased incidence of side 
effects, such as stroke.
Statin therapy for perioperative cardiac risk reduction
Statins are widely prescribed in patients with or at risk of coronary artery disease (CAD) because of 
their lipid lowering capacity. Beyond this property, statins may stabilize coronary artery plaque and 
thereby prevent plaque rupture and subsequent MI in the perioperative period27.
Multiple clinical trials and large observational studies have demonstrated a beneficial effect of peri-
operative statin use5,6,28-30. The first prospective, randomized controlled, clinical trial evaluating the 
effects of statin therapy on perioperative cardiovascular complications was performed by Durazzo et 
al.6 After six months follow-up, the incidence of cardiovascular events was more than 3-fold higher 
with placebo than with atorvastatin (26% vs. 8%, p=0.031).
A major concern of statin therapy is the potential for side effects including myopathy and rhabdomy-
olysis. In a retrospective study, Schouten et al. studied the potential risk of myopathy from periop-
erative statin therapy31. After correcting for cardiac risk factors and clinical risk factors for myopathy, 
length of surgery remained the only factor independently associated with creatine kinase elevations. 
Rhabdomyolysis was not observed. Considering that the risk of perioperative cardiovascular com-
plications is far greater than the risk of statin-induced myopathy and rhabdomyolysis, the potential 
benefits of perioperative statin use seem to outweigh the hazards. However, despite a numerical 
reduction in cardiac events in patients on fluvastatin therapy, statistical significance was not achieved 
in this study. Larger randomized controlled trials investigating perioperative statin therapy are indi-
cated.
Limitations
A potential limitation of this study was is its open-label design and lack of blinding, with a consequent 
risk of treatment bias. However, since beta-blocker therapy cannot be titrated to heart rate in a double-
blind setting, an open-label design was employed. In addition, the recognizable hemodynamic effects 
of bisoprolol potentially decrease the effectiveness of a double-blind design. The statin arms of this 
study were also not blinded, as this would severely complicate the 2 by 2 study design.  The study was 
terminated before the target sample size was achieved, with a resultant decrease in statistical power. 
This may explain the failure to achieve statistical significance regarding the efficacy of fluvastatin 
therapy. Therefore, further large, randomized controlled trials of statin therapy are indicated. Finally, 
our results are applicable only to intermediate-risk patients undergoing non-cardiovascular surgery 
and are not applicable to the large population of low-risk patients.
Conclusion
Although, the identification of patients at risk has improved recently, no widely applicable periopera-
tive cardiovascular risk reduction strategies for intermediate-risk patients have been developed. The 
current trial demonstrates that bisoprolol treatment, begun one month preoperatively, and titrated 
to heart rate, significantly reduces the incidence of perioperative cardiac death and MI, without 
increasing morbidity or non-cardiac mortality. This represents a significant advance in the manage-
ment of this sizable patient population.
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ABSTRACT
Background: Perioperative beta-blocker therapy has been proposed to improve outcome. However, 
most of the trials conducted lacked statistical power to evaluate the incidence of hard cardiac events 
and the relation to the type of surgery. Therefore we conducted a meta-analysis of all randomized 
controlled trials in which beta-blocker therapy was evaluated.
Methods: An electronic search of published reports on Medline was undertaken to identify stud-
ies published between January 1980 and November 2004 in English language journals. All studies 
reported on at least one of three end-points: perioperative myocardial ischemia, perioperative non-
fatal MI, and cardiac mortality. Type of surgery, defined as low, intermediate and high risk according 
to ACC/AHA guidelines, was noted.
Results: In total 15 studies were identified, which enrolled 1077 patient. There were no significant 
differences in baseline clinical characteristics between patients randomized to beta-blocker therapy 
and control/placebo. Beta-blocker therapy was associated with a 65% reduction in perioperative 
myocardial ischemia (11.0% versus 25.6%; OR 0.35, 95%CI 0.23-0.54; p<0.001). Furthermore, a 56% 
reduction in MI (0.5% vs. 3.9%, OR 0.44, 95% CI 0.20-0.97; p=0.04), and a 67% reduction (1.1% vs. 
6.1%, OR 0.33, 95% CI 0.17-0.67; p=0.002) in the composite endpoint of cardiac death and non-fatal 
MI was observed. No statistical evidence was observed for heterogeneity in the treatment effect in 
subgroups according to type of surgery (p for heterogeneity 0.2).
Conclusion: This meta-analysis shows that beta-blocker use in non-cardiac surgical procedures is 
associated with a significant reduction of perioperative cardiac adverse events.
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INTRODuCTION
It is estimated that annually 4-10% of the population of the United States is scheduled for non-cardiac 
surgery1. Patients undergoing major non-cardiac surgery are at a significant risk of cardiac events due 
to underlying (a-) symptomatic coronary artery disease (CAD). Although the overall perioperative 
event rate has declined over the past 30 years, 30-day cardiovascular mortality remains as high as 3% 
to 5%2,3. Myocardial infarction (MI) is the most frequent fatal complication in this respect, accounting 
for 10-40% of postoperative fatalities4,5.
The high incidence of perioperative adverse cardiac events has resulted in the development of cardiac 
risk scores and guidelines, in relation to the risk of specific procedures, to identify patients at risk6-12. 
Based on these models, several clinical trials have been conducted to improve outcome and to study 
whether cardioprotective medical therapy and/or preoperative coronary revascularization are associ-
ated with risk reduction. The results of the recently published CARP-trial showed that preoperative 
coronary revascularization does not reduce perioperative MI and long-term survival in a group of 510 
patients at high risk13. The ineffectiveness of preoperative revascularization was partially explained 
by improved medical therapy, in particular by the wide spread use of perioperative beta-adrenergic 
blocking agents in approximately 90% of the control group.
The use of beta-blockers has been associated with a reduced risk on the surrogate end point of 
perioperative myocardial ischemia. However, most of the trials conducted so far lacked the statisti-
cal power to evaluate the cardioprotective effect of beta-blockade on the incidence of hard cardiac 
endpoints, such as myocardial infarction and cardiac death. Also the influence of the risk of specific 
procedures remains unknown. Therefore we conducted a meta-analysis of all randomized controlled 
trials in which the effectiveness and safety of perioperative beta-adrenergic blockade on periopera-
tive cardiac events was studied against placebo/control therapy for specific types of surgery.
METhODS
Although the principles that lie behind a meta-analysis of randomized clinical trials have been 
described in detail, we will highlight the relevant principles applied herein. Due to the limited sample 
size and variable risk reductions noted across trials, the synthesis of available evidence may better 
aid in discerning the weighted evidence on the use of beta-blockers from existing randomized trial 
data.
Trial selection
We intended to include all trials reported since January 1980 with the following subject headings: 
randomization of patients scheduled for elective non-cardiac surgical interventions; and comparison 
of an adrenergic beta-antagonists (beta-blockers) with placebo or control therapy. To be included in 
the analysis, studies had to report one or more of three end-points: perioperative (i.e. < 30 days after 
surgery) myocardial ischemia, perioperative nonfatal MI, or cardiac mortality. Using these selection 
criteria, a total of 15 randomized clinical trials were identified (n=1,077).
A systematic electronic search of published reports on Medline was undertaken to identify studies 
published between January 1980 and January 2005 in English language. To identify eligible trials 
the following Medical Subject Heading (MESH) terms, or a combination of these, were used: adren-
ergic beta-antagonist, myocardial infarction, myocardial ischemia, mortality, and perioperative care. 
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Furthermore, we examined the reference lists of identified articles and published recommendations 
for perioperative cardiac risk management.
Data management
Pertinent data from the selected studies were extracted independently by two investigators (OS and 
DP), using standardized spreadsheets. Discrepancies were resolved by consensus and oversight from 
a 3rd investigator (EB). Information extracted included reference data (first author, journal, institu-
tion), publication year, number of patients, mean age, proportion of male patients, type of surgery, 
type of beta-blocker therapy, duration and dose of beta-blocker therapy, duration of follow-up, 
history of coronary artery disease, incidence of myocardial ischemia, myocardial infarction, death, 
and cause of death. The type of surgery was classified as intermediate or high risk according to the 
guidelines of the ACC/AHA (TABLE 13.1)14. Furthermore we also extracted data on possible beta-
blocker side effects including bradycardia, hypotension, AV-block, bronchospasm, and pulmonary 
edema. Because of known difficulties in quality scoring of randomized trials, we did not score the 
quality of the included trials.
Table 13.1 Classification of surgical procedures according to the ACC/AHA guidelines14.
high Risk Surgical Procedures Emergent major operations
Aortic and major vascular surgery
Peripheral vascular surgery
Anticipated prolonged surgical procedures
Intermediate Risk Procedures Carotid endarterectomy
Head and neck surgery
Intraperitoneal and intrathoracic surgery
Orthopedic surgery
Prostate surgery
High risk surgical procedures, > 5% chance on cardiac death or non-fatal MI, and intermediate risk surgical procedures, 
1-5% chance on cardiac death or non-fatal MI.
Table 13.2 Definitions of myocardial ischemia in 12 trials that reported perioperative myocardial ischemia.
Study Definition of myocardial ischemia
Bayliff et al.15 Not specified
Coleman et al.17 ST segment changes
Cucchiara et al.18 Transient ST-shifts
Davies et al.19 Chest pain
Magnusson et al.21 ST60-depression exceeds or is equal to 1.0 mm in males and 1.5 mm in females, or T-inversion 
appeared, or both
Magnusson et al.22 Downward sloping ST-segments
Raby et al.24 ST-segment depression that is horizontal and down-sloping, >1 mm from a predefined baseline, and 
lasting >1 min
Rosenberg et al.25 Change in ST level >0.1 mV from baseline measured at 60 ms from the J point
Stone et al.26 New ST-segment depression of at least 1 mV with a horizontal or downsloping configuration
Urban et al.27 ST-segment depression that is horizontal and down-sloping, >1 mm from a predefined baseline, and 
lasting >1 min
Wallace et al.28 Reversible ST segment changes ≥ 1 min and involving a shift from baseline of ≥ to 0.1 mV of ST 
depression ( slope <or= to 0), or a shift from baseline of ≥ 0.2 mV of ST-T elevation at J-point
Zaug et al.29 New horizontal or downsloping ST-segment depressions ≥ 0.1 mV, persisting ≥ 60 ms after the J 
point, or ST-segment elevations of ≥ 0.2 mV lasting > 2 min. With ST depression at baseline, a further 
depression of ≥ 0.15 mV  was necessary
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Definitions of efficacy and safety endpoints
Myocardial ischemia, infarction, and/or cardiac death were part of the composite efficacy endpoint of 
all trials, but the applied definitions were different (see TABLES 13.2 and 13.3). Still, since we know that 
heterogeneity in an endpoint definition will not lead to invalid results, we applied the trial-specific 
definition of myocardial infarction for practical reasons. There were also between-trial differences 
with regard to the definition of adverse effects, i.e. bradycardia, hypotension, AV-block, bronchos-
pasm and pulmonary edema. The trial-specific definitions were retained.
Table 13.3 Definitions of myocardial infarction in all 15 trials.
Study Definition of myocardial infarction
Bayliff et al.15 Not specified
Bohm et al.16 Not specified
Coleman et al.17 Not specified
Cucchiara et al.18 Not specified
Davies et al.19 CK-MB > 80 units, and new Q-waves on ECG
Jakobsen et al.20 Not specified
Magnusson et al.21 Not specified
Magnusson et al.22 Not specified
Poldermans et al.23 Serum creatine kinase level > than 110 U per liter, with an MB isoenzyme fraction of > 10 percent, 
and a finding of new Q waves lasting > 0.03 second on the electrocardiogram
Raby et al.24 Any creatine kinase (CK) increase associated with a CK MB increase >5%
Rosenberg et al.25 Not specified
Stone et al.26 Not specified
Urban et al.27 Serum CPK-MB fraction isoenzyme index >=3.0. ECG changes included new ST-T changes, T 
inversions, Q waves, and/or a bundle branch block
Wallace et al.28 (1) a CPK-MB isoenzyme concentration ≥ to threshold (0.83 mmol per liter per second [or 50 units/
liter]), and (2) either new Q waves (Minnesota Code I or II), or persistent (4 days) changes in the ST-T 
wave (Minnesota Code IV or V), or autopsy evidence of acute infarction
Zaug et al.29 new Q wave, persistent ST–T wave changes as defined by Minnesota Codes, association with any 
elevation of creatine kinase with creatine kinase MB increase > 5%
Statistical analysis
From each of the randomized trials, a 2 x 2 frequency data was calculated for each of the available 
endpoints and side effect data. The 2 x 2 frequency data was input into the Comprehensive Meta 
AnalysisTM program (www.meta-analysis.com, version 1.0.25). Available data from each trial was 
input into this program for calculation of individual and summary odds ratio (95% CI) data. Summary 
odds ratios (95% CI) were calculated for cardiac death, all-cause death, combined cardiac death or 
myocardial infarction, nonfatal myocardial infarction, and ischemia. For side effects, a summary odds 
ratio (95% CI) was AV block, bradycardia, bronchospasm, hypotension, pulmonary edema, as well as 
for a summary side effect odds ratio (95% CI). A chi-square test for heterogeneity (Mantel-Haenszel) 
was calculated in order to examine the combinability of each of the endpoints and side effects. 
The adequacy of combining the data was noted when the p-value was non-significant (p>0.05). 
The Number Needed to Treat (NNT) is defined as the number of patients who need to be treated 
to prevent 1 adverse outcome. We reported the NNT as a whole number and it was calculated as 1/ 
odds ratio and accompanied by its 95% confidence interval (CI). The calculation was applied based 
upon methods defined by http://www.jr2.ox.ac.uk/bandolier/band36/b36-2.html#Table, access 
date: June 25, 2005.
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RESuLTS
Based on the trial selection criteria, 15 trials were identified and subsequently analysed15-29. The 
characteristics of the analyzed trials are shown in TABLE 13.4.
Patients’ characteristics
The trials altogether enrolled 1,077 patients. There were no important differences in baseline char-
acteristics between patients randomized for beta-blocker therapy (n=551) and those randomized 
for placebo or control (n=526, TABLE 13.5). Two hundred fifty one patients underwent non-cardiac 
vascular surgery, 561 general surgery, 134 thoracic non-cardiac surgery, 107 orthopedic surgery, and 
24 ENT procedures. In total 188 patients received atenolol, 123 bisoprolol, 88 metoprolol, 52 a combi-
nation of esmolol and metoprolol, 51 esmolol only, and 49 received propanolol treatment. High-risk 
surgery was performed in 211 patients (3 trials) and intermediate risk in 866 patients (13 trials). None 
of the trials reported on the effects of beta-blockers in low risk surgery. Beta-blocker therapy resulted 
in a lower preoperative heart rate (72.9 ± 6.8 bpm vs. 78.8 ± 4.9 bpm, p=0.001).
Efficacy endpoints
The occurrence of myocardial ischemia was reported in 12 trials, including 410 treated and 407 con-
trol patients. Beta-blocker use was associated with a 65% relative reduction in the odds of periopera-
tive myocardial ischemia (11.0% versus 25.6%; OR 0.35, 95%CI 0.23-0.54; p<0.001, FIGURE 13.1). The 
absolute risk reduction was over 14% (number needed to treat  = 7). There was no statistical evidence 
of heterogeneity in treatment effect among the separate trials.
All trials reported the occurrence of non-fatal myocardial infarction. Overall, beta-blocker use was 
associated with a 56% decreased risk on myocardial infarction (p=0.04, FIGURE 13.1). The number 
needed to treat (NNT) for this endpoint was 32.
The use of beta-blockers was not significantly associated with a reduction in cardiac death (0.54% 
vs. 2.22%, p=0.14). This might be due to a type II error since only 3 patients in the treated group and 
12 patients in the control group died due to cardiac causes. On the other hand, beta-blocker use 
resulted in a 67% relative reduction in the combined endpoint of cardiac death and non-fatal MI 
(1.1% vs. 6.1%, OR 0.33, 95% CI 0.17-0.67; p=0.002, NNT = 20, FIGURE 13.1).
Endpoint
Treated
(n=551)
Control
(n=526) OR 95% CI p Value
Cardiac Death 0.54% 2.22% 0.55 (0.25-1.22) 0.140
All-Cause Death 1.27% 1.85% 0.79 (0.36-1.76) 0.568
Cardiac Death or MI 1.09% 6.10% 0.33 (0.17-0.67) 0.002
Nonfatal MI 0.54% 3.88% 0.44 (0.20-0.97) 0.043
Ischemia 10.98% 25.55% 0.35 (0.23-0.54) <0.0001
Summary OR 2.45% 7.00% 0.42 (0.32-0.56) <0.0001
Rx
Effect
< 45%
< 21%
< 67%
< 56%
< 65%
< 58%
0.1
0.1
0.2
0.2
0.5
0.5
1
1
2
2
5
5
10
10
Lower Risk Higher Risk
Figure 13.1 Comparison of perioperative/near-term outcomes in patients treated with beta-blocker therapy vs. no 
drug/placebo.
Ischemic event data was available from 11/15 studies (n=410 treated and n=407 controls); OR, odds 
ratio; Rx, treatment; MI, myocardial infarction.
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As is shown in FIGURE 13.2, the cardioprotective effect of beta-blockers was comparable in patients 
undergoing high and intermediate risk surgery according to the AHA classification. The odds ratio 
for the composite endpoint of myocardial infarction and cardiac death in respectively high risk and 
intermediate risk surgery was 0.06 (95% CI 0.01-0.29, NNT = 6) and 0.28 (95% CI 0.09-0.84, NNT = 42), 
and the p-value for heterogeneity 0.2.
Safety endpoints
Nine trials reported bradycardia as a safety-endpoint. In these studies which included 350 treated 
patients and 346 control patients, beta-blocker use was associated with a 4.3 fold increased risk 
of bradycardia (p=0.006, TABLE 13.6). Patients on beta-blocker therapy did not have a significantly 
increased risk on hypotension (14.1% vs. 10.7%, p=0.73). Other side effects were reported less fre-
quently; AV-block was systematically reported in 1 study (27 treated, 30 controls), pulmonary edema 
in 2 studies (93 treated, 89 control), and bronchospasm in 2 studies (85 treated, 87 control). None 
0.01 0.1 1 10
Odds ratio
High-risk surgery
(3 trials)
Intermediate-risk surgery
(13 trials)
Any type of surgery
Pheterogeneity = 0.2
Figure 13.2 Odds ratio according to type of surgery.
Table 13.5 Clinical characteristics of the 15 published reports.
Beta Blocker
N = 551
No Drug / Placebo
N = 526
Mean age (years) 62.8 62.8
Prior MI 27.1% 27.5%
Angina 32.7% 21.9%
COPD 30.4% 25.0%
Hypertension 52.7% 60.7%
CHF 8.2% 7.6%
Diabetes 24.0% 21.8%
Hypercholesterolemia 15.3% 16.0%
Chronic renal failure 4.3% 0.0%
CVA or TIA 1.9% 0.0%
Current smoker 34.4% 36.3%
This table looks at the rate in the trials where each of the historical variables were reported. MI = myocardial infarction; 
COPD = chronic obstructive pulmonary disease; CHF = congestive heart failure; CVA = cerebrovascular accident; TIA = 
transient ischemic attack
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of these three safety endpoints were statistically associated with beta-blocker use. However overall, 
beta-blocker therapy was associated with a 1.5 fold risk of the combined safety endpoints (p=0.005, 
TABLE 13.6).
DISCuSSION
This meta-analysis indicates that perioperative beta-blocker use is associated with a substantial reduc-
tion in perioperative myocardial ischemia, myocardial infarction, and the composite end point of cardiac 
death and non-fatal myocardial infarction in patients undergoing non-cardiac surgery. No difference 
was observed in the cardioprotective effect of beta-blockers in subgroups of patients according to type 
of surgery. As expected the use of beta-blockers was associated with a higher incidence of bradycardia. 
However, the risk of bronchospasm and pulmonary edema was not increased by beta-blockers.
Beta-blockers are well established in the treatment of ischemic heart disease and heart failure and 
have been shown to improve outcome in non-surgical cardiac patients30. Hence it is not surprising 
that perioperative beta-blocker use in patients at risk for CAD undergoing non-cardiac surgery 
reduced risk of cardiac complications. We did not observe statistical evidence for heterogeneity in the 
treatment effect of beta-blockers in subgroups according to type of surgery. The absolute treatment 
effect was highest (and the NNT lowest) in patients undergoing high-risk surgery. The mechanisms by 
which beta-blockers exert their perioperative cardioprotective effect are multifactorial. Beta-blockers 
decrease myocardial oxygen demand by reduction of heart rate and myocardial contractility31,32. 
Furthermore, beta-blockers reduce the adrenergic activity, which results in reduced levels of free 
fatty acid, thus causing a shift in the myocardial metabolism towards glucose uptake33.
Our results are in line with a previously reported meta-analysis that showed a positive association 
between beta-blocker use and reduction of perioperative cardiovascular mortality and morbidity. 
In an analysis of 11 randomized trials (866 patients), Stevens et al.34 found a significant decrease in 
perioperative myocardial ischemia (OR 0.32, 95% CI 0.17-0.58), postoperative myocardial ischemia 
(OR 0.46, 95% CI 0.26-0.81), non-fatal MI (OR 0.19, 95% CI 0.08-0.68), and cardiac mortality (OR 0.25, 
95% CI 0.09-0.73). Auerbach and Goldman describe the results of 5 randomized trials35. The reported 
NNT of these trials were between 2.5 to 6.7 for myocardial ischemia, and between 3.2 and 8.3 for 
cardiac or all-cause mortality, indicating a substantial benefit for patients on beta-blocker therapy. In 
our study the benefits of beta-blocker therapy on perioperative myocardial ischemia were similar to 
those reported by Stevens et al. Recently Devereaux et al. reported no difference in a meta-analysis 
of 22 studies36. However, in that meta-analysis also studies that were presented at scientific meet-
ings only (and not yet published in peer-reviewed journals) were included. Besides this, they also 
included trials not reporting on myocardial damage but on side effects only while our meta-analysis 
was primarily focused on the cardioprotective value of perioperative beta-blocker therapy.
Table 13.6 Weighted average difference in the rate of side effects for β-blocker therapy vs. no drug/placebo.
Side Effects Treated Control Rate 95% CI P-value
AV block 1 / 27 0 / 30 2.5% -7.8% - 12.8% 0.63
Bradycardia 51 / 530 14 / 346 4.3% 1.3% - 7.4% 0.006
Bronchospasm 13 / 85 16 / 87 1.2% -5.5% - 8.0% 0.72
Hypotension 64 / 315 59 / 309 0.8% -3.9% - 5.6% 0.73
Pulmonary edema 17 / 93 9 / 89 8.1% -1.9% - 18.0% 0.11
Overall S.E. 146 / 870 98 / 861 3.3% 1.0% - 5.6% 0.005
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Tight heart rate control in patients on beta-blockers indeed seems to reduce perioperative ischemia 
as has been shown by Raby et al24. In their study 150 patients were monitored by ambulatory ECG. In 
26 of these patients ischemia occurred. These patients were then randomized to receive either tight 
heart rate control, i.e. 20% less than the ischemic threshold but >60 bpm, or normal beta-blocker 
therapy. Tight heart rate control in patients on beta-blockers was associated with a reduced inci-
dence of myocardial ischemia. Unfortunately it is practically impossible to achieve such a control 
by oral medication alone. Intravenous administration of beta-blockers is possible but continuous 
infusion of beta-blockers in every patient on a normal care ward is simply not feasible. However close 
monitoring and dose adjustment of intravenous medication can and should be done during surgery 
and at the intensive care unit.
Another important question that remains to be answered is when to start beta-blocker therapy and 
when to discontinue after surgery. In the trials analyzed in this study, the time window of treatment 
differed preoperatively from hours to 37 days and postoperative from just a single dose to a week or 
more. So far no study has assessed the optimal run-in period for beta-blockers. However, based on 
the evidence of published trials it is probably safe to conclude that beta-blocker therapy should be 
initiated prior to surgery and dose titration has to be done up to the induction of anesthesia. Recent 
publications suggest that for high-risk patients, e.g. vascular surgery patients, beta-blocker therapy 
has to be continued lifelong37. Coronary artery disease remains an important risk factor for later car-
diac complications. Therefore proper cardiac medication is just as important for these patients as for 
patients with established CAD who are not referred for surgery. Whether this is also true for patients 
at moderate or low risk remains undefined. However, prolonging beta-blocker therapy beyond the 
surgical procedure seems to be important for all patients since the risk of myocardial ischemia and 
infarction remains high in the first postoperative week.
Side effects
In our meta-analysis we found a higher incidence of bradycardia in patients on beta-blocker therapy. 
This finding was also reported in the study by Stevens et al., in which they found an OR of 3.76 (95% CI 
2.45-5.77). The rate of pulmonary adverse events was similar between treated and untreated patients, 
a finding that is confirmed in recent publications on cardioselective beta-blockers. Based on these 
publications, obstructive pulmonary disease should not be considered a contraindication for the 
perioperative use of beta-blockers. Also AV-block and hypotension were not more frequently noted 
in patients using beta-blockers. Though this might be due to relatively low number of patients, it 
seems that the benefits of beta-blocker therapy outweigh the potential side effects. Another side 
effect ascribed to beta-blocker therapy in vascular surgery patients is worsening of intermittent 
claudication. None of the analyzed trials reported on the incidence of claudication. However other 
publications suggest that there is no negative effect on microcirculation or symptoms in claudicants 
on beta-blocker therapy38,39.
Conclusion
This meta-analysis showed that the use of beta-adrenergic receptor antagonists is associated with a 
significant reduction in cardiac morbidity in patients undergoing non-cardiac surgery, irrespective 
whether patients were scheduled for high or intermediate risk surgery.
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Safety and efficacy of beta-blocker therapy in 
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ABSTRACT
Background: Perioperative beta-blocker therapy is associated with a reduction in cardiac events. 
However, concerns exist regarding beta-blocker use in patients undergoing esophagectomy because 
of a possible increased risk of ischemia and leakage of the esophagogastric anastomosis. Therefore, 
we selected patients from the randomized DECREASE IV undergoing esophagectomy and evaluated 
the efficacy and safety of beta-blocker therapy.
Methods: A total of 101 patients scheduled for esophagectomy were randomized to beta-blocker 
therapy (n=52) or no beta-blocker therapy (n=49). Postoperatively data on troponin release and ECG 
were collected on day 1, 3, 7, and before discharge. Results of radiology, gastroscopy, and clinical 
signs of ischemia or leakage of the esophagogastric anastomosis were noted.
Results: Beta-blocker use was associated with a reduction in the combination of myocardial damage, 
myocardial infarction and cardiac death (16% vs. 4%, p=0.04). The rate of radiological anastomotic 
leakage was similar in both groups (16% vs. 16%, p=0.96), as well as the rate of ischemia at gastros-
copy (26% vs. 17%, p=0.32) and the number of reoperations (16% vs. 14%, p=0.69).
Conclusion: Perioperative beta-blocker use in patients undergoing esophagectomy is associated 
with a reduction in cardiac events and is not associated with an increased risk for ischemic complica-
tions.
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INTRODuCTION
Patients undergoing major non-cardiac surgery are at significant risk of cardiovascular morbidity and 
mortality. Although the perioperative event rate has declined over the past 30 years, 30-day cardio-
vascular mortality in major non-cardiac surgery remains as high as 3% to 6%1. Myocardial infarction 
(MI) is the most frequent fatal complication in this respect, accounting for up to 50% of postoperative 
fatalities2,3.
Due to the role of sympathetic activation in adverse perioperative cardiac outcomes, beta-adrenergic 
receptor blocking drugs have been proposed as a means for providing cardioprotection. Potential 
cardioprotective mechanisms of beta-blockers include a reduced heart rate and contractility and 
subsequently lower myocardial oxygen demand; a shift in energy metabolism from free fatty acids 
to the more energy efficient glucose; anti-arrhythmic effects; anti-renin/angiotensin properties; and 
anti-inflammatory effects possibly promoting plaque stability4,5. Several studies have suggested 
that perioperative beta-blocker use is indeed associated with a reduction of perioperative cardiac 
complications in patients at high cardiac risk6,7.
According to the recent ACC/AHA guidelines patients undergoing esophagectomy for cancer are at 
increased risk for perioperative events8. Therefore this group of patients might benefit from periop-
erative beta-blocker therapy. However, there are serious concerns on the safety of perioperative beta-
blocker use in this patient population. The blood flow to the new esophagogastric anastomosis after 
esophagectomy is of critical importance and might be compromised by the use of beta-blockers. 
Consequently this might lead to an increased incidence of anastomotic leakage and reoperation, 
resulting in major morbidity.
The randomized Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography 
IV study (DECREASE IV) was set up to test whether patients at intermediate cardiac risk benefit from 
perioperative beta-blocker and/or statin therapy. We used data of patients undergoing esophagec-
tomy in this study to evaluate the possible cardioprotective effect of beta-blocker use and assess the 
safety of beta-blockers after esophagectomy.
METhODS
Patient population
The study design of the DECREASE IV study has been published previously9. A total of 1,066 patients 
were randomized for the DECREASE IV trial and received either perioperative beta-blocker therapy, 
statin therapy, both or neither10. For the current study we selected those patients who underwent 
esophagectomy for cancer, either by means of extended transthoracic resection or by limited tran-
shiatal resection, and compared patients who were allocated to perioperative beta-blocker therapy 
(with or without statins) or no beta-blocker therapy (with or without statins).
Briefly, patients who were (1) aged 40 years or older, (2) scheduled for elective non-cardiac surgery 
and (3) have an estimated risk for cardiovascular death of more than 1%, were eligible for enrollment 
in the DECREASE-IV trial. Importantly, according to the ACC/AHA 2007 guidelines on perioperative 
cardiovascular evaluation and care for non-cardiac surgery8 esophagectomy should be considered 
an intermediate risk surgical procedure with a cardiac risk of >1%.
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Exclusion criteria for the trial were: (1) current use of beta-blockers, (2) contraindication for beta-
blocker use, (3) the use of statins prior to randomization, (4) a contraindication for statin use, (5) 
unstable coronary artery disease, (6) extensive stress induced myocardial ischemia suggestive for left 
main disease or equivalent, (7) emergency surgery, (8) previous participation in the same trial study, 
(9) inability or unwillingness to provide written informed consent.
Beta-blocker treatment regimen
The starting dose of bisoprolol, a so-called cardioselective beta-blocker, was 2.5 mg orally per day, if 
resting heart rate was >50 bpm. During hospitalization, resting heart rate was evaluated on a daily 
basis and drug dose was modified with steps of 1.25 or 2.5 mg per day, up to a maximum dose of 10 
mg, aiming at a heart rate of 50-70 bpm. The use of an open-label design was therefore necessary in 
order to titrate the bisoprolol dose to the therapeutic heart rate. Patients unable to take bisoprolol 
orally received intravenous metoprolol until the patient was able to switch back to oral medication. 
Bisoprolol administration was temporarily withheld if any of the following developed: resting heart 
rate <50 bpm; systolic blood pressure <100 mmHg; heart failure; bronchospasm; PR interval >0.30 s; 
second or third degree AV block.
Efficacy endpoint
The efficacy endpoint for the current study was a composite of myocardial damage, assessed by 
cardiac troponin T (cTnT) release, cardiac death and non-fatal myocardial infarction (MI) until 30-days 
after surgery. Cardiac troponin T was sampled systematically on days 1, 3 and 7 postoperatively and 
whenever clinically indicated. Additionally ECGs were collected on the same days. Nonfatal MI required 
any two of the following: (1) characteristic ischemic symptoms lasting > 20 minutes; (2) ECG changes 
including acute ST elevation followed by appearance of Q waves or loss of R waves, or new left bundle 
branch block, or new persistent T wave inversion for at least 24 hours, or new ST segment depression 
which persists for at least 24 hours; (3) a positive troponin T measurement with characteristic rise and 
fall11. All deaths were classified as either cardiovascular or non-cardiovascular. Cardiovascular death 
is defined as any death with a cardiovascular complication as the primary or secondary cause, and 
includes deaths following myocardial infarction, cardiac arrhythmia, resuscitation, heart failure, or 
stroke. Non-cardiovascular death is defined as any death with a primary non-cardiovascular cause, 
including surgery-related bleeding complications, cancer, trauma and infection. Sudden death in a 
previously stable patient is considered as cardiovascular12.
Safety endpoint
The safety endpoints for the current analysis consisted of radiological anastomotic leakage, clinical 
anastomotic leakage or infection of the cervical wound requiring opening of the wound, signs of 
ischemia during gastroscopy, and reoperation. It should be noted that these endpoints were not 
pre-specified in the original DECREASE IV study design. Data on these safety endpoints were identi-
fied independently by two investigators by meticulous screening of medical charts, radiology reports 
and reports of gastroscopy. If consensus could not be reached, the opinion of a third, independent 
investigator was final.
Statistical analysis
Continuous data are presented as median values and corresponding 25th and 75th percentiles, 
whereas dichotomous data are presented as percentages. Differences in clinical characteristics 
between patients with or without beta-blocker therapy evaluated by Wilcoxon’s nonparametric tests, 
Chi-square tests or Fisher’s exact tests, as appropriate. Differences in the incidence of the endpoints 
were evaluated by a Chi-square test or Fisher’s exact tests. The limit of statistical significance was set 
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at p = 0.05 (two-sided). All analysis was performed using the statistical software SPSS for Windows 
15.0.1 (SPSS Inc., Chicago, Illinois, USA).
RESuLTS
Baseline characteristics
A total of 101 patients underwent esophagectomy, 72 by transhiatal resection and 29 by transthoracic 
resection. Baseline clinical characteristics are shown in TABLE 14.1. Due to randomization there were 
no statistically significant differences in baseline characteristics and medication use. Preoperative 
ECG abnormalities were found in 39 (39%) patients; Q-waves in 10 (10%), right bundle branch block 
in 8 (8%), left bundle branch block in 5 (5%), left ventricular hypertrophy in 4 (4%), and preventricular 
contractions in 6 (6%). Heart rate was similar at baseline in both groups, i.e. 77 ± 12.4 beats/min in 
patients allocated to beta-blocker therapy and 80 ± 12.7 beats/min in patients allocated to the control 
group. Importantly at the day of hospital admission, median 34 days after the start of beta-blocker 
therapy, patients on beta-blocker therapy had a significantly lower mean heart rate (62 ± 7.4 beats/
min vs. 79 ± 12.6 beats/min, p<0.001).
Table 14.1 Baseline characteristics and medication use per treatment group.
Beta-blocker
(N=52)
Control
(N=49)
P-value
Baseline characteristics
 Male gender (%) 46 (85) 37 (76) 0.23
 Age, years (IQR) 64.5 (56,72) 61.8 (57,71) 0.64
 Diabetes Mellitus (%) 3 (6) 5 (10) 0.48
 Angina Pectoris (%) 1 (2) 3 (6) 0.35
 Myocardial infarction (%) 2 (4) 3 (6) 0.67
 Chronic heart failure (%) 1 (2) 0 1
 Stroke (%) 1 (2) 0 1
 Renal failure (%) 0 0 1
Medication use
 Statins (%) 24 (46) 21 (42) 0.67
 Diuretics (%) 4 (8) 2 (4) 0.68
 Aspirin (%) 4 (8) 1 (2) 0.36
 Calcium antagonists (%) 2 (4) 0 0.50
 ACE inhibitors (%) 5 (10) 4 (4) 0.44
 Angiotensin II inhibitors (%) 3 (6) 2 (4) 1
 Anticoagulants (%) 1 (2) 1 (2) 1
 Oral antidiabetics (%) 1 (2) 1 (2) 1
 Insuline (%) 1 (2) 4 (8) 0.20
 Glucocorticoids (%) 4 (8) 4 (8) 1
*IQR denotes interquartile range; ACE denotes angiotensin converting enzyme
Perioperative cardiac outcome
A total of 10 (9.9%) patients reached the combined efficacy endpoint of myocardial damage, myocar-
dial infarction and cardiac death. Patients on beta-blocker therapy had a significant reduced risk for 
perioperative events; 3.8% vs. 16.3% (OR 0.21, 95% CI 0.04-0.98, p=0.036, FIGURE 14.1).  The majority 
of cardiac events were asymptomatic. If no routine sampling of cTnT would have been performed 8 
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out of 10 events would have been missed. Of the 10 patients who reached the combined efficacy 
endpoint 5 met the criteria for myocardial infarction. All of these patients were allocated to the 
control group.
Safety outcome
The safety outcomes are shown in TABLE 14.2. Of the 101 patients 87 (86%) underwent X-ray with 
contrast. There was no difference in the incidence of radiological anastomotic leakage; 7/44 (15.9%) 
patients on beta-blockers vs. 7/43 (16.3%) patients not on beta-blockers (p=0.96). Clinical leakage 
or infection of the cervical wound requiring opening of the wound was scored in 19 patients, 9/52 
(17.3%) vs. 10/49 (20.4%) for users and non-users respectively (p=0.69). Gastroscopy was performed 
in 91 (91%) patients. Ischemia was found in 8/48 (16.7%) using beta-blockers and in 11/43 (25.6%) 
of patients not using beta-blockers (p=0.32). In total 15 (16.8%) patients underwent reoperation, 
7/52 (13.5%) beta-blocker users and 8/49 (16.3%) non-users (p=0.69). Overall 41 (40.6%) patients had 
either a radiological and/or clinical anastomotic leakage and/or ischemia during gastroscopy or a 
reoperation. There was no difference in the incidence of the combined safety endpoint between both 
groups; 38.5% vs. 42.9% for users and non-users respectively (p=0.65).
Table 14.2 Safety outcome.
Beta-blocker Control P-value
Radiological anastomotic leakage 7/44 7/43 0.96
Clinical leakage or infection of the cervical wound 17.3% 20.4% 0.69
Ischemia at gastroscopy 8/48 11/43 0.32
Reoperation, any 13.5% 16.3% 0.69
Reoperation, because of ischemia 5.8% 6.1% 1.0
Combined 38.5% 42.9% 0.65
Combined is the combination of radiological anastomotic leakage, clinical leakage or infection of the cervical wound, 
ischemia at gastroscopy, and reoperation.
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Figure 14.1 Perioperative cardiac damage in beta-blocker users vs. control
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DISCuSSION
The current study shows that perioperative beta-blocker therapy in patients undergoing esophagec-
tomy for cancer is associated with a reduction in cardiac events. Importantly the blood flow to the 
gastroesophageal anastomosis seems not to be affected by the use of selective beta-blockers as the 
rate of anastomotic leakage and ischemia is similar in users and non-users.
Patients undergoing major non-cardiac surgery are at increased risk for perioperative cardiac 
events even if the number of clinical risk factors is limited. As described in the ACC/AHA guidelines 
esophagectomy should be considered an intermediate risk surgical procedure in terms of cardiac 
risk8. The pathophysiology of perioperative cardiac events is complex and not fully understood. 
However, similar to the non-operative setting two mechanisms seems to be involved in most cases: 
(1) coronary plaque rupture leading to thrombus formation and subsequent vessel occlusion, and (2) 
increased myocardial oxygen demand (e.g. tachycardia and increased contractility) leading to myo-
cardial oxygen supply/demand mismatch that when sustained might lead to myocardial infarction. In 
patients undergoing noncardiovascular surgical procedures in particular the latter mechanism seems 
to play an important role. Due to the role of myocardial oxygen/supply mismatch in adverse periop-
erative cardiac outcomes, beta-adrenergic receptor blocking drugs have been proposed as a means 
for providing cardioprotection. In particular beta-blockers reduce heart rate and contractility and 
subsequently lower myocardial oxygen demand, cause a shift in energy metabolism from free fatty 
acids to the more energy efficient glucose, have anti-arrhythmic effects and some other potentially 
cardioprotective characteristics.
Large series of patients undergoing esophagectomy have shown cardiac complication rates, such as 
myocardial infarction, of approximately 1%13-15. It must be noted however that in these studies there 
was no systematic screening for adverse cardiac events such as the frequent sampling of cardiac 
troponins which was performed in the current study. This might explain why the event rate in the 
current study was higher than what has been reported in literature so far. It should be noted that 80% 
of perioperative cardiac events in the current study would have been missed if routine sampling of 
cTnT had not been performed. In postoperative patients, symptoms of cardiac complications might 
very well be atypical or absent even when ECG and/or biomarkers are abnormal. It is important to 
realize that myocardial infarction might occur with atypical symptoms, or even without symptoms, 
being detected only by ECG, biomarker elevations, or cardiac imaging. Classical symptoms of myo-
cardial ischemia include various combinations of chest, upper extremity, jaw, or epigastric discomfort 
with exertion or at rest. Often, the discomfort is diffuse, not localized, not positional, not affected by 
movement of the region, and it may be accompanied by dyspnea, diaphoresis, nausea, or syncope. 
Considering these classical symptoms it is hardly surprising that such a large number of episodes of 
myocardial ischemia and infarction are missed in the perioperative period because symptoms are 
masked by residual anesthetic effects, administration of analgesic agents, competing somatic stimuli 
such as incisional pain, and other factors.
Though beta-blockers have shown to be effective in reducing the risk of cardiac events, they have 
also been linked to serious adverse events in the perioperative period. The recently published POISE 
trial showed that starting high doses of metoprolol hours before surgery resulted in an increased 
risk for postoperative stroke16. Most of these strokes seem to have been attributable to perioperative 
episodes of hypotension, which might have been caused by beta-blocker use. On the other hand, in 
the DECREASE trials, starting bisoprolol at a relatively low dose of 2.5 mg approximately 30 days prior 
to surgery, there was no association between beta-blocker use and perioperative stroke17. Similar to 
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the brain the new gastroesophageal anastomosis after esophagectomy is vulnerable for hypotensive 
episodes. These episodes may lead to an insufficient blood flow to the anastomosis resulting in 
ischemia and subsequently leakage of the anastomosis. This fear might prevent the prescription of 
perioperative beta-blocker therapy in these patients. However, as shown in the current study, a regi-
men of perioperative beta-blocker use starting low dose cardioselective beta-blockers approximately 
30 days prior to surgery did not result in an increased risk for anastomotic leakage or ischemia nor in 
an increased risk for reoperation.
In conclusion, though the number of studied patients is relatively small, patients undergoing 
esophagectomy seem to benefit from perioperative beta-blocker therapy, as it is associated with 
improved cardiac outcome while the gastroesophageal anastomosis is not compromised.
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Perioperative cardiac complications are a major cause of morbidity and mortality in patients undergo-
ing non-cardiac surgery. Annually an estimated 100 million adults undergo non-cardiac surgery. The 
incidence of cardiac death after non-cardiac surgery is estimated at 0.5%1. Consequently, each year 
approximately 500 000 patients die perioperatively due to cardiac causes. According to the study by 
Lee et al. in a relatively unselected group of patients the overall risk for myocardial infarction (MI) after 
non-cardiac surgery is 1.1%2, i.e. 1.1 million MI’s annually worldwide.
Although the pathophysiology of a perioperative MI is not entirely clear, coronary plaque rupture, 
leading to thrombus formation and subsequent vessel occlusion seems to be an important caus-
ative mechanism behind such complications, similar to myocardial infarctions occurring in the 
non-operative setting3. The incidence of plaque rupture, with superimposed thrombosis, is possibly 
increased by the stress response to major surgery. This stress response includes a catecholamine 
surge with associated hemodynamic stress, vasospasm, reduced fibrinolytic activity, platelet activa-
tion and consequent hypercoagulability4. In patients with severe stenotic CAD, perioperative MI may 
also be caused by a sustained myocardial supply / demand imbalance due to prolonged tachycardia 
and increased myocardial contractility. The association of perioperative MI with prolonged, severe, 
perioperative myocardial ischemia, and the frequency of non-transmural or circumferential subendo-
cardial infarction in the perioperative setting support this mechanism5. At least two studies evaluat-
ing the pathophysiology of perioperative MI using non-invasive tests, coronary angiography, and 
autopsy results showed that coronary plaque rupture and thrombus formation occurred in around 
50% of all fatal cases, while a sustained mismatch of oxygen supply and demand was responsible for 
the remaining 50%3,6.
Mechanism of the protective effect of beta-blockers
The mechanisms by which beta-blockers exert their cardioprotective effect are multifactorial. Beta-
blockers reduce heart rate and contractility and subsequently myocardial oxygen demand; induce a 
shift from free fatty acids as the main cardiac energy substrate towards glucose resulting in improved 
energy efficiency and an improved outcome; possess an anti-arrhythmic effect and anti-renin/angio-
tensin properties; and have anti-inflammatory qualities7-9. The effects on heart rate, contractility, and 
energy substrate shift occur almost instantly. However, the effect on inflammatory response may only 
be observed after a prolonged period of beta-blocker use. For example, in a randomized study of 200 
surgical patients at risk for CAD Mangano et al. found no difference in the incidence of perioperative 
cardiac events among beta-blocker users, but there was a reduced incidence of late fatal cardiac 
events10. The benefits of beta-blocker use were not immediately apparent but evolved over the first 
6 to 8 months after initiation of beta-blocker therapy11.
Clinical evidence for the effectiveness of perioperative beta-blocker therapy
Although widely prescribed during non-cardiac surgery, the evidence for perioperative beta-blocker 
use is mainly based on only two small randomized prospective clinical trials and several observa-
tional studies. The first trial evaluated the effect of atenolol in high-risk patients undergoing non-
cardiac surgery10. In this study 200 patients with risk factors for or known ischemic heart disease 
were randomized for atenolol (50 or 100 mg) or placebo prior to surgery. Atenolol therapy was not 
associated with an improved in-hospital outcome (cardiac death or myocardial infarction), however, 
continuous 3-lead Holter monitoring showed a 50% reduction of myocardial ischemia in the atenolol 
treated group during the first 48 hours after surgery. The second trial showed, in a selected high-risk 
population of 112 vascular surgery patients, a tenfold reduction in the incidence of perioperative car-
diac death and myocardial infarction, compared to patients without beta blockers (3.4% vs. 34%)12. 
The high incidence of perioperative cardiac events was explained by the patient selection: from a 
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population of 1,351 patients only 112 were included with stress-induced myocardial ischemia during 
dobutamine echocardiography.
These promising results were not supported by two recent trials evaluating the effect of beta-blockers 
in respectively vascular surgery patients and diabetics13,14. In the POBBLE trial low-risk patients, those 
with a history of ischemic heart disease were excluded, scheduled for vascular surgery were random-
ized for metoprolol (n=55) or placebo (n=48). Metoprolol, 25 mg or 50 mg, depending on patient’s 
weight was started the day before surgery. Holter monitoring and repeated troponin measurements 
were performed during hospital stay. No difference was observed in the incidence of perioperative 
cardiovascular events; 15 (34%) vs. 17 (32%), in patients on placebo vs. metoprolol. The only differ-
ence was observed in the length of hospital stay, which was significantly shorter in those taking 
metoprolol, 10 vs. 12 days.  The more recently presented DIPOM study, evaluating the cardioprotec-
tive effect of a fixed dose of metoprolol on the evening before major non-cardiac surgery in 921 
diabetics showed no difference in 30 day morbidity and mortality. However the study was powered 
for a 10% difference after one year of follow-up.
how can the conflicting results of perioperative beta-blocker trials be explained?
Dosing of perioperative beta-blocker therapy
In a study by Raby et al. of 150 patients ischemia was observed prior to vascular surgery using ambu-
latory ECG monitoring in 26 patients6. The heart rate at which ischemia occurred was noted (ischemic 
threshold), these patients were randomized to either tight heart rate control, i.e. 20% less than the 
ischemic threshold but >60 bpm, or normal, non adjusted beta-blocker therapy. In 13 patients with 
heart rates below the ischemic threshold 1 (7.7%) had postoperative ischemia versus 12 out of 13 (92%) 
patients with less tight control. Based on this study it seems obvious that beta-blockers should not be 
considered a “fire-and-forget” therapy. Monitoring of the heart rate and consequent dose adjustment 
of beta-blockers in case of inadequate lowering of the heart rate is of critical importance.
The design of the POBBLE trial was such that patients received a fixed dose of metoprolol according 
to weight, i.e. 25 or 50 mg, and dosage was not adjusted in case of unsatisfactory heart rate control. 
Double-blind randomized controlled trials are very important in medical research. However, a double 
blind trial in case of perioperative beta-blockers is simply not possible since heart rate control seems 
to play such a pivotal role in the effectiveness of perioperative beta-blocker therapy. This same critique 
also applies for the DIPOM trial. Also in this trial patients received a fixed dose of metoprolol and dos-
age was not adjusted in case of inadequate lowering of the heart rate. It might be argued that even a 
small reduction in heart rate is beneficial to patients, though the benefits might be less pronounced. 
Consequently, such trials should be powered on a less extensive effect of beta-blockade.
Timing of perioperative beta-blocker therapy
The onset of the cardioprotective effect has important implications for perioperative management. 
The effects on heart rate, contractility, and energy substrate shift occur almost instantly. However, the 
effect on inflammatory response may only be observed after a prolonged period of beta-blocker use. 
In a randomized study of 200 surgical patients at risk for CAD Mangano et al. found no difference in the 
incidence of perioperative cardiac events among beta blocker users, but there was a reduced incidence 
of late fatal cardiac events10. The benefits of beta-blocker use were not immediately apparent but 
evolved over the first 6 to 8 months after initiation of beta-blocker therapy. It could be possible that 
immediately after initiation of therapy not all effects are achieved and the benefits of beta-blockers will 
become evident only after weeks to months of treatment. Both the DIPOM and POBBLE trial started 
beta-blocker therapy on the day before surgery as well. Based on the unknown time interval between 
Perioperative beta-blocker therapy 199
initiation and optimal effectiveness it might be argued that beta-blocker therapy should be initiated 
well before surgery. The DECREASE-trial showed the largest effect of perioperative beta-blocker 
therapy. The time between beta-blocker therapy initiation and surgery was 37 days in this trial.
Other aspects influencing effectiveness of beta-blocker therapy
Besides timing and dosage some other factors may influence the effectiveness of beta-blocker 
therapy. Recently Lanfear et al. described the influence of gene polymorphisms and response to beta-
blockers15. In their article they conclude that survival in patients receiving beta-blocker therapy after 
an acute coronary syndrome is different according to different types of ADRB2 genotypes. Whether 
this also plays a role in perioperative beta-blocker therapy remains unclear but is very likely. The 
idea of genotyping patients before surgery to identify those who will benefit most of perioperative 
beta-blockade is tempting though currently not yet feasible.
Another point that might influence the effectiveness of beta-blocker therapy is its withdrawal just 
shortly prior to surgery or in the immediate postoperative days. As has been reported sudden 
withdrawal of beta-blockers lead to a “rebound” effect resulting in blood pressure and heart rate 
increase, and plasma noradrenalin concentrations changes16. This might lead to an excess in cardiac 
complications in the perioperative setting. Recently, Redelmeier et al. provided new evidence for 
these concerns17. In their study they showed that the long-acting atenolol was superior to the short-
acting metoprolol in the perioperative setting, probably due to the acute withdrawal effect after 
missed doses in short-acting beta-blockers.
Should all patients at increased cardiac risk be on perioperative beta-blocker therapy?
Based on existing evidence, a simple answer would obviously be “yes”. However the next question 
would then be which patients are at increased risk for perioperative cardiac complications and how is 
this increased risk defined? In a recent large cohort study performed by Lindenauer et al. in 663 635 
patients it was shown that patients at intermediate or high risk, i.e. ≥ 2 risk factors according to the 
Revised Cardiac Risk Index, benefited from beta-blocker therapy18. On the other hand, in patients at 
low risk perioperative beta-blocker therapy was associated with no benefit and even possible harm. 
This finding indicates that perioperative beta-blocker therapy is effective but patients should be 
selected based on their cardiac risk as assessed by preoperative screening.
The Revised Cardiac Risk Index by Lee et al. identified 6 predictors (high-risk surgery, ischemic heart 
disease, congestive heart failure, cerebrovascular disease, diabetes mellitus, and renal failure) of major 
cardiac complications2. Based on the presence of 0, 1, 2, or 3 or more of these predictors, the rate of 
major cardiac complications was estimated to be 0.4%, 0.9%, 7%, and 11%, respectively. Though the 
Lee index is considered by many clinicians and researchers as the most relevant index for predict-
ing perioperative cardiac risk in non-cardiac surgery, the patients studied by Lee et al can hardly be 
considered as an average non-cardiac surgical population. Thoracic, vascular and orthopedic patients 
were overrepresented in this study population. Recently Boersma et al. validated the Lee risk index in 
a large cohort (n=108,593) of all types of non-cardiac surgical procedures1. The Lee index was predic-
tive of cardiovascular mortality with odds ratios of 1 (reference), 2.0, 5.1, and 11.0. When the Lee index 
was adapted and information of preoperative ECG and more detailed information on the surgical risk 
of the procedure were added, the predictive value improved substantially.
Conclusion
Perioperative beta-blocker use is effective in patients at high cardiac risk when beta-blockers are 
administered in such a way that tight-heart rate control is achieved. It is recommended to start 
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beta-blocker therapy well before surgery to achieve the optimal protective effect. In patients at 
intermediate cardiac risk the benefits of perioperative beta-blocker use seems less clear. The results 
of randomized trials in patients at intermediate risk conducted so far (i.e. DIPOM and POBBLE) can 
not be considered conclusive since poor heart rate control and the short interval between initiation 
and surgery may have seriously influenced the outcome of these two studies. The results of two 
large ongoing trials, i.e. POISE and DECREASE IV, have to be awaited to make firm conclusions on the 
effectiveness of perioperative beta-blocker use in patients at intermediate risk.
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Recently the results of the PeriOperative Ischemic Evaluation (POISE) study have caused concern 
regarding beta-blocker use in the perioperative setting1. Though beta-blocker therapy was associated 
with an improved cardiac outcome, overall mortality was increased in the metoprolol treated group. 
This was partially related to the increased incidence of postoperative stroke occurring early after 
surgery. These findings might have important implications on perioperative beta-blocker use, not 
only for initiation of therapy prior to surgery in beta-blocker naïve patients but also whether or not to 
continue therapy throughout surgery. This commentary reviews the incidence and pathophysiology 
of perioperative stroke and the relation of beta-blockers and perioperative stroke, focusing on non-
cardiac surgery.
The risk of clinically apparent perioperative brain injury such as stroke varies widely among different 
types of surgery. Whereas patients undergoing general surgery appear to be at low risk (0.08-0.7%), 
those undergoing heart valve surgery and aortic arch repair have a high incidence of perioperative 
stroke (8-10%)2. In Europe annually 40 million general surgical procedures are performed. Therefore 
it is estimated that 32,000–280,000 patients suffer from postoperative stroke. However, the true 
incidence of cerebral complications is probably underestimated as subtle forms of brain injury are 
commonly classified as delirium that may only be detected by rigorous neuropsychological testing.
The knowledge of the pathophysiology of postoperative cerebral complications is predominantly 
based on cardiothoracic surgery patients. It is estimated that 62% of strokes in this population have 
an embolic origin, 10% are related to hypoperfusion, and 10% have multiple causes2. Importantly, 
only 1% of strokes are caused by intracerebral hemorrhage. Early strokes are mostly attributable to 
manipulations of the heart and aortic arch and events caused by the cardiopulmonary bypass pump. 
In the other half (delayed) stroke seems to be related to adverse postoperative cardiac events such as 
myocardial infarction and atrial fibrillation.
Compared to stroke after cardiac surgery, the pathophysiology of stroke after non-cardiac surgery is 
ill defined. Perioperative hemodynamic instability and cardiac events, such as myocardial infarction 
and arrhythmias likely play a major role. Recently, the POISE study identified a new risk factor for 
perioperative ischemic strokes: high-dose metoprolol succinate initiated for cardiac protection in 
patients undergoing non-cardiac surgery.
Perioperative beta-blockade
Beta-blockers in the non-surgical setting are used widely and proven effective in patients with 
documented coronary artery disease (CAD) to restore the balance of myocardial oxygen demand 
and supply3. Although initially contraindicated in patients with heart failure and peripheral athero-
sclerotic disease, beta-blockers are now recommended therapy for these patients4,5. Similar to the 
non-surgical setting, beta-blockers are advocated for patients with documented CAD undergoing 
vascular surgery. However, there is still controversy regarding perioperative beta-blocker use in the 
general surgical population.
Several randomized studies have shown a beneficial cardiac effect of perioperative beta-blocker 
use. In a placebo-controlled trial involving 200 high-risk patients, Mangano et al. found that atenolol 
(50 or 100 mg), administered intravenously beginning 30 minutes prior to surgery and then orally 
throughout hospitalization, did not lower the risk of death from cardiac causes or myocardial infarc-
tion during hospitalization7. However, it did result in a 50 percent reduction in myocardial ischemia as 
assessed by continuous 48-hour Holter monitoring. The authors observed a non-significant increase 
in incidence of stroke (i.e. 4% vs. 1%, p=0.21). The DECREASE study (Dutch Echocardiographic Cardiac 
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Risk Evaluation Applying Stress Echocardiography) confirmed the benefits of beta-blockers in non-
cardiac surgery. In a high-risk population of 112 patients with a positive dobutamine echocardiog-
raphy for CAD undergoing vascular surgery, the rate of perioperative cardiac death and myocardial 
infarction among patients who were randomly assigned to bisoprolol therapy (5 or 10 mg) started 
at least 30 days before surgery was 90 percent lower than that among patients assigned to standard 
care (3.4 percent vs. 34 percent)8.
More recent studies have shown mixed results of beta-blocker therapy (FIGURE 16.1). The MaVS 
(Metoprolol After Vascular Surgery) trial randomized 496 patients to metoprolol or placebo starting 
2 hours before surgery until hospital discharge or a maximum of 5 days after surgery9. No significant 
differences in outcome were observed at 30 days and 6 months after surgery. In the POBBLE (Periop-
erative Beta-Blockade) trial, 103 patients undergoing vascular surgery were randomized to metoprolol 
or placebo, starting less than 24 hours before surgery until 7 days after, and showed no difference 
in 30-day cardiovascular outcome10. Within 30 days, cardiovascular events occurred in 32% and 34% 
patients in the metoprolol and placebo groups, respectively (adjusted RR 0.87, 95% CI 0.48 to 1.55). The 
DIPOM (Diabetic Postoperative Mortality and Morbidity) trial, which started therapy at the earliest in the 
evening before major non-cardiac surgery, again showed no difference in 30-day cardiac outcome11.
These mixed results necessitated a large randomized trial. In the landmark study of the POISE inves-
tigators, 8351 patients were randomly assigned to either metoprolol succinate controlled release or 
placebo. The primary endpoint of cardiac death, non-fatal myocardial infarction, or non-fatal cardiac 
arrest was reduced in the metoprolol CR group compared with placebo (5.8% vs. 6.9%, hazard ratio 
0.84, 95% CI 0.70–0.99, p=0.04). However, this beneficial cardiac effect was at the cost of an increased 
incidence of all-cause mortality and stroke. The incidence of stroke was increased from 0.5% to 1.0% 
in patients randomized to metoprolol treatment. Stroke was associated with perioperative hypoten-
sion, bleeding, atrial fibrillation, and a history of stroke or transient ischemic attack.
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Figure 16.1 Odds ratios of randomized beta-blocker trials for perioperative myocardial infarction.
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Perioperative beta-blocker therapy and stroke
The increased risk for perioperative stroke in the POISE trial has caused concerns on the safety profile 
of perioperative beta-blocker therapy. This has been augmented by the meta-analysis published in 
the same Lancet article. The meta-analysis demonstrated that overall perioperative beta-blocker 
therapy was associated with a 2.19-fold (95% CI 1.06-4.50) increased risk for nonfatal perioperative 
stroke; however, the DECREASE I and IV studies were not included. Importantly, the impact of differ-
ent dosing regimens, timing of initiation and type of beta-blocker therapy were not fully appreciated 
in this analysis. If the results of DECREASE I and IV are added to the meta-analysis, beta-blockers are 
still associated with an increased risk for perioperative stroke. However, as is shown in FIGURE 16.2, 
the overall result in the randomized low-dose bisoprolol studies show no association with periopera-
tive stroke at all (OR 1.06, 95% CI 0.32–3.56) in contrast to studies using metoprolol (OR 2.07, 95% CI 
1.27–3.39). It should be noted that the cardioprotective effect was clear for both beta-blocker types; 
OR for bisoprolol 0.40 (95% CI 0.20–0.81) and OR for metoprolol 0.74 (95% CI 0.61–0.89, FIGURE 16.1). 
The key question is whether it is the type of beta-blockers that makes the difference or that other 
factors play a significant role in these results. Considering this, there are several potential pitfalls in 
the perioperative administration of beta-blockers that should be considered including: timing of 
initiation of therapy, dosage of beta-blockers, the impact of beta-blocker withdrawal, and treatment 
targets.
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Figure 16.2 Odds ratios of randomized beta-blocker trials for perioperative stroke.
Timing
Timing of initiation of perioperative beta-blocker therapy seems to play a pivotal role in the risk of 
stroke, as shown in FIGURE 16.3. In studies starting beta-blocker therapy hours before surgery, the 
incidence of postoperative stroke was higher compared to those who were on beta-blockers for at 
least a week prior to surgery. It should be noted that the same study group performed the two trials 
that started beta-blockade weeks in advance of surgery, using bisoprolol. Although bisoprolol is not 
commonly used in the US for patients with proven CAD, it would be interesting to determine whether 
other centers achieve similar results with this low-dose bisoprolol regimen. In most non-surgical 
studies, in particular in heart failure, there is a similar up titration of beta-blockers. In other words, 
beta-blocker therapy is started at a relative low dose and is subsequently up titrated according to 
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blood pressure and heart rate. This approach has been shown to be effective and safe in heart failure 
patients4. In patients undergoing surgery in which beta-blocker therapy is initiated within hours 
before surgery, there might be an increased risk of hypotension and bradycardia if beta-blockers 
are administered too aggressively. The response to beta-blocker therapy cannot be adequately 
monitored during this short period of time leading to a danger of overdosing. Importantly, patients 
on chronic beta-blocker therapy should continue their therapy in the perioperative period as sudden 
beta-blocker withdrawal increases the risk of adverse cardiac events.12
Dosing
Closely related to the issue of timing in perioperative beta-blocker therapy is the question regarding 
what dosing scheme should be used. In contrast to other beta-blocker studies, patients random-
ized in the POISE trial could receive up to 400 mg metoprolol succinate controlled release the day 
of surgery; 100 mg 2-4 hours prior to surgery, another 100 mg within 6 hours after surgery and 200 
mg within 12-18 hours after the first postoperative dose. In the non-surgical setting, lower starting 
doses and slower up titration are commonly recommended. For instance, in patients with heart 
failure, 12.5–25 mg a day is started for 2 weeks and for hypertension the initial dose is 25–100 mg, 
usually increased at weekly intervals. This is important since a large proportion of high-risk elderly 
patients undergoing surgery may have some form of (asymptomatic) left ventricular dysfunction. 
The DECREASE treatment regimes start 2.5 mg bisoprolol, which is approximately the same strength 
as 50 mg of metoprolol. The starting dose of metoprolol succinate in the POISE trial was 2–8 times 
the commonly prescribed dose for perioperative beta-blocker therapy; other trials using metoprolol 
start usually at ranges from 50 to 100 mg per day9-11. It is noteworthy that in the DECREASE II trial, 
starting with 2.5 mg bisoprolol once daily, in approximately 75% of patients the target heart rate of 
60-65 beats per minute was achieved without dose adjustment13.
In conclusion, initiating prophylactic high-dose beta-blocker therapy in patients undergoing non-
cardiac surgery is associated with fewer cardiac events but with an increase in strokes. However, if 
prophylactic beta-blocker therapy is initiated at a low dose and up titrated in the preoperative period, 
the risk of stroke seems to be similar to that of patients not on beta-blockers while the cardioprotec-
tive effect is maintained. Preferably these results should be confirmed in a large-scale trial, starting 
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Figure 16.3 Relation between timing of initiation of beta-blocker therapy and the risk for perioperative stroke.
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beta-blocker weeks before surgery at a low dose, as well as determining the optimal approach in 
patients at high risk of perioperative cardiac morbidity and present the morning of surgery without 
having been placed on a beta-blocker.
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INTRODuCTION
Patients undergoing major non-cardiac vascular surgery are at significant risk of cardiovascular 
morbidity and mortality due to underlying symptomatic or asymptomatic coronary artery disease 
(CAD)1. Though developments in anesthesiological and surgical techniques, e.g. locoregional 
anesthesia and endovascular treatment modalities have improved postoperative cardiac outcome 
considerably, perioperative cardiac complications remain a significant problem. The incidence of 
perioperative myocardial infarction in major non-cardiac vascular surgery is around 3 to 4%2 and the 
prevalence of (a)symptomatic perioperative myocardial ischemia as assessed by serum troponin I or 
serum troponin T is even 15 to 25%3,4.
Although the pathophysiology of perioperative cardiac complications is not entirely clear, two 
causative mechanisms seem to be responsible for the majority of these complications: (1) vulnerable 
coronary plaque rupture5,6, leading to thrombus formation and subsequent vessel occlusion, and 
(2) a sustained mismatch of coronary artery oxygen supply and demand due to increased oxygen 
demand during the perioperative period.  Each of these mechanisms seem to account for approxi-
mately half of all fatal myocardial infarctions as was found in two studies using non-invasive tests, 
coronary angiography, and autopsy results7,8. A similar mechanism, i.e. vulnerable atherosclerotic 
plaque rupture, is proposed to explain perioperative strokes in patients undergoing carotid endart-
erectomy for carotid artery stenosis9.
Recently, 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors (statins) have gained atten-
tion as a possible new strategy for the prevention of vulnerable atherosclerotic plaque rupture10. 
Acetyl-CoA +Acetoacetyl-CoA
HMG-CoA
Mevalonate
Isopentenyl-PP
Geranyl-PP Farnesyl-PP
Squalene
Cholesterol
Geranylgeranyl-PP
↑ Cellular growth, ↑ proliferation, ↑ migration, ↑ apoptosis, ↑ adhesion, 
matrix degredation, coagulation, ↓angionesis
Statins
Figure 17.1 Cholesterol-lowering and pleiotropic effects of statins.
(Partially derived from Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase 
inhibitors: statins as antiinflammatory agents? Circulation 2004;109:II18-26).
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Numerous clinical trials have clearly demonstrated that statin use is associated with a substantial 
long-term reduction in the risk for cardiovascular morbidity and mortality in patients with or at risk of 
coronary heart disease. However, lipid lowering seems not to be the only beneficial effect of statins. 
Other, so-called pleiotropic, effects of statins have recently been described (FIGURE 17.1)11. One of 
these pleiotropic effects may be the stabilization of vulnerable plaques during surgical procedures. 
This may result in a reduced perioperative cardiovascular mortality and morbidity rate.
In this clinical update we will review recent clinical evidence on the efficacy and safety of statins and 
their role in the prevention perioperative cardiovascular complications.
Vulnerable plaque and statins
Arterial plaques at high risk of rupture are known as vulnerable plaques. The prevalence of vulnerable 
plaques is high, also in seemingly stable patients. However, it is impossible to predict whether struc-
turally vulnerable plaques may become unstable weeks, months, or years after their detection. For the 
cardiac situation, surgery imposes extra myocardial workload, resulting in mechanical stress, stress-
induced inflammation and possibly spasms. This can cause vulnerable plaques to become unstable, 
leading to the cascade of plaque rupture, thrombus formation, myocardial ischemia and eventually 
myocardial infarction. Factors leading to unstable arterial plaques are multiple and complex. However, 
in general, the risk of plaque rupture is related to two factors: the intrinsic individual plaque char-
acteristics and an extrinsic force triggering plaque disruption. Intrinsic factors include, for example, 
plaque morphology. As reported by Naghavi et al, in their extensive review on vulnerable plaques, 
inflammation is one of the major extrinsic factors involved in the rupture of vulnerable plaques5,6.
The pleiotropic effects of statins include several possible plaque stabilizing effects such as the 
increased expression of endothelial nitric oxide synthase, the reduced production of endothelin-1 
and the generation of reactive oxygen species, an improvement of the thrombogenic profile, and, 
importantly, a reduction in inflammation via the reduced expression of inflammatory cytokines, 
chemokines, adhesion molecules and a lowering of CRP levels. Therefore the perioperative prescrip-
tion of statins might improve plaque stability.
Statins in major vascular, non-cardiac surgery
There have been several recent studies that addressed the beneficial effect of statin use in patients 
undergoing non-cardiac surgery including vascular surgery (TABLE 17.1).  In a case-control study 
among 2,816 patients who underwent major vascular surgery statin use was associated with a 
significant four-fold reduction in all-cause mortality (adjusted odds ratio 0.22 and 95% confidence 
interval, 0.10 to 0.47) compared to patients with no statin use12. The beneficial effect of statin use was 
consistent in subgroups of patients according to the type of vascular surgery, cardiac risk factors, and 
cardioprotective medication use including aspirin and beta-blockers.
Kertai et al. found similar effects of statins in vascular surgery patients for the composite endpoint of 
30-day nonfatal myocardial infarction or all-cause death (adjusted odds ratio 0.24, 95% CI: 0.10-0.70). 
Importantly they also found the effect of statins to be independent of beta-blocker use13.
The first blinded, placebo-controlled, randomized trial, in which the influence of statin use on 
perioperative cardiovascular complications was investigated, has been reported by Durazzo14. In 
their study, this research group randomly assigned 100 patients to treatment with either 20 mg 
atorvastatin or placebo. Patients received treatment for 45 days and at least 2 weeks before surgery. 
One month after surgery patients with elevated cholesterol levels were advised to continue or start 
statin therapy. The outcome of this trial was the endpoint of cardiovascular events, defined as cardiac 
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death, non-fatal MI, stroke or unstable angina pectoris. Patients were followed up to 6 months after 
the surgical procedure. Of 100 patients 90, 44 statin users and 46 non-users, underwent elective 
vascular surgery. The 6-month incidence of cardiovascular events was 3.1-fold reduced in statin users 
compared with non-users (p = 0.022). Lindenauer et al. also confirmed the beneficial effects of statins 
based on the results of their large-scale retrospective studies. Lindenauer performed a retrospective 
cohort study based on the hospital discharge and pharmacy records of over 780,000 patients in 329 
hospitals throughout the United States. All patients underwent elective major surgical procedures 
and survived at least the first two postoperative days. In total, 70,159 of these patients were identified 
as statin users. After correction for numerous baseline differences, statin users had a 1.4-fold reduced 
risk of in-hospital mortality. Subsequently, Lindenauer concluded that perioperative statin use might 
result in a reduced risk of death after major surgical procedures15. Finally, O’Neil-Callahan et al. col-
lected data of 1,163 patients who underwent non-cardiac vascular surgery and found that patients 
who were statin users had a substantially lower perioperative cardiac complication rate than patients 
without statin use (odds ratio 0.52, 95% confidence interval, 0.35 to 0.77)16. The protective effect of 
statin use was similar across different risk group categories, and persisted after accounting for the 
likelihood of statin use in patients with hypercholesterolemia.
Statins in carotid artery surgery
Another type of surgery, associated with less cardiac complications but a relatively high risk of cere-
bral complications, is carotid endarterectomy. Recently McGirt et al.17 showed a decreased incidence 
in perioperative all-cause mortality in statin users (n= 657) compared to non-users (n = 909) who 
underwent carotid endarterectomy (adjusted OR 0.21, 95% CI 0.05–0.96, TABLE 17.2), a type of sur-
gery considered to be an intermediate risk procedure according to the current ACC/AHA guidelines18. 
The incidence of myocardial infarction was not significantly different between statin users and non-
users in this report (1.2% vs. 2.1%, p = 0.19), probably due to the relatively low number of events. 
Table 17.1 Studies of the effectiveness of perioperative statin use in major vascular, non-cardiac surgery.
Author year Type of study N Type of surgery Rx prior to 
surgery
Poldermans et al.12 2003 Case-control 480 Vascular Chronic use
Kertai et al.13 2004 Cohort 570 Vascular Chronic use
Durazzo et al.14 2004 RCT 100 Vascular 30 days
Lindenauer et al.15 2004 Cohort 780,591 General Chronic use
O’Neil-Callahan et al.16 2005 Cohort 1,163 Vascular Chronic use
Cont’d End Point Event rate in 
controls
Odds Ratio NNT
Poldermans et al.12 30-day all cause mortality Not reported 0.22 Not reported
Kertai et al.13 30-day mortality or nonfatal MI 11.0% 0.24 14
Durazzo et al.14 Death, nonfatal MI, ischemic 
stroke, unstable angina within 6 
months after surgery
26% 0.31 6
Lindenauer et al.15 In-hospital all cause mortality 3.2% 0.71 109
O’Neil-Callahan et al.16 Composite of death, MI, 
ischemia, congestive heart 
failure, ventricular tachycardia 
during hospitalization
16.5% 0.52 15
RCT = Randomized Controlled Trial; CEA = Carotid Endarterectomy; MI = Myocardial Infarction; NNT = Number Needed 
to Treat
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Unfortunately in their report the authors did not consider the combined endpoint of nonfatal MI and 
cardiac death. In the same report McGirt et al. showed a reduced incidence of perioperative strokes 
in patients undergoing carotid endarterectomy (1.2% vs. 4.5%, p < 0.01).
Previously Kennedy showed a similar 2-fold reduction in perioperative strokes in a group of 2,031 
symptomatic patients (815 statin users) who underwent carotid endarterectomy (OR 0.55, 95% CI 
0.32–0.95) and a 4-fold reduction in perioperative all-cause mortality (OR 0.25, 95% CI 0.07–0.90)9. 
However in the same report, no benefit was found for asymptomatic patients who underwent carotid 
endarterectomy, neither on the incidence of perioperative stroke, nor on the incidence of periopera-
tive mortality. These findings might be explained by the proven presence of vulnerable (unstable) 
plaques in symptomatic patients. Though it is only circumstantial evidence, if statins indeed stabilize 
vulnerable atherosclerotic plaques, it seems logical that patients with vulnerable atherosclerotic 
plaques benefit more from statin use than patients without this type of lesions.
Safety of perioperative statin use
A major concern of perioperative statin therapy has been the risk of statin-induced elevated serum 
transaminases, myopathy and rhabdomyolysis. Although elevated transaminases are observed 
frequently, no data are available on changes perioperatively, but there is little or no evidence that 
statins cause progressive liver disease19. In the non-operative setting Thompson et al. found a fatal 
rhabdomyolysis rate of <1 per million prescriptions, except for cerivastatin20. In their analysis of all 
randomized controlled trials published up to 2004 they found an incidence of persistent CK eleva-
tions (i.e. > 4x Upper Limit of Normal) of 0.07%, compared to 0.01% in the control groups.
An important potential risk factor in the perioperative setting is the use of concomitant medica-
tions. The risk of myopathy might increase with concomitant drugs that are myotoxic or increase 
serum statin levels. Though statins seem to be highly selective 3-HMG-CoA reductase inhibitors 
that do barely interfere with other drugs at their site of action, there are other factors that influ-
ence the pharmacokinetics of statins. Of special interest in this respect is the cytochrome P450 (CYP) 
isoenzyme system. Most drugs are metabolized in the liver by the CYP 3A4 isoenzyme21. This might 
cause interaction with statins, resulting in elevated plasma levels and consequently an increased risk 
of adverse events. Lovastatin, simvastatin, and atorvastatin are also metabolized by this pathway. 
Table 17.2 Studies of the effectiveness of perioperative statin use in carotid artery endarterectomy.
Author year Type of study N
Type of 
surgery
Rx prior to 
surgery
Kennedy et al.*9 2005 Cohort 2,031 Carotid Chronic use
McGirt et al.17 2005 Cohort 1,666 Carotid Chronic use
Cont’d End Point
Event rate in 
controls
Odds Ratio NNT
Kennedy et al.*9 Perioperative stroke and all cause 
death*
4.5% 0.55 63
In hospital all-cause death* 1.2% 0.25 125
McGirt et al.17 Perioperative stroke 4.5% 0.29 30
30-day all-cause death 2.1% 0.21 56
* Only symptomatic patients are shown in this table. No significant benefit was found in asymptomatic patients. NNT = 
Number Needed to Treat
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Fluvastatin and rosuvastatin on the other hand have only limited interactions with the CYP 3A4 
pathway. Fluvastatin is mainly metabolized by the CYP 2C9 isoenzyme whereas rosuvastatin is not 
extensively metabolized and has only minor interaction with the 2C9 iosenzyme (TABLE 17.3). In the 
non-operative setting most statin induced rhabdomyolysis cases were associated with the use of 
mibefradil, fibrates, cyclosporine, macrolide antibiotics, warfarin, digoxin, or azole antifungals.
Besides concomitant medication use, other factors which might increase the risk of statin-induced 
myopathy are numerous in the perioperative setting, e.g. the impairment of renal function after 
major surgery, and the use of analgesic agents and postoperative pain which might mask signs of 
myopathy. Failure to detect statin-induced myopathy may then lead to continuous statin use and 
the subsequent development of rhabdomyolysis and acute renal failure. Probably on the basis of 
the assumptions of these risk factors, the guidelines of the ACC/AHA/NHLBI suggest that there is an 
increased risk of rhabdomyolysis during the perioperative period22. However, no studies have been 
published that support this fear, except for some case reports23,24. In a retrospective study of 885 con-
secutive patients undergoing major vascular surgery (211 on statins), no case of rhabdomyolysis or 
a significant higher creatinine kinase level in statin users was observed (FIGURE 17.2)25. Considering 
that the risk of cardiovascular complications is far greater than the risk of statin-induced myopathy 
and rhabdomyolysis, the potential benefits of perioperative statin use seem to outweigh the potential 
hazards. However, the safety of statins should be confirmed in blinded, randomized trials.
Other considerations
The optimal timing and dosing of statins for the prevention of perioperative events has not yet been 
established. The pleiotropic effects of statins are thought to occur within a few days, though no clear 
evidence on the optimal run in period has been published so far. If there are no contraindications, 
starting statin therapy at the first preoperative outpatient clinic visit seems to be the most safe and 
practical way to ensure an optimal run-in period.
Table 17.3 Clinically used drugs, metabolized by human cytochrome P450 isoenzymes.
CyP2C9
Fluvastatin
CyP2C19
Rosuvastatin
CyP3A4
Atorvastatin, lovastatin, simvastatin
Hexobarbital
Phenytoin
Tolbutamide
Warfarin
Alprenolol
Diclofenac
Diazepam
Ibuprofen
Mephenytoin
Methylphenobarbital
Omeprazole
Phenytoin
Proguanil
Clarithromycin
Cyclosporine
Diltiazem
Erythromycin
Itraconazole
Ketoconazole
Lacidipine
Mibefradil
Midazolam
Nefazodone
Nifedipine
Protease Inhibitors
Quinidine
Sildenafil
Amiodarone
Terbinafine
Verapamil
Warfarin
Fluvastatin is primarily metabolized by CYP2C9, and less by CYP3A4 and CYP2C8. Rosuvastatin is not extensively 
metabolized but has some interactions with the CYP2C19 enzyme. Derived from Bellosta S, Paoletti R, Corsini A. Safety of 
statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109:III50-7.
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In the acute coronary syndrome setting it has been suggested that acute statin withdrawal might 
result in a flare up of cardiac events26. So far, no data are available that show whether acute statin 
therapy withdrawal in the perioperative setting results in an increased risk for cardiac events. Patients 
with major abdominal surgical procedures, such as open abdominal aortic aneurysm repair, might 
be unable to take oral medication shortly after surgery. Since there are no intravenous formulas for 
statins the effect of acute statin withdrawal is a major concern. Therefore, statins with a prolonged 
half-life time or with a slow release formula are to be preferred in the perioperative setting until more 
data on the acute withdrawal effect are available.
Recommendations
Perioperative statin use in vascular surgical patients is associated with an improved perioperative 
outcome, without signs of an increased incidence of side effects. The recommendations are sum-
marized in TABLE 17.4.
Safety
Prior to the initiation of statin therapy liver function, i.e. ALAT and ASAT, and CK-levels should be 
measured (see TABLE 17.5)22. However, since side effects are difficult to assess clinically in the periop-
erative period repeated measurements immediately prior to surgery and in the perioperative period 
of CK-levels, e.g. on day 1, 3, and 7, and liver function is advisable until more data, preferably from 
blinded randomized trials are available.
Selection of type of statin
Several statins are currently available including: simvastatin, atorvastatin, pravastatin, fluvastatin, 
lovastatin, and rosuvastatin. In terms of adverse events no major difference could be identified so 
far. In the clinical studies performed on the effectiveness of perioperative statin use all types of 
statins except rosuvastatin have been described. Based on the currently available information no 
specific single type of statins seems to be preferable over other statins. However, it must be taken 
into account that sudden interruption of statin therapy in patients with acute coronary syndromes 
seems to worsen outcome. This may also apply to patients suffering adverse cardiac events after 
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Figure 17.2 Safety of perioperative use.
Percentage of statin users and nonusers with normal postoperative creatine kinase (CK) levels, 
moderately elevated CK levels, and severely elevated CK levels. ULN, Upper limit of normal.
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major surgery. Therefore one should consider using statins with a prolonged half-life time or with 
a slow-release formula in patients who cannot take medication orally such as patients undergoing 
major vascular surgery.
Dosing and timing
The optimal dose and run in period of perioperative statin use is not yet defined. The pleiotropic 
effects of statins probably take place within several hours after initiation of statin therapy. A practical 
guideline would be to prescribe statins to patients on the preoperative outpatient screening visit 
or, according to recent ACC/AHA guidelines, start statins in patients with PAD at the first outpatient 
visit27. So far, there is no evidence that a high dose of statins results in more or other pleiotropic 
effects, and in a larger perioperative cardioprotective effect. Therefore it is advisable that dosing is 
done according to current national guidelines or according to the ACC/AHA guidelines which recom-
mend a dosing to reach a target LDL cholesterol of less than 100 mg/dL or less than 70 mg/dL in 
patients at high risk of ischemic events.
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No clinical data are available on the influence of perioperative statin use on postoperative myopathy 
in patients undergoing major non-cardiac surgery except for some case reports1-3. Therefore, the 
current study aimed to clarify the potential risk of myopathy in statin users who underwent major 
non-cardiac surgery.
METhODS
The study population was composed of patients who underwent major elective vascular surgery 
between January 1998 and January 2004 at Erasmus MC Rotterdam, the Netherlands. The study was 
approved by the medical ethics committee of our hospital.
All patients were screened for cardiac risk factors, including age, hypertension, angina pectoris, previ-
ous myocardial infarction, heart failure, stroke, renal failure (serum creatinine > 2 mg/dl), and diabetes 
mellitus. Prior to surgery cholesterol levels were measured in all. Those patients with elevated total 
serum cholesterol levels, i.e. > 5.5 mmol/l4, were prescribed statins, acute statin users. The type and 
dose of statin therapy was left to the discretion of the treating physician. The average time interval 
between the prescription of statins and surgery was 40 days (range 31-52). Patients already on statin 
therapy, chronic statin users, continued their statin use. In addition, potential confounding factors 
for statin myopathy5 were evaluated including length of surgery, concomitant medical therapy, liver 
dysfunction, statin dose and hypothyroidism. Baseline characteristics of the analyzed patients are 
presented in TABLE 18.1. Statins were discontinued only if oral intake was not feasible and restarted 
as soon as possible, either orally or by naso-gastric tube.
Muscle complaints, i.e. weakness and pain, were assessed immediately prior to surgery (baseline), 
and at day 1, 3, and 7 after surgery and before discharge. At these same time points blood and plasma 
samples for the derivation of creatine phosphokinase (CK) levels, CK-MB, aspartate transaminase, 
alanine aminotransaminase and Troponin T, and electrocardiography were collected.
Table 18.1 Baseline characteristics.
Statin user
yes No p-value
Characteristic (N=211) (N=674)
Men – no. (%) 152 (72%) 524 (78%) n.s.
Age (years)
 Mean 64 68 <0.001
 Range 31-85 29-91
Myocardial infarction – no. (%) 74 (35) 161 (24) 0.002
Angina pectoris  – no. (%) 61 (29) 107 (16) <0.001
Hypertension  – no. (%) 82 (39) 194 (29) 0.006
Diabetes mellitus  – no. (%) 25 (12) 74 (11) n.s.
Congestive heart failure – no. (%) 9 (4) 34 (5) n.s.
COPD – no. (%) 23 (11) 101 (15) n.s.
CVA or TIA  – no. (%) 24 (11) 81 (12) n.s.
Renal failure – no. (%) 9 (4) 40 (6) n.s.
Median of CK at baseline (U/L) 75 46 0.002
CK = creatine phosphokinase, TIA =  transient ischemic attack, CVA = cerebrovascular accident, COPD = chronic obstructive 
pulmonary disease
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Patients with a non-fatal perioperative MI were excluded from analysis. Myocardial infarction was 
defined as the presence of 2 of the following 3 criteria: (1) Characteristic ischemic symptoms lasting 
>20 minutes, (2) Electrocardiographic changes including acute ST elevation followed by appearance 
of Q waves or loss of R waves, or new left bundle branch block, or new persistent T wave inversion for 
at least 24 hours, or new ST segment depression which persists >24 hours, and (3) A positive troponin 
T, i.e. >0.10 ng/ml, or peak CK-MB >8% of an elevated total CK with characteristic rise and fall6.
Myopathy was defined as CK elevations, with or without muscle complaints. Rhabdomyolysis was 
considered present if CK levels exceeded the upper limit of normal > 10 times, with an elevated 
creatinine level consistent with pigment-induced nephropathy7. Use of analgesics and postoperative 
pain may mask signs of these muscle-related complaints. Therefore, we considered elevated CK levels 
as a sign of myopathy as well. CK levels were defined as normal if the upper limit of normal, i.e. 170 
U/L for females and 200 U/L for males, was not exceeded. An increment of CK < 5 times upper limit of 
normal was defined as mildly elevated, between 5 and 10 times upper limit of normal as moderately 
elevated and > 10 times of upper limit of normal was considered as severely increased.
Continuous variables were described as mean value (range), and categorical variables as percent 
frequencies. Univariate differences between patient subgroups were evaluated by using the t-test 
or chi-square test, as appropriate. Multivariate linear regression analysis was performed to study the 
relation between statin use, cardiac risk factors and length of surgery, and CK levels. All analysis was 
performed using SPSS statistical software (SPSS Inc., Chicago, Illinois, version 10.1).
RESuLTS
A total of 981 patients were screened. In 44 (5%) patients serum cholesterol level was elevated and 
statins were prescribed, while 182 (19%) were already on statins. Patients on perioperative statin 
therapy were younger, had more often a history of hypertension, a history of a myocardial infarction, 
and angina pectoris. Other cardiac risk factors did not significantly differ between both groups (TABLE 
18.1). A non-fatal perioperative myocardial infarction occurred in 98 (9.8%) patients, 81 (10.8%) in the 
non-user group and in 15 (6.7%) patients on statin therapy (p< 0.01). Perioperative death occurred 
in 35 patients, 5 (2.1%) statin users and 30 (3.9%) non-users. None of these deaths was ascribed to 
rhabdomyolysis. The combined end-point of perioperative death and myocardial infarction occurred 
in statin and non-statin users in respectively 22 (8.8%) vs. 111(14.7%), p<0.01. Thus, 885 patients, 674 
non-users and 211 statin users, were left for analysis.
Simvastatin was prescribed to 87 (41%) patients, fluvastatin to 48 (23%), pravastatin to 44 (21%), and 
atorvastatin to 32 (15%). The dose of statins is shown in TABLE 18.2. Total serum cholesterol levels 
decreased substantially after initiation of statin therapy (6.9 mmol/L vs. 5.0 mmol/L, p<0.001). Patients 
on statin therapy had a significantly higher CK level at hospital admission (75 U/L vs. 46 U/L, p=0.002), 
though CK levels did not exceed the upper limit of normal and there were no muscle complaints. The 
prevalence of risk factors associated with statin induced myopathy is shown in TABLE 18.3.
Discontinuation of statin therapy was necessary in 124 (59%) patients, as oral intake was temporar-
ily not feasible after surgery. Therapy was restarted after a median of 1 day (range 1-4 days). There 
was no relation between temporarily interruption of statins and perioperative myocardial infarction 
(p=0.143).
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Abdominal aortic repair was performed in 527 of the enrolled patients, 129 (61%) used statins and 
398 (59%) were non-users. In 82 (39%) patients on statins and 276 (41%) non-users lower extremity 
revascularization was performed. Mean length of surgery was 295 ± 104 minutes in non-users and 
304 ± 101 minutes in patients on statin therapy (p=0.225).
None of the patients reported muscle weakness or muscle pain in the perioperative period. Median 
maximum CK level was 301 U/L (range 16-13377) in statin users and 192 U/L (range 8–30390) in non-
users (p=0.003). However, corrected for length of surgery, cardiac risk factors, and risk factors for 
myopathy, the difference between users and non-users was not significant (p=0.142). The only factor 
independently associated with CK elevation was length of surgery (p<0.001). The CK levels in acute 
vs. chronic statin users were similar (p=0.564). Statin users more often had mild elevated CK levels 
(p=0.003). The incidence of moderate and severe increment of CK levels on the other hand did not 
differ significantly between both groups (TABLE 18.4).
Table 18.2 Type and dosage of prescribed statins.
Statin Dose (mg) Maximum daily dose (mg) N
Simvastatin 10 80 37
20 41
40 9
Fluvastatin 80 80 48
Pravastatin 10 40 4
20 29
40 11
Atorvastatin 10 80 10
20 11
40 7
80 4
Total 211
Maximum daily dose as recommended in Pharmacotherapeutisch kompas, Amstelveen, the Netherlands.
Table 18.3 Prevalence of risk factors for statin induced myopathy.
Statin users
Characteristic (N=211)
Renal dysfunction  – no. (%) 9 (4)
Hepatic dysfunction – no. (%) 0
Hypothyroidism – no. (%) 7 (3)
Concomitant medication
 Fibric acid derivates – no. (%) 6 (3)
 Niacin – no. (%) 0
 Cyclosporine – no. (%) 5 (2)
 Azole antifungals – no. (%) 0
 HIV protease inhibitors – no. (%) 0
 Nefadozone – no. (%) 0
 Verapamil and diltiazem – no. (%) 23 (11)
 Amiodarone – no. (%) 0
 Oral anticoagulants – no. (%) 41 (19)
Ch
ap
te
r 1
8
226
DISCuSSION
In this study we found that perioperative statin use in a large group of patients was not associated 
with an increased risk of myopathy, i.e. CK elevation with or without muscle complaints, after major 
vascular surgery. Prior to surgery CK levels were higher in statin users, however there were no muscle 
complaints. In the perioperative period there were no differences in CK levels between statin users 
and non-users and no patient experienced muscle complaints. After correcting for cardiac risk factors 
and clinical risk factors for myopathy, length of surgery remained the only independent predictor 
for myopathy. No case of rhabdomyolysis was observed. Also we observed no difference in CK levels 
between patients on chronic statin therapy and patients who started statin therapy only shortly 
before surgery. Neither was there an association between statin dose and myopathy.
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Postoperative CK-levels in statin users and non-users, divided into normal (≤1x ULN), mildly elevated
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Statin user
Post-operative Ck levels
yes
% (95% CI)
No
% (95% CI)
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>1x, ≤5x ULN 43 (36-50) 33 (29-37)
>5x, ≤10x ULN 9 (5-13) 6 (4-8)
>10x ULN 8 (4-12) 10 (8-12)
ULN = Upper Limit of Normal, CI = Confidence Interval.
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ABSTRACT
Background: Ischemic-reperfusion injury is an important cause for renal dysfunction after major 
vascular surgery and increases postoperative morbidity and mortality. The aim of the present study 
was to assess the effect of statins on renal function in patients at high-risk for renal dysfunction, i.e. 
those undergoing suprarenal aortic cross clamping-declamping.
Methods: All 77 patients (28 statin users, 57 men, age 69 ± 8 years) with a normal preoperative renal 
function requiring suprarenal aortic cross clamping-declamping during vascular surgery between 
1995-2005 were studied. Creatinine levels were obtained prior to surgery, and on day 1, 2, 3, 7, and 30 
after surgery. An ANOVA model for repeated measurements was applied to compare creatinine levels 
between statin users and non-users, with adjustment for clamping time and blood loss.
Results: There were no differences in baseline clinical characteristics, preoperative creatinine levels 
(0.93 mg/dL vs. 0.96 mg/dL; p=0.59), and glomular filtration rate (79 ml/min vs. 73 ml/min; p=0.1). 
Postoperative creatinine levels during 30 days after surgery were significantly lower in statin users 
than in non-users (ANOVA p-value <0.01, 1.17 mg/dL versus 1.98 mg/dL). Postoperative hemodialysis 
was required (temporarily) in 7 patients (9.1%), all non-users.
Conclusion: These findings suggest an association between statin use and preserved renal function 
after suprarenal aortic clamping.
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INTRODuCTION
In surgery requiring suprarenal aortic clamping-declamping renal hypoxia-reperfusion injury is 
an inevitable consequence of the procedure. Consequently, up to 20-30% of patients experience 
postoperative renal dysfunction1,2. This is attributed to impaired renal perfusion, with subsequent 
reperfusion leading to acute inflammatory changes and loss of function. Experimental studies have 
shown that statins might reduce this ischemic-reperfusion injury by altering the inflammatory 
response and an upregulation of endothelial nitric oxid synthase3-7. To investigate whether statins 
preserve renal function after major vascular surgery we selected a group of patients undergoing 
aortic aneurysm repair with suprarenal cross clamping-declamping and compared renal function 
between statin users and non-users.
METhODS
The study population was composed of all consecutive patients who underwent elective abdominal 
aneurysm repair requiring suprarenal clamping-declamping between January 1995 and January 
2005 at the Erasmus MC, Rotterdam, the Netherlands. Patients with impaired preoperative renal 
function were excluded from analysis. Baseline serum creatinine levels were considered elevated if 
they exceeded the upper limit of normal in our institution, i.e. creatinine >1.3 mg/dl for males and 
>1.1 mg/dl for females. The Cockroft-Gault formula was used to estimate the individual glomular 
filtration rate8.
All patients were screened for cardiac risk factors, including age, hypertension, angina pectoris, previ-
ous myocardial infarction, heart failure, stroke, renal failure, and diabetes mellitus. All prescription 
and over-the-counter medications were noted at the time of the first outpatient clinic visit and on the 
day of admission and were classified as follows: statins, β-blockers, aspirins, angiotensin converting 
enzyme inhibitors, calcium channel blockers; dihydropyridines or non-dihydropyridines, diuretics, 
nitrates, coumarins and digoxin. Statin users were on chronic therapy. Medication was continued 
until on the morning of surgery. Patients unable to take medication orally perioperatively were 
switched to intravenous formula. If no intravenous formula was available, i.e. statins and Angiotensin 
Converting Enzyme (ACE)-inhibitors, oral medication was restarted as soon as possible after surgery.
Repair was done through a thoracolaparotomy or midline laparotomy. The aortic clamp was placed 
above both renal arteries or above the celiac arteries, using a “clamp-and-sew” technique without 
protection of the kidneys apart from flushing the renal arteries with heparin. The site of clamping 
was dictated by aneurysm extent, i.e. juxta- or suprarenal. Possible intra-operative confounders for 
renal outcome were noted; duration of surgery, clamping time, perioperative blood loss, episodes of 
hypotension defined as a systolic blood pressure of < 70 mmHg lasting more than 5 minutes, transfu-
sion requirements, body temperature, and use of antibiotics. Serum creatinine levels and glomular 
filtration rate were obtained prior to surgery (baseline), and on day 1, 2, 3, 7, and 30 after surgery. 
The necessity of dialysis was left to the discretion of the treating physician. Dialysis was scored as 
temporary or chronic, based on the status at discharge.
Dichotomous data are described as counts and percentages, continuous data as mean values with 
corresponding standard deviation. Differences in baseline characteristics between statin users and 
non-users were evaluated by unpaired Student’s T-tests, chi-square tests or Fisher’s exact tests, as 
appropriate. An ANOVA model for repeated measurements was applied to compare creatinine levels 
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between statin users and non-users, with adjustment for clamping time and blood loss. All statistical 
tests were 2-sided, and a p-value <0.05 was considered significant. All analyses were performed using 
SPSS statistical software (SPSS Inc., Chicago, Illinois, version 12.1).
RESuLTS
The study population consisted of 77 patients (74% men). Mean age was 69 ± 8 years. In total, 28 
(36%) were statin users. Of these patients, 16 were on simvastatin therapy, 6 on atorvastatin, 3 on 
fluvastatin, and 3 on pravastatin. Prior to surgery, serum cholesterol levels were similar in users and 
non-users (5.3 ± 1.0 vs. 5.7 ± 0.8 mmol/L, p=0.1). The baseline clinical characteristics and medication 
use are presented in TABLE 19.1, no significance differences were observed between the two groups. 
Preoperative creatinine levels and glomular filtration rate (estimated by the Cockroft-Gault formula8) 
were similar in users vs. non users, respectively 0.93 ± 0.18 mg/dL vs. 0.96 ± 0.15 mg/dL (p=0.5) and 79 
± 21 ml/min vs. 73 ± 19 ml/min (p=0.1). All patients were treated with prophylactic systemic antibiot-
ics prior to surgery. Operative characteristics are shown in TABLE 19.2.
Nine patients (11.7%) died within 30 days after surgery, 8 (16.3%) non-users and 1 (3.6%) user 
(p=0.09). Postoperative creatinine levels during 30 days after surgery were significantly lower in 
statin users than in non-users (ANOVA p-value <0.01, 1.17 mg/dL versus 1.98 mg/dL, FIGURE 19.1). In 
multivariable analysis, after correction for suprarenal clamping time, hypotension, type of aneurysm 
and blood loss, statin use was associated with lower median creatinine level at day 1 (1.17 vs. 1.74 
mg/dL, p=0.005), 2 (1.10 vs. 1.97 mg/dL, p=0.005), 3 (1.07 vs. 1.98 mg/dL, p=0.016), 7 (0.85 vs. 1.47 
Table 19.1 Baseline clinical characteristics.
Statin users
yes No P-value
(N=28) (N=49)
Male – no. (%) 19 (68) 38 (77) 0.41
Age –  years (SD) 68 (9.7) 70 (7.9) 0.37
Total cholesterol – mgl/dl (SD) 205 (39) 220 (30) 0.13
Medical history
 Angina pectoris – no. (%) 6 (21) 11 (22) 1.0
 Myocardial infarction – no. (%) 8 (29) 18 (37) 0.62
 Congestive heart failure – no. (%) 1 (4) 5 (10) 0.41
 Coronary bypass or angioplasty – no. (%) 5 (18) 10 (20) 1.0
 Stroke or TIA – no. (%) 3 (11) 9 (18) 0.52
 Diabetes mellitus – no. (%) 1 (4) 3 (6) 1.0
 Hypertension – no. (%) 10 (36) 25 (51) 0.24
 COPD – no. (%) 7 (39) 19 (39) 1.0
Medications
 ACE inhibitors – no. (%) 6 (21) 14 (29) 0.59
 Aspirin – no. (%) 8 (25) 12 (29) 0.79
 Calcium antagonists – no. (%) 8 (29) 21 (43) 0.23
 Diuretics – no. (%) 9 (32) 10 (20) 0.28
 Nitrates – no. (%) 4 (14) 12 (25) 0.39
 Beta-blockers – no. (%) 19 (68) 26 (53) 0.28
COPD = chronic obstructive pulmonary disease; ACE = angiotensin converting enzyme.
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mg/dL, p=0.041), and 30 (0.88 vs. 1.14 mg/dL, p=0.038).  Postoperative hemodialysis was required in 7 
patients (9.1%), all non-users. Three out of these patients were on chronic hemodialysis at discharge.
DISCuSSION
This study showed an association between statin use and preserved renal function after suprarenal 
aortic clamping-declamping in patients undergoing major vascular surgery. Serum creatinine levels 
were significantly lower up to 30 days after surgery in statin users compared to non-users. Moreover, 
10% of the non-users required (temporary) hemodialysis whereas none of the statin users required 
such therapy.
Table 19.2 Operation characteristics.
Statin users
yes No P-value
(N=28) (N=49)
Site of aneurysm
 Juxtarenal – no. (%) 19 (68%) 31 (63%) 0.80
 Suprarenal – no. (%) 9 (32%) 18 (37%) 0.80
Intraoperative
 Mean time of suprarenal clamping – minutes (SD) 47 (19) 54 (21) 0.13
 Mean duration of surgery – minutes (SD) 250 (60) 280 (72) 0.14
 Total blood loss – ml (SD) 3585 (2507) 4100 (2779) 0.39
 Units of homologues blood – (SD) 3 (2.5) 4 (4.7) 0.20
 Hypotension – no. (%) 3 (11%) 5 (10%) 0.86
 Mean body temperature – oC (SD) 35.6 (0.7) 35.6 (0.7) 0.51
min, minutes; SD, standard deviation; ml, milliliter; oC, degrees Celcius.
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Figure 19.1 Median creatinine levels preoperatively and 1, 2, 3, 7, and 30 days after surgery in statin users (dashed 
line) and nonusers (solid line), p <0.01 (analysis of variance for repeated measurements).
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Statins are frequently prescribed in the perioperative setting, as both retrospective and prospective 
studies have shown an improved outcome in statin users, mainly by a reduction of cardiac events9-11. 
As shown recently by Lindenauer et al, statin use was associated with a 1.4-fold reduction of post-
operative mortality in 780,591 patients12. These effects were independent of serum cholesterol 
levels and attributed to the so-called pleiotropic or non-lipid lowering effects of statins. The same 
pleiotropic effects might be responsible for the prevention of renal ischemia-reperfusion injury.
Recently, statins have shown to poses a renal protective effect in animals after ischemic-reperfusion 
injury. This model is comparable to the suprarenal clamping-declamping injury during vascular 
surgery. For the renal protective effect two important pleiotropic effects of statins are considered: 
the influence on endothelial function and inflammation. Both disruption of endothelial function 
and inflammation have been described to play a pivotal role in ischemic-reperfusion injury13,14. As 
discussed by Liao in a recent review article statins influence endothelial function and inflammation15. 
This has been confirmed in several animal models of renal ischemic-reperfusion injury.
The present study is the first clinical report on the effects of statins on perioperative renal ischemic-
reperfusion injury. Though our study suggests an association between statin use and preserved renal 
function after ischemic-reperfusion injury several issues remain unsolved. All patients in our study 
population were chronic statin users. It therefore remains to be assessed when statin therapy has to 
be initiated prior to surgery. In addition the optimal dosing of statins has to be assessed in terms of 
effectiveness and safety. In the perioperative setting with multiple drug interactions statin metabo-
lism might be influenced resulting in an increased risk of adverse events16. Since no intravenous 
formula of statins are clinically available concern has risen about a possible detrimental effect of 
statin interruption17. Because of the impairment of intestinal function early after surgery patients are 
often unable to take medication orally. This is especially common in patients undergoing abdominal 
aortic repair. Until more data are available it is recommended to have this interruption period as short 
as possible and consider administration by a naso-gastric tube.
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ABSTRACT
Background: Acute kidney injury (AKI) after major vascular surgery is an important risk factor for 
adverse long-term outcomes. The pleiotropic effects of statins may reduce kidney injury caused by 
perioperative episodes of hypotension and/or suprarenal clamping and improve long-term out-
comes.
Methods: Of 2170 consecutive patients undergoing lower extremity bypass or abdominal aortic 
surgery from 1995 to 2006, cardiac risk factors and medication were noted. A total of 515/1944 (27%) 
patients were statin users. Creatinine clearance (CrCl) was assessed preoperatively and at 1, 2 and 3 
days after surgery. Outcome measures were postoperative AKI and long-term mortality. Postopera-
tive kidney injury was defined as a >10% decrease in CrCl on Day 1 or 2, compared to the baseline. 
Recovery of kidney function was defined as a CrCl >90% of the baseline value at Day 3 after surgery. 
Multivariable Cox regression analysis, including baseline cardiovascular risk factors, baseline CrCl and 
propensity score for statin use, was applied to evaluate the influence of statins on early postoperative 
kidney injury and long-term survival.
Results: AKI occurred in 664 (34%) patients [median –25% CrCl, range (–10% to –71%)]. Of these 
664 patients, 313 (47%) had a complete recovery of kidney function at Day 3 after surgery. Age, 
hypertension, suprarenal cross-clamping and baseline CrCl predicted the development of kidney 
injury during the postoperative period. The incidence of kidney injury was similar among statin users 
and non-users (29% versus 25%, OR 1.15, 95% CI 0.9–1.5). However, if kidney function deteriorated, 
statin use was associated with increased odds of complete kidney function recovery (OR 2.0, 95% CI 
1.0–3.8). During a mean follow-up of 6.24 years, half of the patients died (55%). Importantly, statin 
use was also associated with an improved long-term survival, irrespective of kidney function change 
(HR 0.60, 95% CI 0.48–0.75).
Conclusion: Statin use is associated with improved recovery from AKI after major surgery and has a 
beneficial effect on long-term survival.
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INTRODuCTION
Acute kidney injury (AKI) is characterized by sudden (i.e. hours to days) impairment of kidney func-
tion1. AKI is now established to be an increasingly common complication in hospitalized patients, 
and the mortality is commonly 50–80% in critically ill patients2,3. Perioperative AKI is among the most 
common etiologies of kidney injury in hospitalized patients that markedly increases perioperative 
morbidity and mortality1–4. Despite benefits of acute dialysis therapy and numerous advances in 
critical care, perioperative AKI remains a catastrophic complication1,5. Therefore, the identification 
of interventions that have the potential of preventing the occurrence or shortening the course of 
postoperative AKI is essential.
3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) have pleiotropic effects inde-
pendent of lipid lowering6–8. Statins are known to be effective for primary and secondary prevention 
of cardiovascular events in hyperlipidaemic subjects9,10 and patients with chronic kidney disease 
(CKD) not requiring dialysis11–13. Recently, statins have been reported to increase the survival of CKD 
patients with sepsis or infectious complications and to have a beneficial effect on the course of AKI in 
ageing rats14–16. However, the association of statins with the course of postoperative AKI in humans 
remains unknown. Furthermore, data regarding the association between statin therapy and long-
term mortality of patients undergoing major vascular surgery are scarce.
In the present study, we hypothesized that statin usage would be associated with a shorter course of 
kidney dysfunction after controlling for other important risk factors. We examined the association of 
preoperative statin usage on the onset of AKI, the recovery of AKI in the postoperative period and the 
influence on long-term survival of patients undergoing major vascular surgery.
SuBjECTS AND METhODS
Study design and patient selection
Between January 1995 and June 2006, 2170 patients underwent major open non-cardiac vascular 
surgery at Erasmus Medical Center, Rotterdam, the Netherlands. All patients underwent lower limb 
arterial reconstruction (LLR) procedures or elective abdominal aortic aneurysm (AAA) surgery and 
were entered into a computerized database. The Medical Ethics Committee of the Erasmus Medical 
Center was informed about the study protocol, and no official approval was requested per institu-
tional practice.
Patients on chronic haemodialysis, with a baseline creatinine clearance (CrCl) <30 mL/min, and those 
who required renal revascularization and died within 3 days after surgery were excluded. The analysis 
was made according to whether or not patients were taking statins on the day of hospital admission, 
and does not incorporate changes in medical treatment during the follow-up period.
Baseline characteristics
On all patients the information on cardiovascular risk factors was recorded and included age, gender, 
hypertension (defined as systolic blood pressure 140 mmHg, diastolic blood pressure 90 mmHg or 
use of anti-hypertensive medication), diabetes mellitus (the presence of a fasting blood glucose 140 
mg/dL or requirement for insulin or oral hypoglycemic agents), smoking status, hypercholester-
olemia (total cholesterol of >200 mg/dL), chronic obstructive pulmonary disease (COPD) according to 
symptoms and pulmonary function tests (i.e. forced expiratory volume in one second (FEV1) <70% of 
Ch
ap
te
r 2
0
238
maximal age and gender predictive value), body mass index (BMI), serum creatinine, the presence of 
ischemic heart disease (prior myocardial infarction (MI), prior coronary revascularization and angina 
pectoris), heart failure (defined according to the New York Heart Association classification (NYHA)), 
cerebrovascular disease (history of cerebrovascular accident or transient ischemic attack), the 
occurrence of suprarenal cross-clamping during surgery and preoperative medication use (statins, 
β-blockers, diuretics, angiotensin-converting-enzyme inhibitors (ACE inhibitors), calcium antagonists, 
nitrates, aspirin and anti-coagulants). Of note, baseline body weight was used to calculate BMI. All 
prescription and over-the-counter medications were noted on the day of admission and ascertained 
if medication was documented at least 1–3 months prior to hospital admission for surgery.
kidney function assessment
Fasting serum creatinine was measured preoperatively at baseline in all patients, either at the 
outpatient preoperative screening visit or on the day of hospital admission, and on days 1, 2 and 3 
after surgery. Serum creatinine was assessed by a nonkinetic alkaline picrate (Jaffe) method. Kidney 
function was estimated with the Cockcroft and Gault equation from age, gender, serum creatinine 
and body weight17. Additional analyses were performed using the above definitions of AKI measured 
by the Modification of Diet in Renal Disease (MDRD) prediction equation18.
Clinical follow-up and end-points
Postoperative clinical information was retrieved from an electronic database of patients followed in 
our hospital. From the municipal civil registries, we obtained the survival status. The follow-up was 
complete in 98.2%.
The primary end-point of this study was postoperative AKI with and without complete recovery. 
AKI was defined as >10% decrease in CrCl on day 1 or 2, compared to the baseline value. Complete 
recovery of kidney function was defined as a CrCl >90% of the baseline value at day 3 after surgery.
The secondary end-point of this study was all-cause long-term mortality, which was defined as death 
occurring in the first 11 years after surgery.
Statistical analysis
Continuous data are described as mean values and standard deviation (±SD) or median values and 
range, and dichotomous data are described as percentage frequencies. The chi-square test was used 
for categorical variables and the analysis of variance (ANOVA) was used for continuous variables. 
Multivariable logistic regression analysis was used to evaluate whether statin use prevented kidney 
injury within 2 days after surgery. If kidney injury was present, multivariable logistic regression analy-
sis was used to evaluate if statin use was associated with an increased chance of complete recovery 
of kidney function at day 3 after surgery. Multivariable analysis included the following covariates: 
a propensity score for statin use, age, gender, hypertension, diabetes mellitus, smoking, hyperc-
holesterolemia, COPD, BMI, type of surgery, history of MI, coronary revascularization, heart failure, 
angina, cerebrovascular disease, baseline kidney function, suprarenal aortic cross-clamping, year 
of surgery and statin, β-blockers, diuretics, ACE inhibitors, calcium antagonists, nitrates, aspirin and 
anti-coagulation usage at baseline. Year of surgery was included as a categorical variable (January 
1995 through December 1999 and January 2000 through June 2006). We included the time period 
of surgery to adjust for possible confounding (i.e. change in perioperative management) due to the 
long follow-up period of the analysis.
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Incidence of patients requiring postoperative dialysis was compared between statin users and non-
statin users, using the chi-square test. Postoperative dialysis requirement was defined as the need of 
renal replacement therapy in the perioperative period, during the initial 30 days of hospitalization 
or after hospital discharge but within 30 days after surgery. The relation between statin use and 
requirement of postoperative dialysis was further investigated using multivariable analysis includ-
ing all baseline risk factors, propensity score for statin use, year of surgery and medication usage at 
baseline.
In addition, multivariable Cox regression analysis was performed to describe the influence of statin 
use on long-term all-cause mortality. Variables included in this model were propensity score for statin 
use, age, gender, hypertension, diabetes mellitus, smoking, hypercholesterolemia, COPD, BMI, type of 
surgery, history of MI, coronary revascularization, heart failure, angina, cerebrovascular disease, the 
presence of kidney injury, suprarenal aortic cross-clamping, year of surgery, baseline kidney function, 
postoperative dialysis and statin, β-blockers, diuretics, ACE inhibitors, calcium antagonists, nitrates, 
aspirin and anti-coagulation usage at baseline.
Unadjusted and adjusted odds and hazard ratios (ORs and HRs) were reported with corresponding 
95% confidence intervals (CIs). A p-value of <0.05 was considered to be significant. All computations 
were performed with SPSS software version 12.0.1 (SPSS Inc., Chicago, IL, USA).
RESuLTS
Patient characteristics
A total of 2170 patients underwent non-cardiac vascular surgery. After the exclusion of patients on 
chronic haemodialysis (n = 31), with a baseline CrCl <30 mL/min (n = 140), those who required renal 
revascularization (n = 7), and those who died within 3 days after surgery (n = 48), the final study 
population included in the analysis was 1944 patients. All patients underwent open major vascular 
surgery, and none of the patients were treated with endovascular devices.
The mean age of the study population was 66.6 ± 11 years and 78% were male (TABLE 20.1). In total, 
1031 patients (53%) underwent AAA surgery and 913 patients (47%) underwent LLR surgery. The 
mean serum creatinine at baseline was 1.17 ± 0.8 mg/dL, and the mean CrCl was 74.9 ± 33 mL/min.
A total of 515 patients (26.5%) were statin users. An approximately twofold increase in statin prescrip-
tion was observed over time. In the period from January 1995 through December 1999, a total of 
190/1035 patients (18.4%) were statin users, and in the period from January 2000 through June 2006, 
this number increased to 325/909 statin users (35.8%) (p < 0.001).
Primary end-point
Of the 1944 patients, AKI within 2 days after surgery occurred in 664 patients (34%). The median 
change of kidney function, using the Cockcroft and Gault equation, for these patients was –24.7% 
(–10%, –71%) on day 1 or day 2, compared to CrCl at baseline. The remaining 1330 patients (66%) 
had no AKI with a median change of +10.5% (–10%, +43%) from baseline. Patients with kidney injury 
were older, underwent more frequently AAA surgery and suprarenal aortic cross-clamping, had 
higher incidences of COPD and hypertension and received more β-blockers and calcium antagonists. 
Importantly, no differences in baseline serum creatinine and CrCl were observed between patients 
with and without kidney injury.
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Table 20.1
Baseline characteristics of all patients, according to the presence of renal dysfunction within two days after 
major vascular surgery.
All patients
1944 (100%)
No renal dysfunction
1280 (66%)
Renal dysfunction
664 (34%) P-value
Demographics (%)
 Mean age (± SD) 66.6 (± 11) 66.1 (± 11) 67.6 (± 11) 0.04
 Male 77 76 78 0.5
 Abdominal aortic surgery 53 45 68 <0.001
 Lower limb arterial
 reconstruction
47 55 32 <0.001
 Suprarenal clamping 10 4 19 <0.001
Cardiovascular risk factor (%)
 Hypertension 48 45 55 <0.001
 Diabetes Mellitus 16 16 16 0.7
 Current smoker 28 28 28 0.8
 Hypercholesterolemia 20 19 20 0.7
 COPD 22 20 24 0.04
 Body mass index (± SD) 24.8 (± 5) 24.5 (± 4) 25.5 (± 6) 0.005
 Myocardial Infarction 29 28 30 0.5
 Coronary revascularization 26 27 26 0.5
 Heart failure 7 6 7 0.6
 Angina 17 17 18 0.5
 Cerebrovascular disease 8 7 8 0.6
Baseline kidney function (%)
 Serum creatinine (mg/dl ± SD) 1.17 (± 0.8) 1.17 (± 0.85) 1.17 (±0.80) 0.8
 Creatinine clearance (ml/min ± SD) 74.9 (± 33) 74.0 (± 30) 76.5 (± 38) 0.2
Medication use (%)
 Statins 27 25 29 0.1
 β-blockers 36 35 40 0.03
 Diuretics 21 21 20 0.6
 ACE-inhibitors 34 34 35 0.9
 Calcium antagonists 36 34 41 0.004
 Nitrates 21 21 20 0.8
 Aspirin 32 32 31 0.9
 Anti-coagulation 24 26 19 0.001
ACE-inhibitors = angiotensin-converting-enzyme inhibitors; COPD = chronic obstructive pulmonary disease; *renal 
dysfunction = >10% decrease in creatinine clearance on day 1 or 2, compared to baseline value
Table 20.2 Independent predictors for developing renal dysfunction after major vascular surgery.
Multivariate odds ratio,
95% confidence interval
Age (per 1 year increase) 1.03 (1.02 – 1.04)
Hypertension 1.40 (1.10 – 1.78)
Suprarenal cross-clamping 4.47 (3.09 – 6.50)
AAA surgery vs. LLR surgery 1.96 (1.54 – 2.48)
Baseline creatinine clearance (per 1 ml/min increase) 1.01 (1.006 – 1.014)
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Of note, the incidence of statin use was similar between patients with and without AKI, 322/1280 
patients (29%) versus 193/664 patients (25%), p = 0.11. In multivariable analysis, statin use was not 
associated with decreasing incidence of kidney injury 2 days after surgery (adjusted OR 1.15, 95% CI 
0.86–1.54). Independent predictors for postoperative AKI were age, hypertension, suprarenal aortic 
cross-clamping, AAA surgery versus LLR surgery and baseline CrCl per 1 mL/min increase of CrCl 
(TABLE 20.2).
In total, 46 patients (2.4%) required postoperative dialysis within 30 days after surgery (37 and 9 
patients required temporary and chronic therapy, respectively). The proportion of statin users and 
non-statins users was similar between patients who did and did not require dialysis therapy (26.7% 
non-statin users versus 19.6% statin users, p = 0.28). In multivariable analysis, statin use was not asso-
ciated with the prevention of postoperative dialysis (adjusted OR 0.80, 95% CI 0.31–2.08). Patients 
with suprarenal aortic cross-clamping had a sevenfold increased risk for the requirement of dialysis 
(adjusted OR 7.08, 95% CI 2.92–17.18). Furthermore, patients with lower levels of baseline CrCl were 
also at a higher risk (adjusted OR 0.987, 95% CI 0.974–0.999 per 1 mL/min increase).
Perioperative blood loss and suprarenal aortic cross-clamping time were found to be significantly 
associated with the presence of postoperative kidney injury. In addition, statin users had the same 
total perioperative blood loss and suprarenal aortic cross-clamping time, compared with non-statin 
users (2565 mL versus 2245 mL (p = 0.13) and 57.7 min versus 58.5 min (p = 0.93), respectively).
Of the 664 patients with AKI, 313 patients (47%) had a complete recovery of kidney function at day 
3 after surgery. The median change of kidney function for these patients was –7.4% (–10%, +24%) at 
day 3, compared with CrCl at baseline. The remaining 351 patients (53%) did not achieve complete 
recovery and their median decrease in kidney function was –27.8% (–10%, –91%), compared with 
CrCl at baseline.
In multivariable analysis, statin use and diabetes mellitus were independently associated with com-
plete recovery of kidney function. Statin use was associated with increased odds of complete recovery 
of kidney function (adjusted OR 1.96, 95% CI 1.02–3.75), while diabetes mellitus was associated with 
decreased odds of renal recovery (adjusted OR 0.52, 95% CI 0.26–0.99). In addition, we observed 
no differences between the two different surgical groups, regarding the effect of statin therapy on 
kidney injury recovery. Patients undergoing AAA surgery had a 1.85-fold increased chance of com-
plete kidney function recovery (95% CI 1.09–3.52). Patients undergoing LLR surgery had a 2.24-fold 
increased chance of recovery (95% CI 1.05–4.07).
Secondary end-point
In total, 1062 patients (55%) died during 6.2 ± 3.6 years of follow-up. Statin use was associated with 
long-term all-cause mortality, irrespective of the presence of kidney injury after surgery (FIGURE 
20.1). The adjusted HR for statin use was 0.60 (95% CI 0.48–0.75). Importantly, statin use was associ-
ated with an improved outcome for patients who develop kidney injury (adjusted HR 0.53, 95% CI 
0.37–0.77), as well as for patients without AKI (adjusted HR 0.65, 95% CI 0.49–0.86).
Other independent predictors for long-term all-cause mortality are listed in TABLE 20.3. Importantly, 
the presence of AKI after surgery was associated with an adverse outcome (adjusted HR 1.24, 95% CI 
1.06–1.45). Baseline CrCl (per 1 mL/min increase) was also independently associated with all-cause 
mortality, with an adjusted HR of 0.993, 95% CI 0.990–0.996. In a sub-analysis among the 48 patients 
who died within 3 days after surgery, statin therapy was associated with a decreased chance of 
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immediate postoperative death (unadjusted OR 0.40, 95% CI 0.17–0.94, p-value = 0.035). We were 
unable to perform multivariate analysis, because of decreased statistical power to detect differences 
in outcomes in this subgroup.
DISCuSSION
The main finding of our study is that in patients who developed AKI in the postoperative period, 
statin usage was associated with a twofold increase in kidney function recovery when compared 
to participants not receiving statins. Statin usage was not associated with lower total perioperative 
blood loss, shorter suprarenal aortic cross-clamping time or a decrease in dialysis requirement in the 
postoperative period. Moreover, statin use was associated with increased long-term survival inde-
pendent of change in kidney function in the postoperative period. In this study, age, hypertension, 
Table 20.3 Independent predictors for all-cause mortality during 6.24 ± 4.2 years follow-up.
Multivariate hazard ratio,
95% confidence interval
Age (per 1 year increase) 1.04 (1.03 – 1.05)
Diabetes Mellitus 1.23 (1.02 – 1.49)
COPD 1.42 (1.19 – 1.70)
Smoking 1.32 (1.13 – 1.54)
Old myocardial infarction 1.24 (1.04 – 1.48)
Baseline creatinine clearance (per 1 ml/min increase) 0.992 (0.989 – 0.996)
Renal dysfunction 1.34 (1.13 – 1.48)
Statin use 0.56 (0.44 – 0.70)
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Figure 20.1 All-cause long-term mortality in vascular surgery patients, according to the presence of kidney injury 
and statin use.
Kidney injury: >10% decrease in creatinine clearance on day 1 or 2, compared to the baseline value. 
Mean follow-up is 6.24 ± 4.2 years.
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suprarenal cross-clamping and baseline kidney function were significant predictors of AKI. To our 
knowledge, there are few observational studies examining the relationship of statins on the recovery 
of AKI caused by major vascular surgery and long-term outcome. In addition, the results of our study 
remained the same when kidney function was calculated with the Cockcroft and Gault or the MDRD 
prediction equations.
AKI occurred in 34% of the cohort within 2 days after undergoing major vascular surgery. The comparison 
of the incidence of kidney injury with earlier studies is complicated by the lack of a standardized defini-
tion for AKI. Two recent prospective studies observed an incidence of 20% and 48%, respectively, when 
AKI was defined as a 20–25% increase in plasma creatinine from the baseline within 3 days after sur-
gery19,20. These reports suggest that the etiology of AKI post-vascular surgery is multifactorial, including 
pre-existing atherosclerosis, hypertension, suprarenal aortic cross-clamping time, nephrotoxic agents 
as well as inflammatory and neuroendocrine stress response to surgery1,19,20. In the current analysis, 
statin use was associated with a twofold increased odds of complete recovery of kidney function at 
day 3 after surgery. However, recovery from AKI at 7 or 30 days after surgery could not be assessed. This 
does limit the inferences that could be drawn regarding statin therapy and recovery from AKI.
Clinical studies have shown a significant association of statin usage with decreased mortality from 
bacterial infections or sepsis in a CKD and non-CKD patient population21,22; however, similar studies 
evaluating the effects of statin on the course of AKI in the post-surgical period are lacking. In the 
animal model of sepsis induced AKI (i.e. cecal ligation and puncture)23, pretreatment with simvas-
tatin improved kidney function, as measured by serum creatinine and blood urea nitrogen. In this 
study, simvastatin was observed to improve tubular vacuolar degeneration and reverse the increase 
vascular permeability, renal microperfusion and hypoxia seen in this model. Similarly, Sabbatini and 
colleagues24 examined whether treatment with atorvastatin could improve the course of AKI after 
ischemia-reperfusion injury in ageing rats compared with untreated age-matched rats. These inves-
tigators were able to show that pre-administration of atorvastatin mitigated renal vasoconstriction 
and restored glomerular filtration values to the baseline by increasing nitric oxide availability and, 
therefore, improving renal hemodynamics. In addition to preserving endothelial nitric oxide synthase 
function, statins have also been shown to regulate other mediators of vascular permeability, including 
vascular endothelial growth factors and matrix metalloproteinases25,26. Our findings extend previous 
observations to patients with AKI after major vascular surgery.
Another important observation in the current analysis is that statin therapy is associated with an 
improved long-term outcome in patients undergoing major vascular surgery, irrespective of the pres-
ence of kidney injury after surgery. Patients undergoing major vascular surgery are at an increased 
risk of morbidity and mortality in the postoperative period. In the current analysis, about half of the 
patients (55%) died during long-term follow-up. During 6 years of follow-up, patients receiving statins 
had a 40% reduced rate of all-cause mortality, compared to patients not receiving statins. Similarly, 
Kertai and colleagues examined the long-term benefit of statins in 510 patients undergoing AAA 
surgery27. These investigators observed that statin therapy was associated with reduced all-cause 
and cardiovascular mortality during 4.7 years of follow-up (60% and 70% reduction, respectively). 
Hence, the juxtaposition of the above results suggests that statin therapy has a long-term protec-
tive effect in patients undergoing major vascular surgery. Besides reducing cholesterol synthesis, 
lipid-lowering agents have been shown to lower peripheral vascular resistance, have antithrombotic 
effects, improve endothelial function and even reduce inflammation28,29. These effects may stabilize 
atherosclerotic plaques present in patients undergoing major vascular surgery, resulting in preven-
tion of plaque rupture and myocardial ischemia in the postoperative period30.
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Our study has certain limitations. First, observational studies are limited due to confounding by 
indication for treatment because of lack of randomization. Despite using a propensity score to 
adjust for the bias inherent in the decision about statin therapy, we cannot exclude the possibility of 
residual confounding. Second, the arbitrary definition of AKI used in this study is conservative when 
compared to other available definitions. Although we investigated small changes of kidney function 
(e.g. >10% decrease of CrCl) in the postoperative period, a recent publication illustrated that these 
subtle changes are related with a worse short- and long-term outcome after major vascular surgery, 
independent of baseline cardiovascular risk factors, kidney function and postoperative complica-
tions31. Third, the association of time of statin exposure with short- and long-term outcomes was also 
not investigated, since the data on duration of therapy were not available. Fourth, kidney function 
estimating equations (e.g. Cockcroft Gault) are derived in patients who are in a steady state. Since 
we reported perioperative estimates of CrCl changes (within 3 days after surgery) such a steady state 
is difficult to establish, which might underestimate true changes in kidney function. Unfortunately, 
there are no practical ways to readily measure kidney function in the acute setting. Finally, our find-
ings are based on an almost entirely Caucasian (96%) patient population without advanced kidney 
disease who only underwent two specific types of vascular surgery (LLR and AAA) and caution should 
be used in the generalization of these findings.
In this large observational study, the perioperative usage of statins was associated with clinically 
significant recovery of AKI after undergoing high-risk elective vascular surgery. More importantly, 
statin therapy was associated with a beneficial effect during long-term follow-up, irrespective of the 
presence of AKI. Although the data reported in this cohort suggest a beneficial association of statins 
with recovery of kidney injury and long-term outcomes, clinical trials are needed to evaluate the 
safety and efficacy of statins in patients with AKI post-vascular surgery.
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ABSTRACT
Background: Discontinuation of statin therapy in patients with an acute coronary syndrome has 
been associated with an increase of adverse coronary events. Patients undergoing major surgery 
frequently are not able to take oral medication shortly after surgery. Since there is no intravenous 
formula for statins, interruption of statins in the postoperative period is a serious concern. The objec-
tive of this study was to assess the effect of perioperative statin withdrawal on postoperative cardiac 
outcome. Also, the association between outcome and type of statin was studied.
Methods: In 298 consecutive chronic statin users undergoing major vascular surgery a detailed 
cardiac history was obtained and medication use was noted. Postoperatively troponin levels were 
measured on day 1,3,7,30 and whenever clinically indicated by electrocardiographic changes. End-
points were postoperative troponin release, myocardial infarction, and a combination of non-fatal 
myocardial infarction and cardiovascular death. Multivariable analyses and propensity score analyses 
were performed to assess the influence of type of statin and discontinuation of statins for these 
endpoints.
Results: Statin discontinuation was associated with an increased risk for postoperative troponin 
release (HR 4.6, 95%CI 2.2–9.6), and the combination of myocardial infarction and cardiovascular 
death (HR 7.5, 95% CI 2.8–20.1). Fluvastatin extended release was associated with less perioperative 
cardiac events compared to atorvastatin, simvastatin, and pravastatin.
Conclusion: The present study showed that statin withdrawal in the perioperative period is associ-
ated with an increased risk for perioperative adverse cardiac events. Furthermore there seems to be a 
better outcome in patients who received statins with an extended release formula.
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INTRODuCTION
Patients undergoing major vascular surgery frequently are not able to take oral medication shortly 
after surgery, for example because of postoperative paralytic ileus. Since there is no intravenous 
formula for statins, interruption of statin therapy in the immediate postoperative period is a serious 
concern, especially since it is known that these vascular surgical patients are at highest risk for adverse 
cardiac events in the first 3 days after operation1. We hypothesized that statin withdrawal among 
chronic statin users undergoing major vascular surgery might be associated with an increased risk of 
adverse cardiac events. Therefore, we evaluated the effect of sudden perioperative statin withdrawal 
compared to continuous use on postoperative adverse events. In addition, the association between 
outcome and the type of statin was studied.
METhODS
The study population consisted of 298 patients on chronic statin therapy undergoing elective 
major vascular surgery at Erasmus MC in Rotterdam, the Netherlands, during the period July 2000 
to August 2006. Chronic statin therapy was defined as the use of statins at the first preoperative 
vascular outpatient clinic visit. These patients were identified in a prospectively maintained database 
of all patients undergoing vascular surgery at this institution. The study was approved by the Medical 
Ethics Committee of Erasmus MC.
Prior to surgery, a detailed cardiac history was obtained and patients were screened for hypertension 
(blood pressure >140/90 mmHg, or medical therapy to control hypertension), diabetes mellitus (fast-
ing glucose level >7.0 mmol/L, or medication to control diabetes), and renal failure (serum creatinine 
level ≥ 2.0 mg/dL). The presence of coronary artery disease was indicated by a previous myocardial 
infarction, previous coronary intervention, present stable angina pectoris, and positive cardiac stress 
test. Other cardiovascular risk factors scored in all patients included a history of a cerebrovascular 
accident or transient ischemic attack, age over 70 years, chronic heart failure, and chronic obstructive 
pulmonary disease (defined as a FEV1 < 70% of age and gender predictive value or medication use). 
The type and dosage of chronic statin therapy was noted in all.
All patients received perioperative beta-blocker therapy. At our institution beta-blockers are with-
held if patients presented with a systolic blood pressure <100 mmHg or with a heart rate <50 beats 
per minute. The dosage of beta-blockers on the day of surgery and after surgery is kept similar to the 
preoperative beta-blocker dose. It is ascertained that beta-blockers are administered on the morning 
of surgery and on each day after surgery until discharge. There was no strict protocol on the use of 
statins in the perioperative period, i.e. the decision to continue or withhold statin therapy was left 
to the discretion of the treating physician. Medication use in the perioperative period was extracted 
from medical charts and/or the electronic hospital registration system in which all medication use is 
recorded. Interruption of statin therapy was defined as any missed dose of statins. Surgical procedures 
were classified as abdominal aortic surgery (154 patients, 52%), and lower extremity revascularization 
(144 patients, 48%).
At our institution troponin T levels are routinely measured in patients undergoing major vascular 
surgery on postoperative day 1, 3, 7, 30 and whenever clinically indicated by electrocardiographic 
changes, consistent with myocardial ischemia or infarction. Routinely electrocardiograms were 
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recorded preoperatively and on day 1, 3, 7, and 30 after surgery. Troponin T level was measured using 
a whole blood rapid test (TropT version 2, Roche Diagnostics, Mannheim, Germany).
Endpoints were postoperative troponin release (myocardial damage), non-fatal myocardial infarc-
tion, cardiovascular death within 30 days after surgery, and a combination of non-fatal myocardial 
infarction and cardiovascular death within 30 days after surgery.
Myocardial infarction was defined as the presence of 2 out of the following 3 criteria: (1) Characteristic 
ischemic symptoms lasting > 20 minutes, (2) electrocardiographic changes including acute ST eleva-
tion followed by appearance of Q waves or loss of R waves, or new left bundle branch block, or new 
persistent T wave inversion for at least 24 hours, or new ST segment depression which persists > 24 
hours, and (3) a positive troponin T, i.e. >0.10 ng/ml, or peak creatine kinase-MB >8% of an elevated 
total creatinine phosphokinase with characteristic rise and fall2. Cardiovascular death was defined as 
any death with a cardiovascular cause, including those deaths following a cardiac procedure, cardiac 
arrest, myocardial infarction, pulmonary embolus, stroke, or sudden deaths not ascribed to other 
causes3.
The cardiac risk score for each patient in our dataset was calculated according to the score of the 
DECREASE I and II studies4,5 and one point was assigned to each of the following characteristics: 
history of myocardial infarction, history of angina pectoris, history of congestive heart failure, history 
of cerebrovascular disease, diabetes mellitus, renal failure, and age over 70 years. Patients with no 
risk factors are considered to be at low cardiac risk, with one or two risk factors to be at intermediate 
cardiac risk, and with ≥ 3 risk factors to be at high cardiac risk.
Dichotomous data are described as numbers and percentages, and continuous data are presented as 
means with standard deviations (SD). Differences in baseline characteristics between statin users were 
evaluated by analysis of variances (ANOVA) and Chi-square tests, where appropriate. We developed 
a propensity score for the likelihood of receiving continuous statin therapy, and used applied mul-
tivariable logistic regression analysis to calculate the propensity score. The variables included in the 
model were: type of surgery, gender, year of surgery, hypertension, chronic obstructive pulmonary 
disease, cardiac risk factors, calcium-channel blockers, angiotensin converting enzyme inhibitors, 
angiotensin-receptor blockers, diuretics, oral nitrates, antiplatelet agents. The performance of the 
propensity score model was studied with respect to discrimination and calibration. Discrimination 
refers to the ability to distinguish statin continuation from statin interruption; it was quantified by 
the c-statistic. Calibration refers to whether the predicted probability of continuous statin use is in 
agreement with the observed probability and was measured with the Hosmer-Lemeshow goodness-
of-fit-test. The method of Kaplan-Meier was used to describe the incidence of myocardial infarction 
and cardiac death over time. A log-rank test was applied to study differences in survival between 
continuous users and stoppers. These relations were further evaluated by multivariable Cox’ propor-
tional hazard regression analysis, with adjustment for confounders and propensity score. All potential 
confounders were entered in the multivariable model to ensure giving an as unbiased as possible 
estimate for the relation between statin discontinuation and perioperative cardiac outcome. Crude 
and adjusted Hazard ratios are reported with corresponding 95% confidence intervals (CI). For all 
tests, a p-value <0.05 (two-sided) was considered significant. All statistical analyses were performed 
using SPSS statistical software.
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RESuLTS
The baseline characteristics of the 298 patients (mean age 64.9 +/- 10.5, 75% male) are presented in 
TABLE 21.1. Patients were on fluvastatin extended release (n=100), simvastatin (n=86), atorvastatin 
(n=35), or pravastatin (n=77). There was no difference in total cholesterol levels, high density lipopro-
tein, and low density lipoprotein between the different statin types measured at the first outpatient 
clinic visit as is shown in TABLE 21.2.
In a total of 70 (23%) patients statin therapy was interrupted in the perioperative period. The median 
duration of statin interruption was 3 days (interquartile range 2.7–8 days). Within the propensity 
score analysis, baseline variables that significantly predicted interruption of statin therapy were aortic 
surgery (HR = 23.8, 95%CI = 8.6–66.0), and number of cardiac risk factors (HR = 2.6, 95% CI 0.9–7.2, 
for intermediate risk and 4.6, 95% CI 1.2-16.8, for high-risk). The c-statistic of the propensity score was 
0.79. Calibration with use of the Hosmer and Lemeshow test gave a non-significant outcome.
Myocardial damage, myocardial infarction, and cardiovascular death occurred in 26.8%, 11.4%, and 
3.0% respectively for the entire study cohort. In univariable analysis patients who continued statin 
therapy had a significantly better cardiac outcome compared to patients who interrupted statin 
therapy: myocardial ischemia 16.7% vs. 60.0%, myocardial infarction 5.7% vs. 30.0%, cardiovascular 
death 1.8% vs. 7.1% and the combination of cardiovascular death and non-fatal myocardial infarction 
Table 21.1 Patient characteristics.
Total Continuation Withdrawal P-value
(N=298) (N=228) (N=70)
Male – no. (%) 233 (75) 168 (74) 55 (79) 0.44
Mean age, years (SD) 64.9 (10.5) 64.2 (10.5) 67.0 (10.3) 0.02
Myocardial infarction – no. (%) 98 (33) 70 (31) 28 (40) 0.15
Angina pectoris – no. (%) 92 (31) 57 (25) 35 (50) 0.001
Heart failure – no. (%) 12 (4) 7 (3) 5 (7) 0.16
CVA or TIA – no. (%) 53 (18) 36 (16) 17 (24) 0.15
CABG or PTCA – no. (%) 77 (26) 50 (22) 27 (39) 0.008
Renal failure – no. (%) 11 (4) 7 (3) 4 (6) 0.30
Diabetes mellitus – no. (%) 82 (28) 64 (28) 18 (26) 0.76
Hypertension – no. (%) 133 (45) 97 (43) 36 (51) 0.27
COPD – no. (%) 108 (36) 75 (33) 33 (47) 0.05
Clinical cardiac risk 0.002
 Low cardiac risk* – no. (%) 67 (23) 58 (25) 9 (13)
 Intermediate cardiac risk* – no. (%) 169 (57) 131 (58) 38 (54)
 High cardiac risk* – no. (%) 62 (21) 39 (17) 23 (33)
Type of Surgery 0.001
 Aortic – no. (%) 154 (52) 91 (40) 63 (90)
 Lower extremity revascularization – no. (%) 144 (48) 137 (60) 7 (10)
Type of statin 0.48
 Fluvastatin extended release – no. (%) 100 (34) 78 (34) 22 (31)
 Simvastatin – no. (%) 86 (29) 65 (29) 21 (30)
 Pravastatin – no. (%) 35 (12) 30 (13) 5 (7)
 Atorvastatin – no. (%) 77 (26) 55 (24) 22 (31)
* According to the Erasmus index; SD = standard deviation
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(5.7% vs. 31.4%). Other univariable predictors of adverse cardiac outcome are shown in TABLES 
21.3A-C. Also in multivariable analysis statin interruption remained an independent predictor of 
adverse cardiac outcome (TABLES 21.3A-C). When the propensity score was included in the model 
with all the covariates to adjust for the chance of interruption of statins, the effect of continuous 
statin therapy and withdrawal was comparable to the analysis adjusted for only covariates (TABLES 
21.3A-C).
Table 21.2 Characteristics of patients on different types of statins.
Fluvastatin Simvastatin Pravastatin Atorvastatin
Variable (N=100) (N=86) (N=35) (N=77)
Cholesterol, mg/dL – mean (SD) 184 (42) 181 (41) 182 (44) 182 (63)
Low density lipoprotein, mg/dL – mean (SD) 114 (40) 106 (39) 103 (41) 110 (58)
High density lipoprotein, mg/dL – mean (SD) 49 (46) 47 (16) 47 (14) 47 (19)
Triglycerides, mg/dL – mean (SD) 184 (100) 183 (111) 170 (97) 187 (129)
Statin dosing (mg)
 10 – no. (%) 0 10 (12) 5 (14) 19 (25)
 20 – no. (%) 0 50 (58) 11 (31) 25 (33)
 40 – no. (%) 0 24 (28) 19 (54) 28 (36)
 80 – no. (%) 100 (100) 2 (2) 0 5 (7)
Aortic surgery – no. (%) 48 (48) 51 (59) 11 (31) 44 (57)
Cardiac risk
 Low cardiac risk – no. (%) 27 (27) 14 (16) 8 (23) 18 (23)
 Intermediate cardiac risk – no. (%) 56 (56) 48 (56) 19 (54) 46 (60)
 High cardiac risk – no. (%) 17 (17) 24 (28) 8 (23) 13 (17)
SD= standard deviation
Table 21.3a Predictors for myocardial damage.
Univariable analysis Multivariable analysis Multivariable analysis*
Variable HR 95% confidence 
interval
HR 95% confidence 
interval
HR 95% confidence 
interval
Statin interruption 7.5 4.2 – 13.6 5.1 2.5 – 10.4 4.6 2.2 – 9.6
Cardiac Risk
 Low risk 1 1 1
 Intermediate risk 2.8 1.2 – 6.7 3.2 1.2 – 8.4 3.0 1.1 – 8.9
 High risk 8.6 3.4 – 21.7 9.3 3.1 – 27.7 8.5 2.4 – 30.2
Type of statin
 Fluvastatin 1 1 1
 Simvastatin 2.8 1.4 – 5.8 2.5 1.1 – 6.1 2.7 1.1 – 6.5
 Pravastatin 3.2 1.3 – 7.9 6.1 2.0 – 18.2 6.6 2.2 – 19.6
 Atorvastatin 3.3 1.6 – 6.9 4.3 1.8 – 10.7 4.2 1.7 – 10.4
Surgical Site
 Peripheral 1 1 1
 Aortic 3.6 2.1 – 6.4 2.6 1.2 – 5.4 2.2 0.7 – 7.3
COPD 1.5 0.9 – 2.6 1.2 0.6 – 2.2 1.2 0.6 – 2.2
Hypertension 1.9 1.1 – 3.1 1.8 0.9 – 3.5 1.8 0.9 – 3.4
C-index 0.82 0.83
*Propensity score included in analysis; HR = Hazard ratio
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Table 21.3b Predictors for myocardial infarction.
Univariable analysis Multivariable analysis Multivariable analysis*
Variable HR 95% confidence 
interval
HR 95% confidence 
interval
HR 95% confidence 
interval
Statin interruption 7.1 3.3 – 15.1 7.1 2.7 – 18.7 7.5 2.8 – 20.1
Cardiac Risk
 Low risk 1 1 1
 Intermediate risk 8.8 1.2 – 67.4 7.7 1.0 – 62.0 9.5 1.1 – 82.6
 High risk 17.5 2.2 – 138.4 12.3 1.4 – 105.3 17.8 1.8 – 181.2
Type of statin
 Fluvastatin 1 1 1
 Simvastatin 4.7 1.5 – 14.8 4.1 1.2 – 14.2 3.7 1.0 – 13.3
 Pravastatin 4.0 1.0 – 15.9 5.2 1.1 – 24.1 5.1 1.1 – 23.9
 Atorvastatin 4.0 1.2 – 13.1 3.8 1.1 – 13.6 4.0 1.1 – 14.1
Surgical Site
 Peripheral 1 1 1
 Aortic 2.1 1.0 – 4.5 0.9 0.3 – 2.7 1.5 0.3 – 7.2
COPD 0.9 0.4 – 2.0 0.7 0.3 – 1.6 0.7 0.3 – 1.7
Hypertension 1.6 0.8 – 3.4 1.3 0.6 – 2.9 1.3 0.6 – 3.1
C-index 0.82 0.83
*Propensity score included in analysis; HR = Hazard ratio; COPD = chronic obstructive pulmonary disease
Table 21.3c Predictors for the combined endpoint of nonfatal myocardial infarction and cardiac death.
Univariable analysis Multivariable analysis Multivariable analysis*
Variable HR 95% confidence 
interval
HR 95% confidence 
interval
HR 95% confidence 
interval
Statin interruption 7.6 3.6 – 16.1 7.3 2.8 – 18.9 7.5 2.8 – 20.1
Cardiac Risk
 Low risk 1 1 1
 Intermediate risk 8.9 1.2 – 67.4 8.0 1.0 – 64.6 8.8 1.0 – 76.5
 High risk 19.3 2.4 – 151.4 14.6 1.7-123.9 17.3 1.7 – 174.8
Type of statin
 Fluvastatin 1 1 1
 Simvastatin 4.7 1.5 – 14.8 4.4 1.3– 15.1 4.1 1.1 – 14.8
 Pravastatin 4.0 1.0 – 15.9 5.9 1.3– 27.6 5.7 1.2 – 26.8
 Atorvastatin 4.4 1.4 – 14.3 4.5 1.3 – 16.1 4.6 1.3 – 16.3
Surgical Site
 Peripheral 1 1 1
 Aortic 2.2 1.1 – 4.7 1.0 0.4 – 2.8 1.3 0.3 – 6.1
COPD 1.0 0.5 – 2.1 0.8 0.3 – 1.7 0.8 0.3 – 1.8
Hypertension 1.5 0.7 – 3.1 1.2 0.5 – 2.6 1.2 0.5 – 2.8
C-index 0.83 0.84
* Propensity score included in analysis; HR = Hazard ratio; COPD = chronic obstructive pulmonary disease
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In univariable analysis patients who were on fluvastatin extended release therapy had a lower risk of 
adverse cardiac events compared to patients on simvastatin, pravastatin, or atorvastatin. Troponin 
T release was present in 14.0%, 31.4%, 34.3%, and 35.1% respectively for fluvastatin, simvastatin, 
pravastatin, and atorvastatin, while myocardial infarction occurred in 4.0%, 16.3%, 14.3%, and 14.3% 
respectively. The incidence of cardiovascular death did not differ significantly between statin types, 
2.0%, 3.5%, 5.7%, and 2.6% respectively. As is shown in TABLES 21.3A-C also in multivariable analysis, 
adjusting for covariates and propensity score, patients who were on fluvastatin extended release had 
a significantly lower rate of adverse cardiac events.
DISCuSSION
This study showed that acute statin withdrawal in the perioperative period is associated with an 
increased risk of perioperative cardiac events compared to statin continuation among chronic users. 
The extended release formula of fluvastatin appears to have beneficial effects over other statins in 
patients who discontinued statin therapy.
The possible detrimental effects of sudden statin withdrawal have been reported previously in chronic 
statin users with an acute coronary syndrome6-9. In a cohort study the GRACE-investigators found 
that 428 chronic statin users in whom statin therapy was discontinued at admission for an acute 
coronary syndrome had the same risk for the composite of death, stroke, and myocardial infarction 
as non-users6. In contrast, 3,628 patients who continued statin therapy throughout the admission 
had a significant 34% relative risk reduction compared to non-users. Another large observational 
study found the same effect of statin withdrawal in patients admitted for non-ST-segment elevation 
myocardial infarction: no difference in in-hospital death rate between 4,870 patients who discontin-
ued statin therapy and 54,635 non-users whereas 9,001 patients who continued statin therapy had a 
highly significant 45% relative risk reduction compared to non-users7.
The lipid-lowering effects of statins might explain most of the beneficial effects of chronic statin use 
in patients at increased risk for coronary artery disease. However, this might not explain the effects 
of sudden statin withdrawal in the current study. All patients were chronic statin users up to the day 
of surgery and significant changes in serum lipid levels may take days to weeks. Another explana-
tion might be the effect of sudden statin withdrawal on its pleiotropic properties. These pleiotropic 
effects include inhibition of inflammation, modulation of endothelial function, and antithrombotic 
effects. Pleiotropic effects of statins are present within hours to days after statin therapy initiation. 
Importantly, several studies have shown that these pleiotropic effects might be lost within hours 
after statin withdrawal while lipid levels remained continuously low. Vulnerable coronary plaque rup-
ture10,11, leading to thrombus formation and subsequent vessel occlusion is one of the main causative 
mechanisms of perioperative cardiac complications. The pleiotropic effects of statins are thought to 
influence the susceptibility of vulnerable plaques for rupture. While the surgical patient is at highest 
cardiac risk within the first three days after surgery, possibly also because of the detrimental effects of 
surgery on mechanisms leading to vulnerable plaque rupture, statin therapy is discontinued.
The current study showed that statin therapy is interrupted in about 25% of patients undergoing 
major non-cardiac surgery. The main cause for interruption was the inability to take oral medication 
shortly after surgery. Since statins are not available as intravenous formulas this leads to unintended 
statin withdrawal. Our current study suggests that fluvastatin might be associated with a better 
outcome after major non-cardiac surgery compared to other statins. There are several possible 
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explanations for these observations. Fluvastatin is the only statin with an extended release formula. 
Since most patients with statin withdrawal restarted statin therapy within 3 to 4 days after surgery 
it might be hypothesized that the fluvastatin extended release formula is capable of extending the 
duration of pleiotropic effects of statins. Furthermore the pharmacokinetics of statins might be 
influenced by concomitant drug use in the perioperative period. Of special interest in this respect is 
the cytochrome P450 (CYP) isoenzyme system. Most drugs are metabolized in the liver by the CYP 
3A4 isoenzyme. As a consequence this might cause interaction with simvastatin and atorvastatin that 
are also metabolized by this pathway12. Fluvastatin on the other hand has only limited interactions 
with the CYP 3A4 pathway since it is mainly metabolized by the CYP 2C9 isoenzyme. As was shown 
in a review by Bellosta et al. other differences between statins include half-life, systemic exposure, 
maximum plasma concentration, bioavailability, protein binding, lipophilicity, presence of active 
metabolites, and excretion routes13. Fluvastatin is the only statin that is a racemic compound, half 
of the molecule being presumably inactive at reducing plasma cholesterol. It is not excluded that 
some of the beneficial pleiotropic effects may be shared by the “non-active” half therefore potentially 
increasing that capacity.
The non-randomized nature of the current study has certain limitations. It could be argued that 
patients with more complex, lengthy and difficult operations in a rather poorer general condition 
were less likely to recover soon and have their oral medication. These are however the type of 
patients that is more likely to end up with cardiovascular complications. The propensity score indeed 
showed that patients with aortic aneurysms and high cardiac risk were more likely to be in the statin 
withdrawal group. However, in multivariate analysis the propensity score was included to minimize 
the potential bias resulting from this.
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ABSTRACT
Background: Coronary plaque instability due to the stress of surgery is an important cause of 
adverse cardiac events after vascular surgery. We hypothesized that lipid lowering therapy with anti-
inflammatory effects would stabilize coronary plaques, prevent rupture and improve postoperative 
outcome.
Methods: In this double-blind, placebo-controlled trial, statin naïve patients were randomly assigned 
to receive, in addition to beta-blocker, either 80 mg fluvastatin extended release once daily or placebo, 
starting 37 days prior to surgery. Interleukin-6 and C-reactive protein were measured at randomiza-
tion and prior to surgery. The primary endpoint was the occurrence of myocardial ischemia, defined 
as transient ECG abnormalities and troponin T release within 30 days after surgery. The secondary 
endpoint was the composite of cardiac death and myocardial infarction.
Results: Two hundred fifty patients were assigned to fluvastatin and 247 to placebo. Interleukin-6 
and C-reactive protein levels remained unchanged in the placebo group (-4% and +3% respectively) 
and decreased in the fluvastatin group (-33% and -21% respectively, P<0.001). The incidence of 
myocardial ischemia in the fluvastatin and placebo groups was, respectively, 10.8% vs. 19.0%, hazard 
ratio 0.55; 95% confidence interval [CI] 0.34 to 0.88. The incidence of cardiac death or myocardial 
infarction was 4.8% vs. 10.1%, hazard ratio 0.47; 95% CI 0.24 to 0.94. Importantly, fluvastatin use was 
not associated with an increased risk for myopathy, liver dysfunction or all-cause death.
Conclusions: In patients undergoing vascular surgery, fluvastatin therapy is associated with an 
improved postoperative cardiac outcome and a reduction of inflammation activity.
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INTRODuCTION
Vascular patients are at high risk for postoperative cardiac events, such as myocardial infarction (MI) 
and cardiac death. Cardiac events occur in up to 24 percent in high-risk cohorts1 and are related to 
the high incidence of underlying coronary artery disease. Hertzer et al, routinely performing coro-
nary angiography in 1000 patients scheduled for vascular surgery, found that only 8% had a normal 
coronary artery tree2.
Although the pathophysiology of perioperative MI is not entirely understood, it is well accepted 
that coronary plaque rupture, leading to thrombus formation and subsequent vessel occlusion, 
plays an important role. The surgical stress response elicits a catecholamine surge with associated 
hemodynamic stress, vasospasm, reduced fibrinolytic activity, platelet activation, and consequent 
hypercoagulability3. Inflammatory processes in general and monocyte-derived macrophages in 
particular, play a critical role in coronary plaque progression and plaque destabilization.
Large trials in the non-surgical population have shown a beneficial role for long-term 3-hydroxy-
3-methylglutaryl co-enzyme A reductase inhibitors (statins) on cardiac outcome4. These effects are 
related to a reduction of low-density lipoprotein (LDL) cholesterol levels and inflammation5. Reduc-
tion in inflammation might, independent of patients’ cholesterol levels, prevent coronary plaque 
destabilization induced by the stress of surgery. So far, no adequately powered placebo-controlled 
trial has been conducted to assess the effect of statins on postoperative outcome6.
We therefore conducted a single-center, double-blind placebo-controlled trial: the Dutch Echo-
graphic Cardiac Risk Evaluation Applying Stress Echo III (DECREASE III) trial. We hypothesized that 
perioperative statin therapy with fluvastatin extended release would reduce the perioperative 
incidence of adverse cardiac events in patients undergoing elective vascular surgery.
METhODS
Study participants
All patients over 40 years of age scheduled for non-cardiac vascular surgery at Erasmus MC, Rot-
terdam, the Netherlands, between June 2004 and April 2008 were candidates for inclusion in the 
trial. Patients had to be scheduled for abdominal aortic aneurysm repair, abdominal aortic stenosis 
surgery, lower limb arterial reconstruction or carotid artery stenosis repair. Furthermore, patients 
were to have at least 51 points on the pre-specified risk index (appendix A).
Exclusion criteria for the trial were: (1) current statin therapy, (2) contraindication for statin therapy, 
(3) surgery which interferes with continuous 12-lead ECG recording, such as thoracic and upper 
abdominal surgery, (4) emergency surgery, (5) unstable coronary artery disease, (6) extensive stress 
induced myocardial ischemia suggestive for left main disease or equivalent, (7) previous participation 
in this study, (8) reoperation within 30 days of an initial surgical procedure.
All patients were on perioperative beta-blockers according to the DECREASE protocols7. Patients on 
chronic beta-blocker therapy continued their medication, otherwise bisoprolol 2.5 mg once a day 
was initiated at the screening visit. The beta-blocker dose was adjusted at admission to surgery to 
achieve a resting heart rate of 60 to 65 beats per minute. The same dose was continued postopera-
tively except in patients who were unable to take medication orally. In these patients, heart rate was 
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monitored continuously at the intensive care unit or hourly at the ward, and intravenous metoprolol 
was administered to maintain a target heart rate of 60-65 beats per minute. The heart rate and blood 
pressure were measured immediately before each scheduled dose of beta-blockers. Beta-blockers 
were withheld if the heart rate was <50 beats/min or the systolic blood pressure was <100 mm Hg.
Study intervention
Patients were randomized to receive either placebo or fluvastatin extended release (Novartis, Basel, 
Switzerland) at a dose of 80 mg once daily. Placebo was identically supplied and formulated. Treat-
ment was started at the outpatient clinic on the day of randomization, at a median of 37 days prior 
to the surgical procedure and was continued for at least 30 days after surgery. Patients remained on 
the same treatment allocation throughout the study. A computer-generated randomization list was 
drawn up by the study statistician and given to the pharmacy department. Independent pharmacists 
dispensed either active or placebo drugs according to this computer generated randomization list. 
The researchers responsible for seeing the patients allocated the next available number on entry 
into the trial. Study personnel and participants were blinded to the treatment assignment for the 
duration of the study. The treatment assignment code was broken when recruitment, data entry and 
laboratory analyses were complete.
Study objectives
The objective of this trial was to study the relationship between fluvastatin therapy and the incidence 
of cardiac complications in patients undergoing non-cardiac vascular surgery.
Study outcomes
The primary study outcome was the occurrence of myocardial ischemia, defined as the composite 
of transient electrocardiographic signs of ischemia and troponin T release. Electrocardiographic 
monitoring was performed using continuous ECG registration in the 48 hours following surgery and 
ECG recordings on days 3, 7 and 30. Troponin T measurements were performed on days 1, 3, 7, and 30. 
If patients were discharged prior to day 7, troponin T was measured at the day of discharge.
Electrocardiographic data were initially processed by a technician and analyzed by 2 experienced 
cardiologists who were blinded to the patient’s clinical data. After excluding all abnormal QRS 
complexes, the ambulatory ECG recordings were analyzed for ST segment deviations. A continuous 
ST segment trend was generated, and all potential ischemic episodes were identified. Episodes of 
ischemia were defined as reversible ST segment changes, lasting at least 1 minute and shifting from 
baseline to more than 0.1 mV (1 mm). ST segment change was measured 60 ms after the J point. If the 
J point fell within the T-wave, the ST segment change was measured 40 ms after that point.
The secondary endpoint was the composite of cardiovascular death and nonfatal MI. All deaths were 
classified as either cardiovascular or non-cardiovascular. Cardiovascular death was defined as any 
death with a cardiovascular complication as the primary or secondary cause, and includes deaths 
following myocardial infarction, cardiac arrhythmia, resuscitation, heart failure, or stroke. Non-
cardiovascular death was defined as any death with a primary non-cardiovascular cause, including 
surgery-related bleeding complications, cancer, trauma and infection. Sudden death in a previously 
stable patient was considered as cardiovascular8.
A nonfatal MI was defined if any two of the following criteria occurred: (1) characteristic ischemic 
symptoms lasting > 20 minutes; (2) ECG changes including acute ST elevation followed by appearance 
of Q waves or loss of R waves, or new left bundle branch block, or new persistent T wave inversion for 
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at least 24 hours, or new ST segment depression which persisted for at least 24 hours; (3) a positive 
troponin T measurement with characteristic rise and fall9.
The other secondary study outcome was the relationship between fluvastatin and inflammatory 
markers, i.e. high-sensitivity C-reactive protein and Interleukin-6, and their relation to postopera-
tive cardiac events. These markers were measured prior to initiation of treatment and on the day of 
admission for the surgical procedure.
The safety outcome measures included: (1) creatinine kinase (CK) elevations; (2) alanine aminotrans-
ferase (ALAT) elevations; (3) myopathy; (4) rhabdomyolysis. Blood samples were drawn prior to 
randomization, on the day of hospital admission and on days 1, 3, 7, and 30 after surgery. Study drug 
was withheld if ALAT levels exceeded by more than 3-fold the upper limit of normal, or if CK levels 
exceeded by more than 10-fold the upper limit of normal, or if patients experienced myopathy or 
rhabdomyolysis.
Sample size
Based on previous study results the anticipated incidence of the primary endpoint, perioperative 
myocardial ischemia, was 18.0% in the placebo group. Treatment with fluvastatin was expected to be 
associated with a 50% relative risk reduction. A sample size of 500 – 250 in each treatment group – 
would yield over 80% power to detect the anticipated 50% risk reduction associated with fluvastatin 
therapy, with an α = 0.05 (two-sided).
Statistical analysis
The time to the first occurrence of the primary efficacy endpoint was determined according to the 
Kaplan-Meier method, and differences between allocated groups were evaluated by log-rank sta-
tistics. The Cox proportional hazards model was applied to obtain treatment effects on the primary 
and secondary efficacy endpoints, which are presented as hazard ratio’s (HR) and 95% confidence 
intervals (CI). The assumption of proportional hazards (PH) was assessed by visual judgment of the 
log-minus-log survival plots. These plots demonstrated reasonably parallel lines, indicating that the 
PH assumption was not violated. Analyses of other endpoints were based on Mann-Whitney U tests, 
independent-samples T tests and chi-square tests. Exploratory analyses for the primary outcome 
were evaluated with the use of tests for interaction for baseline features. All analyses were performed 
according to the intention-to-treat principle. All statistical tests were 2-sided, and a p-value <0.05 was 
considered significant.
RESuLTS
Baseline characteristics
Patient characteristics are presented in TABLE 22.1. Of the 497 patients included 253 (51%) had a 
baseline total cholesterol level of less than 5.5 mmol per liter and 194 (39%) had a baseline LDL-
cholesterol level of less than 3.0 mmol per liter (TABLE 22.2).
The primary analysis was intention-to-treat and included all patients who were randomly assigned 
to either fluvastatin or placebo. Between randomization and the surgical procedure no patient expe-
rienced an adverse cardiac outcome. Four patients did not receive the intended treatment strategy; 
3 patients allocated to fluvastatin did not take the study drug and 1 patient allocated to placebo 
mistakenly received preoperative statin treatment because of elevated cholesterol levels. In total 34 
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(6.8%) patients discontinued study treatment due to side effects; 16 (6.4%) in the fluvastatin group 
and 18 (7.3%) in the placebo group. After surgery, study treatment was temporarily discontinued 
in 115 (23%) patients because of an inability to take the study drug orally (appendix B, CONSORT 
flowchart).
Primary Outcome
Myocardial ischemia was detected in 74 (14.9%) patients within 30 days of the initial vascular surgical 
procedure. A total of 27/250 (10.8%) patients allocated to fluvastatin reached the primary endpoint 
compared to 47/247 (19.0%) patients allocated to placebo treatment (HR 0.55; 95% CI 0.34-0.88, 
FIGURE 22.1A). Hence, the number needed to treat (NNT) to prevent one patient experiencing myo-
cardial ischemia was 12 patients.
Secondary Outcome
A total of 18 (3.6%) patients died within 30 days after surgery of which 12 (67%) deaths were attribut-
able to cardiovascular causes. Eight patients allocated to placebo died due to cardiovascular causes 
versus 4 patients allocated to fluvastatin. Additionally, 25 (5.0%) patients experienced a nonfatal MI; 
Table 22.1 Clinical characteristics, medication use, and type of surgery*.
Placebo Fluvastatin
N=247 N=250
Age – yr 65.8 ± 11.5 66.0 ± 10.5
Male – no. (%) 178 (72) 194 (78)
Risk factors
 Myocardial infarction – no. (%) 66 (27) 73 (29)
 Angina pectoris – no. (%) 59 (24) 52 (21)
 Congestive heart failure – no. (%) 19 (8) 13 (5)
 Diabetes mellitus – no. (%) 42 (17) 55 (22)
 CVA or TIA – no. (%) 66 (27) 75 (30)
 Renal insufficiency – no. (%) 31 (13) 23 (9)
 Hypertension – no. (%) 143 (58) 142 (57)
 COPD – no. (%) 71 (29) 74 (30)
Medication use
 Beta-blocker – no. (%) 247 (100) 250 (100)
 Antiplatelet therapy – no. (%) 146 (59) 160 (64)
 Anticoagulant therapy – no. (%) 73 (30) 62 (25)
 ACE-inhibitor – no. (%) 73 (30) 76 (30)
 Calciumantagonist – no. (%) 59 (24) 56 (22)
 A-II antagonist – no. (%) 37 (15) 40 (16)
 Nitrates – no. (%) 23 (9) 20 (8)
 Prednison – no. (%) 63 (26) 54 (22)
 Diuretics – no. (%) 78 (32) 64 (25)
Surgery
 Carotid artery surgery – no. (%) 32 (13) 37 (15)
 Abdominal aortic surgery – no. (%) 115 (47) 121 (48)
  Open surgery – no. (%) 54 (22) 58 (23)
  Endovascular surgery – no. (%) 61 (25) 63 (25)
 Lower limb arterial surgery – no. (%) 100 (41) 92 (37)
*CVA denotes cerebrovascular accident, TIA transient ischemic attack, COPD chronic obstructive pulmonary disease, ACE 
angiotensin-converting enzyme and A-II angiotensin II.
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17 patients allocated to placebo and 8 patients allocated to fluvastatin. The combined endpoint of 
cardiovascular death and nonfatal MI was reached in 37 (7.4%) patients. A total of 12/250 (4.8%) 
patients allocated to fluvastatin therapy reached the combined endpoint, compared to 25/247 
(10.1%) allocated to placebo. Hence, fluvastatin therapy was associated with a 53% relative reduction 
in the incidence of cardiovascular death or nonfatal MI (HR 0.47; 95% CI: 0.24-0.94, FIGURE 22.1B). The 
NNT for the composite endpoint of cardiovascular death or nonfatal MI was 19.
The median baseline high-sensitivity C-reactive protein level was 5.93 mg per liter; levels were similar 
in patients allocated to fluvastatin (5.93 mg per liter) or placebo (5.80 mg per liter). At hospital admis-
sion, median 37 days after randomization, fluvastatin treated patients had a median decrease in high-
sensitivity C-reactive protein levels of 21% compared with an increase of 3% in the placebo group 
(p<0.001, TABLE 22.2). The median Interleukin-6 levels at baseline were similar in patients allocated 
Table 22.2
Levels of lipids and inflammatory markers at baseline and at day of admission after a median 
treatment of 37 days.
Placebo Fluvastatin P-value
Level at baseline
Cholesterol (mmol/l)
 Total 5.30 ± 1.20 5.40 ± 1.14 0.34
 LDL 3.26 ± 0.93 3.36 ± 1.06 0.27
 HDL 1.53 ± 0.70 1.61 ± 0.81 0.27
Triglycerides (mmol/l) 1.46 1.63 0.67
 Median – interquartile range (1.07 to 2.32) (1.28 to 2.30)
High-sensitivity C-reactive protein (mg/l) 5.80 5.93 0.32
 Median – interquartile range (3.00 to 10.40) (2.42 to 10.89)
Interleukin-6 (pg/ml) 8.76 8.55 0.80
 Median – interquartile range (2.54 to 15.66) (1.26 to 16.59)
Level before surgery
Cholesterol (mmol/l)
 Total 5.09 ± 1.16 4.32 ± 0.79 <0.001
 LDL 3.16 ± 0.91 2.55 ± 0.84 <0.001
 HDL 1.55 ± 0.51 1.59 ± 0.53 0.40
Triglycerides (mmol/l) 1.62 1.64 0.90
 Median – interquartile range (1.18 to 2.40) (1.26 to 2.36)
High-sensitivity C-reactive protein (mg/l) 6.00 4.66 0.02
 Median – interquartile range (2.90 to 11.90) (1.99 to 8.83)
Interleukin-6 (pg/ml) 8.45 5.75 0.005
 Median – interquartile range (2.28 to 15.35) (1.00 to 11.41)
Percent change from baseline
Cholesterol
 Total - 3.9 ± 4.6 - 19.0 ± 9.6 <0.001
 LDL - 3.1 ± 6.4 - 23.2 ± 11.4 <0.001
 HDL + 4.3 ± 14.8 + 2.5 ± 16.1 0.20
Triglycerides 0 + 1.0 0.58
 Median – interquartile range (-10.2 to 19.4) (-23.8 to 32.1)
High sensitivity C-reactive protein +3.3 - 20.5 <0.001
 Median – interquartile range (-20.5 to 30.3) (-26.8 to -12.0 )
Interleukin-6 -4.2 - 32.7 <0.001
 Median – interquartile range (-16.7 to 10.2) (-42.3 to -21.6)
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to fluvastatin (8.55 pg per milliliter) or placebo (8.76 pg per milliliter), and were significantly lower at 
the time of surgery in patients on fluvastatin (-33% vs -4%, p=<0.001).
Adverse events
The proportion of patients experiencing a CK increase >10 times upper limit of normal was 4.0% in 
the fluvastatin group and 3.2% in the placebo group, respectively (TABLE 22.3). The median peak CK 
level was 141 U per liter in patients assigned to fluvastatin and 113 U per liter in patients assigned 
to placebo (p=0.24). The proportion of patients with significant increase in ALAT levels (i.e. > 3 times 
upper limit of normal) was 3.2% in the fluvastatin group and 5.3% in the placebo group. The median 
peak ALAT level was 24 U per liter in patients allocated to fluvastatin and 23 U per liter in patients 
allocated to placebo (p=0.43). Myopathy or rhabdomyolysis within 30 days after surgery was not 
reported.
Table 22.3 Safety measures of statin use*.
Placebo Fluvastatin P-value
N=247 N=250
Discontinuation of treatment
 Temporarily – no. (%) 54 (22) 61 (24) 0.53
 Permanently – no (%) 18 (7.3) 16 (6.4) 0.73
CK > 10x ULN – no. (%) 8 (3.2) 10 (4.0) 0.81
CK  (U/L), median – interquartile range 113 (66-369) 141 (77-380) 0.24
ALAT > 3x ULN – no. (%) 13 (5.3) 8 (3.2) 0.27
ALAT (U/L), median – interquartile range 23 (15-37) 24 (17-50) 0.43
Myopathy – no. (%) - -
Rhabdomyolysis – no. (%) - -
All-cause death – no. (%) 12 (4.9) 6 (2.4) 0.14
Non-cardiovascular death – no. (%) 4 (1.6) 2 (0.8) 0.40
*CK denotes creatinine kinase , ULN upper limit of normal, U/L units/liter, and ALAT alanine aminotransferase.
0
5
10
15
20
0 7 14 21 28
M
yo
ca
rd
ia
l i
sc
he
m
ia
 (%
)
Days after surgery
HR 0.55; 95% CI 0.34-0.88
Fluvastatin
Placebo
0 7 14 21 28
Days after surgery
HR 0.47; 95% CI: 0.24-0.94
0
5
10
15
C
ar
di
ov
as
cu
la
r d
ea
th
 o
r M
I (
%
)
Fluvastatin
Placebo
Figure 22.1a Kaplan–Meier curves of the cumulative 
probability of perioperative myocardial 
ischemia (primary outcome).
Figure 22.1b Kaplan–Meier curves of the cumulative 
probability of perioperative cardiovascular 
death or nonfatal MI (secondary outcome).
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Exploratory findings
The relative difference with regard to the primary outcome of perioperative myocardial ischemia 
between the groups assigned to fluvastatin or placebo was consistent across multiple exploratory 
subgroup analyses (FIGURE 22.2). In light of recent concerns about the safety of perioperative beta-
blockers we also evaluated the incidence of stroke. Three patients suffered a nonfatal postoperative 
stroke; 2 (0.8%) in patients allocated to placebo and 1 (0.4%) to fluvastatin.
DISCuSSION
In our study, we compared fluvastatin extended release 80 mg once daily, initiated 37 days prior to 
vascular surgery, with placebo in statin-naive patients with mean total cholesterol of 5.35 mmol per 
liter. We showed that fluvastatin reduced the risk of perioperative myocardial ischemia. Though the 
trial was not powered for this endpoint, we also found a reduction in the composite of cardiovascular 
death and nonfatal MI while the safety profile appeared to be favorable. Furthermore, fluvastatin 
treatment was associated with a significant decrease in inflammatory activity, reflected by a reduc-
tion in high-sensitivity C-reactive protein and Interleukin-6 levels.
The exact pathophysiology of perioperative cardiac events remains complex. Autopsy studies suggest 
that approximately half of fatal MIs are attributable to a sustained myocardial oxygen-demand sup-
ply mismatch while coronary plaque rupture is accountable for the other half10,11. It is thought that 
statins might be particularly well suitable for influencing the latter pathophysiological mechanism by 
stabilizing unstable coronary plaques. Factors leading to unstable coronary plaques are complex. In 
general, the risk of plaque rupture is related to two factors: intrinsic plaque morphology characteris-
tics and an extrinsic force triggering plaque disruption12,13. Although it has been proven that statins 
Overall 47/247 27/250
No 36/193 18/189
Yes 11/54 9/61
High 20/49 13/54
Intermediate 22/141 14/141
< 5.5 mmol/l 26/125 15/128
> 5.5 mmol/l 21/122 12/122
< 3.0 mmol/l 16/92 12/102
> 3.0 mmol/l 31/155 15/148
< 5.0 mg/l 20/111 8/111
> 5.0 mg/l 27/136 19/139
Endovascular 8/61 2/63
Open 39/186 25/187
< 70 years 21/147 10/138
> 70 years 26/100 17/112
Low 5/57 0/41
Temporary discontinuation
Cardiac risk
Baseline total cholesterol
Baseline LDL cholesterol
Baseline hsCRP
Type of surgery
Age
Placebo FluvastatinSubgroup
No. events/no. patients
Hazard ratio (95% CI) Pheterogeneity
0.78
0.24
0.37
0.54
0.94
0.42
0.54
Fluvastatin better Placebo better
10.1 10
Figure 22.2 Hazard ratios for the primary outcome of myocardial ischemia according to post hoc specified baseline 
characteristics.
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are capable of positively altering plaque morphology, it is implausible that this would occur within 
a few weeks, however, statins might play a pivotal role in counteracting the extrinsic factors causing 
plaque disruption. The pleiotropic effects of statins include several plaque-stabilizing effects such as 
the increased expression of endothelial nitric oxide synthase, the reduced production of endothe-
lin-1, and the generation of reactive oxygen species, an improvement of the thrombogenic profile, 
and importantly, a reduction in inflammation via the reduced expression of inflammatory cytokines, 
chemokines, adhesion molecules, and a lowering of C-reactive protein levels14,15. As demonstrated 
by the findings from the DECREASE III trial fluvastatin reduces inflammatory activity within weeks 
even in patients without hypercholesterolemia. Whether, indeed, the decrease in inflammation is 
responsible for the beneficial effects of perioperative statin use remains unclear.
These findings on the perioperative benefits of statins are in line with previous retrospective studies 
and one small randomized trial. In the double-blind randomized trial 100 patients were allocated 
to 20 mg atorvastatin or placebo once a day for 45 days, irrespective of their serum cholesterol 
levels16. Vascular surgery was performed on average 31 days after randomization, and patients 
were followed up over 6 months. During these 6 months of follow-up, atorvastatin significantly 
reduced the incidence of cardiac events (8% vs 26%, p=0.03). Though not powered to assess 30-day 
postoperative outcome there was a clear trend indicating the beneficial effect of statins: 3 (6%) of 
patients on atorvastatin had a nonfatal MI or cardiac death versus 9 (18%) in the placebo group (OR 
0.23, 95% CI 0.09-1.30). This relative risk reduction was similar to the 4.5-fold relative risk reduction in 
perioperative mortality that was found in a case control study conducted by our group comparing 
chronic statin users with non-users (adjusted OR 0.22, 95% CI 0.10 to 0.47)17. Since then several other 
retrospective studies have reported a potential beneficial effect for perioperative statin use with 
respect to various cardiovascular outcomes with ORs ranging from 0.24 to 0.71.18-20 The findings of 
the DECREASE III trial, with a relative risk reduction of 45% for myocardial ischemia and 53% for the 
composite of cardiac death or nonfatal MI, are consistent with these previous reports. Importantly, 
we found no heterogeneity of effects in patients with several different baseline characteristics, such 
as clinical cardiac risk, cholesterol levels, type of surgery and inflammatory status.
A concern with perioperative statin treatment is the inability to avoid treatment interruption when 
oral administration is not feasible in the early postoperative phase. This might be potentially hazard-
ous as sudden withdrawal of statins in the non-surgical setting has been associated with diminished 
beneficial effect. In a cohort study the GRACE-investigators observed that 428 patients with an acute 
coronary syndrome who stopped statins had the same risk for the composite of late death, stroke, 
and myocardial infarction as non-users21. In contrast, 3,628 patients who continued statin therapy 
throughout the admission had a significant 34% relative risk reduction compared to non-users. In the 
present study, in approximately a quarter of patients fluvastatin had to be interrupted for a median 
of 2 days after surgery. However, when corrected for baseline characteristics and type of surgery, we 
did not observe a significant increase in adverse outcome in patients who interrupted fluvastatin 
compared with those who continued on fluvastatin treatment (OR 1.1, 95% CI 0.48-2.52). To our 
knowledge the relationship between the time course or extent of a possible rebound in inflammation 
or of thrombogenic effects following statin interruption after surgery and specific pharmacokinetic 
or pharmacodynamic characteristics of statins has not been investigated. However, the present find-
ings support the hypothesis that fluvastatin extended release therapy is capable of bridging a period 
of one to two days after surgery, when oral intake is not yet feasible.
Recent guidelines, based on retrospective studies, from the American College of Cardiology/Ameri-
can Heart Association (ACC/AHA)22 and the TransAtlantic Inter-Society Consensus document on the 
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treatment of patients with peripheral arterial disease23 indicate that statin use is appropriate for 
patients undergoing vascular surgery with or without other clinical risk factors. The results of the 
current study confirm these recommendations. It should also be noted that current guidelines state 
that long-term treatment with a statin is indicated for all patients with peripheral arterial disease. 
However, the timing of initiation of statin therapy remained a matter of debate. Should the patient 
start with statin therapy at the preoperative screening visit while there is (1) a possible increased 
risk for perioperative statin-induced side effects such as myopathy, as suggested by the ACC/AHA/
NHLBI clinical advisory on the use and safety of statins, (2) a possibly increased cardiac risk if statin 
therapy has to be interrupted in the perioperative period, as is to be expected in approximately 25% 
of patients, and (3) the evidence supporting the perioperative use of statins is based on retrospective 
studies. With the results of DECREASE III it now seems clear that the benefit of perioperative statin 
use outweigh the risks. To initiate or continue statin treatment during preoperative screening of 
candidates for vascular surgery should therefore be considered in order to prevent cardiovascular 
events during the immediate perioperative period as well as for long-term cardiac risk reduction in 
these patients.
In conclusion, fluvastatin therapy is associated with an improved postoperative cardiac outcome and 
a reduction of inflammation activity in patients undergoing vascular surgery, irrespective of baseline 
cholesterol levels. It should be emphasized that the findings of the current study do not imply that 
statins are to be prescribed for all patients undergoing non-cardiac surgery. Vascular surgery patients 
represent a group of patients with a high atherosclerotic burden and a high cardiac risk. Results from 
further trials will be necessary in order to make firm conclusions on the effectiveness of perioperative 
statin use in non-vascular patients.
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Appendix A.  Erasmus MC risk index
AGE __ __  POINTS
≤ 40 years 0
41 – 50 5
51 – 60 10
61 – 70 15
71 – 80 20
> 80 25
GENDER __ __  POINTS
Female 0
Male 1
TYPE OF SURGERY   3  0    POINTS
Vascular 30
PROCEDURE __ __  POINTS
Endovascular 0
Open 5
CLINICAL RISK FACTORS __ __  POINTS
CAD 2
Renal Failure 2
DM 5
Hypertension 5
Heart failure 10
TOTAL __ __  POINTS
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Appendix B. Flowchart of the DECREASE III study
      
Assessed for eligibility
(n= 1669)
Excluded  (n=1172)
  Not meeting inclusion criteria
(n=356)
  Statin users
(n=798)
  Other reasons 
(n=18)
Analyzed  (n= 250)
Lost to follow-up at 30 days (n=0)
Temporarily discontinued intervention
  (n= 61)
Permanently discontinued intervention
(n=16)
Allocated to Fluvastatin
 (n=250)
Received allocated intervention
 (n=247)
Did not receive allocated intervention
  (n=3)
Lost to follow-up at 30 days (n= 0)
Temporarily discontinued intervention
(n= 54)
Permanently discontinued intervention
(n=18)
Allocated to Placebo
 (n=247)
Received allocated intervention
 (n=246)
Did not receive allocated intervention
   (n=1)
Analyzed  (n=247)
Allocation
Analysis
Follow-Up
Enrollment
Randomization
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Management of patients with cardiac stents 
undergoing non-cardiac surgery
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ABSTRACT
Purpose of review: Coronary stenting is performed in over 4 million patients annually. Approximately 
5% of these patients undergo a non-cardiac surgical procedure within 1 year after stenting. Surgery 
might induce hypercoagulability. This causes increased concern on the effects of previous coronary 
stenting on postoperative cardiac outcome, in particular in-stent thrombosis. On the other hand, 
patients with multiple cardiac risk factors are at high risk for postoperative adverse cardiac events 
and might even benefit from preoperative prophylactic coronary revascularization.
Recent findings: Early non-cardiac surgery after coronary stent placement is associated with an 
increased risk of major adverse cardiac events. The majority of these events are attributable to in-stent 
thrombosis. Antiplatelet therapy interruption in the perioperative period seems to be associated with 
an increase in adverse cardiac events, in particular in patients who undergo non-cardiac surgery early 
after coronary stenting. Furthermore, prophylactic coronary revascularization for high cardiac risk 
patients is not associated with an improved outcome.
Summary: Early non-cardiac surgery after coronary stenting increases the risk of postoperative 
cardiac events. Interruption of antiplatelet therapy seems to play an important role in this increased 
event rate. Prophylactic coronary revascularization in cardiac stable, but high-risk patients does not 
seem to improve outcome.
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INTRODuCTION
Percutaneous coronary angioplasty with stenting is commonly used for treatment of symptomatic 
coronary artery disease, with annually over 4 million stents being implanted worldwide. The intro-
duction of stents has reduced the incidence of restenosis, one of the major drawbacks of coronary 
angioplasty, and proved to be an alternative treatment for bypass surgery. However, uncoated stents 
still have a restenosis rate of about 15-30%1,2. Recently, drug-eluting stents were introduced as a 
means to lower restenosis rates even further. Since then drug eluting stents have been implanted 
in nearly 6 million patients worldwide3. To prevent early in-stent thrombosis all patients receiving a 
coronary stent are prescribed dual antiplatelet therapy for a certain period, depending on the type of 
stent used. However, there is an increased concern on late thrombosis in coronary stents, in particular 
in drug eluting stents, which might be attributable to interruption of antiplatelet therapy4.
It is estimated that approximately 5% of patients who undergo coronary stenting requires some form 
of non-cardiac surgery within 1 year after stenting5. Since non-cardiac surgery is known to induce 
hypercoagulability, this causes increased concern on the effects of previous coronary stenting on 
postoperative cardiac outcome, in particular in-stent thrombosis. On the other hand, patients with 
multiple cardiac risk factors are at high risk for postoperative adverse cardiac events and might even 
benefit from preoperative prophylactic coronary revascularization.
This article will review recent literature on the topic of non-cardiac surgery in patients with coronary 
stents, in particular perioperative antiplatelet therapy and timing of surgery. Furthermore, recent 
evidence on the issue of preoperative prophylactic coronary revascularization in high-risk patients 
scheduled for non-cardiac surgery will be reviewed.
Bare metal stents and non-cardiac surgery
The introduction of bare metal stents has reduced the incidence of restenosis, one of the major 
drawbacks of coronary angioplasty. However, initially stent placement causes complete denudation 
of the arterial endothelial surface and stent struts may damage the media or penetrate into the lipid 
core inducing inflammatory and coagulation activity. These factors temporarily increase the risk 
of in-stent thrombosis until a neo intima has been formed. Fortunately, the introduction of dual-
antiplatelet therapy (aspirin and clopidogrel) has overcome this complication and reduced the rate 
of in-stent thrombosis to less than 1%. According to the guidelines of the ACC/AHA bare metal stents 
require at least one month of dual antiplatelet therapy for the prevention of early in-stent thrombosis 
and life-long aspirin therapy6.
Several reports have been published on the influence of timing on the risk of non-cardiac surgery 
after bare metal coronary stent placement. In 2000 Kaluza et al. reported a shocking perioperative 
mortality rate of 32% in 25 patients who underwent non-cardiac surgery within 2 weeks after stent 
placement7. Importantly 75% of these deaths were attributable to cardiac complications. One addi-
tional patient experienced a myocardial infarction but survived because of an emergency PTCA. In 
contrast, no patient who underwent surgery after 2 weeks after stent placement died. Similar trends 
of high complication rates early after surgery were found in other studies. In the study of Sharma et al. 
a mortality rate of 26% was found in 27 patients undergoing surgery within 3 weeks after bare metal 
stent placement versus only 5% in 20 patients who underwent surgery after this period8.  Recently 
Leibowitz et al confirmed the high mortality rate in patients with recent coronary stent placement; 
24% of patients with surgery within 2 weeks died versus 9% of patients who had surgery after 2 
weeks9.
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Other reports suggest that surgery after bare metal stenting should be postponed at least 6 weeks. 
The analysis of the Mayo Clinic database showed a mortality rate of 4% in 168 patients who under-
went surgery within 6 weeks after bare metal stent placement versus no deaths in the group of 39 
patients in whom surgery was performed at least 6 weeks after stent placement10. Reddy and Vaitkus 
found similar results: 25% mortality in patients operated within 6 weeks versus again no mortality in 
patients operated at least 6 weeks after bare metal stent placement11.
A recent review of 10 studies encompassing a total of 980 patients who underwent non-cardiac sur-
gery after coronary stent placement also showed that studies with a short median interval between 
stenting and non-cardiac surgery reported higher cardiac complication rates as compared to reports 
with longer median time interval. Importantly, when studies with a longer median interval between 
coronary stenting and non-cardiac surgery are evaluated in more detail, patients with early surgery 
experienced more cardiac events than those with late surgery (Schouten et al, in press).
Because of the complete denudation of the arterial endothelial surface and stent struts damaging 
the media or penetrating into the lipid core inducing inflammatory and coagulation activity, patients 
undergoing bare metal stenting are at increased risk for in-stent thrombosis within the first weeks 
after stent placement. As mentioned, the introduction of dual-antiplatelet therapy has overcome 
this complication. However in patients undergoing non-cardiac surgery antiplatelet therapy is often 
interrupted in the perioperative period because of the fear for excessive bleeding. Possibly, the inter-
ruption of antiplatelet therapy in the crucial first weeks after stent placement, while the patient is in 
a hypercoaguable state, is the explanation for the catastrophic outcome in most studies reporting 
on the outcome of patients undergoing non-cardiac surgery shortly after coronary stenting. Unfor-
tunately, not all studies provided data on the number of patients that stopped antiplatelet therapy 
prior to surgery. However, if data were available, there was a clear trend towards a higher incidence 
of perioperative events after stopping antiplatelet therapy. In the report of Kaluza et al. 6 out of 8 
patients who died in the perioperative period were without antiplatelet therapy7. The same trend was 
found by Sharma et al.; 86% of patients who discontinued antiplatelet therapy died perioperatively 
versus only 5% in the group of patients who continued antiplatelet therapy8. Recently data from the 
Erasmus MC database confirmed this finding in a study of 192 patients. In particular in patients with 
early non-cardiac surgery there was a marked difference in major adverse cardiac events between 
patients who discontinued antiplatelet therapy and those who continued; 30% vs. 0% respectively 
for patients who stopped and continued antiplatelet therapy12.
Drug eluting stents and non-cardiac surgery
Drug eluting stents have been introduced to lower the incidence of restenosis after coronary stent 
placement even more than bare metal stents. The use of these stents has grown exponentially over 
the last few years and over 6 million drug eluting stent have been used worldwide. As stated in an 
editorial by Shuchman in a recent issue of the New England Journal of Medicine, the Food and Drug 
Administration states that drug-eluting stents are safe and effective for discrete and relatively short 
lesions (up to 28 mm in the case of one approved stent and up to 30 mm in the other) in relatively 
small, native blood vessels (2.5 to 3.5 or 3.75 mm in diameter). However, drug-eluting stents are also 
widely used on an off-label basis for longer lesions, larger vessels, and multivessel lesions3. If indeed 
5% of patients with a drug eluting stent require some form of non-cardiac surgery within 1 year 
after coronary stent placement, at least 300,000 patients with a drug eluting stent have underwent 
non-cardiac surgery. However in literature only little is known on the influence of drug eluting stents 
in patients undergoing non-cardiac surgery.
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In a recent study of 192 patients, including 99 patients with drug eluting stents, undergoing non-
cardiac surgery there was no difference in the incidence of perioperative major adverse cardiac 
events between patients with drug eluting stents and those with bare metal stents (2.2% vs. 3.0%, 
p=0.70)12. In line with reports of bare metal stents patients undergoing early surgery were at higher 
risk. In this study the definition of early surgery was based on the duration of which clopidogrel 
was required during the pivotal trials that led to approval of the devices and is contained in their 
labels (i.e. 3 months after sirolimus and 6 months after paclitaxel eluting stent placement). A report 
by Compton et al also suggested a low risk of complications in patients with drug eluting stents 
undergoing non-cardiac surgery in their study of 41 surgical procedures. In these patients aspirin and 
clopidogrel were continued during the perioperative period in 78% and 41%, respectively13.
Recently concerns have risen on the optimal dual antiplatelet therapy after drug eluting stents. Though 
the above mentioned two small reports on drug eluting stent and non-cardiac surgery suggested a 
relatively low incidence of cardiac events after non-cardiac surgery, the concerns on the duration of 
dual antiplatelet therapy requires attention. What happens if clopidogrel is stopped early, i.e. within 
3-6 months, after DES placement? The PREMIER registry showed that up to 1 in every 7 patients dis-
continues clopidogrel within 1 month after placement14. Importantly, those patients who stopped 
clopidogrel therapy prematurely had a 9-fold increased risk for mortality during the first 11 months 
after stent placement. Iakovou et al. found similar results in their analysis of 2229 patients; those 
who discontinued antiplatelet therapy too early had an 89-fold increased risk for in-stent thrombosis 
during a follow-up of 9 months15. Recent studies showed that even if clopidogrel is stopped after 
the recommended 3 to 6 months those who continue clopidogrel therapy have a better survival 
and less late in-stent thrombosis compared to those patients who discontinued clopidogrel and had 
only single (i.e. aspirin) antiplatelet therapy after this time period. These studies, including CREDO, 
support a prolonged therapy of at least 1 year of dual antiplatelet therapy, especially in patients with 
a recent acute coronary syndrome16. This observation has recently been confirmed by a study of 
Eisenstein et al.17 They reported the results of a cohort of 1501 patients treated with DES and found 
that patients who were still on clopidogrel therapy at 6 and 12 months after stent placement had a 
significantly better cardiac event free survival and overall survival after up to 24 months of follow-up. 
This suggests that a prolonged or even life-long period of dual antiplatelet therapy might be neces-
sary to prevent late in-stent thrombosis in DES. The devastating effects of late in-stent thrombosis 
were shown by the BASKET-LATE investigators: 88% of in-stent thrombosis presented as a myocardial 
infarction or death18.
Bleeding risk of continued perioperative antiplatelet therapy
Prolonged dual antiplatelet therapy might reduce the risk for in-stent thrombosis, especially in 
patients with a drug eluting stent. However, dual antiplatelet therapy in the perioperative period 
might be associated with an increased risk for bleeding complications.
In their extensive review on the impact of antiplatelet therapy on perioperative bleeding complica-
tions, Harder et al. concluded that monotherapy with aspirin or clopidogrel alone usually does not 
have to be discontinued in the perioperative period19. This conclusion was confirmed in the meta-
analysis of Burger et al. In 41 studies including a total of 49,590 patients undergoing a variety of 
non-cardiac surgical procedures (14,981 on perioperative aspirin, and 34,609 not on aspirin) they 
found that aspirin continuation led to a 1.5 times increased risk of bleeding complication but not 
to a higher level of the severity of bleeding complications20. They concluded that based on their 
meta-analysis aspirin should only be discontinued perioperatively if “bleeding risks with increased 
mortality or sequels are comparable with the observed cardiovascular risks after aspirin withdrawal”. 
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Since patients who undergo surgery early after coronary stent placement are at high risk for adverse 
cardiac events, the cardiovascular risk of these patients exceeds the risk for bleeding risk with 
increased mortality or sequels in the majority of non-cardiac surgical procedures. In fact vascular 
surgical procedures, such as carotid endarterectomy are performed while antiplatelet therapy is 
continued, without an increase in major bleeding complications.
Another issue of perioperative antiplatelet therapy in the perioperative period is the type of anesthe-
sia to be used, in particular if neuraxial block is warranted. Several studies have shown that neuraxial 
block can be safely performed if a patient without a history of bleeding disorders is on aspirin21,22. 
Whether clopidogrel or even double antiplatelet therapy increases the risk of a neuraxial haematoma 
remains to be determined. As mentioned in the current guidelines of the American Society of Regional 
Anesthesia and Pain Medicine (ASRA), NSAIDs seem not to be associated with added significant risk 
for the development of spinal haematoma in patients having epidural or spinal anesthesia. However, 
the same guidelines suggest stopping clopidogrel 7 days prior to surgery23.
In patients also receiving venous thrombosis prophylaxis by means of low-molecular weight 
heparin (LMWH) neuraxial block seems to be contra-indicated. As the majority of surgical procedures 
require thrombosis prophylaxis by means of LMWH, a neuraxial block is probably not feasible in most 
patients with a recent history of coronary stenting.
However, as with the interruption of perioperative antiplatelet therapy, the benefits and risks of 
each type of anesthesia should be considered and an individualized patient approach should be 
applied.
Preoperative prophylactic coronary revascularization in high-risk patients scheduled 
for non-cardiac surgery.
Patients with multiple cardiac risk factors scheduled for major surgery are at increased risk of 
perioperative cardiac complications. According to the guidelines of the American College of Car-
diology /American Heart Association (ACC/AHA), it is highly recommended to refer these patients 
for non-invasive cardiac stress testing prior to surgery24. The guidelines also recommend coronary 
angiography for patients with high-risk noninvasive test results, and myocardial revascularization in 
patients with prognostic high-risk anatomy in whom long-term outcome is likely to be improved. 
This recommendation was supported by the Coronary Artery Surgery Study that showed a reduced 
incidence of non-fatal myocardial infarctions after previous bypass surgery among vascular surgery 
patients compared to those treated medically, 8.5 vs. 0.6% (p = 0.001)25. More recently, the data from 
the Bypass Angioplasty Revascularization Investigation trial showed that bypass surgery and percu-
taneous coronary intervention had similar low rates of postoperative cardiac events in non-cardiac 
surgery26. However, these studies were not designed to assign the optimal strategy in severely ill 
patients with extensive coronary artery disease immediately prior to major non-cardiac surgery. In 
addition, these studies could not address the concern of delaying the non-cardiac surgical procedure 
because of testing, revascularization, and initiation of antiplatelet therapy since the time between 
revascularization and non-cardiac surgery in these studies was respectively 4.1 and 2.4 years.
The randomized Coronary Artery Revascularization Prophylaxis (CARP) trial was the first study that 
addressed the strategy of prophylactic revascularization compared to optimal medical therapy in 
patients with clinically stable coronary artery disease who were scheduled for major non-cardiac 
vascular surgery27. This trial showed that prophylactic revascularization was safe but did not improve 
perioperative or long-term outcome. The long-term (median follow-up 2.7 years) mortality was 22% 
in patients allocated to prophylactic coronary revascularization, compared to 23% in the medical 
only strategy, p=0.92. Also the incidence of perioperative non-fatal myocardial infarction was similar, 
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respectively 12 and 14%, p = 0.37. However, it must be noted that the majority of patients in the 
CARP trial had only 1 or 2 vessel disease. The recently conducted DECREASE V randomized pilot study 
in which the majority of patients had 3-vessel disease also showed no perioperative and long-term 
(follow-up 1 year) benefit of prophylactic coronary revascularization28. The findings of both CARP 
and DECREASE V support the current guidelines of the ACC/AHA on perioperative management in 
high-risk patients to reserve revascularization only for cardiac unstable patients. After successful non-
cardiac surgery these patients should be regularly screened for the presence of ischemic complaints 
and aggressive anti-ischemic therapy, both medical and invasive, should be considered. In these 
patients at high risk scheduled for major non-cardiac vascular surgery prophylactic revascularization 
might be switched to late revascularization, preventing the delay of surgery.
Patients with unstable coronary artery disease or significant left main disease might still benefit from 
preoperative prophylactic revascularization. In this respect it should be noted that aside from the 
inclusion criteria from the pivotal randomized trials for drug eluting stents, the current guidelines 
of the European Society of Cardiology suggest that there are other applications for DES that might 
be associated with improved outcome compared to BMS; small vessels, chronic total occlusions, 
bifurcational/ostial lesions, bypass stenosis, insulin-dependent diabetes mellitus, multi-vessel dis-
ease, unprotected left main stenosis, and in-stent restenosis29. However, these indications are for 
patients with an ACS and are not specifically issued for prophylactic revascularization. Furthermore, it 
should be noted that DES requires a prolonged period of dual antiplatelet therapy and consequently, 
if one is not willing to operate under dual antiplatelet regimen, a postponement of the index surgical 
procedure.
Conclusion
Early non-cardiac surgery after coronary stent placement is associated with an increased risk of 
major adverse cardiac events. The majority of these events are attributable to in-stent thrombosis. 
Antiplatelet therapy interruption in the perioperative period seems to be associated with an increase 
in adverse cardiac events, in particular in patients who undergo non-cardiac surgery early after 
coronary stenting. Furthermore, prophylactic coronary revascularization for high cardiac risk patients 
scheduled for major surgery seems not to be associated with an improved perioperative or long-term 
outcome.
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Percutaneous coronary intervention (PCI), angioplasty with stenting is commonly used for treatment 
of symptomatic coronary artery disease. The introduction of stents has reduced the incidence of 
restenosis, one of the major drawbacks of coronary angioplasty, and proved to be an alternative 
treatment for bypass surgery. This strategy may be attractive compared to bypass surgery in patients 
scheduled for general surgery as the delay of the index surgical procedure is prevented. However, 
initially stent placement causes complete denudation of the arterial endothelial surface and stent 
struts may damage the media or penetrate into the lipid core inducing inflammatory and coagula-
tion activity. These factors temporarily increase the risk of in-stent thrombosis until a neo intima has 
been formed. Fortunately, the introduction of dual-antiplatelet therapy (aspirin and clopidogrel) has 
overcome this complication and reduced the rate of in-stent thrombosis to less than 1%.
However, recent stent placement might be potentially harmful for patients undergoing non-cardiac 
surgery. Surgery increases the thrombosis risk due to a perioperative stress response including 
sympathetic activation promoting sheer stress on arterial plaques, enhanced vascular reactivity 
conducive to vasospasm, reduced fibrinolytic activity, platelet activation, and hypercoagulability. In 
addition, while the surgical patient is in a hypercoagulable state dual antiplatelet therapy is often 
interrupted because of the fear for excessive bleeding complications during surgery.
This double-edged sword of coronary stenting, prevention of cardiac complications on one hand and 
an excess of bleeding risk on the other, remains a controversial issue in perioperative management. 
Therefore we have reviewed the currently available evidence on stent related complications in the 
perioperative period in which timing of surgery and antiplatelet strategy seems to play a pivotal 
role.
A systematic electronic search of published reports on Medline was undertaken to identify studies 
published between January 1995 and October 2006 in English language that reported on periop-
erative cardiac outcome after non-cardiac surgery in patients with a history of PCI with stenting. To 
identify eligible studies the following Medical Subject Heading terms, or a combination of these, were 
used: stent; myocardial revascularization; surgery; postoperative complications; mortality; myocardial 
infarction, and perioperative care. Furthermore, we examined the reference lists of identified articles 
and published recommendations for perioperative cardiac risk management. Eventually, a total of 
ten relevant studies were identified1-10. Pertinent data from the selected studies were extracted 
independently by two investigators.
The ten studies encompass a total of 980 patients who underwent non-cardiac surgery after coronary 
stent placement. The median time from PCI to non-cardiac surgery ranged from 13 to 284 days. The 
majority of reports included bare metal stent use and only 2 recent studies reported the outcome of 
drug eluting stents8,10. Perioperative myocardial infarction and death were common complications, 
with myocardial infarction rates ranging from 2% to 28% and death from 3% to 20% (FIGURE 24.1). 
Studies with a short median interval between PCI and non-cardiac surgery reported higher cardiac 
complication rates as compared to reports with longer median time interval. Importantly, when stud-
ies with a longer median interval between PCI and non-cardiac surgery are evaluated in more detail, 
patients with early surgery experienced more cardiac events than those with late surgery (TABLE 
24.1). Discontinuation of antiplatelet therapy is an important factor in this respect. Unfortunately, not 
all studies provided data on the number of patients that stopped antiplatelet therapy prior to surgery. 
However, if data were available, there was a clear trend towards a higher incidence of perioperative 
events after stopping antiplatelet therapy. In the report of Kaluza et al. 6 out of 8 patients who died in 
the perioperative period were without antiplatelet therapy1. The same trend was found by Sharma et 
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al.; 86% of patients who discontinued antiplatelet therapy died perioperatively versus only 5% in the 
group of patients who continued antiplatelet therapy3. Recently we confirmed this finding in a study 
of 192 patients. In particular in patients with early non-cardiac surgery there was a marked difference 
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Figure 24.1 Incidence of perioperative complications in studies with different median times between percutaneous 
transluminal coronary angioplasty plus stenting and non-cardiac surgery.1–10
MI = myocardial infarction.
Table 24.1 Incidence of perioperative events in non-cardiac surgery after coronary stent placement.
Study Time to surgery N Mortality Myocardial Infarction
Wilson et al. 4 < 6 weeks 168 4% 6%
> 6 weeks 39 0 0
Kaluza et al.1 < 2 weeks 25 32% 28%
> 2 weeks 15 0 0
Sharma et al.3 < 3 weeks 27 26% 22%
> 3 weeks 20 5% 10%
Reddy et al.2 < 6 weeks 16 25% 38%
> 6 weeks 40 0 0
Brichon et al.5 < 3 months 32 3% 9%
Godet et al.9 5-8 weeks 78 5% 9%
Schouten et al.10 Early* 30 13% 13%
Late* 162 2% 0.6%
Leibowitz et al.6 < 2 weeks 29 24% 7%
> 2 weeks 65 9% 8%
Vicenzi et al.7 < 35 days 22 72%**
35-90 days 25 44%**
> 90 days 56 34%**
* Early surgery was defined as within 1 month after bare metal stenting, within 3 months after sirolimus drug
eluting stenting, and within 6 months after paclitaxel drug eluting stenting.
** Not only perioperative events but also events < 3 months within surgery are included. Events were
defined as: cardiac death, myocardial infarction, re-percutaneous coronary interventions, congestive heart
failure, unstable angina, significant arrhythmias, and myocardial cell injury.
The study of Ward et al. is not included in this table since they did not report the incidence of adverse events separately for 
PCI + stent procedures.
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in major adverse cardiac events (30% vs. 0% respectively for patients who stopped and continued 
antiplatelet therapy)10.
The minimal period in which antiplatelet therapy should be prescribed prior to non-cardiac surgery 
is ill-defined. A period of four weeks seems to be too short as shown by the study of Brichon et 
al. In a group of 20 patients two experienced perioperative in-stent thrombosis, suggesting that a 
prolonged period of antiplatelet therapy may be required5. A period of six weeks is supported by 
the results of the studies of Wilson4 and Reddy2.  In a group of 79 patients undergoing non-cardiac 
surgery after an interval of six weeks no major cardiac events occurred. These results were questioned 
by the study of Vicenzi et al. In 56 patients who underwent non-cardiac surgery more than 90 days 
after PCI the cardiac event rate was as high as 34% within 3 months after surgery7. However, it should 
be taken into account that in a number of patients antiplatelet therapy was stopped 3 days prior 
to non-cardiac surgery which may be related to adverse outcome.  Ferrari et al. showed that stop-
ping antiplatelet therapy, even after a long period since stenting (mean time between stenting and 
withdrawal 15.5 ± 6.5 months), was a significant risk factor for adverse cardiac events11.
In conclusion, the current available literature suggests that non-cardiac surgery after PCI with stent-
ing should be delayed at least 6 weeks and dual antiplatelet therapy is associated with improved 
outcome.
REFERENCES
 1. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE: Catastrophic outcomes of noncardiac surgery soon 
after coronary stenting. J Am Coll Cardiol 2000; 35: 1288-94
 2. Reddy PR, Vaitkus PT: Risks of noncardiac surgery after coronary stenting. Am J Cardiol 2005; 95: 755-7
 3. Sharma AK, Ajani AE, Hamwi SM, Maniar P, Lakhani SV, Waksman R, Lindsay J: Major noncardiac surgery 
following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv 2004; 63: 141-5
 4. Wilson SH, Fasseas P, Orford JL, Lennon RJ, Horlocker T, Charnoff NE, Melby S, Berger PB: Clinical outcome 
of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll 
Cardiol 2003; 42: 234-40
 5. Brichon PY, Boitet P, Dujon A, Mouroux J, Peillon C, Riquet M, Velly JF, Ris HB: Perioperative in-stent throm-
bosis after lung resection performed within 3 months of coronary stenting. Eur J Cardiothorac Surg 2006; 
30(5): 793-6
 6. Leibowitz D, Cohen M, Planer D, Mosseri M, Rott D, Lotan C, Weiss AT: Comparison of cardiovascular risk 
of noncardiac surgery following coronary angioplasty with versus without stenting. Am J Cardiol 2006; 
97: 1188-91
 7. Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H: Coronary artery stenting and non-
cardiac surgery--a prospective outcome study. Br J Anaesth 2006; 96: 686-93
 8. Ward HB, Kelly RF, Thottapurathu L, Moritz TE, Larsen GC, Pierpont G, Santilli S, Goldman S, Krupski WC, 
Littooy F, Reda DJ, McFalls EO: Coronary artery bypass grafting is superior to percutaneous coronary 
intervention in prevention of perioperative myocardial infarctions during subsequent vascular surgery. 
Ann Thorac Surg 2006; 82: 795-800; discussion 800-1
 9. Godet G, Riou B, Bertrand M, Fleron MH, Goarin JP, Montalescot G, Coriat P: Does preoperative coronary 
angioplasty improve perioperative cardiac outcome? Anesthesiology 2005; 102: 739-46
 10. Schouten O, Van Domburg RT, Bax JJ, de Jaegere PJ, Dunkelgrun M, Feringa HH, Hoeks SE, Poldermans D: 
Noncardiac Surgery After Coronary Stenting: Early Surgery and Interruption of Antiplatelet Therapy Are 
Associated With an Increase in Major Adverse Cardiac Events. J Am Coll Cardiol 2007; 49: 122-124
 11. Ferrari E, Benhamou M, Cerboni P, Marcel B: Coronary syndromes following aspirin withdrawal: a special 
risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-9

Chapter 25
A clinical randomized trial to evaluate the 
safety of a noninvasive approach in high-risk 
patients undergoing major vascular surgery: 
the DECREASE-V Pilot Study
Don Poldermans
Olaf Schouten
Radosav Vidakovic
Jeroen J. Bax
Ian R. Thomson
Sanne E. Hoeks
Harm H.H. Feringa
Martin Dunkelgrün
Peter J. de Jaegere
Alexander Maat
Marc R.H.M. van Sambeek
Miklos D. Kertai
E. Boersma
J Am Coll Cardiol. 2007;49(17):1763-9.
Ch
ap
te
r 2
5
288
ABSTRACT
Background: Prophylactic coronary revascularization in vascular surgery patients with coronary 
artery disease does not improve postoperative outcome. If a beneficial effect is to be expected, then 
at least those with extensive coronary artery disease should benefit from this strategy. The purpose of 
this research was to perform a feasibility study of prophylactic coronary revascularization in patients 
with preoperative extensive stress-induced ischemia.
Methods: One thousand eight hundred eighty patients were screened, and those with ≥ 3 risk fac-
tors underwent cardiac testing using dobutamine echocardiography (17-segment model) or stress 
nuclear imaging (6-wall model). Those with extensive stress-induced ischemia (≥ 5 segments or ≥ 3 
walls) were randomly assigned for additional revascularization. All received beta-blockers aiming at 
a heart rate of 60 to 65 beats/min, and antiplatelet therapy was continued during surgery. The end 
points were the composite of all-cause death or myocardial infarction at 30 days and during 1-year 
follow-up.
Results: Of 430 high-risk patients, 101 (23%) showed extensive ischemia and were randomly assigned 
to revascularization (n = 49) or no revascularization. Coronary angiography showed 2-vessel disease 
in 12 (24%), 3-vessel disease in 33 (67%), and left main in 4 (8%). Two patients died after revascular-
ization, but before operation, because of a ruptured aneurysm. Revascularization did not improve 
30-day outcome; the incidence of the composite end point was 43% versus 33% (odds ratio 1.4, 95% 
confidence interval 0.7 to 2.8; p = 0.30). Also, no benefit during 1-year follow-up was observed after 
coronary revascularization (49% vs. 44%, odds ratio 1.2, 95% confidence interval 0.7 to 2.3; p = 0.48).
Conclusions: In this randomized pilot study, designed to obtain efficacy and safety estimates, 
preoperative coronary revascularization in high-risk patients was not associated with an improved 
outcome.
DECREASE V 289
INTRODuCTION
Patients with multiple cardiac risk factors scheduled for major vascular surgery are at increased 
risk of perioperative cardiac complications. According to the guidelines of the American College of 
Cardiology/American Heart Association (ACC/AHA), it is highly recommended to refer these patients 
for noninvasive cardiac stress testing before surgery1. The guidelines also recommend coronary 
angiography for patients with high-risk noninvasive test results, and myocardial revascularization in 
patients with prognostic high-risk anatomy in whom long-term outcome is likely to be improved.
However, noninvasive testing may delay surgery and run the risk of aortic aneurismal rupture or exac-
erbation of critical limb ischemia. Furthermore, coronary revascularization is commonly performed 
by percutaneous coronary intervention (PCI) with stent placement instead of bypass surgery (CABG). 
Although this approach prevents further delay of the index surgical procedure, it necessitates the 
prolonged use of extensive antiplatelet therapy, which may aggravate the risk of perioperative bleed-
ing complications. But temporary discontinuation of antiplatelet therapy is potentially harmful, as it 
may lead to in-stent thrombosis2,3.
The current ACC/AHA recommendations are based on small observational, noncontrolled studies 
and expert opinion4,5. The usefulness of the strategy of prophylactic revascularization was not 
confirmed by the recently completed CARP (Coronary Artery Revascularization Prophylaxis) random-
ized trial6. In this trial, the incidence of perioperative myocardial infarction was similar in patients 
allocated to prophylactic revascularization versus those allocated to optimal medical therapy (12% 
vs. 14% events). There was also no beneficial effect observed during long-term follow-up. However, 
it should be realized that the vast majority of patients included in the CARP trial had single- or 2-ves-
sel disease with a preserved left ventricular function. Indeed, based on previous research from our 
group, sufficient cardioprotection by medical therapy can be expected in these patients, which may 
explain the CARP trial findings7. In contrast, patients with multiple cardiac risk factors and extensive 
stress-induced myocardial ischemia are insufficiently protected7.
Hence, if a beneficial effect of the invasive strategy of prophylactic revascularization is to be expected, 
then at least patients with extensive coronary artery disease should benefit from this strategy. We 
therefore undertook the DECREASE (Dutch Echocardiographic Cardiac Risk Evaluation Applying 
Stress Echo)-V pilot study to assess the feasibility and to obtain initial efficacy and safety estimates for 
the design of an adequately powered randomized controlled clinical trial in these patients.
METhODS
Patients
This study was conducted during 2000 to 2005 in 6 hospitals in Belgium (until 2001), Brazil (until 2001), 
the Netherlands, Italy, Serbia, and Montenegro. The early cessation in participation to the study of 2 
centers was due to logistic reasons. A total of 1,880 patients undergoing elective open abdominal 
aortic or infrainguinal arterial reconstruction were screened for the prevalence of cardiac risk factors 
(FIGURE 25.1). These included age over 70 years, angina pectoris, prior myocardial infarction on the 
basis of history or a finding of pathologic Q waves on electrocardiography, compensated congestive 
heart failure or a history of congestive heart failure, drug therapy for diabetes mellitus, renal dysfunc-
tion (serum creatinine >160 μmol/l), and prior stroke or transient ischemic attack7. Patients with at 
least 3 risk factors underwent cardiac stress testing before surgery. All patients who experienced 
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extensive stress-induced ischemia were enrolled in the DECREASE-V pilot study. All patients provided 
informed consent, and the study was approved by the Erasmus Medical Center Medical Ethics Com-
mittee and local research ethics committees.
Cardiac testing
Left ventricular ejection fraction (LVEF) was measured from resting echocardiographic images using 
the biplane Simpson’s rule. Cardiac stress testing was performed by dobutamine echocardiography 
or dobutamine or dipyridamole perfusion scintigraphy, as previously described8,9. Test results were 
scored by the extent of stress-induced ischemia using a 17-segment model in dobutamine echocar-
diography and a 6-wall model in stress perfusion scintigraphy. Limited ischemia was defined by 
the presence of 1 to 4 ischemic segments or 1 to 2 ischemic walls, whereas extensive ischemia was 
defined by ≥ 5 ischemic segments or ≥ 3 ischemic walls.
Allocated treatment
Perioperative beta-blocker therapy was installed in all patients at the screening visit, regardless of 
test results. A computer algorithm was used at each center to assign patients with extensive stress-
induced ischemia randomly, in a 1:1 ratio, to 1 of the 2 strategies. The sealed envelope method was 
used to conceal treatment allocation, and it was assured that envelopes were opened in consecutive 
order. Patients were randomized to either an invasive approach followed by revascularization or a 
Scheduled for major vascular surgery (N=1880)
Inclusion (N=101)
Randomization (N=101)
Not meeting inclusion criteria (N=1779)
No risk factors (N=462)
1 or 2 risk factors (N=988)
>3 risk factors but no or mild ischemia on stress testing (N=329)
Revascularization  (N=49) No revascularization  (N=52)
30-day follow-up (N=49) 30-day follow-up (N=52)
Surgery (N=46) 
Cardiovascular death
or nonfatal MI (N=3)
Surgery (N=52)           
Figure 25.1 Flowchart of the study.
Cardiac risk factors included age over 70 years, angina pectoris, prior myocardial infarction (MI) on the 
basis of history or a finding of pathologic Q waves on electrocardiography, compensated congestive 
heart failure or a history of congestive heart failure, current treatment for diabetes mellitus, renal 
dysfunction (serum creatinine >160 μmol/l), and prior stroke or transient ischemic attack. Patients with 
≥3 risk factors and extensive ischemia were randomly (1:1) assigned to coronary revascularization.
DECREASE V 291
noninvasive approach. Quantitative analysis of all coronary angiographies was reviewed centrally at 
Erasmus Medical Center, Rotterdam, the Netherlands, by 2 experienced cardiologists. They assessed 
independently the number of affected vessels. The mode of revascularization, CABG or PCI with 
stenting, was decided by the treating physicians, based on coronary anatomy and the possible delay 
of the index surgical procedure. Patients allocated to the medical-only strategy were referred for 
surgery without further delay.
Beta-blocker therapy
Patients on chronic beta-blocker therapy continued their medication. Patients without beta-blockers 
started with bisoprolol 2.5 mg once a day at the screening visit. Beta-blocker dose was adjusted in 
all patients at admission to the hospital and on the day before surgery to achieve a resting heart 
frequency of 60 to 65 beats/min. The same dose of beta-blockers was continued postoperatively 
except in patients who were unable to take medication orally or by nasogastric tube postoperatively. 
In these patients, the heart rate was monitored continuously at the intensive care unit or hourly at 
the ward, and intravenous metoprolol was administered at a dose sufficient to keep the heart rate 
between 60 to 65 beats/min. The heart rate and blood pressure were measured immediately before 
each scheduled dose of beta-blockers. Beta-blockers were withheld if the heart rate was <50 beats/
min or the systolic blood pressure was <100 mm Hg. After discharge, patients continued beta-blocker 
therapy, and dose adjustments were carried out during outpatient visits to achieve a resting heart 
frequency of 60 to 65 beats/min.
Perioperative management
Anesthetic management, monitoring, and other aspects of perioperative management were at the 
discretion of the attending physician. Results of preoperative testing and coronary revascularization 
were discussed with the attending physicians, and hemodynamic management was implemented 
accordingly. Anticoagulant and antiplatelet therapy was continued after PCI and during the index 
surgical procedure. Intraoperative ischemia was treated at the discretion of attending physicians, and 
additional beta-blockers were permitted.
End point definition
All patients were monitored for cardiac events after screening. Twelve-lead electrocardiogram (ECG) 
and serum troponin-T level were systematically determined 1, 3, 7, and 30 days after surgery. Outpa-
tient follow-up was performed at 30 days if a patient had been discharged from the hospital. At the 
outpatient clinic, all patients were screened at 3-month intervals for cardiac events by clinical history 
and 12-lead ECG. All data were collected by the participating centers and evaluated in a blinded 
fashion by members of the adverse-events committee. The primary end point was the composite 
of all-cause death and nonfatal myocardial infarction that occurred between screening and 30-days 
after the index surgical procedure. Patients were followed-up during at least 1 year after surgery, and 
the composite of all-cause death and nonfatal myocardial infarction during this period was consid-
ered as secondary end point. Myocardial infarction within 48 h after CABG was defined as a creatine 
kinase (CK)-MB rise above 5× the local upper limit of normal. Myocardial infarction within 48 h after 
PCI was defined as a CK-MB rise above 3× the upper limit of normal. Myocardial infarction within 30 
days after the index surgical procedure was defined as a positive troponin-T level in combination with 
new Q waves on the ECG lasting more than 0.03 s. In all other situations, myocardial infarctions were 
defined by new Q waves lasting more than 0.03 s.
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Sample size
The purpose of this pilot study was to assess the feasibility of prophylactic revascularization in high-
risk patients scheduled for major vascular surgery, and to obtain initial efficacy and safety estimates 
needed for the design of an adequately powered randomized controlled clinical trial. We aimed for 
the enrollment of 100 patients, 50 in each strategy. Based on the DECREASE-I study7, an incidence 
of 33% of the primary end point was expected in the patients allocated to optimal medical therapy 
only. It was recognized a priori that a modest, but clinically relevant, risk reduction by prophylactic 
revascularization would not be detectable given this sample size. However, if the beneficial effect of 
revascularization was similar to the observations in the CASS (Coronary Artery Surgery Study) registry 
(85% risk reduction associated with prior CABG in vascular surgery), then our study has 93% power 
(type II error of 7%), based on a 2-sided test with a type I error of 5%.
Statistical analysis
All analyses were based on the intention-to-treat principle. Continuous data are presented as median 
values and corresponding 25th and 75th percentiles, whereas dichotomous data are presented as 
percentages. Differences in clinical and surgical characteristics between patients allocated to revas-
cularization or no revascularization were evaluated by Wilcoxon nonparametric tests, chi-square tests, 
or Fisher exact tests, as appropriate. Differences in the incidence of the end points were evaluated 
by a chi-square test. The incidence of events over time was further examined by the Kaplan-Meier 
method, whereas a log-rank test was applied to evaluate differences between the allocated treat-
ment strategies. Analyses were performed according to the intention-to-treat principle. All statistical 
tests were 2-sided, and a p-value <0.05 was considered significant.
RESuLTS
Characteristics of patients
A total of 1,880 vascular surgery patients were enrolled and screened for cardiac risk factors (FIGURE 
25.1), and 430 (23%) were classified as high risk, who were referred for cardiac testing. Testing showed 
extensive ischemia in 101 (22%). Dobutamine echocardiography was performed in 88 (88%), and 
stress scanning in 13 (13%). No serious side effects occurred during stress testing. Of 101 patients 
with extensive stress-induced ischemia, 49 patients were randomized for coronary revascularization. 
A reduced LVEF (<35%) was observed in 43 (43%) patients. No patient had significant valve disease 
such as aortic stenosis or mitral valve regurgitance. Coronary angiography, performed in patients 
allocated to the invasive strategy, showed 2-vessel disease in 12 (24%), 3-vessel disease in 33 (67%), 
and left main disease in 4 (8%). A PCI was performed in 32 patients, using a drug-eluting stent in 
30 and a bare-metal stent in 2, and bypass surgery in 17. There were no differences in the presence 
of ischemic heart disease (i.e. previous myocardial infarction and angina pectoris) or other baseline 
characteristics between the randomized groups (TABLE 25.1). Complete revascularization was 
achieved in 42 (86%). Incomplete revascularization occurred in 7 (15%) patients initially scheduled 
for a percutaneous intervention. Bypass surgery was considered not feasible in these patients as the 
index procedure could not be further delayed. The median duration of revascularization to operation 
was 29 (13 to 65) days in the 17 patients undergoing bypass surgery and 31 (19 to 39) days in the 32 
patients undergoing a percutaneous intervention.
Antiplatelet therapy, using aspirin and clopidogrel, was continued during surgery in all patients 
who underwent a PCI. The median perioperative blood transfusion requirement in patients with and 
without antiplatelet therapy was similar: 2 versus 3 U (p value = 0.25).
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Perioperative cardiac events
Two patients died before vascular surgery because of a ruptured aneurysm after successful bypass 
surgery. Their aortic diameters were, respectively, 62 and 73 mm. In 1 patient, a myocardial infarc-
tion occurred after an incomplete coronary revascularization. This precluded the proceeding of 
the scheduled vascular surgery. Revascularization did not improve 30-day outcome after vascular 
surgery. Troponin elevation was found in 38.8% in the noninvasive group versus 34.7% in the invasive 
group. The incidence of all-cause death or nonfatal myocardial infarction for patients with preopera-
tive revascularization or medical treatment only was 43% versus 33%, respectively (odds ratio [OR] 
1.4, 95% confidence interval [CI] 0.7 to 2.8; p = 0.30) (TABLE 25.2). Also, no difference was observed 
in the incidence of perioperative cardiac events between patients treated by prophylactic bypass 
surgery or percutaneous intervention (41.1% vs. 43.8%, respectively).
Late cardiac events
The incidence of the 1-year end point all-cause death or nonfatal myocardial infarction in high-risk 
patients was 47%. In high-risk patients, no long-term benefit was observed after coronary revascu-
larization; respectively, 49% versus 44% of patients with preoperative revascularization or medical 
treatment only died or experienced a nonfatal myocardial infarction (OR 1.2, 95% CI 0.7 to 2.3; p = 
0.48) (FIGURE 25.2). No patients initially randomized for medical therapy underwent revascularization 
Table 25.1 Baseline characteristics.
Revascularisation No revascularisation
N = 49 N = 52
Age, years – median (interquartile range) 71 (64, 74) 70 (63, 75)
Men – no. (%) 42 (86) 47 (90)
History of diabetes – no. (%) 18 (37) 15 (29)
Current angina pectoris – no. (%) 25 (51) 22 (42)
History of myocardial infarction – no. (%) 49 (100) 50 (96)
History of congestive heart failure – no. (%) 23 (47) 24 (46)
History of cerebrovascular accident – no. (%) 20 (41) 13 (25)
History of renal failure – no. (%) 9 (18) 11 (21)
Aspirin use – no. (%) 37 (76) 30 (58)
Beta-blocker – no. (%) 34 (70) 36 (69)
ACE-inhibitor use – no. (%) 28 (57) 22 (42)
Statin use – no. (%) 34 (69) 30 (58)
Type of surgery  – no. (%)
 Thoraco-abdominal 5 (10) 5 (10)
 Tube graft 11 (22) 14 (27)
 Bifurcated graft 10 (20) 15 (29)
 Femoro-popliteal 23 (47) 18 (35)
Right coronary artery disease – no. (%) 39 (80) -
Left artery descending – no. (%) 46 (94) -
Left circumflex artery – no. (%) 37 (76) -
Left main disease – no. (%) 4 (8) -
Number of diseased vessels  – no. (%)
 1 0 -
 2 12 (24) -
 3 33 (67) -
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within 1 year of follow-up. One patient randomized to the invasive strategy underwent a redo PCI 
because of myocardial infarction in the first year of follow-up.
Implications for a study design
Assuming that the event rates in the 101 studied patients are representative of what would occur 
in the planned study, the required sample size for a randomized study to establish definitively that 
coronary revascularization is superior to medical therapy to improve postoperative outcome in high-
risk patients by 20% (relative risk) compared to optimal medical therapy would be over 300 patients 
per arm. This would require a sample size of 9,000 major vascular surgery patients, of which 2,000 
patients have 3 or more cardiac risk factors at screening.
DISCuSSION
The concept of a beneficial effect of prophylactic coronary revascularization before major vascular 
surgery is based on the assumption that perioperative myocardial infarctions arise at locations in 
coronary arteries with hemodynamically critical stenosis, elicited by the stress of surgery. Preoperative 
coronary revascularization might prevent this devastating event and, in addition, improve long-term 
outcome. This hypothesis was supported by the CASS study that showed a reduced incidence of non-
fatal myocardial infarctions after previous bypass surgery among vascular surgery patients compared 
to those treated medically (8.5% vs. 0.6%, p = 0.001)4. More recently, the data from the BARI (Bypass 
Angioplasty Revascularization Investigation) trial showed that bypass surgery and PCI had similar 
low rates of postoperative cardiac events in non-cardiac surgery5. However, these studies were not 
designed to assign the optimal strategy in severely ill patients with extensive coronary artery disease 
immediately before major vascular surgery. In addition, these studies could not address the concern 
of delaying the vascular surgical procedure because of testing, revascularization, and initiation of 
antiplatelet therapy since the time between revascularization and non-cardiac surgery in these stud-
ies was, respectively, 4.1 and 2.4 years.
The randomized CARP trial was the first study that addressed the strategy of prophylactic revas-
cularization compared with optimal medical therapy in patients with clinically stable coronary 
artery disease who were scheduled for major vascular surgery6. This trial showed that prophylactic 
Table 25.2 Patient outcome.
Revascularisation No revascularisation HR and 95% CI P-value
N=49 N=52
Events prior to surgery
 All cause mortality – no. (%) 2 (4.1) 0 - 0.23
 Myocardial infarction – no. (%) 1 (2.1) 0 -
 Composite – no. (%) 3 (6.1) 0 - 0.11
Events up to 30 days post surgery
 All cause mortality – no. (%) 11 (22.5) 6 (11.5) 2.2 (0.74-6.6) 0.14
 Myocardial infarction – no. (%) 17 (34.7) 16 (30.8) -
 Composite – no. (%) 21 (42.9) 17 (32.7) 1.4 (0.73-2.8) 0.30
Events up to 365 days post surgery
 All cause mortality – no. (%) 13 (26.5) 12 (23.1) 1.3 (0.55-2.9) 0.58
 Myocardial infarction – no. (%) 18 (36.7) 19 (36.5) -
 Composite – no. (%) 24 (49.0) 23 (44.2) 1.2 (0.68-2.3) 0.48
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revascularization was safe but did not improve perioperative or long-term outcome. The long-term 
mortality was 22% in patients allocated to prophylactic coronary revascularization, compared with 
23% in the medical only strategy (p = 0.92). Also, the incidence of perioperative nonfatal myocardial 
infarction was similar, respectively, 12% and 14% (p = 0.37). In the present study, the effect of prophy-
lactic revascularization was comparable to the effect reported by McFalls et al.6, although the study 
population is different. The current study population consisted of 12% women, 43% of the patients 
had a reduced left ventricular function (LVEF <35%), and the vast majority of patients, 75%, had 
3-vessel or left main disease compared with 33% in the CARP trial. In a subgroup of 37 comparable 
patients of the CARP trial (i.e. 3 or more cardiac risk factors and extensive stress-induced ischemia 
assessed by noninvasive testing), prophylactic coronary revascularization was associated with a 
favorable, nonsignificant trend for long-term survival (OR 4.0, 95% CI 0.8 to 19). If a beneficial effect 
of revascularization was to be expected, this should have occurred in the selected population with 
high-risk anatomy. However, this was not observed, although the current study was not powered to 
test this strategy. A study to establish the effect of coronary revascularization would require, based on 
the findings of this pilot study, a screening population of 9,000 patients, of which 2,000 would have 
3 or more risk factors, and of these 600 would have extensive stress-induced ischemia during cardiac 
testing and be eligible for randomization to revascularization.
Our findings support the current guidelines of the ACC/AHA on perioperative management in high-
risk patients to reserve revascularization only for cardiac unstable patients. After successful vascular 
surgery, these patients should be regularly screened for the presence of ischemic complaints, and 
aggressive anti-ischemic therapy, both medical and invasive, should be considered. As shown in 
FIGURE 25.2, a trend was observed for a “catch up” of late cardiac events in patients treated medically. 
In these patients at high risk scheduled for major vascular surgery, prophylactic revascularization 
might be switched to late revascularization, preventing the delay of surgery.
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Figure 25.2 Incidence of all-cause death or myocardial infarction during 1-year follow-up according to the 
allocated strategy in patients with 3 or more cardiac risk factors with extensive stress-induced 
ischemia.
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The apparent lack of benefit of coronary revascularization of the present study is not fully under-
stood. Most likely, patients with stress-induced ischemia not only suffer from a blood flow-limiting 
coronary lesion but also from (multiple) nonsignificant lesions that are vulnerable to rupture due 
to the stress of surgery10. The perioperative stress response, which includes a cytokine response, 
catecholamine surge with associated hemodynamic stress, vasospasm, reduced fibrinolytic activity, 
platelet activation, and consequent hypercoagulability, triggers coronary plaque rupture, leading 
to thrombus formation and subsequent vessel occlusion11,12. Autopsy results have shown that this 
mechanism is responsible for at least half of all perioperative infarctions10,12. These findings are in line 
with dobutamine echocardiography results that show a correlation between the assessment of the 
preoperative culprit coronary lesion and the location of the perioperative myocardial infarction in 
only half of all cases13. Surgical or percutaneous treatment of the culprit coronary lesion(s) apparently 
provides insufficient protection for rupture of these instable lesions.
The optimal perioperative evaluation and management of patients with multiple risk factors and 
extensive stress-induced ischemia remains controversial. Success will depend on careful collaboration 
between cardiologists, anesthesiologists, and surgeons. In patients with aortic aneurysms, a surgical 
repair is performed to reduce the chance of aneurysm-related death. It might be hypothesized that 
abdominal aortic aneurysm repair should not be performed in this high-risk group. As the current 
trial shows, open repair poses an unacceptable 30-day cardiac event rate of approximately 30%, 
whereas the chance of aneurysm rupture is around 9 per 100 person-years. Endovascular treatment 
modalities may be an alternative for these high-risk patients. Although the EVAR (Endovascular Aneu-
rysm Repair)-2 trial showed no benefit of elective endovascular repair in patients deemed unfit for 
open repair because of comorbidities14, these findings were not confirmed in the recently conducted 
study by the Society for Vascular Surgery Outcomes Committee. In a group of 565 high-risk patients, 
matched for the EVAR-2 inclusion criteria, undergoing endovascular repair, perioperative mortality 
was 2.9%. These promising results need to be confirmed in a large study population. Importantly, in 
all cases, an individualized strategy should be performed, weighing the chances of future aneurysms 
rupture or limb salvage instead of amputation and short-term perioperative events.
Conclusions
In this small randomized pilot study, designed to obtain initial efficacy and safety estimates for the 
design of an adequately powered randomized controlled clinical trial, preoperative coronary revas-
cularization in high-risk vascular surgery patients with extensive stress-induced ischemia was not 
associated with an improved postoperative and long-term outcome.
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Non-cardiac surgery early after percutaneous coronary intervention (PCI) with stenting has been 
associated with adverse cardiac events in the perioperative period1,2. However, these reports were on 
patients with bare-metal stents, did not include drug-eluting stents, and did not compare patients 
who continued their antiplatelet therapy during surgery with those who interrupted this therapy. 
Therefore, we conducted the current study.
Patients who underwent non-cardiac surgery between 1999 and 2005 and had a successful PCI 
because of unstable coronary artery disease within the 2 years before surgery were enrolled. The data 
on PCI procedures were part of a prospectively maintained registry including a total of 574 proce-
dures. Data on the surgical procedure, as well as 30-day cardiovascular outcome, were retrospectively 
collected by screening of medical charts. The medical ethics committee of our hospital approved 
the study. All patients underwent PCI using either bare-metal or drug-eluting stents (paclitaxel or 
sirolimus). Patient characteristics included the indication for PCI, the number of affected and stented 
coronary arteries, whether the procedure was successful, left ventricular function, and medication 
use during and after PCI. In addition, cardiac risk factors were scored. Patients with bare-metal stents 
were prescribed lifelong aspirin and clopidogrel for at least 1 month at the discretion of the treating 
physician (median 30 days, interquartile range 30 to 90 days). Patients with drug-eluting stents usu-
ally received lifelong aspirin as well as clopidogrel for at least 3 months (sirolimus, median 90 days, 
interquartile range 60 to 180 days) to 6 months (paclitaxel, median 180 days, interquartile range 180 
to 180 days), or longer at the discretion of the treating physician.
The surgical procedures were categorized according to surgical risk, based on the definition of the 
Revised Cardiac Risk Index3. Furthermore, the cardiac risk factors and medication use assessed during 
the initial PCI procedures were updated at the time of operation and were used to assess the Revised 
Cardiac Risk Index for each patient3. Importantly, there was no protocol for perioperative antiplatelet 
use in the population studied. Consequently, some patients received aspirin and/or clopidogrel 
throughout the surgical procedure, whereas in other patients aspirin and clopidogrel were stopped 
1 week before operation.
Medical charts were reviewed for the composite end point of 30-day major adverse cardiac events 
(MACE), defined as nonfatal myocardial infarction and/or cardiac death as previously defined accord-
ing to guidelines of the American College of Cardiology/European Society of Cardiology4. Patients 
with an increased cardiac risk (i.e. previous PCI) were routinely screened for postoperative cardiac 
end points using serial troponin T and electrocardiographic monitoring on days 1, 3, and 7 after 
surgery. Additional tests were performed at the discretion of the treating physician. Blood loss during 
operation and the necessity and quantity of perioperative transfusion requirements were noted in all 
patients.
In total, 192 patients underwent surgery within 2 years after the initial PCI procedure (TABLE 26.1). 
Patients were arbitrarily divided in an early-surgery group (defined as non-cardiac surgery during 
which clopidogrel was required during the trials that led to approval of these devices and accord-
ing to their labels: bare-metal stents 1 month, sirolimus-eluting stents 3 months, paclitaxel-eluting 
stents 6 months) and a late-surgery group. Thirty patients underwent early surgery according to this 
classification.
During the first 30 postoperative days, 5 patients (2.6%) experienced a MACE (all fatal, see TABLE 26.2 
for characteristics of these patients). In the early-surgery group, 4 MACEs (13.3%) occurred, whereas 
in the late-surgery group, only 1 MACE (0.6%) occurred (Fisher exact test p = 0.002) (TABLE 26.3). In 91 
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patients (47%), antiplatelet medication was interrupted during the perioperative period. There was 
no significant difference in surgical risk between patients in whom antiplatelet therapy (both clopi-
dogrel and aspirin) was interrupted versus those in whom antiplatelet therapy was continued. The 
interruption was associated with a significantly higher incidence of MACE in patients who stopped 
versus those who continued (5.5% vs. 0%, Fisher exact test p = 0.023). In the group of patients with 
a MACE, all 5 patients discontinued antiplatelet therapy, whereas in the group without a MACE, only 
Table 26.1 Baseline characteristics of all patients.
N=192
Medical history – no (%)
 Ischemic heart disease 192 (100)
 Congestive heart failure 5 (3)
 Diabetes mellitus 47 (25)
 Renal impairment 29 (15)
 History of CVA or TIA 23 (12)
Revised Cardiac Risk Index – no (%)
 1 risk factor 65 (34)
 2 risk factors 74 (39)
 3 or more risk factors 53 (28)
Medical therapy – no (%)
 Beta-blockers 131 (68)
 Statins 136 (71)
 Calcium antagonists 50 (26)
 Nitrates 20 (10)
 Diuretics 24 (13)
 ACE-inhibitors 47 (24)
 Antiplatelet therapy during surgery 101 (53)
Coronary stenting – no (%)
 Bare metal 93 (48)
 Drug eluting 99 (52)
 Number of vessels dilated
  1 91 (47)
  2 60 (31)
  3 41 (21)
 Stenting successful 192 (100)
Type of non-cardiac surgery – no (%)
 Abdominal 31 (16)
 Vascular peripheral 30 (16)
 Eye 23 (12)
 Urologic 24 (13)
 Orthopedic 23 (12)
 Renal transplantation 12 (6)
 ENT 10 (5)
 Aortic 9 (5)
 Reconstructive 9 (5)
 Gynaecologic 5 (3)
 Neurologic 4 (2)
 Carotid 3 (2)
 Other 9 (5)
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46% (86 of 187) patients discontinued their antiplatelet therapy. In particular, in patients in whom 
antiplatelet therapy was stopped before the required time for clopidogrel use (early-surgery group), 
the discontinuation of antiplatelet therapy had a detrimental effect: an incidence of MACEs of 30.7% 
in the discontinuation group versus 0% in patients who continued antiplatelet therapy (Fisher exact 
test p = 0.026) (TABLE 26.4). Again, all 4 patients with a MACE discontinued antiplatelet therapy, 
whereas only 35% (9 of 26) of the patients without a MACE discontinued antiplatelet therapy.
There was no difference in the incidence of MACE between patients with drug-eluting stents and 
those with bare-metal stents (2.2% vs. 3.0%, p = 0.70); neither was there a significant difference 
within the early-surgery group (28.6% for bare-metal stents and 8.7% for drug eluting stents, p = 
0.23). Remarkably, in 57% of the patients with bare-metal stents, antiplatelet therapy was interrupted 
in the early-surgery group, whereas antiplatelet therapy was interrupted in 39.1% of the drug-eluting 
stent group.
Excessive blood loss during surgery was noted in the medical charts of 2 patients (1 receiving anti-
platelet therapy). Blood transfusion was required in 44 patients (24% vs. 20% for those who continued 
vs. those who discontinued antiplatelet therapy, respectively, p = 0.50). In patients requiring blood 
Table 26.2 Characteristics of patients with perioperative MACE.
Patient Age gender Type of surgery
Time from 
PCI
Target vessel
Type of 
stent
Aspirin 
withheld
Clopidogrel 
withheld
A 58 M Abdominal 1 LAD Bare metal Yes Yes
B 69 M Esophagectomy 28 RCA, LCx Bare metal Yes Yes
C 64 M Abdominal 30 RCA Paclitaxel Yes Yes
D 47 M ENT 80 RCA, LAD Sirolimus Yes Yes
E 65 M Urologic 253 LAD, RCA, LCx Paclitaxel Yes N/A
Patient Complication
A MI, thrombosis LAD stent (angiography)
B MI, thrombosis RCA stent (autopsy)
C MI, left main thrombosis, no stent thrombosis (autopsy)
D MI, thrombosis LAD stent (ECG)
E MI, thrombosis LAD stent (angiography)
Table 26.3 Incidence of nonfatal MI or cardiac death within 30 days after non-cardiac surgery.
Late Surgery (n = 162) Early Surgery (n = 30)
No MACE 161 (99.4%) 26 (86.7%)
MACE 1 (0.6%) 4 (13.3%)
MACE = major adverse cardiac events; MI = myocardial infarction.
Table 26.4
Incidence of nonfatal MI or cardiac death within 30 days after non-cardiac surgery in patients with early (n = 
30) surgery after PCI who either continued or discontinued antiplatelet therapy.
Late Surgery (n = 162) Early Surgery (n = 30)
No MACE 17 (100%) 9 (69.3%)
MACE 0 (0%) 4 (30.7%)
MACE = major adverse cardiac events; MI = myocardial infarction; PCI = percutaneous coronary intervention.
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transfusion, the number of units of homologues’ blood did not differ between those who continued 
versus those who discontinued antiplatelet therapy (median 2 vs. 3 U, p = 0.51).
This study showed an association between early non-cardiac surgery after coronary artery stenting 
and perioperative adverse cardiovascular events. Importantly, in patients undergoing early surgery, 
discontinuation of antiplatelet therapy during the perioperative period may be a major cause of the 
increase in MACE. The type of stent (i.e. bare-metal or drug-eluting) did not influence cardiovascular 
outcome in this cohort of patients.
In recent studies, an association between early non-cardiac surgery after PCI and adverse cardiac out-
come has been reported as well1,2,5. However, these reports did not include the use of drug-eluting 
stents. The excessive risk of early surgery after PCI might be attributable to the high risk of in-stent 
thrombosis during the perioperative period. This thrombosis risk is possibly increased by the stress 
response to major surgery. The stress response includes sympathetic activation promoting shear 
stress on arterial plaques, enhanced vascular reactivity conducive to vasospasm, reduced fibrinolytic 
activity, platelet activation, and hypercoagulability. Because procoagulant clotting factors increase 
while fibrinolysis decreases, the surgical patient is in a hypercoaguable state. Furthermore, coronary 
stenting results in denudation of the endothelial surface. This might also contribute to the high risk 
of patients with early surgery because re-endotheliazation takes up to 8 weeks. This hypothesis is 
supported by our finding that all MACEs in the early-surgery group occurred in patients in whom 
antiplatelet therapy was discontinued, including 3 events in the 17 patients with bare-metal stents 
in whom antiplatelet therapy was discontinued and 2 events in 9 patients with drug-eluting stents 
without antiplatelet therapy. In contrast to our findings, Reddy et al.5 did not show an association 
between discontinuation of antiplatelet therapy and perioperative MACEs in 56 patients with prior 
bare-metal stenting. This might have been attributable to the small number of events in their study.
The small number of events is also a limitation of the current study. Multivariate analysis could not 
be performed because of this small number. However, the difference found between those patients 
who continued their antiplatelet therapy and those who did not deserves attention, and, until more 
evidence is available, antiplatelet therapy during surgery should be continued unless there is an 
absolute contraindication.
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ABSTRACT
Background: The aim of the present study was to determine the perioperative and long-term cardiac 
outcomes of patients who underwent elective open or endovascular major vascular surgery corrected 
for cardiac risk factors and dobutamine stress echocardiography.
Methods: Patients who underwent either endovascular (n = 123) or open (n = 560) vascular surgery 
from 1996 to 2004 at Erasmus Medical Center were enrolled. Patients were screened for cardiac 
risk factors (advanced age, gender, angina pectoris, myocardial infarction, heart failure, diabetes, 
stroke, renal failure), cardioprotective medication, and the presence of stress-induced ischemia by 
dobutamine stress echocardiography. Postoperative data on troponin release, CK-MB, and electrocar-
diography were routinely collected on days 1, 3, and 7 and before discharge. After discharge, patients 
were regularly screened at the outpatient clinic. The main outcome measures were perioperative and 
long-term cardiac death and myocardial infarction.
Results: The incidence of perioperative cardiac events was significantly less in endovascular-treated 
patients compared with conventionally treated patients, also after adjustment for clinical risk fac-
tors, dobutamine stress echocardiography, and medication (hazard ratio [HR] 0.19, 95% confidence 
interval [CI] 0.07 to 0.53). In contrast, during long-term follow-up (median 3.8 years, range 0 to 8.4), 
the incidence of long-term cardiac mortality and myocardial infarction were similar in the 2 groups 
(HR 0.89, 95% CI 0.52 to 1.52).
Conclusion: Endovascular stent grafting is associated with a reduced incidence of perioperative 
complications compared with open vascular surgery. Despite the initial perioperative survival benefit, 
patients who undergo endovascular surgery remain at high risk for late cardiac events.
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INTRODuCTION
A major limitation of nonrandomized comparative studies between open and endovascular surgical 
procedures conducted so far is the difference in baseline characteristics1. Endovascular therapy is 
reserved for patients with distinct vascular anatomy and may be preferred for patients at high cardiac 
risk. These factors may bias perioperative and long-term mortality. Apart from differences in surgical 
techniques, a number of other factors have been associated with perioperative and late adverse 
cardiac events, including stress-induced myocardial ischemia during dobutamine stress echocar-
diography and cardioprotective medication use2-10. Because these issues have not been addressed 
previously, the present study was conducted to determine the perioperative and long-term cardiac 
outcomes of patients who underwent elective open or endovascular major vascular surgery adjusted 
for differences in clinical and surgical characteristics.
METhODS
The study population was composed of patients who underwent elective abdominal aneurysm or 
iliacofemoropopliteal bypass surgery from January 1996 to January 2004 at Erasmus Medical Center, 
Rotterdam, The Netherlands. Hence, it was a retrospective study of prospectively collected data. The 
medical ethics committee of our hospital approved the study protocol.
Preoperative cardiac risk assessment
All patients were routinely screened for cardiac risk factors, including age, hypertension, angina pec-
toris, previous myocardial infarction, heart failure, stroke, renal failure (serum creatinine >2 mg/dl), 
and diabetes mellitus. Routinely, all patients underwent dobutamine stress echocardiography before 
surgery, evaluating wall motion at rest as a marker of left ventricular function and stress-induced 
new wall motion abnormalities as a marker of ischemia. Dobutamine stress echocardiography 
was performed as previously described, and test results were considered positive if stress-induced 
ischemia occurred11. Perioperative and long-term medication use was noted, including angiotensin-
converting enzyme inhibitors, platelet aggregation inhibitors, β-blockers, calcium antagonists, 
coumarin derivatives, diuretics, nitrates, and statins. Patients unable to take medications orally 
perioperatively were switched to intravenous formulas. If no intravenous formulas were available (i.e. 
statins and angiotensin-converting enzyme inhibitors), oral medications were restarted as soon as 
possible after surgery.
Procedure
The site of procedure was classified as abdominal aneurysm repair and procedures involving the ili-
acofemoropopliteal arteries. All abdominal aneurysms were infrarenal aneurysms, and no suprarenal 
cross clamping was necessary in the open group. The choice of procedure (i.e. open or endovascular) 
was left to the discretion of the treating vascular surgeon and was mainly based on anatomic consid-
erations. For endovascular procedures, locoregional anesthesia was used, and for open procedures, 
a combination of locoregional and general anesthesia was used. During the postoperative period, 
blood and plasma samples for cardiac troponin T, creatinine phosphokinase levels, creatinine phos-
phokinase-MB levels, and electrocardiography were routinely collected on days 1, 3, and 7 and before 
discharge. After discharge, all patients were followed up at the outpatient clinic every 6 months.
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Outcome
The primary outcome of the study was the incidence of perioperative and late cardiovascular events, 
including cardiac death and nonfatal myocardial infarction. Myocardial infarction was defined as the 
presence of 2 of the following 3 criteria: (1) characteristic ischemic symptoms lasting >20 minutes; (2) 
electrocardiographic changes, including acute ST elevation followed by the appearance of Q waves 
or the loss of R waves, new left bundle branch block, new persistent T-wave inversion for ≥ 24 hours, 
or new ST-segment depression persisting >24 hours; and (3) positive troponin T results (i.e. >0.10 ng/
ml) or peak creatine kinase-MB ≥ 8% of elevated total creatinine phosphokinase, with characteristic 
increases and decreases12. Cardiovascular death was defined as any death with a cardiovascular 
cause, including those deaths following cardiac procedures, cardiac arrest, myocardial infarction, 
pulmonary embolus, or stroke, or sudden deaths not ascribed to other causes.
Statistical analysis
Continuous variables are described as mean value (range) and categorical variables as percentage 
frequencies. Univariate differences between patient subgroups were evaluated using Student’s t 
test or the chi-square test as appropriate. Kaplan-Meier survival curves were constructed to assess 
perioperative and long-term cardiac event–free and reintervention-free survival. Multivariate (Cox) 
regression was used to compare cardiac event–free survival after endovascular and open vascular 
surgery. The number of outcome events in the study was limited. Therefore, to avoid overfitting and 
to enable the assessment of the relation between clinical risk factors and the perioperative composite 
end point, we used the Revised Cardiac Risk Index13. Odds ratios and corresponding 95% confidence 
intervals (CIs) are reported. The limit of statistical significance was set at p = 0.05 (2-sided). All analysis 
was performed using the statistical software SPSS for Windows version 10.1 (SPSS, Inc., Chicago, 
Illinois).
RESuLTS
A total of 683 vascular surgery patients were included in the study; 123 patients underwent endo-
vascular procedures, and 560 underwent conventional open vascular surgery. Cardiac risk factors 
and dobutamine stress echocardiographic results for all patients are listed in TABLE 27.1. In total, 
25 patients (3.6%), 21 (3.8%) in the open group and 4 (3.3%) in the endovascular group, underwent 
preoperative coronary revascularization because of extensive stress-induced myocardial ischemia 
during dobutamine stress echocardiography.
Perioperative cardiac outcome
Perioperative cardiac events occurred in 4 (3.1%) patients treated by endovascular procedures and in 
122 (21.8%) patients treated conventionally. The hazard ratio (HR), corrected for cardiac risk factors, 
dobutamine stress echocardiography results, cardioprotective medication, and site of procedure was 
0.19 (95% confidence interval 0.07 to 0.53) in favor of the endovascular treated patients. This improved 
outcome however was only observed in patients undergoing abdominal aortic procedures (HR 0.20, 
95% confidence interval 0.06-0.63, FIGURE 27.1A), while the difference in peripheral procedures was 
not significantly different (HR 0.40, 95% confidence interval 0.05 to 3.22, FIGURE 27.1B). Multivariate 
analysis showed that both beta-blocker use (HR 0.66, 95% confidence interval 0.46-0.95) and statin 
use (HR 0.58, 95% confidence interval 0.39-0.87) were associated with an improved outcome (TABLE 
27.2). In particular for the open group this association was significant. For the endovascular group no 
multivariate analysis could be performed because of the low number of events, i.e. 4 cardiovascular 
complications.
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Table 27.1 Baseline characteristics of the analyzed patients.
Total
(N = 683)
Open
(N = 560)
Endovascular
(N = 123)
Men – no. (%) 532 (77) 423 (76) 106 (86)
Age, years – mean (range) 68 (30-97) 68 (30-93) 69 (40-97)
Peripheral procedure – no. (%) 260 (38) 194 (35) 66 (54)*
Abdominal procedure – no. (%) 423 (62) 366 (65) 57 (46)*
Previous angina pectoris – no. (%) 164 (24) 138 (25) 25(20)
Previous myocardial infarction – no. (%) 252 (37) 224 (40) 28 (22)*
Previous heart failure – no. (%) 66 (10) 56 (10) 10 (8)
CVA or TIA  – no. (%) 90 (13) 83 (15) 6 (6)
Diabetes Mellitus – no. (%) 85 (12) 70 (13) 15 (12)
Systemic hypertension – no. (%) 351 (51) 283 (51) 65 (53)
Renal Failure – no. (%) 53 (8) 46 (8) 7 (6)*
COPD – no. (%) 171 (25) 142 (25) 28 (23)
ACE-inhibitor therapy – no. (%) 193 (28) 165 (30) 27 (22)
Aspirin therapy – no. (%) 225 (33) 191 (34) 34 (28)
Beta-blocker therapy – no. (%) 366 (53) 303 (54) 61 (50)
Ca-antagonist therapy – no. (%) 179 (26) 153 (27) 25 (20)
Warfarin derivates – no. (%) 140 (20) 117 (21) 22 (18)
Diuretic therapy – no. (%) 114 (17) 101 (18) 13 (11)*
Nitrate therapy – no. (%) 96 (14) 88 (16) 8 (7)*
No new wall motion abnormalities  – no. (%) 546 (80) 437 (78) 109 (89)
New wall motion abnormalities – no. (%) 137* (20) 123 (22) 14 (11)‡
Rest wall motion score (mean) – no. (%) 1.32 1.33 1.26
‡ = 58% of patients with new wall motion abnormalities on DSE were on β-blocker therapy. * = p<0.05; COPD = chronic 
obstructive pulmonary disease; ACE = angiotensin converting enzyme; CVA = cerebrovascular accident; TIA = transient 
ischemic attack
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Figure 27.1a Perioperative cardiovascular death or 
myocardial infarction in open abdominal 
vascular surgery (solid line) and 
endovascular abdominal surgery (dotted 
line).
Figure 27.1b Perioperative cardiovascular death or 
myocardial infarction in open peripheral 
surgery (solid line) and endovascular 
peripheral surgery (dotted line).
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Long-term outcome
Cardiovascular events occurred in 125 patients during a median of 3.8 years (range 0 to 8.4). In the 
endovascular group, 20 events occurred, and in the open group, there were 105 events (16% vs. 19%). 
In univariate analysis, there was no difference in survival rates between the endovascular and con-
ventionally treated patients (FIGURE 27.2). After correction for cardiac risk factors, cardioprotective 
medication use, dobutamine stress echocardiographic results, and site of procedure, there was no 
significant difference between the open and endovascular groups (HR 0.89, 95% CI 0.52 to 1.52).
Neither aortic nor iliacofemoral procedures had a cardiovascular event–free survival benefit after 
endovascular treatment (HR 0.31, 95% CI 0.72 to 2.90, and HR 0.59, 95% CI 0.28 to 1.25, respectively). 
Also, the results of the multivariate analysis showed that β-blocker and statin users had significantly 
reduced incidence of long-term cardiac events irrespective of clinical risk factors and type of surgery 
(TABLE 27.3). Stress-induced myocardial ischemia during dobutamine stress echocardiography was 
also associated with late adverse cardiac events (HR 2.63, 95% CI 1.87 to 3.71). During long-term 
Table 27.2
Multivariable predictors and estimated risk of perioperative cardiovascular events, i.e. cardiovascular 
death and mortality.
HR
(95% Confidence interval)
P-value
Endovascular 0.19 (0.07-0.53) 0.001
Abdominal procedure 3.79 (2.29-6.28) <0.001
Revised cardiac risk index
 1 risk factor 1.0
 2 risk factors 1.75 (1.03-2.97) 0.037
 3 or more risk factors 2.72 (1.72-4.29) <0.001
Beta-blocker use 0.66 (0.46-0.95) 0.025
Statin use 0.58 (0.39-0.87) 0.008
HR = Hazard ratio
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Figure 27.2 Long-term cardiovascular death or myocardial infarction in open (solid line) and endovascular (dotted 
line) vascular surgery patients who survived the first 30 postoperative days.
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follow-up, the number of reinterventions due to technical failure was significantly greater in the 
endovascular-treated patients compared with the conventional group (3% vs. 25%, p <0.001). This 
was mainly due to persistent type II endoleaks. This high incidence of reinterventions was not associ-
ated with a higher mortality rate related to the new operative procedures.
DISCuSSION
This study showed that endovascular therapy for the exclusion of an abdominal aortic aneurysm 
was associated with improved perioperative outcomes compared with patients who underwent 
open abdominal aortic aneurysm repair, even after corrections were made for significant cardiac risk 
factors and dobutamine stress echocardiographic results. However, no difference in perioperative 
outcome was observed in patients who underwent either open or endovascular peripheral vascular 
procedures. Patients who underwent endovascular surgery had a lower perioperative cardiac event 
rate, but during long-term follow-up, the cardiac event rate significantly increased and became 
similar to the long-term cardiac event rate of conventionally treated patients.
The results of our study showed that the incidence of perioperative cardiac complications was less 
often observed in patients who underwent endovascular procedures compared with conventional 
vascular procedures. This reduced incidence of perioperative cardiac events is likely to be associated 
with reduced myocardial stress during endovascular procedures2,3,14,15. In patients who undergo 
endovascular procedures, no aortic clamping and declamping are performed; the procedure is done 
under locoregional anesthesia, and in combination with reduced blood loss, a more hemodynamic 
stable condition is achieved16-20. Cuypers et al16 also confirmed these assumptions in an observational 
study of 120 vascular patients. The incidence of perioperative myocardial ischemia was compared 
between 49 patients who underwent endovascular treatment and 71 patients who underwent 
conventional aortic surgical procedures using transesophageal echocardiography and electrocardi-
ography. During aortic clamping and declamping in the conventional surgery group, hemodynamic 
instability occurred, which was associated with a higher incidence of myocardial ischemia16.
The perioperative cardiac event rate of patients who underwent peripheral endovascular procedures 
was also lower compared with the cardiac event rate of patients who underwent conventional sur-
gery. However, after adjustment was made for significant clinical characteristics and cardioprotective 
medications, this association was no longer significant. There are no studies of the perioperative 
outcomes of patients who undergo endovascular or conventional peripheral vascular surgery. The 
lack of a significant association observed in our study is most likely associated with a relatively small 
number of events in these groups of patients. Therefore, future studies are necessary to test these 
findings.
Table 27.3 Multivariable predictors and estimated risk of long term cardiovascular death.
HR
(95% Confidence interval)
P-value
Endovascular 0.89 (0.52-1.52) 0.267
Positive dobutamine stress echocardiography 2.63 (1.87-3.71) <0.001
Beta-blocker use 0.63 (0.45-0.86) 0.004
Statin use 0.62 (0.43-0.88) 0.008
HR = Hazard ratio
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Although the perioperative cardiac complication rate was significantly lower in patients who 
underwent endovascular procedures, surprisingly, the incidence of long-term cardiac mortality was 
similarly high in patients who underwent endovascular or open procedures. Our study period from 
1996 to 2004 was long with regard to endovascular abdominal aneurysm repair, considering that 
endovascular devices have improved substantially. Although this might influence the number of 
required reinterventions, it will probably not change the rate of long-term adverse cardiac events. 
There is considerable research on the late survival of patients who undergo conventional vascular 
surgery, but there are only limited data available about the long-term survival of patients who 
undergo endovascular procedures. May et al21 found that endovascular abdominal aortic aneurysm 
repair was associated with a significantly better 3-year event-free survival rate compared with open 
abdominal aortic aneurysm repair. In contrast, Moore et al22 reported higher and similar long-term 
cardiac mortality rates during an average 5-year follow-up period in patients who underwent endo-
vascular treatment compared with patients who underwent conventional surgery. In agreement 
with these findings, in our study, we also found that the incidence of long-term cardiac mortality 
was similar between the endovascular and conventional surgery groups. This finding also highlights 
the importance of using preoperative cardiac risk evaluation and subsequent long-term cardiac 
risk assessment and management in patients who undergo endovascular procedures. Patients who 
undergo endovascular surgery identified at increased cardiac risk may benefit from the use of long-
term cardioprotective medication, such as β-blockers and statins23,24.
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ABSTRACT
Objective: Dobutamine stress echocardiography (DSE) provides an objective assessment of the pres-
ence and extent of coronary artery disease. Therefore we compared cardiac outcome in patients at 
high-cardiac risk undergoing open or endovascular repair of infrarenal AAA using preoperative DSE 
results.
Methods: Consecutive patients with ≥ 3 cardiac risk factors (age >70 years, angina pectoris, myocar-
dial infarction, heart failure, stroke, renal failure, and diabetes mellitus) undergoing infrarenal AAA 
repair were reviewed retrospectively. All underwent cardiac stress testing using DSE. Postoperatively 
data on troponin release and ECG were collected on day 1, 3, 7, before discharge, and on day 30. 
The main outcome measures were perioperative myocardial damage and myocardial infarction or 
cardiovascular death.
Results: All 77 patients (39 endovascular, 38 open) had a history of cardiac disease. The number and 
type of cardiac risk factors were similar in both groups. Also DSE results were similar: 55 vs. 56%, 24 
vs. 28%, and 21 vs. 18% had no, limited, or extensive stress induced myocardial ischemia respectively. 
The incidence of perioperative myocardial damage (47% vs. 13%, p = 0.001) and the combination of 
myocardial infarction or cardiovascular death (13% vs. 0%, p = 0.02) was significantly lower in patients 
receiving endovascular repair.
Conclusion: In patients with similar high cardiac risk, endovascular repair of infrarenal aortic aneu-
rysms is associated with a reduced incidence of perioperative myocardial damage.
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INTRODuCTION
Patients scheduled for abdominal aortic aneurysm repair with multiple cardiac risk factors are at 
increased risk of perioperative cardiac events. The incidence of adverse perioperative cardiac compli-
cations ranges from 1.1% to 2.4% and 9.9% for patients with no, 1 or 2, and ≥ 3 clinical cardiac risk fac-
tors1. While cardioprotective medication, i.e. beta-blocker and statin therapy, reduces the incidence 
of adverse perioperative cardiac events in most vascular surgery patients, those at highest risk do not 
seem to benefit1. In addition, more aggressive therapy, i.e. prophylactic coronary revascularization, 
did not show a reduction in perioperative adverse cardiac events in those at high-risk2.
A major improvement for these patients at high cardiac risk might be expected from endovascular 
aneurysm repair. However, no randomized trials comparing open and endovascular treatment have 
been reported on patients at high cardiac risk. Less than half of the patients in the DREAM trial (44%) 
and EVAR-1 trial (43%) had a history of cardiac disease3,4. A major limitation of non-randomized 
comparative studies between open and endovascular surgical procedures conducted so far is the 
lack of objective criteria for baseline cardiac condition5. Preoperative cardiac stress testing such as 
dobutamine stress echocardiography (DSE) and nuclear imaging provide an objective assessment 
of the presence and extent of coronary artery disease6. Therefore we conducted the present study, 
in which patients with an infrarenal aortic aneurysm were assessed preoperatively by cardiac stress 
testing, to compare cardiac outcome in high-risk patients treated by either open or endovascular 
repair.
METhODS
Patients
The study population was composed of consecutive patients with 3 or more cardiac risk factors, 
retrospectively identified by screening of medical charts, who underwent elective abdominal aneu-
rysm repair between January 2000 and January 2006 at a tertiary referral center, Erasmus University 
Medical Center Rotterdam, the Netherlands. The choice for either repair method was at the discretion 
of the treating vascular surgeon and was based mainly on anatomical considerations. Open repair 
requiring suprarenal aortic clamping or renal artery bypass were not included in this analysis. The 
study was approved by the Erasmus MC medical ethics committee.
Preoperative cardiac risk assessment
All patients were routinely screened for cardiac risk factors, including age over 70 years, history of or 
presence of angina pectoris, previous myocardial infarction, heart failure, stroke, renal failure (serum 
creatinine >2 mg/dl), and diabetes mellitus1. The presence of hypertension and chronic obstructive 
pulmonary disease (COPD) was noted. A patient was classified as having COPD at the preoperative 
screening visit according to symptoms and pulmonary function test (i.e. FEV1 <70% of maximal age 
and gender predictive value). According to the ACC/AHA guidelines all patients with 3 or more risk 
cardiac risk factors underwent cardiac stress testing prior to surgery7.
Perioperative medication use was noted including ACE-inhibitors, platelet aggregation inhibitors, 
beta-blockers, calcium antagonists, oral anticoagulants, diuretics, nitrates, and statins. Patients 
unable to take medication orally perioperatively were switched to intravenous formula. If no intrave-
nous formula was available, i.e. statins and ACE-inhibitors, oral medication was restarted as soon as 
possible after surgery.
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Patients on chronic beta-blocker therapy continued their medication. Patients without beta-blockers 
started with bisoprolol 2.5 mg once a day at the preoperative screening visit. Beta-blocker dose was 
adjusted in all patients at admission to the hospital and on the day prior to surgery to achieve a 
resting heart frequency of 60–65 beats per minute. The same dose of beta-blockers was continued 
postoperatively except in patients who were unable to take medication orally. In these patients, the 
heart rate was monitored continuously at the intensive care unit or hourly at the ward, and intrave-
nous metoprolol was administered at a dose sufficient to keep the heart rate between 60–65 beats 
per minute.
Cardiac stress testing
Resting echocardiography was used to estimate the left ventricular ejection fraction using the 
Simpson rule. Cardiac stress testing was performed by dobutamine echocardiography as previously 
described8. Myocardial stress induced ischemia was assessed using a semi-quantitative evaluation; a 
5-point score in a 17-segement model. Limited ischemia was defined by the presence of 1–4 ischemic 
segments, while extensive ischemia was defined by ≥ 5 ischemic segments. The overall sensitivity of 
this technique for the detection of significant coronary artery disease (diameter stenosis greater than 
or equal to 50%) is reported to be 95%; specificity 82% and accuracy 92%9.
Outcome
All patients were monitored for cardiac events after abdominal aortic aneurysm repair. Twelve-lead 
ECG and serum troponin-T level were systematically determined one, three, seven, and 30 days after 
surgery. Outpatient follow-up was performed at 30 days if a patient had been discharged from the 
hospital. All patients had a follow-up at 30 days after surgery, except for patients who died within 30 
days.
The primary outcome of the study was the incidence of perioperative myocardial damage defined as 
a rise and fall in serum levels of cardiac troponin T. Secondary outcomes included the incidence of 
myocardial infarction and the combination of myocardial infarction and cardiovascular death were 
assessed. Myocardial infarction was defined as the presence of 2 out of the following 3 criteria: (1) 
Characteristic ischemic symptoms lasting >20 minutes, (2) electrocardiographic changes including 
acute ST elevation followed by appearance of Q waves or loss of R waves, or new left bundle branch 
block, or new persistent T wave inversion for at least 24 hours, or new ST segment depression which 
persists >24 hours, and (3) a positive troponin T, i.e. >0.10 ng/ml, or peak CK-MB ≥ 8% of an elevated 
total creatinine phosphokinase with characteristic rise and fall10. Cardiovascular death was defined as 
any death with a cardiovascular cause, including those deaths following a cardiac procedure, cardiac 
arrest, myocardial infarction, pulmonary embolus, stroke, or sudden deaths not ascribed to other 
causes11.
Statistical analysis
Continuous data are presented as median values with interquartile range, whereas dichotomous data 
are presented as percentages. Differences in clinical characteristics between patients undergoing 
endovascular repair or open repair were evaluated by Wilcoxon non-parametric tests, Chi-square tests 
or Fisher’s exact tests, as appropriate. Differences in the incidence of the endpoints were evaluated by 
a Chi-square test. The limit of statistical significance was set at p = 0.05 (two-sided). All analysis was 
performed using the statistical software SPSS for Windows 12.0.1 (SPSS Inc., Chicago, Illinois, USA).
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RESuLTS
Patient characteristics
A total of 77 patients were identified with ≥ 3 cardiac risk factors who underwent either endovascular 
(n = 39) or open (n = 38) infrarenal aortic aneurysm repair. The number and type of cardiac risk factors 
did not differ significantly between the treatment groups (TABLE 28.1). The majority of patients (97%) 
received perioperative beta-blocker therapy. Other cardioprotective medication use was similar in 
patients with open or endovascular repair (TABLE 28.2).
Table 28.1 Baseline characteristics (all patients ≥ 3 risk factors).
Open Endovascular
N=38 N=39
Male – no. (%) 35 (92) 38 (97)
Age, years – mean (SD) 73.6 (5.6) 73.3 (6.8)
Cardiac risk factors – no. (%)
 Myocardial infarction 31 (82) 32 (82)
 Angina pectoris 25 (66) 27 (69)
 Congestive heart failure 5 (13) 10 (25)
 Diabetes mellitus 6 (16) 5 (13)
 Renal insufficiency 6 (16) 7 (18)
 CVA or TIA 13 (34) 9 (23)
 Age >70 years 30 (79) 32 (82)
Other risk factors
 Hypertension – no. (%) 16 (42) 16 (41)
 Previous CABG or PCI – no. (%) 14 (37) 17 (44)
 COPD – no. (%) 17 (45) 15 (39)
 BMI, kg/m2 – mean (SD) 25.9 (3.9) 25.9 (3.7)
 AAA size, mm - median 60 61
Dobutamine stress echocardiography  – no. (%)
 Left ventricular ejection fraction < 35% 23 (61) 22 (56)
 No ischemia 21 (55) 21(54)
 Limited ischemia 9 (24) 11(28)
 Extensive ischemia 8 (21) 7 (18)
CVA = cerebrovascular accident, TIA = transient ischemic attack, CABG = coronary artery bypass graft, PCI = percutaneous 
coronary intervention, COPD = chronic obstructive pulmonary disease, BMI = body mass index, AAA = abdominal aortic 
aneurysm
Table 28.2 Perioperative medication use.
Open Endovascular
N=38 N=39
Medical therapy – no.  (%)
 Statin 25 (66) 22 (56)
 Beta-blocker 37 (97) 38 (97)
 Aspirin 23 (61) 23 (59)
 Warfarin 4 (11) 7 (18)
 ACE-inhibitor 14 (37) 13 (34)
 Calcium antagonists 10 (26) 11 (29)
 Diuretics 16 (42) 13 (33)
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Forty-five (58%) patients had a left ventricular ejection fraction of <35%, 61% in the open group 
and 56% in the endovascular group (p = 0.82). Almost half (45%) of the patients had stress induc-
ible myocardial ischemia during stress testing, 45% in the open group and 46% in the endovascular 
group. Also the extent of myocardial ischemia did not differ significantly between the open and 
endovascular group, 55 vs. 54%, 24 vs. 28%, and 21 vs. 18% had no, limited, or extensive stress- induc-
ible myocardial ischemia respectively. Based on these test results and at the discretion of the treating 
physician 6 patients underwent pre-operative cardiac revascularization to optimize cardiac condition 
(2 in the open group and 4 in the endovascular group).
Outcome
Myocardial damage, i.e. a rise in serum levels of cardiac troponin T, was found in 18 (47%) patients 
undergoing open repair and in 5 (13%) patients undergoing endovascular repair (p = 0.001, TABLE 
28.3). Five patients with elevated cardiac troponin T levels had renal dysfunction. Importantly all of 
these patients had troponin concentrations of >0.10 ug/l. When these patients are excluded, patients 
undergoing open repair still had a significantly higher incidence of myocardial ischemia compared to 
those undergoing endovascular repair (44% vs. 12%, p = 0.006).
Table 28.3 30-day cardiac outcome.
Open Endovascular P-value
N=38 N=39
Positive Troponin T – no. (%) 18 (47) 5 (13) 0.001
Myocardial Infarction – no. (%) 5 (13) 0 0.02
All-cause death – no. (%) 3 (8) 0 0.11
CV death or MI – no. (%) 5 (13) 0 0.02
Length of stay (median, range) 11 (3-123) 3 (1-32) <0.001
CV = cardiovascular, MI = myocardial infarction
Three (8%) patients in the open repair group died within 30 days after surgery whereas in the endo-
vascular group all patients survived. Five (13%) in the open group experienced a myocardial infarction 
versus none in the endovascular group (p = 0.02). The incidence of the combined endpoint of cardio-
vascular death or nonfatal MI for patients in the open group was 13% versus 0% in the endovascular 
group (p = 0.02). Importantly, patients with no, or only limited, stress-induced myocardial ischemia 
at preoperative testing had a lower incidence of perioperative MI than patients with extensive stress 
induced ischemia (3% vs. 21%, p = 0.03).
DISCuSSION
Perioperative cardiac complications are a major cause for morbidity and mortality in patients with 
multiple cardiac risk factors undergoing abdominal aortic aneurysm repair. The optimal treatment 
for these patients is not well defined. Perioperative beta-blocker use reduces the incidence of peri-
operative cardiac complications in patients with no or limited stress inducible myocardial ischemia 
at preoperative testing1,12. However, patients with extensive stress inducible ischemia remain at high 
cardiac risk despite beta-blocker use with a perioperative event rate of approximately 30%1. It was 
hypothesized that prophylactic revascularization might provide sufficient protection in this patient 
group. Unfortunately, a recently conducted study on prophylactic coronary revascularization failed to 
show an improvement in perioperative cardiac outcome in 510 patients undergoing major vascular 
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surgery2. The current study showed that, in patients at high-risk with similar extent of coronary artery 
disease, endovascular treatment reduces the incidence of perioperative myocardial complications as 
compared to open repair.
The low incidence of myocardial damage in endovascular aneurysm repair has been described 
previously. Abraham et al. found a 10% incidence of myocardial ischemia in endovascular treated 
patients13. Interestingly, in our group of patients with a higher risk profile we found a similar inci-
dence of myocardial ischemia. The extent of coronary artery disease as assessed by the number 
of stress inducible ischemic segments correlated well with the extent of perioperative myocardial 
damage in the open repair group, 5%, 11%, 38% myocardial infarctions for patients with no, limited, 
and extensive stress inducible ischemia respectively. In the endovascular repair group no such cor-
relation was found. This difference might be explained by the reduced myocardial stress during an 
endovascular procedure14. In patients undergoing an endovascular procedure no aortic clamping 
and declamping are performed, the procedure is done under loco-regional anesthesia, and in com-
bination with a reduced blood loss a more hemodynamic stable condition is achieved15-18. Cuypers 
et al. also confirmed these assumptions in an observational study of 120 vascular patients15. The 
incidence of perioperative myocardial ischemia was compared between 49 patients who underwent 
endovascular treatment and 71 patients who underwent conventional aortic surgical procedures 
using transesophageal echocardiography and electrocardiography. During aortic clamping and dec-
lamping in the conventional surgery group hemodynamic instability occurred, which was associated 
with a higher incidence of myocardial ischemia.
Unfortunately endovascular repair can only be performed in patients with a distinct aortic anatomy. 
Endovascular repair of juxtarenal and suprarenal aortic aneurysms is not common practice so far. 
However, technological development continues apace and the first results of branched endografts 
are promising. Recently O’Neill described the results of 119 patients with an AAA anatomy unsuitable 
for conventional endovascular repair19. These patients were treated with fenestrated stents. Only one 
(0.8%) patient died (due to a non-cardiac cause) within 30 days after the procedure.
In contrast, the results of the EVAR 2 trial, in which patients deemed unfit for open repair were ran-
domized for endovascular or no aneurysm repair, showed a 30-day mortality of 9% after endovascular 
repair20. The main difference between the patients in the EVAR-2 trial and the current analysis is that 
patients in our analysis were not deemed unfit for open surgery. It is of interest that in contrast to the 
100% of patients with a history of cardiac disease in the current analysis, only 69% of the patients in 
EVAR-2 had a history of cardiac disease. Despite that, in the current study we found no myocardial 
infarction or death in the endovascular treated patients. It might be argued that more patients in our 
study received cardioprotective medication; statin use 61% vs. 39% in EVAR-2 and 97% of patients 
were on beta-blocker therapy.
Another important aspect of the comparison between endovascular and open repair of abdominal 
aortic aneurysms is the long-term outcome after repair. Though the DREAM trial and EVAR-1 trial 
showed a perioperative benefit for patients treated endovascularly, both trials failed to show a benefit 
in overall survival after a median follow-up of respectively 1.8 and 2.9 years3,21. In DREAM and EVAR-1 
approximately 30 to 40% of late mortality was attributable to cardiovascular causes, not including 
aneurysm related causes. This is not surprising since more than 60% of vascular surgery patients have 
documented coronary artery disease which will mainly determine adverse late outcome22. In addition, 
previously asymptomatic patients may further progress during follow-up and subsequently increase 
late mortality. Importantly, the EVAR-2 trial results indicate that high-risk patients who undergo 
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endovascular repair have the same rate of cardiovascular related deaths as patients randomized to 
no repair of their aneurysm during a median follow-up of 2.4 years20. Open abdominal aneurysm 
repair might be considered the ultimate cardiac stress test. If a patient survives the operation, the 
overall cardiac prognosis might be not that bad. On the other hand, this “selection” of frail patients 
does not occur in patients who undergo endovascular repair. Consequently, it might be argued that 
survivors of endovascular aneurysm repair are generally in worse cardiac health than survivors of 
open repair. Since long-term outcome after successful repair of an abdominal aortic aneurysm (open 
or endovascular) is related to underlying coronary artery disease, aggressive treatment is of critical 
importance23.
The main limitation of the current study is that it is not a randomized study. Patients were selected 
for open or endovascular repair based on surgeon’s preference and anatomical features. It might be 
so that if patients would have been randomized for open or endovascular repair, thereby reducing 
the extent of surgery in the conventional group (less challenging anatomy), the difference in cardiac 
outcome might be slightly less pronounced. However, the results of the preoperative cardiac stress 
tests showed that the two groups had similar prevalence and extent of coronary artery disease.
In conclusion, endovascular therapy seems to be associated with less perioperative adverse cardiac 
events compared to open surgery in patients with 3 or more cardiac risk factors, irrespective of the 
extent of underlying coronary artery disease.
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The long-term prognosis after successful repair of an abdominal aortic aneurysm is related to the 
presence and extent of underlying coronary artery disease1. Blankensteijn et al.2 showed that the 
favorable response to endovascular repair, as compared with open surgery, at 30 days dissipated 
after one year.
We analyzed 396 patients with an abdominal aortic aneurysm (57 who had undergone endovascular 
repair and 339 who had undergone open repair) for long-term prognosis with regard to the presence 
or absence and the extent of coronary artery disease (FIGURE 29.1), as assessed by the number of 
stress-induced ischemic wall-motion abnormalities determined with the use of a 16-segment model 
during dobutamine echocardiography. During a median follow-up of 2.8 years, 74 deaths from cardiac 
causes and 109 myocardial infarctions occurred. Multivariate Cox regression analysis, correcting for 
the type of surgery and cardiac risk factors (age and the presence or absence of angina, myocardial 
infarction, diabetes, heart failure, and stroke) showed that prognosis was related to the presence of 
ischemic wall-motion abnormalities (hazard ratio, 2.54; 95 percent confidence interval, 1.70 to 3.79) 
and to the increasing extent of such abnormalities (hazard ratio, 3.37; 95 percent confidence interval, 
2.11 to 5.40), whereas the type of aneurysm repair was not related to long-term survival (hazard ratio, 
0.82; 95 percent confidence interval, 0.45 to 1.50). Since the long-term outcome after successful 
repair of an abdominal aortic aneurysm is related to underlying coronary artery disease, aggressive 
treatment is of critical importance3.
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Figure 29.1 Long-term prognosis after repair of abdominal aortic aneurysm, according to the presence or absence 
of coronary artery disease.
Among 396 patients with an abdominal aortic aneurysm, the preoperative presence of stress-induced 
myocardial ischemia during dobutamine echocardiography was associated with a worse long-term 
prognosis (p<0.001).
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Patients scheduled for non-cardiac vascular surgery are at significant risk of cardiovascular morbidity 
and mortality due to underlying symptomatic or asymptomatic coronary artery disease (CAD). As was 
shown by Hertzer et al. in their landmark study in 1984 using coronary angiography in 1000 patients 
undergoing non-cardiac vascular surgery, 61% of all patients did have at least one significant lesion1. 
In fact, only 8% of all patients had no abnormalities. More recent studies using functional tests for 
CAD such as dobutamine stress echocardiography confirmed these findings. In a study population of 
1097 vascular surgical patients, the incidence of rest wall motion abnormalities was nearly 50%, while 
one-fifth of patients had stress-induced myocardial ischaemia2.
The high prevalence of CAD in vascular surgical patients explains the adverse outcome in this patient 
population. The incidence of perioperative myocardial infarction, defined as the presence of two out 
of three of the following markers: (i) the presence of typical chest pain complaints; (ii) ECG abnor-
malities; and (iii) increased troponin levels, is 5%. Importantly, 75% of the perioperative myocardial 
infarctions remain asymptomatic and may therefore be difficult to assess. This might be attributable 
to the disguising effects of sedation and the simultaneous occurrence of symptoms directly related 
to surgery such as nausea. The incidence of troponin release is even up to 25% in the vascular surgery 
population. However, the impact of perioperative asymptomatic myocardial ischemia on long-term 
outcome is not fully appreciated.
The preoperative evaluation offers a unique opportunity to identify patients at increased periop-
erative risk and initiate appropriate lifestyle changes and risk reduction therapy, as these will also 
improve long-term outcome. Importantly, patients should live long enough to enjoy the benefits of 
surgery. The preoperative evaluation of high-risk patients is hampered by the complex pathophysiol-
ogy of a perioperative myocardial infarction (MI). Both coronary plaque rupture, leading to thrombus 
formation and subsequent vessel occlusion, and a sustained oxygen supply–demand mismatch 
contribute equally to the incidence of a perioperative MI3,4. The former is related to the inflammatory 
status of the coronary artery tree. This has important implications on perioperative and long-term risk 
reduction strategies. A single intervention, for instance aiming at restoration of the supply–demand 
mismatch, may offer insufficient protection for coronary plaque instability. Therefore, treatment of 
the coronary culprit lesion only offers limited protection as the disseminated inflammatory disease 
of the coronary artery tree progresses.
Recently Kertai et al. used a total of 2310 patients to develop a Bayesian model for the prediction of 
all-cause mortality in patients undergoing all types of open vascular surgery5. The type of surgery 
was a strong risk factor; patients with a ruptured abdominal aortic aneurysm had the worst out-
come, followed by elective thoracoabdominal and abdominal aortic surgery, lower extremity arterial 
bypass surgery, and carotid surgery. Risk factors based on medical history, in order of descending 
risk, were: renal dysfunction, congestive heart failure, ischemic heart disease, cerebrovascular event, 
hypertension, and pulmonary disease. The data of the Coronary Artery Revascularization Prophylaxis 
(CARP) study of McFalls et al.6 confirm these preoperative risk factors and offer the clinician hints for 
long-term outcome. Recently biomarkers such as high sensitive C-reactive protein (hsCRP) have also 
emerged as potential predictors of adverse cardiovascular events after vascular surgery. As shown 
by Owens et al. in a group of 91 vascular surgery patients, a preoperative hsCRP level >5 mg/L was 
associated with a 2.3-fold increased risk for adverse cardiovascular events during a mean follow-up 
of 12 months7.
Another well known biomarker, in the CARP study assessed after the stress of surgery, is troponin 
release. In line with these findings, Landesberg et al. showed in 2003 that patients with a perioperative 
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troponin T release >0.03 ng/mL and/or a troponin I release >0.6 ng/mL had a significant 2-fold 
increased risk for long-term mortality during a mean follow-up of 32 months, irrespective of the type 
of vascular surgery and clinical risk factors8. This was also confirmed in a study of 393 vascular surgery 
patients by Kertai et al.: an increase in troponin T level >0.1 ng/mL was associated with a 1.9-fold 
increased risk for all-cause mortality during a median follow-up of 4 years9.
Although the combination of clinical cardiac risk factors and biomarkers offers a unique opportunity 
to stratify patients according to the long-term risk, outcome in patients with peripheral arterial disease 
(PAD) remains poor. The 5-year event rate of cerebrocardiovascular events is 20%, with mortality rates 
of up to 30%. The Reduction of Atherothrombosis for Continued Health (REACH) Registry, including 
55 814 patients with known atherosclerotic disease (CAD, PAD and cerebrovascular disease) showed 
that patients with polyvascular disease, i.e. the combination of PAD and CAD, have a significantly 
worse outcome compared with patients with CAD only10. An explanation for the high event rate 
is the medical undertreatment of patients with PAD. Recently a report from Denmark confirmed 
the undertreatment of PAD patients as compared with CAD patients. Patients with PAD were less 
likely to receive antiplatelet therapy, statins, angiotensin-converting enzyme (ACE) inhibitors, and 
β-blockers. For all of these therapies there is substantial evidence that they are associated with an 
improved event-free survival. In fact, current guidelines recommend the aggressive use of statins, 
antiplatelet therapy, and blood pressure lowering in these patients11. The investigators of CARP are to 
be congratulated for their effort in giving their patients so-called best medical treatment; 80% were 
on β-blockers during 2 years of follow-up, 85% were on antiplatelet therapy, 70% on statins, and 60% 
on ACE inhibitors.
For the improvement of the long-term prognosis of patients with PAD it is advisable that current 
guidelines on lifestyle changes and treatment targets of cardiac risk factors are fully disseminated 
among physicians involved in care of these patients. The recent results of the Euro Heart Survey 
underscore the importance of continuous education and surveillance of guideline implementation.
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ABSTRACT
Background: The presence of peripheral arterial disease (PAD) is considered to be a risk factor for 
adverse late outcome. This study was designed to compare the long-term outcomes of patients with 
PAD with a risk factor matched population of coronary artery disease (CAD) patients, but without 
PAD.
Methods: A total of 2,730 PAD patients undergoing vascular surgery were categorized into groups: 1) 
carotid endarterectomy (n = 560); 2) elective abdominal aortic surgery (AAA) (n = 923); 3) acute AAA 
surgery (r-AAA) (n = 200), and 4) lower limb reconstruction procedures (n = 1,047). All patients were 
matched using the propensity score, with 2,730 CAD patients who underwent coronary angioplasty. 
Survival status of all patients was obtained. In addition, the cause of death and complications after 
surgery in PAD patients were noted. The Kaplan-Meier method was used to compare survival between 
the matched PAD and CAD population and the different operation groups. Prognostic risk factors and 
perioperative complications were identified with the Cox proportional hazards regression model.
Results: The PAD patients had a worse long-term prognosis (hazard ratio 2.40, 95% confidence 
interval 2.18 to 2.65) and received less medication (beta-blockers, statins, angiotensin-converting 
enzyme inhibitors, aspirin, nitrates, and calcium antagonists) than CAD patients did (p < 0.001). 
Cerebro-cardiovascular complications were the major cause of long-term death (46%). Importantly, 
no significant difference in long-term survival was observed between the AAA and lower limb 
reconstruction groups (log rank p = 0.70). After vascular surgery, perioperative cardiac complications 
were associated with long-term cardiac death, and non-cardiac complications were associated with 
all-cause death.
Conclusions: Long-term prognosis of vascular surgery patients is significantly worse than for patients 
with CAD. The vascular surgery patients receive less cardiac medication than CAD patients do, and 
cerebro-cardiovascular events are the major cause of late death.
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INTRODuCTION
Atherosclerosis is a systemic disease affecting numerous vascular beds. In patients with peripheral 
arterial disease (PAD), coronary artery disease (CAD) has a prevalence of 46% to 71%1,2. Post-operative 
and long-term prognosis after vascular surgery is predominantly determined by underlying CAD3. 
Furthermore, cardiac death accounts for approximately 40% of 30-day mortality, and the 1-year 
mortality has been estimated at 6% to 10%4-7. To improve outcomes of patients with PAD requiring 
surgery, assessment and aggressive therapy of atherosclerotic risk factors is recommended. Hence, 
the secondary prevention for subjects with PAD is similar to the measures for patients with CAD8,9. 
However, data are scarce about the survival and treatment of patients with PAD compared with 
patients with CAD.
In addition, long-term outcomes in vascular surgery patients with PAD are ill-defined and often not 
considered in the immediate pre-operative workup. To provide information on long-term prognosis 
after open vascular surgery repairs among an entire stratum of procedures, it would be important 
to understand the relationship between pre-operative characteristics and nonfatal perioperative 
complications with long-term all-cause mortality and cardiac events in a large cohort of patients with 
PAD. Therefore, in this analysis, we compared survival and treatment of patients with PAD scheduled 
for open vascular surgery procedures with a risk factor matched large cohort of patients with docu-
mented severe myocardial ischemia referred for coronary angioplasty in the same clinical setting, 
without signs or symptoms of PAD.
METhODS
Study design and patient selection
Between January 1993 and June 2006, 2,730 PAD patients underwent major vascular surgery at 
the Erasmus Medical Center, Rotterdam, the Netherlands, and were entered into a computerized 
database. All patients underwent open surgery and were categorized into 4 groups, respectively: 1) 
carotid endarterectomy (CEA); 2) elective infrarenal abdominal aortic surgery (AAA); 3) acute infra-
renal AAA surgery (r-AAA); and 4) lower limb arterial reconstruction procedures (LLR). The medical 
ethics committee of the Erasmus Medical Center was informed about the study protocol, and per 
institutional practice, no official approval was requested.
Operation groups
Patients in the CEA group underwent an elective reconstruction or desobstruction of the carotid 
artery. The AAA group underwent open infrarenal AAA repair (aortic-to-aortic or aortic-bifurcation 
prostheses procedures, removal of infected prostheses, and other operations of the abdominal aorta). 
Those with a rupture of the infrarenal abdominal aorta were classified as r-AAA. Finally, patients of 
the LLR group underwent iliac-femoral, femoral-popliteal, or femoral-tibial artery bypass procedures; 
removal of infected prostheses; peripheral desobstruction; and other elective peripheral arterial 
surgical reconstructions.
Propensity score risk factor matched CAD population
To compare the risk of underlying vascular disease (PAD or CAD) on long-term mortality, we 
compared the prognosis of patients undergoing vascular surgery (PAD patients) with the survival 
of a separate group of 15,993 patients diagnosed with severe myocardial ischemia (CAD patients), 
who were referred to the Erasmus Medical Center in the same period (1993 to 2006) for coronary 
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angioplasty without signs or symptoms of PAD obtained from review of medical records. Because of 
the differences in baseline characteristics between the PAD and CAD populations, propensity score 
methodology was used to identify comparable patients with the same risk. First, a propensity score 
for each patient was constructed, providing an estimate of the propensity toward belonging to 1 
patient group versus the other using multivariate logistic regression with the type of population as 
end point (PAD coded as 0, CAD coded as 1). Included in the analysis were the following available 
cardiovascular risk factors: age, gender, year of operation, hypertension, diabetes mellitus, smok-
ing status, prior percutaneous coronary intervention, prior coronary artery bypass graft, and prior 
myocardial infarction (MI). Then, each PAD patient was matched with 1 CAD patient with the same 
propensity score, rounded off at 2 deciles. The graphical method of examination by box plots showed 
a balance of the estimated propensity score between PAD and CAD patients within each decile of the 
propensity score. As a result, the matched CAD population resembled the PAD cohort after matching 
for cardiovascular risk factors (TABLE 31.1). Finally, a total of 2,730 PAD patients were matched with 
2,730 CAD patients.
In addition, medication use (statins, beta-blockers, angiotensin-converting enzyme inhibitors (ACE 
inhibitors), aspirin, nitrates, and calcium antagonists) of the CAD population was recorded to attempt 
to explain differences in survival between the PAD and CAD populations.
Patients’ characteristics
For all PAD patients, we recorded age, gender, hypertension (defined as systolic blood pressure ≥ 140 
mm Hg, diastolic blood pressure ≥ 90 mm Hg, and/or use of antihypertensive medication), diabetes 
mellitus (the presence of a fasting blood glucose ≥ 140 mg/dl or requirement for insulin or oral 
hypoglycemic agents), smoking status, hypercholesterolemia (total cholesterol of >200 mg/dl and/
or the requirement of lipid-lowering medication), chronic obstructive pulmonary disease according 
to symptoms and pulmonary function tests (i.e. forced expiratory volume in 1 s <70% of maximal 
age and gender predictive value), body mass index, renal dysfunction (baseline serum creatinine 
>1.5 mg/dl), the presence of ischemic heart disease (prior MI, prior coronary revascularization (coro-
nary artery bypass graft or percutaneous coronary intervention) and angina pectoris), heart failure 
(defined according the New York Heart Association functional classification), and medication (statins, 
diuretics, ACE inhibitors, calcium antagonists, nitrates, beta-blockers, aspirin, and anticoagulants). All 
prescription and over-the-counter medications were noted on the day of admission.
Table 31.1
Propensity score risk factor matched peripheral arterial disease (PAD) and coronary artery disease (CAD) 
population.
Before matching After matching‡
PAD
n=2,730
CAD
n=15,993
p-value PAD
n=2,730
CAD
N=2,730
p-value
Age (yr ± SD) 66 (± 11) 61 (± 13) <0.001 66 (± 11) 66 (± 12) 1.0
Male (%) 75 72 <0.001 75 75 1.0
Hypertension (%) 45 33 <0.001 44 45 0.9
Diabetes mellitus (%) 15 11 <0.001 14 12 0.8
Smoking (%) 23 24 0.008 23 21 0.8
Prior PCI† (%) 10 11 0.02 10 11 0.9
Prior CABG* (%) 19 27 <0.001 19 22 0.4
Prior myocardial infarction (%) 25 38 <0.001 25 25 1.0
*Prior coronary artery bypass graft and prior myocardial infarction; †prior percutaneous coronary intervention; ‡matched 
for age, gender, year of operation, hypertension, diabetes mellitus, smoking status, prior percutaneous coronary 
intervention
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Clinical follow-up and end points
Post-operative clinical information was retrieved from an electronic database of patients followed in 
our hospital. On occasion, missing data were abstracted retrospectively by reviewing patients’ medi-
cal records. Routinely, all vascular surgery patients are screened for adverse post-operative outcome 
by repeated cardiac isoenzyme measurements and electrocardiographic recording. Additional tests 
are performed at the discretion of the attending physician. After surgery, patients visit the outpa-
tient clinic regularly and are screened for late cardiac events. From the municipal civil registries, we 
obtained the survival status. At the reference date, January 2007, follow-up was complete in 99.3% of 
cases. The mean follow-up of the PAD patients was 6.37 ± 4.08 years, the mean follow-up of the CAD 
patients was 9.17 ± 4.14 years. The primary end point was long-term all-cause mortality in the PAD 
and CAD populations. The secondary end point was the composite of perioperative mortality and 
nonfatal events in the PAD population.
Perioperative and long-term mortality
Perioperative all-cause mortality was defined as death occurring during 30-day in-hospital stay or as 
death occurring after hospital discharge but within the first 30 days after surgery. Cardiac death was 
defined as death secondary to MI, heart failure, or arrhythmias. Long-term all-cause mortality was 
defined as death beyond 30 days after surgery; deaths that occurred in the 30-day period were thus 
excluded from the long-term period.
The cause of death in the PAD population was grouped into a cerebro-cardiovascular (CCV), a non-CCV, 
and an unknown cause of death. A CCV death was defined as any death with a cerebro-cardiovascular 
complication as the primary or secondary cause and included deaths following MI, serious cardiac 
arrhythmias (defined as the presence of a sustained cardiac rhythm disturbance that required urgent 
medical intervention), congestive heart failure, stroke (cerebrovascular accident or transient ischemic 
attack), surgery-related bleeding complications (only a post-operative cause of death), and others. 
Sudden unexpected death was classified as a CCV death. An MI was defined as the presence of 2 out 
of the following 3 criteria: 1) typical chest pain complaints; 2) electrocardiographic changes including 
acute ST-segment elevation followed by appearance of Q waves or loss of R waves, or new left bundle 
branch block, or new persistent T wave inversion for at least 24 h, or new ST-segment depression 
that persisted >24 h; and 3) a positive troponin T (i.e. >0.10 ng/ml) or peak creatinine phosphokinase 
myocardial band ≥ 8% of an elevated total creatinine phosphokinase with characteristic rise and 
fall10. Non-CCV death was defined as any death with a principal non-CCV cause, including infection, 
malignancy, respiratory insufficiency, and others. The cause of death was ascertained by reviewing 
medical records, the computerized hospital database, autopsy reports, or by contacting the referring 
physician or general practitioner.
Nonfatal perioperative events in the PAD population
We recorded the following nonfatal complications within 30 days after surgery: infection (such as 
wound infection, pneumonia, sepsis, and urinary tract infection), MI, arrhythmias, heart failure, stroke, 
reoperation (percutaneous revascularization or bypass surgery to a vessel that has been treated dur-
ing the index procedure), hemorrhage (arterial bleeding leading to hypotension (systolic pressure of 
<100 mm Hg) requiring blood transfusion), thrombectomy, amputation (excluded toe amputation), 
perioperative renal dysfunction (peak post-operative serum creatinine >+0.5 mg/dl within 3 days 
after surgery compared with pre-operative serum creatinine), and the requirement of hemodialysis 
(excluding pre-operative hemodialysis).
Ch
ap
te
r 3
1
342
Statistical analysis
Continuous data are described as mean values and standard deviations, and dichotomous data are 
described as percentage frequencies. The chi-square test was used for categorical variables, and the 
analysis of variance test was used for continuous variables. Kaplan-Meier survival analysis was used 
to compare survival times between the PAD and CAD patients and the 4 PAD subgroups, stratified 
by type of surgery. To test for differences between the resulting curves, the log-rank test was used. 
For the long-term survival analysis using the Kaplan-Meier method, we included those who died 
within 30 days after surgery. A univariate Cox proportional hazard regression model was used to 
explore the association of underlying vascular disease on long-term survival. We used univariate and 
not multivariate analysis because we matched all PAD and CAD patients for the available baseline 
cardiovascular risk factors. For this long-term analysis, we included all survivors within 30 days after 
vascular surgery. Multivariate logistic regression and Cox proportional hazard regression models 
were used to explore the relationship of major baseline risk factors of all PAD patients undergoing 
vascular surgery and perioperative all-cause and cardiac death, respectively. Risk factors entered in 
the risk model were type of operation, age >70 years, gender, chronic obstructive pulmonary disease, 
hypertension, diabetes mellitus, smoking status, hypercholesterolemia, prior MI, prior heart failure, 
prior coronary revascularization, prior angina, and renal dysfunction. For the long-term all-cause 
Table 31.2 Baseline characteristics of all patients with peripheral artery disease, according to type of operation.
Number of patients
All patients
2,730 (100%)
CEA‡
560 (21%)
AAA*
923 (34%)
r-AAA#
200 (7%)
LLR||
1,047 (38%) p-value
Demographics
Mean age (± SD) 66 (± 11) 65 (± 10) 66 (± 11) 71 (± 9) 65 (± 12) <0.001
Male (%) 75 73 78 88 72 <0.001
Cardiovascular risk factor (%)
Body mass index (± SD) 25.0 (± 5) 25.8 (± 3) 24.9 (± 5) 25.4 (± 3) 24.7 (± 4) 0.006
Current smoker 24 11 28 14 29 <0.001
Hypertension 45 34 53 43 46 <0.001
Diabetes Mellitus 15 10 13 10 20 <0.001
Hypercholesterolemia 29 28 37 33 26 <0.001
COPD§ 18 7 26 20 17 <0.001
Renal dysfunction** 12 5 13 20 14 <0.001
Disease history (%)
Angina 15 7 17 14 19 <0.001
Myocardial Infarction 24 9 30 27 31 0.01
Coronary revascularization 24 19 26 20 28 <0.001
Heart failure 5 1 6 5 7 <0.001
Medication use (%)
Statins 26 26 33 19 23 <0.001
Diuretics 18 10 18 19 23 <0.001
ACE-inhibitors† 31 21 35 25 34 <0.001
Calcium antagonists 34 27 43 22 32 <0.001
Nitrates 19 13 21 14 20 <0.001
Beta-blockers 33 26 45 22 29 <0.001
Aspirin 40 73 33 28 32 <0.001
Anti-coagulation 20 6 17 10 33 <0.001
*AAA= elective infrarenal abdominal aortic surgery; †ACE-inhibitors= angiotensin-converting-enzyme inhibitors; ‡CEA= 
carotid endarterectomy; §COPD= chronic obstructive pulmonary disease; ||LLR= lower limb arterial reconstruction 
procedures; #r-AAA= acute infrarenal abdominal aortic surgery; **renal dysfunction= baseline serum creatinine >1.5 mg/dl
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and cardiac mortality, multivariate Cox proportional hazards regression analysis was performed and 
included also all nonfatal perioperative complications.
All univariate risk factors with a p value of <0.10 were entered in the perioperative and long-term 
multivariate analysis, resulting in an adjusted significant odds and hazard ratios (ORs and HRs) or 
as not significant. Unadjusted and adjusted ORs and HRs were reported with corresponding 95% 
confidence intervals (CIs). A p value of <0.05 was considered to be significant. All computations were 
performed with SPSS software version 12.0.1 (SPSS Inc., Chicago, Illinois), running under Windows 
2000 Professional (Microsoft, Redmond, Washington).
RESuLTS
Patient characteristics
The mean age of all patients with PAD (n = 2,730) was 66 ± 11 years and 76% were male. A total of 560 
patients (20%) underwent CEA surgery; 923 patients (34%) underwent AAA surgery (aortic-to-aortic 
n = 206, aortic bifurcation n = 624, infected prostheses n = 51, and others n = 42); 200 patients (7%) 
had a r-AAA; and 1,047 patients (38%) underwent LLR surgery (iliac-femoral n = 208, femoral-popliteal 
n =6 03, femoral-tibial n = 203, and infected prostheses n = 33). Patient’s characteristics are presented 
in TABLE 31.2.
Primary end point
Compared with CAD patients, patients with PAD had a significantly worse long-term prognosis 
(unadjusted HR 2.40, 95% CI 2.18 to 2.65) (FIGURE 31.1). Annual mortality rates of the PAD and CAD 
populations were 5.7% and 3.0% per year (p < 0.001). Importantly, patients with CAD received more 
cardiac medications than the PAD patients did (beta-blockers 74% vs. 34%, calcium antagonists 52% 
vs. 33%, aspirin 88% vs. 40%, nitrates 37% vs. 19%, statins 67% vs. 29%, and ACE inhibitors 57% vs. 
31%, respectively) (FIGURE 31.2).
Secondary end point
Within 30 days after surgery, a total of 153 PAD patients (5.6%) died. The overall mortality of the CEA, 
AAA, r-AAA, and LLR groups was 8 (1.4%), 58 (6.3%), 57 (28.5%), and 30 (2.9%) (p<0.001), respectively. 
The leading causes of death were CCV events (76%) (TABLE 31.3). Specified according to the type 
of surgery, the leading cause of death at 30 days for CEA patients was stroke (38%), for AAA was MI 
(24%), for r-AAA was fatal bleeding (40%), and for LLR was infection (33%). Outcomes at 30 days of 
patients undergoing CEA or LLR were superior to patients undergoing AAA surgery (FIGURE 31.3). 
Patients scheduled for r-AAA surgery had the worst 30-day outcome. Also, in the multivariate Cox 
proportional hazards regression analysis, the type of operation was an important independent risk 
factor for perioperative all-cause mortality and cardiac events (TABLE 31.4).
A total of 1,353 (52.5%) patients with PAD died during 6.37 ± 4.08 years of follow-up, excluding the 
153 patients who died within 30 days post-operatively. Mortality rates among the different surgical 
procedures were 216 (39.1%), 470 (54.3%), 87 (60.8%), and 580 (57.0%) for CEA, AAA, r-AAA, and 
LLR, respectively. Annual mortality rates of CEA, AAA, LLR, and r-AAA are 5.0%, 5.9%, 5.9%, and 6.8% 
per year (log rank p < 0.001), respectively. The leading cause of death was CCV (46%). Myocardial 
infarction accounts for 19% of all causes of long-term mortality. During long-term follow-up, patients 
of the LLR group had a similar prognosis compared with the AAA group (log rank p = 0.70), but 
patients of the r-AAA group had the worst outcome (FIGURE 31.1). However, the multivariate Cox 
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Figure 31.1 Kaplan-Meier estimate of long-term survival of CAD and different types of peripheral surgical patients.
To test for differences between the resulting curves, the log-rank test was used. AAA = elective 
infrarenal abdominal aortic surgery; CAD = coronary artery disease; CEA = carotid endarterectomy; LLR 
= lower limb arterial reconstruction; r-AAA = acute infrarenal AAA.
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Figure 31.2 Medication use according to PAD and CAD patients.
ACE = angiotensin-converting enzyme; PAD = peripheral arterial disease; other abbreviation as in 
figure 31.1.
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proportional hazards regression analysis illustrated that, converse to the perioperative outcome, the 
type of surgery was not related to outcome during long-term follow-up (TABLE 31.5). The propor-
tional hazards assumptions were tested by constructing interaction terms between the variables and 
time to each end point. The Cox proportional hazards regression analyses showed no statistically 
significant interaction with time (each p value >0.05).
Long-term all-cause outcome was affected by age, smoking, chronic obstructive pulmonary disease, 
MI, renal dysfunction, and non-cardiac complications (infection, stroke, and amputation). Pre-
operative cardiac risk factors (age >70 years, diabetes mellitus, prior MI, coronary revascularization, 
heart failure) and perioperative nonfatal cardiac complications (MI, heart failure, arrhythmia) were 
the primary determinants of long-term adverse cardiac outcome.
Table 31.3 Cause of death during the perioperative and long-term period.
Number of patients
All patients
2,730 (100%)
CEA‡
560 (21%)
AAA*
923 (34%)
r-AAA#
200 (7%)
LLR§
1,047 (38%) p-value
Perioperative mortality 153 (6) 8 (1) 58 (6) 57 (29) 30 (3)
Total CCV† death – no. (%) 116 (76) 6 (75) 45 (78) 46 (81) 19 (63) 0.3
 Myocardial infarction 28 (18) 2 (25) 14 (24) 6 (11) 6 (20) 0.3
 Congestive heart failure 15 (10) 0 (0) 7 (12) 4 (7) 4 (13) 0.5
 Arrhythmia 15 (10) 0 (0) 4 (7) 7 (12) 4 (13) 0.5
 Stroke 9 (6) 3 (38) 3 (5) 3 (5) 1 (3) 0.001
 Fatal bleeding 40 (26) 1 (13) 13 (22) 23 (40) 3 (10) 0.01
 Other 9 (6) 0 (0) 5 (9) 3 (5) 1 (3) 0.6
Total n-CCV|| death – no. (%) 37 (24) 2 (25) 13 (22) 11 (19) 11 (37) 0.3
 Infection 22 (14) 0 (0) 4 (7) 8 (14) 10 (33) 0.005
 Malignancy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) NA
 Respiratory insufficiency 9 (6) 2 (25) 4 (7) 2 (4) 1 (3) 0.1
 Others 6 (4) 0 (0) 5 (9) 1 (2) 0 (0) 0.1
Unknown – no. (%) 0 (0) NA NA NA NA NA
Long-term mortality** 1,353 (53) 216 (39) 470 (54) 87 (61) 580 (57)
Total CCV death – no. (%) 625 (46) 91 (42) 203 (43) 36 (41) 295 (51) 0.03
 Myocardial infarction 250 (19) 31 (14) 85 (18) 15 (17) 119 (21) 0.2
 Congestive heart failure 168 (12) 28 (13) 41 (9) 10 (12) 89 (15) 0.01
 Arrhythmia 26 (2) 2 (1) 11 (2) 3 (3) 10 (2) 0.4
 Stroke 96 (7) 22 (10) 33 (7) 5 (7) 35 (6) 0.2
 Others 85 (6) 8 (4) 33 (7) 2 (2) 42 (7) 0.1
Total n-CCV death – no. (%) 412 (31) 66 (31) 150 (32) 30 (35) 166 (29) 0.6
 Infection 78 (6) 4 (2) 26 (6) 7 (8) 41 (7) 0.03
 Malignancy 153 (11) 32 (15) 54 (12) 7 (8) 60 (10) 0.2
 Respiratory insufficiency 85 (6) 9 (4) 31 (7) 10 (12) 35 (6) 0.1
 Others 96 (7) 21 (10) 39 (8) 6 (7) 30 (5) 0.09
Unknown – no. (%) 316 (23) 59 (27) 117 (25) 21 (24) 119 (21) 0.2
*AAA= elective infrarenal abdominal aortic surgery; †CCV=cerebro-cardiovascular; ‡CEA= carotid endarterectomy; §LLR= 
lower limb arterial reconstruction procedures; ||nCCV= non-cerebro-cardiovascular; #r-AAA= acute infrarenal abdominal 
aortic surgery; **Excluding those patients who died within the postoperative period (n=153)
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Table 31.4
Multivariate associations of baseline characteristics with all-cause and cardiac mortality in the perioperative 
period.
Perioperative all-cause mortality Perioperative cardiac death†
Risk factor
OR Univariate
(95% CI)
OR Multivariate
(95% CI)
OR Univariate
(95% CI)
OR Multivariate
(95% CI)
Operation group
 LLR|| (reference) 1.0 1.0 1.0 1.0
 r-AAA# 13.51 (8.40 – 21.74) 12.22 (7.46 – 20.04) 6.86 (3.32 – 14.15) 6.21 (2.94 – 13.12)
 AAA* 2.27 (1.45 – 3.57) 2.00 (1.27 – 3.16) 2.05 (1.06 – 3.97) 1.89 (1.01 – 3.68)
 CEA‡ 0.49 (0.22 – 1.07) NS 0.26 (0.06 – 1.17) NS
Sex 1.19 (0.80 – 1.77) NS 1.40 (0.72 – 2.72) NS
Age >70 year 2.31 (1.66 – 3.21) 1.55 (1.09 – 2.21) 2.57 (1.50 – 4.39) 1.95 (1.12 – 3.39)
Hypertension 1.50 (1.08 – 2.09) 1.55 (1.08 – 2.22) 1.72 (1.02 – 2.92) NS
COPD§ 2.39 (1.68 – 3.40) 2.05 (1.40 – 3.01) 2.06 (1.17 – 3.62) NS
Diabetes Mellitus 1.13 (0.73 – 1.76) NS 1.20 (0.60 – 2.40) NS
Hypercholesterolemia 0.71 (0.40 – 1.23) NS 0.83 (0.36 – 1.96) NS
Current Smoker 1.10 (0.73 – 1.68) NS 0.88 (0.43 – 1.81) NS
Myocardial infarction 1.22 (0.80 – 1.89) NS 1.41 (0.80 – 2.47) NS
Coronary revascularization 0.54 (0.34 – 0.84) NS 0.65 (0.33 – 1.28) NS
Heart failure 1.26 (0.65 – 2.34) NS 2.50 (1.12 – 5.61) NS
Angina 1.11 (0.60 – 2.03) NS 1.27 (0.55 – 2.96) NS
Renal dysfunction** 2.61 (1.77 – 3.84) 2.09 (1.38 – 3.18) 2.88 (1.60 – 5.19) 2.11 (1.15 – 3.88)
*AAA= elective infrarenal abdominal aortic surgery; †cardiac death= death because of mycardial infarction, heart failure 
and arrhythmia; ‡CEA= carotid endarterectomy; §COPD= chronic obstructive pulmonary disease; ||LLR= lower limb arterial 
reconstruction procedures; #r-AAA= acute infrarenal abdominal aortic surgery; **renal dysfunction=baseline serum 
creatinine >1.5 mg/dl
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Figure 31.3 Kaplan-Meier estimate of overall perioperative (30-day) survival of different types of surgical patients.
To test for differences between the resulting curves, the log-rank test was used. Abbreviations as in 
figure 31.1.
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DISCuSSION
Our main finding of this study is that patients with PAD, compared with a matched population for 
cardiac risk factors and year of treatment with CAD, are at increased risk for long-term mortality. In 
addition, PAD patients receive less cardiovascular medical therapy (e.g. beta-blockers, statins, ACE 
inhibitors, calcium antagonists, nitrates, and aspirin) than CAD patients do.
Table 31.5
Multivariate associations of baseline characteristics and non-fatal perioperative complications with long-
term all-cause and cardiac mortality.
Long-term all-cause mortality Long-term cardiac death†
HR Univariate
(95% CI)
HR Multivariate
(95% CI)
HR Univariate
(95% CI)
HR Multivariate
(95% CI)
Baseline risk factors
 Operation group
  LLR|| (reference) 1.0 1.0 1.0 1.0
  r-AAA# 1.29 (1.03 – 1.62) NS 1.11 (0.75 – 1.64) NS
  AAA* 0.97 (0.86 – 1.09) NS 0.75 (0.61 – 0.93) NS
  CEA‡ 0.66 (0.57 – 0.78) NS 0.50 (0.38 – 0.67) NS
 Sex 1.15 (1.01 – 1.30) NS 1.13 (0.91 – 1.41) NS
 Age > 70 year 2.18 (1.96 – 2.43) 2.11 (1.88 – 2.36) 2.00 (1.65 – 2.41) 2.02 (1.66 – 2.47)
 Hypertension 1.15 (1.03 – 1.28) NS 1.18 (0.98 – 1.42) NS
 COPD§ 1.60 (1.41 – 1.81) 1.49 (1.29 – 1.71) 1.29 (1.02 – 1.63) NS
 Diabetes Mellitus 1.32 (1.14 – 1.52) NS 1.87 (1.50 – 2.34) 1.47 (1.16 – 1.87)
 Hypercholesterolemia 1.06 (0.93 – 1.22) NS 1.38 (1.10 – 1.72) NS
 Current Smoker 1.30 (1.16 – 1.46) 1.20 (1.06 – 1.36) 1.44 (1.18 – 1.76) NS
 Myocardial infarction 1.43 (1.28 – 1.62) NS 2.59 (2.15 – 3.13) 1.59 (1.26 – 2.01)
  Coronary revascularization 1.08 (0.96 – 1.22) NS 2.17 (1.80 – 2.62) 1.61 (1.30 – 1.99)
 Heart failure 1.74 (1.41 – 2.14) NS 2.94 (2.19 – 3.94) 1.45 (1.04 – 2.01)
 Angina 1.26 (1.10 – 1.45) NS 2.22 (1.81 – 2.73) 1.21 (1.01 – 1.59)
 Renal dysfunction** 2.23 (1.83 – 2.47) 1.72 (1.47 – 2.02) 2.31 (1.80 – 2.96) 1.60 (1.22 – 2.09)
Postoperative complications
  Non-fatal myocardial infarction 1.45 (1.19 – 1.76) NS 4.07 (2.17 – 7.63) 2.22 (1.15 – 4.28)
 Heart failure 2.20 (1.47 – 3.29) NS 3.36 (1.89 – 5.96) 1.86 (1.01 – 3.43)
 Arrhythmia 2.04 (1.41 – 2.98) 1.65 (1.12 – 2.43) 2.41 (1.33 – 4.40) 1.86 (1.00 – 3.52)
 Infection 1.75 (1.52 – 2.02) 1.51 (1.31 – 1.76) 1.51 (1.17 – 1.96) NS
 Stroke 2.05 (1.55 – 2.72) 1.98 (1.47 – 2.67) 1.57 (0.90 – 2.73) NS
 Amputation 2.03 (1.58 – 2.61) 1.74 (1.33 – 2.29) 1.50 (0.84 – 2.68) NS
 Hemorrhage 1.24 (0.99 – 1.57) NS 0.95 (0.60 – 1.50) NS
 Trombectomy 1.14 (0.87 – 1.48) NS 1.45 (0.96 – 2.19) NS
 Re-operation 1.30 (0.98 – 1.74) NS 1.49 (0.93 – 2.39) NS
 Acute Renal failure†† 1.81 (1.54 – 2.12) 1.44 (1.21 – 1.73) 1.73 (1.31 – 2.29) 1.39 (1.01 – 1.92)
 Hemodialysis‡‡ 2.95 (1.98 – 4.38) 1.67 (1.06 – 2.63) 3.13 (1.61 – 6.06) NS
*AAA= elective infrarenal abdominal aortic surgery; †cardiac death= death because of myocardial infarction, heart failure 
and arrhythmia; ‡CEA= carotid endarterectomy; §COPD= chronic obstructive pulmonary disease; ||LLR= lower limb arterial 
reconstruction procedures; #r-AAA= acute infrarenal abdominal aortic surgery; **renal dysfunction=baseline serum 
creatinine >1.5 mg/dl; ††renal failure= peak post-operative serum creatinine > + 0.5 mg/dl (> 44 umol/L) within three days 
after surgery compared with preoperative serum creatinine ‡‡Excluding patients who were on preoperative dialysis
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Furthermore, we conclude that CCV death is the major cause of perioperative and long-term mortal-
ity among vascular surgical patients with PAD (76% and 46%, respectively). Cardiac risk factors and 
perioperative cardiac complications are associated with long-term cardiac death, but non-cardiac 
complications including infection, stroke, amputation, acute renal failure, and dialysis dependency 
are mainly related with all-cause mortality.
The type of vascular surgery was found to be an independent risk factor for an adverse outcome 
in the perioperative period but not during the long-term follow-up. The long-term prognosis of 
patients undergoing acute repair of the ruptured abdominal aorta is similar to patients undergoing 
elective AAA surgery, contrary to the perioperative period. Similar results were observed by Soisalon-
Soininen et al.11 among 1,070 patients undergoing repair of ruptured and nonruptured abdominal 
aorta aneurysms.
Aggressive treatment of atherosclerotic risk factors (i.e. hypertension, diabetes mellitus, smoking, and 
hypercholesterolemia) and usage of cardioprotective medications (i.e. beta-blockers, statins, aspirin, 
and ACE inhibitors) are recommended for PAD patients, because they are associated with improved 
long-term survival12-14. However, in our matched PAD and CAD population for cardiovascular risk fac-
tors, we clearly observed an underuse of cardiac medication among patients with PAD. McDermott 
et al.8 reported that patients with CAD, compared with PAD patients, are treated more frequently 
with aspirin and lipid-lowering medication (82% vs. 37% and 56% vs. 40%, respectively). Overall, the 
undertreatment of PAD patients can explain their worse long-term outcome when compared with 
CAD patients.
Peripheral atherosclerotic disease is becoming an increasingly important health issue in Western 
society; it affects between 8 to 12 million adults15. The introduction of endovascular repair has the 
potential to improve the outcome for PAD patients undergoing non-cardiac surgery because of its 
reduced perioperative myocardial stress16. This technique is currently considered as a promising alter-
native, especially in high-risk cardiac patients. In addition, new cardioprotective strategies, including 
medical therapy17 and prophylactic coronary interventions18, are currently being evaluated in these 
patients. Though the preliminary results of endovascular repair are promising and associated with 
improved immediate post-operative outcome, the beneficial effect on long-term survival remains 
controversial3,19,20. We described the results of open surgery in a tertiary hospital in relation to long-
term outcome of patients undergoing different types of vascular surgery. The results of this study 
will provide useful information to compare long-term outcome between open and endovascular 
surgery.
We do think that propensity matching is appropriate in this study setting. In this study, we deal with 
patients with the same underlying disease, namely generalized atherosclerosis. However, patients 
with PAD present themselves with different clinical symptoms (e.g. claudication), compared with the 
more cardiac-related complications (e.g. angina) observed in CAD patients. We used the propensity 
score to compare survival of patients with generalized atherosclerosis with the same risk profile with 
2 different treatments (PAD or CAD).
Study limitations
First, the study is not a randomized clinical trial but an observational study of a propensity-matched 
cohort. Despite using propensity to adjust as much as possible for the bias inherent in the decision 
about being PAD or CAD patients, we cannot exclude the possibility of residual confounding. As can 
be seen in TABLE 31.1, the PAD and CAD populations differed significantly, and by using the propensity 
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score matching procedure, the resulting matched CAD cohort ultimately reassembled the PAD cohort. 
We did not match the PAD and CAD database with the risk factor hypercholesterolemia, because of 
the inconsistency of the CAD database regarding the reporting of hypercholesterolemia during the 
early stage of our study period. Second, although data were prospectively collected, this analysis 
is retrospective. Because of the acute setting of r-AAA patients, not all the baseline characteristics 
were completely recorded in the admission data, which might result in an underdiagnosis of some 
risk factors. Third, changes in the perioperative management have evolved markedly over time and 
were not taken into account in our analysis. These include multiple factors ranging from preoperative 
management, such as drug therapy, to anesthesiological and surgical techniques to intensive post-
surgical care management. We tried to adjust for this confounding by adding the year of operation 
in our multivariate analysis (as a categorical variable per 2 years). We did not investigate our results 
across different time periods, because we did not observe different perioperative (30-day) outcomes 
in the PAD database over time. Finally, in our cohort, we found a remarkably low incidence of diabetes 
mellitus (15%). The diagnosis of diabetes mellitus was based on the requirement for insulin therapy, 
hypoglycemic agents, or as fasting blood glucose ≥ 140 mg/dl. In patients qualified as nondiabetics 
with PAD, fasting glucose levels may be normal, and the diagnosis of diabetes is only made after a 
glucose loading test. Unfortunately, we did not routinely perform a loading test for patients with a 
normal fasting glucose. Therefore, the number of diabetics might be underestimated.
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ABSTRACT
Background: Little is known about acute changes of renal function in the postoperative period, and 
outcome of patients undergoing major vascular surgery. Specifically, data are scarce in patients in 
whom renal function is temporarily decreased and returns to baseline at 3 days after surgery.
Methods: 1324 patients who underwent elective open abdominal aortic aneurysm surgery in a 
single center were studied. Renal function (creatinine clearance, CrCl) was measured preoperatively 
and on days 1, 2 and 3 after surgery. Patients were divided into 3 groups: (1) improved or unchanged 
(∆CrCl ± 10% function compared to baseline value); (2) temporary worsening (worsening >10% at 
day 1 or 2, then complete recovery within 10% of baseline value at day 3); (3) persistent worsening 
(>10% decrease compared to baseline value). Outcome measure was all-cause mortality.
Results: 30-day mortality was 1.3%, 5.0% and 12.6% in the three groups, respectively. Adjusted 
for baseline characteristics and postoperative complications, 30-day mortality was the highest in 
patients with a persistent worsening of renal function (hazard ratio [HR]: 7.3, 95% confidence interval 
[CI]: 2.7-19.8), followed by those with temporary worsening (HR: 3.7, 95%CI: 1.4-9.9). During 6.0 ± 3.4 
years follow-up, 348 (36.5%) patients died. The risk of late mortality was 1.7 (95%CI: 1.3-2.3) in the 
persistent worsening group followed by those with temporary worsening (HR: 1.5, 95%CI: 1.2-1.4).
Conclusions: Although renal function may recover completely after aortic surgery temporary 
decreased renal function was associated with an increased long-term mortality.
Perioperative temporary worsening of renal function 353
INTRODuCTION
Atherosclerosis is a generalized disease with symptoms ranging from angina pectoris, myocardial 
infarction, stroke to claudication. The major cause of abdominal aortic aneurysm [AAA] is athero-
sclerosis and is frequently associated with impaired organ function, a true determinant of long-term 
survival following surgery1. Renal dysfunction with or without symptoms is often present, and is 
considered to be a marker for the presence and severity of underlying vascular disease2-4. Postop-
erative decreased renal function is a well known feared complication after major vascular surgery 
and associated with increased long-term mortality5,6. The incidence rate varies between 2 to 45% 
(ranging from mild renal dysfunction to chronic hemodialysis)6-9. The pathogenesis of postoperative 
decreased renal function is multifactorial10. Poor baseline renal function, perioperative blood loss, 
use of nephrotoxic agents, suprarenal aortic cross-clamping time, high intraabdominal pressure, sys-
temic or regional hypoperfusion, temporary hypotension and ligation of renal veins during surgery 
all negatively affect postoperative renal function. All these factors combined can cause acute renal 
failure with a high periprocedural mortality rate of 50–80%11-13. In patients with abnormal kidney 
function at baseline, postoperative chronic renal dysfunction requiring renal replacement therapy is 
common. In order to prevent this devastating complication, it is recommended to take every possible 
measure to minimize the risk5,11,14.  Importantly, even subtle changes in postoperative renal function 
might identify patients at risk.
However, little is known about acute changes of renal function in the postoperative period, and its 
short and long-term outcome of patients undergoing major vascular surgery. Specifically, data are 
scarce in patients in whom renal function is temporarily decreased and returns to baseline value 
within three days after surgery; i.e. temporary worsening of renal function. Hence, the purpose of this 
observational study was to describe the predictive value of postoperative renal function changes, 
especially in those with temporary worsening of renal function, of patients undergoing AAA sur-
gery.
METhODS
Study design and patient selection
Between January 1995 and June 2006, 1 324 patients underwent open infrarenal abdominal aortic 
aneurysm [AAA] repair at the Erasmus Medical Centre, Rotterdam, the Netherlands and were entered 
into a computerized database. Exclusion criteria were patients with a baseline creatinine clearance 
of <30 mL/min (0.5 mL/s), those on chronic hemodialysis, patients who died within three days after 
surgery, endovascular surgery and patients who required additional renal revascularization.
Renal function assessment
Serum creatinine was assessed by a nonkinetic alkaline picrate (Jaffe) method15. The renal function 
or creatinine clearance [CrCl] was computed with the Cockcroft and Gault formula from serum crea-
tinine, age, gender and body weight. The following equation was used: Creatinine clearance (CrCl, 
mL/min/1.73m²) = (140 – age/years) * (body weight/kg)/72 * serum creatinine (mg/dL), multiplied by 
0.85 in women16.
This equation gives a more accurate assessment of renal function than serum creatinine alone17-19.
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Renal function groups
The serum creatinine (mg/dL) was measured preoperatively at baseline, and postoperatively at day 
1, day 2 and day 3. Patients were divided into three groups, based on changes in estimated CrCl from 
baseline to day 1 or 2 and from day 1 or 2 to day 3: group 1: improved or unchanged renal function 
(∆CrCl between -10% to +10% function compared to baseline value); group 2: temporary worsening 
of renal function (temporary worsening of >10% at day 1 or 2, then complete recovery within 10% of 
baseline value at day 3); group 3: persistent worsening of renal function (>10% decrease compared to 
baseline value). Baseline creatinine clearance was defined as the value recorded just before surgery, 
when data were not available, the measurements in the preceding days before surgery were used.
Clinical follow-up and end points
Perioperative clinical information was retrieved from an electronic database of patients maintained 
in our hospital. On occasion, missing data were abstracted retrospectively by reviewing patients’ 
medical records. From the municipal civil registries, we obtained the survival status. The follow-up was 
complete in 98.2%. The primary outcome was overall 30-day and long-term all-cause mortality after 
AAA surgery, verified by contacting the patient’s primary physician and reviewing medical records. 
Mortality at 30 days was defined as all deaths occurring during postoperative in-hospital stay or after 
hospital discharge but within the first 30 days after surgery. Long-term mortality was defined as 
death occurring in the first ten years after surgery. The causes of death were grouped into 3 different 
categories: (1) cerebro-cardiovascular death [CCVD], (2) non-cerebrocardiovascular death [non-CCVD] 
and (3) unknown cause of death. Cerebro-cardiovascular death was defined as any death with a 
cerebro-cardiovascular complication as the primary or secondary cause and included deaths following 
myocardial infarction (MI), serious cardiac arrhythmias (defined as the presence of a sustained cardiac 
rhythm disturbance that required urgent medical intervention), congestive heart failure, stroke [cerebro 
vascular accident (CVA) or transient ischemic attack (TIA)], surgery-related fatal bleeding complications 
and others. Sudden unexpected death was classified as a CCVD. Non-CCVD was defined as any death 
with a principal non-cerebro-cardiovascular cause, including infection, malignancy, respiratory insuffi-
ciency and others. The cause of death was ascertained by reviewing medical records, the computerized 
hospital database, autopsy reports, or by contacting the referring physician or general practitioner. The 
secondary outcome was short-term complications (perioperative and during postoperative in-hospital 
stay within 30 days or after hospital discharge but within the first 30 days after surgery). The complica-
tions noted are infection, stroke, coronary revascularization [coronary artery bypass grafting (CABG) or 
percutaneous coronary intervention (PCI)], heart failure, limb amputation, limb necrosis, hemorrhage 
(vascular bleeding leading to a hypotensive state (systolic pressure of <100 mmHg) and requirement 
of blood transfusions) and new postoperative dialysis (temporary or persistent).
Statistical analyses
Continuous data are described as mean values and its standard deviation (±SD) or as median (and cor-
responding interquartile range), and dichotomous data are described as percentage frequencies. The 
analysis of variance (ANOVA) with Bonferroni test was used for continuous variables and chi-square 
test was used for categorical variables. The probability of all-cause mortality was calculated by the 
Kaplan-Meier method and the resulting curves were compared by the log rank test. We performed 
multivariate Cox regression analyses to investigate the independent value of CrCl for perioperative 
and long-term mortality, after adjustment for age, gender, cardiovascular risk factors [e.g. hyperten-
sion (defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg or use of 
cardiovascular medication), diabetes mellitus (the presence of a fasting blood glucose ≥ 140 mg/
dl (≥ 7.8 mmol/L) or requirement for insulin or oral hypoglycemic agents), smoking status, hyper-
cholesterolemia [total cholesterol of > 200 mg/dl (> 5.2 mmol/L)], chronic obstructive pulmonary 
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disease (COPD), according to symptoms and pulmonary function tests (i.e. forced expiratory volume 
in one second (FEV1) <70% of maximal age and gender predictive value), body mass index (BMI) and 
medication usage (statins, diuretics, angiotensin-converting-enzyme inhibitors, calcium antagonists, 
nitrates, beta-blockers, digitalis and aspirin), presence of ischemic heart disease (prior myocardial 
infarction, prior coronary revascularization and angina pectoris), heart failure (defined according to 
the New York Heart Association classification), baseline creatinine clearance and short-term complica-
tions (infection, stroke, coronary intervention, heart failure, amputation, limb necrosis, hemorrhage 
and dialysis requirement). All prescription and over-the-counter medications were noted on the 
day of admission. Data are presented as Hazard Ratios [HRs] with 95% confidence intervals [CIs]. A 
p value of <0.05 was considered significant. The proportional hazards assumptions were tested by 
constructing interaction terms between the variables and time to each end-point. Cox regression 
analyses showed no statistically significant interaction with time (each p value >0.05). All computa-
tions were performed with SPSS software version 12.0.1 (SPSS Inc., Chicago, Illinois, USA), running 
under Windows 2000 Professional.
RESuLTS
Patient characteristics
A total of 1 324 patients underwent AAA surgery. After exclusion of patients with a preoperative crea-
tinine clearance of <30 mL/min (0.5 mL/s) (n=86), those on chronic hemodialysis (n=8), endovascular 
surgery (n=236), those patients who died within three days after surgery (n=31) and patients who 
required additional renal revascularization (n=11), the population included in the analysis was 952 
patients. Of 28 (2.9%) patients, missing data were abstracted by reviewing patients’ medical records. 
Mean age was 66 ± 14 years and 80% were men. Improved or unchanged renal function, temporary 
worsening of renal function and persistent worsening of renal function were present in 56%, 27% 
and 17% of the patient’s population, respectively. In the whole population, a slight decrease in CrCl 
was observed within three days after surgery (mean CrCl day 1 or 2 after surgery is 76 ± 40 ml/min 
(1.27 ± 0.67 mL/s), on day 3 it was noticed to be 77 ± 44 ml/min (1.28 ± 0.73 mL/s), compared with 
a preoperative CrCl of 81 ± 34 ml/min (1.35 ± 0.57 mL/s). Mean changes in CrCl on day 1 or 2 and 
on day 3 for the temporary and persistent worsening of renal function groups were -30%/-7% and 
-35%/-46% compared with baseline value, respectively (FIGURE 32.1). The baseline characteristics in 
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Figure 32.1 Subdivision of the renal function groups, based on the creatinine clearance [CrCl] response, with mean 
changes of CrCl (% ± SD).
Improved or unchanged renal function: ∆ creatinine clearance between –10% to +10% function 
compared to baseline value; temporary worsening of renal function: temporarily worsening >10% at 
day 1 or 2, then complete recovery within 10% of baseline value at day 3; persistent worsening of renal 
function:>10% decrease compared to baseline value.
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the three groups were similar for renal function and cerebro-cardiovascular risk factors (TABLE 32.1). 
Only a higher incidence of hypertension was observed in the temporary and persistent worsening 
renal function groups. A significant association between total perioperative blood loss and suprare-
nal aortic cross-clamping time was found with worsening of renal function (p <0.001). No significant 
difference in aortic cross-clamping time between the temporary and persistent worsening renal 
function group was observed (p=0.3).
Table 32.1 Baseline characteristics of the abdominal aortic aneurysm group.
All patients
952 (100%)
Improved or
unchanged 
renal function
535 (56%)
Temporary
worsening of 
renal function
258 (27%)
Persistent
worsening of 
renal function
159 (17%)
p-value
Demographics
 Mean age (± SD) 66 (± 14) 65 (± 14) 67 (± 14) 66 (± 14) 0.1
 Male (%) 79 80 76 83 0.2
Cardiovascular risk factor (%)
 Hypertension 41 36 47 50 <0.001
 Diabetes Mellitus 6 6 5 9 0.3
 Current smoker 31 30 33 31 0.8
 Elevated cholesterol 23 23 28 16 0.1
 COPD† 21 19 23 26 0.1
 Body mass index (± SD) 25 (± 4) 25 (± 4) 25 (± 4) 26 (± 3) 0.1
  Baseline serum creatinine (mg/dl) (± SD) 1.0 (± 0.3) 1.0 (± 0.3) 1.0 (± 0.3) 1.1 (± 0.3) 0.5
  Baseline creatinine clearance (mL/min) (± SD) 81 (± 34) 80 (± 30) 80 (± 36) 83 (± 41) 0.7
Disease history (%)
 Previous MI‡ 30 28 31 37 0.3
 Previous CABG* 14 14 16 12 0.5
 Previous PCI° 6 6 7 5 0.8
 Previous heart failure 5 5 4 6 0.6
 Angina 15 15 12 16 0.6
Medication use (%)
 Statins 23 22 27 23 0.3
 Diuretics 12 10 14 13 0.2
 ACE-inhibitors¯ 24 22 25 29 0.2
 Calcium antagonists 30 27 35 33 0.07
 Nitrates 15 16 13 17 0.4
 Beta-blockers 34 34 33 37 0.7
 Digitalis 3 2 4 3 0.6
 Aspirin 21 22 22 18 0.6
Surgery parameters (median ± SD)
 Total blood loss (ml) 2250(± 2720) 2000(± 1946) 2500(± 2449) 3200(± 4356) <0.001
 SACCT (min)ˆ 51 (± 29) 40 (± 21) 54 (± 28) 63 (± 30) <0.001
†COPD= Chronic Obstructive Pulmonary Disease; ‡MI= Myocardial Infarction; *CABG= Coronary Artery Bypass Graft; °PCI= 
Percutaneous Coronary Intervention; ¯ACE-inhibitors= angiotensin-converting-enzyme inhibitors; ˆSACCT= suprarenal 
aortic cross-clamping time Creatinine clearance (ml/min/1.73m²) estimated by Cockcroft and Gault formula; Improved or 
unchanged renal function: ∆ creatinine clearance between –10% to +10% function compared to baseline value; temporary 
worsening of renal function: temporarily worsening >10% at day 1 or 2, then complete recovery within 10% of baseline 
value at day 3; persistent worsening of renal function: >10% decrease compared to baseline value. NOTE. To convert serum 
creatinine in mg/dl to umol/L, multiply by 88.4; creatinine clearance in ml/min to mL/s, multiply by 0.01667.
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Short-term outcome
Overall 30-day mortality was 1.3%, 5.0% and 12.6% in the three renal function groups, respectively. 
The survival was significantly worse in the temporary and persistent worsening renal function 
group, compared with those with an improved or unchanged renal function (p <0.001), as shown 
in the Kaplan-Meier (FIGURE 32.2). Both the unadjusted and adjusted regression analysis showed a 
significant difference in risk of 30-day mortality (TABLE 32.2). The Hazard Ratios of the temporary and 
persistent worsening of renal function groups were compared with the improved or unchanged renal 
function group. The unadjusted HRs were 4.0 (95% CI: 1.6–10.2) followed with 10.9 (95% CI: 4.5–26.2). 
After adjustment, they were 3.7 (95% CI: 1.4–9.9) and 7.3 (95% CI: 2.7–19.8), respectively. The adjusted 
HR for baseline creatinine clearance was 0.975 (95% CI: 0.958–0.993, p=0.007) per 1 ml/min increase 
in CrCl. Other important risk factors were hemorrhage (HR 3.3, 95%CI: 1.3–8.3), COPD (HR 3.0, 95%CI: 
1.4–6.4), myocardial infarction (HR 7.5, 95%CI: 2.1–27.1) and dialysis (HR 6.3, 95%CI: 1.9–21.3). Beta-
blocker use was associated with improved short-term outcome (HR 0.3, 95%CI: 0.1–0.9). Patients with 
a persistent worsening of renal function had more frequently hemorrhages (p <0.001) and required 
postoperative initiation of dialysis more often, compared with the other two renal function groups 
(TABLE 32.3).
Long-term outcome
A total of 348 (36.5%) patients died within the 10 years follow-up (mean 6.0 ± 3.4 years). In the 
improved or unchanged renal function group 30.8% patients died, followed with 43.4% and 46.5% 
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Figure 32.2 All cause short-term mortality in 952 patients who underwent abdominal aortic aneurysm surgery, 
according to three renal function groups.
Improved or unchanged renal function: ∆ creatinine clearance between –10% to +10% function 
compared to baseline value; temporary worsening of renal function: temporarily worsening >10% at 
day 1 or 2, then complete recovery within 10% of baseline value at day 3; persistent worsening of renal 
function>10% decrease compared to baseline value.
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Table 32.2
Unadjusted and adjusted predictors of estimate risk of short and long-tem mortality in the abdominal 
aortic aneurysm group (n=983).
Unadjusted HRs
(95% CI)
Adjusted* HRs
(95% CI)
30-day outcome
 Improved or unchanged renal function 1.0 1.0
 Temporary worsening of renal function 4.0 (1.6 – 10.2) 3.7 (1.4 – 9.9)
 Persistent worsening renal function 10.9 (4.5 – 26.2) 7.3 (2.7 – 19.8)
10-year outcome
 Improved or unchanged renal function 1.0 1.0
 Temporary worsening of renal function 1.7 (1.3 – 2.1) 1.5 (1.2 – 1.9)
 Persistent worsening renal function 2.1 (1.6 – 2.7) 1.7 (1.3 – 2.3)
*Adjusted for age, gender, hypertension, diabetes mellitus, smoking, hypercholesterolemia, COPD, BMI, prior myocardial 
infarction, prior coronary revascularization (percuntaneous coronary intervention and coronary artery bypass grafting), 
angina pectoris, heart failure, baseline creatinine clearance, medication (statins, diuretics, angiotensin-converting-enzyme 
inhibitors, calcium antagonists, nitrates, beta-blockers, digitalis and aspirin) and short-term complications (infection, 
stroke, coronary intervention, hart failure, amputation, limb necrosis, hemorrhage and dialysis). Improved or unchanged 
renal function∆ creatinine clearance between –10% to +10% function compared to baseline value; temporary worsening 
of renal function: temporarily worsening >10% at day 1 or 2, then complete recovery within 10% of baseline value at day 3; 
persistent worsening of renal function: >10% decrease compared to baseline value.
Table 32.3 Short-term complications after abdominal aortic aneurysm surgery.
All patients
952 (100%)
Improved or
unchanged renal 
function
535 (56%)
Temporary
worsening of renal 
function
258 (27%)
Persistent
worsening of renal 
function
159 (17%)
p-value
Complications n (%)
Infection 177 (19) 88 (16) 57 (22) 32 (20) 0.1
 Wound 25 (3) 14 (3) 8 (3) 3 (2) 0.7
 Pneumonia 91 (10) 39 (7) 32 (14) 20 (13) 0.02
 Sepsis 11 (1) 4 (1) 2 (1) 5 (3) 0.05
 Urinary tract infection 32 (3) 22 (4) 10 (4) 0 (0) 0.03
 Rest 18 (2) 9 (2) 5 (2) 4 (3) 0.8
Stroke 21 (2) 8 (2) 6 (2) 7 (4) 0.1
Coronary intervention 13 (1) 5 (<1) 3 (1) 5 (3) 0.2
Heart failure 20 (2) 9 (2) 5 (2) 6 (4) 0.3
Amputation 12 (1) 4 (1) 3 (1) 5 (3) 0.06
Limb necrosis 23 (2) 10 (2) 7 (3) 6 (3) 0.5
Hemorrhage 60 (6) 24 (4) 14 (5) 22 (14) <0.001
Dialysis† 26 (3) 1 (<1) 3 (1) 22 (14) <0.001
 Temporary dialysis 23 (2) 1 (<1) 3 (1) 19 (12) <0.001
 Persistent dialysis 3 (1) 0 (0) 0 (0) 3 (2) 0.001
Coronary intervention=coronary artery bypass grafting or percutaneous coronary intervention; hemorrhage= 
vascular bleeding leading to a hypotensive state (systolic pressure of <100 mmHg) and requirement of packet cells; 
dialysis=requirement of new postoperative temporary or persistent dialysis. Improved or unchanged renal function∆ 
creatinine clearance between –10% to +10% function compared to baseline value; temporary worsening of renal function: 
temporarily worsening >10% at day 1 or 2, then complete recovery within 10% of baseline value at day 3; persistent 
worsening of renal function: >10% decrease compared to baseline value.† excluding 8 patients on chronic haemodialysis
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in the temporary and persistent worsening of renal function groups. During the long-term follow-up, 
patients with temporary worsening of renal function had the same long-term prognosis as patients 
with persistent worsening of renal function (log rank p=0.18) (FIGURE 32.3).
In adjusted analysis, significant risk factors for long-term all-cause mortality included age (HR 1.02, 
95%CI: 1.006–1.03, per 1 year increase in age), COPD (HR 1.8, 95%CI: 1.4–2.3), baseline CrCl (HR 0.992, 
95%CI: 0.988–0.997 per 1 ml/min increase in CrCl), stroke (HR 1.5, 95%CI: 1.1–2.0), dialysis (HR 2.6, 
95%CI: 1.5–4.6) and hemorrhage (HR 1.5, 95%CI: 1.01–2.2). Statin use was associated with improved 
long-term outcome (HR 0.69, 95%CI: 0.5–0.96).
Cerebro-cardiovascular events (157 (45%)) were the major cause of death which included: MI 19%, 
congestive hart failure 9%, arrhythmia 2%, stroke 7%, fatal bleeding 5% and others 3%. The non-
cerebro-cardiovascular (115 (33%)) events included: infection 7%, malignancy 9%, respiratory insuf-
ficient 7% and others 10%. An unknown cause of death was only determined in 76 (22%) patients.
DISCuSSION
The main finding of our study is that renal function changes within the first three days after abdomi-
nal aortic aneurysm (AAA) surgery is a predictor for perioperative and long-term mortality. Although, 
renal function may recover completely after aortic surgery with a more or less favorable 30-day 
outcome, they are at high risk for long-term mortality, while patients with a persistent worsening of 
renal function are most likely to have a poor 30-day and long-term prognosis.
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Figure 32.2 All cause long-term mortality in 952 patients who underwent abdominal aortic aneurysm surgery, 
according to three renal function groups.
Improved or unchanged renal function: ∆ creatinine clearance between –10% to +10% function 
compared to baseline value; temporary worsening of renal function: temporarily worsening >10% at 
day 1 or 2, then complete recovery within 10% of baseline value at day 3; persistent worsening of renal 
function: >10% decrease compared to baseline value.
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The temporary and persistent worsening renal function groups have a higher incidence of hyperten-
sion, compared with the improved or unchanged group. Also the total blood loss and suprarenal 
aortic cross-clamping time as postoperative complications are significantly higher. All these risk 
factors combined, indicate that these two groups are predisposed for a higher risk of postoperative 
renal failure and thereby mortality11,20-22.
As mentioned before, the etiology of developing postoperative renal failure after aortic surgery 
is multifactorial. Renal function prior to surgery, total blood loss, the use of nephrotoxic agents, 
preexisting atherosclerosis, hypertension, suprarenal aortic cross-clamping time and ligation of renal 
veins during the operation all negatively affect postoperative renal function and, in turn, leads to 
death20,23-25.
Suprarenal aortic cross-clamping is required in about 15% of operations for infrarenal vascular disease 
resulting in renal hypoxia reperfusion injury, which is an inevitable consequence. When limb ischemia 
is also present, muscle necrosis and myoglobinuria might also be present, all negatively affecting 
renal function26. A safe renal ischemia time has been determined to be between 45–50 minutes20,27. 
The median cross-clamping times of the temporary and persistent worsening renal groups are higher 
than the above cutoff, however there was no significant differences in clamping time between these 
groups. An intraoperative blood loss exceeding 2000 ml has also been found to be an independent 
predictor of 30-day mortality in patients with a ruptured AAA22.  Since the temporary and persistent 
worsening of renal function groups have a total blood loss higher than 2000 ml, they were at high risk 
for an increase 30-day mortality.
Lassnigg, et al. suggested that patients who survived the first 30 days after cardiothoracic surgery and 
had sufficient recovery of renal functions regained the same long-term prognosis as patients without 
temporary impaired renal function21. In our study, patients with temporary renal function changes 
had a worse 30-day survival than patients without renal function changes (log rank p = 0.002), but 
they never regain the same long-term (10 years) prognosis (log rank p <0.001). Actually, the trend 
is that patients with temporary renal function changes have even a worse long-term outcome than 
those with persistent worsening of renal function. The high-risk patients, with persistent worsening 
of renal function, die mainly within the first 30 days, so the diluting effect of renal function changes is 
less for the long-term mortality outcome. The risk of developing severe non-renal complications that 
might lead to death, is increased further by renal injury itself and can be explained by the extent and 
pattern of preexisting co morbidities.
The effect of acute changes (within the first three days) on renal function after AAA surgery was 
also investigated by Ellenberger, et al6. They reported the highest mortality rate within 30-days 
of patients with serum creatinine increases of > 0.5 mg/dl (> 44 umol/L) compared with baseline, 
again indicating that renal function changes within three days after surgery, is a strong predictor for 
perioperative mortality. However, long-term mortality was not evaluated and serum creatinine was 
used as a marker for renal function. Even though serum creatinine is considered to be a practical 
and reasonable approach to use for the evaluation of renal dysfunction, we chose CrCl as a more 
accurate measurement of renal function, as recommended by the recent National Kidney Foundation 
guidelines28.
In our cohort, we found a remarkably low incidence of diabetes mellitus (6%). Earlier cohorts of 
AAA repair reported an incidence of 12-13%29,30. The diagnosis of diabetes mellitus was based on 
requirement for insulin therapy, hypoglycemic agents or as fasting blood glucose ≥ 140 mg/dl (≥ 7.8 
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mmol/L). However, fasting glucose concentrations were not routinely assessed and may have caused 
an under diagnosis of diabetes.
A major limitation of our study is the retrospective analysis of the data. In addition, not all periopera-
tive data (duration of aortic cross clamping, transfusion requirements, need for additional surgical 
interventions, time to extubation, admission in intensive care unit, use of medication) were available 
to implement these parameters in our analysis. Furthermore, changes in the perioperative manage-
ment have evolved markedly over time and were not taken into account in our analysis. These include 
multiple factors ranging from preoperative management, such as drug therapy, anesthesiological 
and surgical techniques to intensive post-surgical care management.
It is well established that a key impediment in the field of Acute Renal Failure [ARF], is a lack of uni-
form definition in the changes of kidney function. Current definitions that relay on changes in serum 
creatinine and urine output are neither sensitive nor specific. In a recent publication31, the authors 
were able to describe 19 different definitions of ARF (ranging from –20% to –100% changes in serum 
creatinine or an increase in serum creatinine ranging from ≥ 0.3 mg/dl (≥ 27 umol/L) to ≥ 1.0 mg/dl 
(≥ 88 umol/L)). Although none of these cutoffs were evaluated, when comparing our arbitrary defini-
tion of change of kidney function with most other published definitions we found that our cutoff is 
extremely conservative. As the main objective of this study was to evaluate the association between 
small changes of renal function in relation to outcome, we have chosen a cutoff of 10% change. 
Furthermore, kidney function estimating equations (e.g. Cockcroft Gault) are derived in patients 
who were in a steady state. Since we reported perioperative estimated creatinine clearance changes 
(within three days after surgery) by definition, such a steady state is difficult to establish, which might 
underestimate true changes in kidney function. Unfortunately, there are no practical ways to readily 
measure kidney function in the acute setting. The strength of our study is that this retrospective study 
covers a long time period (6.0 ± 3.4 years) and includes a large number of patients. Few studies have 
focused on the long-term outcome of a temporary decrease in renal function shortly after surgery.
In conclusion, patients with temporary worsening of renal function are at high risk for poor 
long-term outcome suggesting that these patients might need more close medical follow-up than 
suggested previously.
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ABSTRACT
Objective: To evaluate the effect of statins on aneurysm growth in a group of consecutive patients 
under surveillance for infrarenal aortic aneurysms (AAA).
Methods: All patients (59 statin users, 91 non-users) under surveillance between January 2002 and 
August 2005 with a follow-up for aneurysm growth of at least 12 months and a minimum of three 
diameter evaluations were retrospectively included in the analysis. Multiple regression analysis, 
weighted with the number of observations, was performed to test the influence of statins on AAA 
growth rate.
Results: During a median period of 3.1 (1.1–13.1) years the overall mean aneurysm growth rate was 
2.95±2.8 mm/year. Statin users had a 1.16 mm/year lower AAA growth rate compared to non-users 
(95% CI 0.33–1.99 mm/year). Increased age was associated with a slower growth (−0.09 mm/year 
per year, p=0.003). Female gender (+1.82 mm/year, p=0.008) and aneurysm diameter (+0.06 mm/
year per mm, p=0.049) were associated with increased AAA growth. The use of non-steroidal anti-
inflammatory drugs, chronic lung disease, or other cardiovascular risk factors were not independently 
associated with AAA growth.
Conclusions: Statins appear to be associated with attenuation of AAA growth, irrespective of other 
known factors influencing aneurysm growth.
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INTRODuCTION
Abdominal aortic aneurysm (AAA) occurs frequently in the elderly population, i.e. a prevalence of 
5–7% in males between 65 and 74 years, increasing to over 10% in males over 74 years of age1-3. 
The overall mortality from ruptured AAA remains high, i.e. up to 75%, and preventive elective repair 
of large AAAs appears to be the best option4. Screening for AAA in populations at increased risk, 
i.e. elderly males, to detect those who will benefit from elective repair seems to be safe and cost-
effective1-5. However, perioperative complications of elective AAA repair remain a significant problem 
despite recent advances such as cardioprotective medication6,7 and endovascular repair8,9.
Therefore, an attractive option would be the slowing of AAA growth, thereby preventing the AAA to 
reach a size requiring surgical intervention. However, the pathogenesis of AAA growth and factors 
that determine this growth, leading eventually to rupture, remain ill-defined. Recently, several stud-
ies were performed to identify risk factors that were associated with aneurysmal growth on the level 
of the human aorta itself using cell cultures obtained by aortic wall biopsies. Important factors in this 
respect are inflammation markers such as interleukin-610,11 and specific matrix metalloproteinases 
(MMPs) inducing collagen and elastin degradation in the aortic wall12. Importantly, drugs with an 
anti-inflammatory action such as prostaglandin synthetase inhibitors reduce the inflammatory 
response and are associated, in a case–control study in humans, with a reduced aneurysm growth 
rate13.
Statins (3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors) are known to be highly 
effective drugs for reducing LDL–cholesterol levels and improve long-term outcome in patients with 
or at risk for coronary artery disease. Recently other, so-called ‘pleiotropic’, effects of statins were 
described14. Statins alter the inflammatory status, e.g. a reduction of IL-6 release, and may modulate 
the release of several substances in the arterial wall, including MMPs15. Recently, results of animal 
studies suggested an association between statin use and suppression of the development of aortic 
aneurysms due to these pleiotropic effects16.
However, so far no data are available on the influence of statins on growth of abdominal aneurysms 
in humans. Therefore, we conducted the present study with the aim to evaluate the effect of statins 
on aneurysm growth in a group of consecutive patients under surveillance for infrarenal aortic 
aneurysms.
METhODS
Patient population
The study population was composed of patients who were under surveillance for infrarenal abdominal 
aortic aneurysm at two hospitals, Erasmus Medical Center in Rotterdam and Reinier de Graaf Gasthuis 
in Delft, in The Netherlands between January 2002 and August 2005. Patients were retrospectively 
identified by screening of surgical medical charts. Patients with an inflammatory (n=12) or mycotic 
aneurysm (n=1) were excluded from analysis. All patients had a follow-up for aneurysm growth of 
at least 12 months. A minimum of three separate diameter evaluations was required to calculate 
aneurysm growth rates. The Medical Ethics Committee of the Erasmus Medical Center was informed 
about the study protocol, and per institutional practice no official approval was requested.
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Patient characteristics
All patients were screened for cardiac risk factors, including age, hypertension, angina pectoris, previ-
ous myocardial infarction, heart failure, stroke, renal failure, diabetes mellitus, and symptoms of other 
peripheral arterial disease, i.e. intermittent claudication. Smoking status (never, current, or former) 
and presence of chronic obstructive pulmonary disease (COPD) was noted as well. All prescription 
and over-the-counter medications were noted at the time of the first outpatient clinic visit and 
were classified as follows: statins, beta-blockers, aspirin, angiotensin converting enzyme inhibitors, 
calcium channel blockers; dihydropyridines or non-dihydropyridines, diuretics, nitrates, coumarins, 
digoxin and non-steroidal anti-inflammatory drugs (NSAIDs). Patients who started statins during the 
surveillance period were analyzed as non-users up to the date statin therapy was initiated. These 
patients were excluded from further analysis after initiation of statin therapy.
Follow-up
The protocol in both hospitals was to screen patients with abdominal aortic aneurysms every 6–12 
months by means of ultrasonography. All ultrasound measurements were performed by either a radi-
ologist or a trained and skilled sonographer. Inter- and intra-observer variability has been estimated, 
based on previous studies from our group, at 96 and 98%, respectively, in our hospital with good 
reproducibility.17 The diameter of the aorta was defined as the maximum anterior–posterior diameter. 
At each follow-up visit changes in medication use were noted. If the diameter of the aortic aneurysm 
exceeded 5.0 cm, the growth rate was more than 1 cm/year, or the aneurysm became symptomatic 
CT angiography was performed to evaluate the exact diameter and the possibility of endovascular 
repair. The results of the CT scan were not considered in this study. Patients who required surgery 
were censored at the last ultrasonographic measurement prior to surgery.
Statistical analysis
Continuous data were expressed as mean (±SD) or median (±interquartile range) and compared 
using the Student’s t-test or Mann–Whitney U-test as appropriate, i.e. whether there was a normal 
distribution or not. Categorical data are presented as percent frequencies and differences between 
proportions were compared using the chi-square test. The change in maximum AAA diameter was 
assumed to be linear over time and modeled using linear regression analysis. Growth rate of the AAA 
for each patient was estimated as the regression coefficient, using time as the independent variable 
and diameter of AAA as the dependent variable. The time unit was set to 6 months and this growth 
rate was then doubled to give AAA growth rate in millimeter per year. Multiple regression analysis 
was performed to test the influence of statins on AAA growth rate. In linear regression analysis annual 
growth rate was the dependent variable and age, gender, AAA diameter at initial presentation, NSAID 
use, statin use, and cardiovascular risk factors were used as independent variables. The analysis was 
weighted with the number of observations (i.e. number of ultrasound measurements) for each 
patient. The limit of statistical significance was set at p=0.05 (two sided). All analysis was performed 
using the statistical software SPSS for Windows 12.1 (SPSS Inc., Chicago, Illinois, USA).
RESuLTS
Baseline characteristics
The study population consisted of 150 patients (88% men). Mean age at first presentation was 69±7.6 
years. In total, 59 patients (39%) were chronic statin users. Of these 59 statin users, 24 were on sim-
vastatin, 19 on atorvastatin, 11 on fluvastatin, and five patients received pravastatin therapy. Baseline 
patient characteristics are shown in TABLE 33.1. There were no significant differences in medical 
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history between groups, except for the presence of intermittent claudication (29% in statin users 
vs. 10% in non-users, p=0.007). Concomitant medication use is presented in TABLE 33.2. Statin users 
more often were on warfarin derivatives (23 vs. 10%, p=0.03) and angiotensin II antagonists (16 vs. 
0%, p<0.001). The mean maximum diameter at first presentation of the AAA was 38±7.7 mm. Statin 
users had a significantly larger aneurysm at first presentation (40 vs. 37 mm, p=0.02).
Follow-up
Patients were under surveillance for a median period of 3.1 years (range 1.1–13.1), 2.9 years for statin 
users and 3.2 years for non-users (p=0.49), with the number of ultrasound examinations varying from 
3 to 12 with a mean of 4.7 measurements per patient (4.6 in users and 4.7 in non-users, p=0.89). The 
overall mean aneurysm growth rate during follow-up was 2.95±2.8 mm/year. Six patients had a nega-
tive value of annual aneurysm growth rate (three non-users and three users). All of these patients 
were included in the analysis. Exclusion of these patients did not result in significant alteration of the 
results.
Table 33.1 Clinical baseline characteristic at first screening visit.
Total Statin users Non-users p-value
N=150 N=59 N=91
Males – no. (%) 126 (88) 51 (91) 75 (86) 0.44
Age – yrs (SD) 69 (7.6) 69 (7.8) 69 (7.5) 0.94
AAA diameter – mm (SD) 38 (7.7) 40 (8.5) 37 (7.0) 0.02
Myocardial infarction – no. (%) 47 (31) 18 (30) 29 (32) 0.86
Angina pectoris – no. (%) 27 (18) 12 (20) 15 (17) 0.83
Congestive heart failure – no. (%) 11 (7) 6 (10) 5 (5) 0.36
CVA or TIA – no. (%) 19 (13) 8 (13) 11 (13) 1.0
Diabetes mellitus – no. (%) 19 (13) 9 (16) 10 (11) 0.32
Renal failure – no. (%) 7 (5) 5 (9) 2 (2) 0.11
Hypertension – no. (%) 64 (43) 28 (48) 36 (39) 0.30
COPD – no. (%) 41 (27) 17 (29) 24 (26) 0.85
Intermittent claudication – no. (%) 26 (17) 17 (29) 9 (10)* 0.01
Smoking – no. (%) 106 (71) 40 (68) 66 (72) 0.72
AAA= abdominal aortic aneurysm; CVA = cerebrovascular accident; TIA = transient ischemic attack; COPD = chronic 
obstructive pulmonary disease
Table 33.2 Medication use.
Total Statin users Non-users p-value
N=150 N=59 N=91
NSAID – no. (%) 60 (40) 27 (45) 33 (37) 0.38
Warfarin derivatives – no. (%) 23 (15) 14 (23) 9 (10)* 0.03
Beta-blockers – no. (%) 53 (35) 24 (41) 29 (32) 0.28
ACE inhibitors – no. (%) 38 (25) 12 (20) 26 (29) 0.24
Diuretics – no. (%) 35 (23) 18 (30) 17 (19) 0.11
Calcium antagonists – no. (%) 30 (21) 12 (21) 18 (21) 1.0
Nitrates – no. (%) 21 (14) 9 (16) 12 (13) 0.63
Angiotensin II antagonists – no. (%) 9 (6) 9 (16) 0* 0.01
Insulin or oral antidiabetic therapy – no. (%) 19 (13) 9 (16) 10 (11) 0.32
Pulmonary medication – no. (%) 21 (14) 6 (11) 15 (16) 0.38
NSAID = non-steroidal anti-inflammatory drugs; ACE = angiotensin converting enzyme
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In univariate analysis statin use was associated with a significant attenuation of aneurysm growth 
(p=0.001, FIGURE 33.1). Increasing age and intermittent claudication (p=0.02) also were associated 
with an attenuation of AAA growth rate. Other potential factors, such as diabetes mellitus, COPD, AAA 
diameter at first presentation or other medication use (in particular NSAID use), were not associated 
with a significant difference in aneurysm growth rate.
The results of multivariate linear regression analysis are shown in TABLE 33.3. In this analysis statin 
use, age, gender, and aneurysm size at first presentation were associated with a difference in AAA 
growth rate. Statin users had a significant 1.16 mm lower annual aneurysm growth rate compared 
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Figure 33.1 Difference in mean annual aneurysm growth rate between statin users (2.0 mm/year) and non-users 
(3.6 mm/year).
Table 33.3 Adjusted (corrected for other factors in the table) estimated difference in mean annual AAA growth.
Adj. estimated difference
(mm/year)
95% Confidence Interval
Lower bound    Upper bound
p-value
Age (per year increase) -0.09 -0.14 -0.03 0.003
Female +1.82 3.15 0.49 0.008
AAA diameter at first screening
(per mm increase)
+0.06 0.01 0.11 0.049
Claudication intermittens -0.89 -1.89 0.11 0.082
Diabetes mellitus -0.01 -1.25 1.24 0.989
COPD +0.70 -0.24 1.64 0.145
Statin use -1.16 -1.99 -0.33 0.006
NSAID use -0.13 -0.97 0.70 0.754
AAA = abdominal aortic aneurysm; COPD = chronic obstructive pulmonary disease; NSAID = non steroidal anti-
inflammatory drug.
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to non-users (95% CI 0.33–1.99 mm/year). For each year increase of age at first presentation the 
mean aneurysm size growth rate was slowed by 0.09 mm (95% CI 0.03–0.14 mm/year). Females had 
a significantly higher growth rate than males (mean difference 1.82 mm/year, 95% CI 0.49–3.15 mm/
year).
Aneurysm diameter at first presentation also was independently associated with annual aneurysm 
growth (0.06 mm/year increase per mm difference in AAA size, 95% CI 0.01–0.11). We did not find a 
significant influence of NSAID use, the presence of COPD, diabetes mellitus, or intermittent claudica-
tion on aneurysm growth rate.
DISCuSSION
This study showed an association between statin use and attenuation of infrarenal abdominal aortic 
aneurysm growth, irrespective of other known factors influencing aneurysm growth.
Statins frequently are prescribed to lower cholesterol levels as large prospective studies have shown 
an improved outcome in statin users, mainly by reduction of late cardiac events18-21. However, 
recently other effects independent of serum cholesterol levels, so-called pleiotropic or non-lipid 
lowering effects, have been described. These recently described pleiotropic effects of statins might 
be related to the observed attenuation of AAA growth.
The pathophysiology of aortic aneurysm development, growth and eventually rupture is still not fully 
understood. Inflammation responses aggravated by a genetic susceptibility are probably important 
determinants. Accumulation and activation of mononuclear inflammatory cells; increased expression 
of proinflammatory cytokines, chemokines and matrix-degrading proteinases; degradation of elastin 
and collagen; oxidative and hemodynamic stress; and depletion of smooth muscle cells seem all to 
play a pivotal role16. Some of these inflammatory responses such as interleukin-6 and matrix metal-
loproteinases (MMPs) could be assessed in animal aortic aneurysm models, by inducing collagen and 
elastin degradation of the aortic wall. The response of interleukin-6 release is also genetically deter-
mined as assessed by the increased levels of interleukin-6 in patients with the 174G/C genotype22. 
The combined effects of inflammatory response and genetic susceptibility in patients with other 
environmental risk factors as elderly age and smoking might be responsible for the development 
and growth of AAA.
Recently, Steinmetz et al.16 have shown in a mice model that statins suppress the development of 
experimental AAAs. The positive effect of statins was ascribed to its properties of preserving medial 
elastin, smooth muscle cells, and beneficially altering aortic wall expression of MMPs16. Also other 
experimental studies have confirmed these positive effects of statins on MMPs23-25. In a study by 
Wilson et al. of 63 infrarenal aortic biopsies obtained during AAA repair the levels of MMP-9 and 
MMP-3 were significantly lower in patients taking statins15. The reduced levels of MMP-9, achieved 
by inhibition of the activation of neutrophils and macrophages, in statin users was confirmed by 
Nagashima and co-workers26.
In our study age, gender, and aneurysm diameter at first presentation were associated with a differ-
ence in AAA growth rate. These results are in line with previously reported studies on the influence of 
these risk factors27. In some studies smoking and diabetes were found to have a significant impact on 
aneurysm growth rate27, however, we did not come across such an association which may be related 
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to the small number of patients with diabetes. Therefore, a type II error might have occurred. Since, 
this analysis is retrospective, for smoking habits we had no information on number of ‘pack years’ and 
current exposure, i.e. number of cigarettes per day.
In the past several medical intervention trials for the prevention of abdominal aneurysm expansion 
have been reported. The propanolol trial investigators did not find a growth benefit of propanolol use 
in a double-blind randomized study in 358 patients28. In a double-blind randomized trial Vammen et 
al. showed that macrolide antibiotic treatment for 4 weeks was associated with a significant lower 
expansion rate compared to placebo29. Mosorin et al. also found a significant lower expansion rate in 
patients taking doxicyclin for a period of 3 months compared to patients receiving placebo.30 These 
findings have been confirmed by Baxter et al. in a phase II trial in 63 patients31. Another therapeutic 
strategy for the prevention of aneurysm growth is to intervene in the inflammatory response present 
in aortic aneurysms. In animal models as well as in a very small case control study indometacin indeed 
seemed to prevent the development and growth of abdominal aortic aneurysms13,32. However, in the 
present study we could not confirm this observation.
A major limitation of this analysis is the use of ultrasonographic examinations for the measurement 
of aortic diameter. The inter- and intra-observer variability of this screening modality might influence 
the outcome of any study based on this type of measurement. However, as shown by Singh et al. 
experienced ultrasonographers and radiologists achieve a high degree of accuracy, which was con-
firmed in the present study with a low inter- and intra-observer variability33. As all non-randomized 
observational studies this study has some other limitations as well. Though we included several 
confounding factors in the multiple regression analysis some might have been missed. One of them 
could be the potentially better blood pressure control in statin users as significantly more statin users 
were on angiotensin-II-antagonist therapy. Unfortunately, we did not have accurate information on 
blood pressure control during the study period. Also several other questions could not be answered 
in this study due to its retrospective nature and should be addressed in future studies including the 
effect of statin therapy duration on AAA growth and the time between statin therapy initiation and 
reduction of AAA growth rate.
In conclusion, this study shows a clear association between statin use and a decreased expansion rate 
of infrarenal aortic aneurysms. This finding is in line with experimental studies in mice and rats, but 
needs to be confirmed by randomized clinical trials.
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ABSTRACT
Objectives: To assess long-term outcome of patients at high cardiac risk undergoing endovascular 
or open AAA repair.
Methods: Patients undergoing open or endovascular infrarenal AAA repair with ≥ 3 cardiac risk fac-
tors and preoperative cardiac stress testing (DSE) at 2 university hospitals were studied. Main outcome 
was cardiac event free and overall survival during a median follow-up of 3.3 years. Multivariate Cox 
regression analysis was used to evaluate the influence of type of AAA repair on long-term outcome.
Results: In 124 patients (55 endovascular, 69 open) the number and type of cardiac risk factors, 
medication use and DSE results were similar in both groups. In multivariable analysis, adjusting for 
cardiac risk factors, stress test results, medication use, and propensity score endovascular repair was 
associated with improved cardiac event free survival (HR 0.54; 95% CI 0.30–0.98) but not with an 
overall survival benefit (HR 0.73; 95% CI 0.37–1.46). Importantly, statin therapy was associated with 
both improved overall survival (HR 0.42; 95% CI 0.21–0.83) and cardiac event free survival (HR 0.45; 
95% CI 0.23–0.86).
Conclusions: The perioperative cardiac benefit of endovascular AAA repair in high cardiac risk 
patients is sustained during long-term follow-up provided patients are on optimal medical therapy 
but it is not associated with improved overall long-term survival.
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INTRODuCTION
Patients undergoing abdominal aortic aneurysm repair are at significant risk for both perioperative 
and long-term cardiovascular events. In particular patients at high cardiac risk might benefit from 
endovascular AAA repair. However, no randomized trials comparing open and endovascular treat-
ment have been reported on patients at high cardiac risk. For example, less than half of the patients 
in the DREAM trial (44%) and EVAR-1 trial (43%) had a history of cardiac disease1,2. A major limitation 
of non-randomized comparative studies between open and endovascular surgical procedures con-
ducted so far is the lack of objective criteria for baseline cardiac condition3.
Preoperative cardiac stress testing such as dobutamine stress echocardiography (DSE) provides an 
objective assessment of the presence and extent of coronary artery disease4. In a previous study 
we used this modality to compare perioperative outcome after open or endovascular AAA repair 
and found that endovascular repair was superior in terms of cardiovascular outcome5. The long-term 
outcome of these high-risk patients however remained ill-defined.
Therefore we expanded the study population of the previous study and conducted long-term 
follow-up of these patients. The aim of the present study was to evaluate the long-term effect of 
endovascular AAA repair compared to open AAA repair in patients at clinical high cardiac risk on 
cardiac complications and mortality.
METhODS
Patients
The study population was composed of patients with 3 or more cardiac risk factors who underwent 
elective abdominal aneurysm repair between January 2000 and January 2006 at two tertiary referral 
centers, Erasmus University Medical Center Rotterdam, the Netherlands and University Medical Cen-
ter Utrecht, the Netherlands and had a preoperative cardiac stress test. The choice for either repair 
method was at the discretion of the treating vascular surgeon and was mainly based on anatomical 
considerations. The study was approved by the Erasmus MC medical ethics committee.
Preoperative cardiac risk assessment
All patients were routinely screened for cardiac risk factors, including age over 70 years, history of or 
presence of angina pectoris, previous myocardial infarction, heart failure, stroke, renal failure (serum 
creatinine >170 μmol/l), and diabetes mellitus. The presence of hypertension and chronic obstruc-
tive pulmonary disease (COPD) was noted as well. A patient was classified as having COPD at the 
preoperative screening visit according to symptoms and pulmonary function test (i.e. FEV1 < 70% of 
maximal age and gender predictive value). According to the ACC/AHA guidelines all patients with 3 
or more cardiac risk factors underwent cardiac stress testing prior to surgery.
Perioperative medication use was noted including ACE-inhibitors, platelet aggregation inhibitors, 
beta-blockers, calcium antagonists, coumarin derivatives, diuretics, nitrates, and statins. Patients 
unable to take medication orally perioperatively were switched to intravenous formula. If no intrave-
nous formula was available, i.e. statins and ACE-inhibitors, oral medication was restarted as soon as 
possible after surgery.
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Cardiac stress testing
Resting echocardiography was used to estimate the left ventricular ejection fraction using the 
Simpson rule. Cardiac stress testing was performed by dobutamine echocardiography as previously 
described6. Myocardial stress induced ischemia was assessed using a semi-quantitative evaluation; a 
5-point score in a 17-segement model. Limited ischemia was defined by the presence of 1–4 ischemic 
segments, while extensive ischemia was defined by ≥ 5 ischemic segments.
Outcome
All patients were monitored for cardiac events after abdominal aortic aneurysm repair. Twelve-lead 
ECG and serum troponin-T levels were systematically determined on days 1, 3, and 7 postoperatively 
or at discharge. The primary outcome of the study was the incidence of all-cause mortality and the 
combination of myocardial infarction and all-cause death during long-term follow-up. Myocardial 
infarction was defined as the presence of 2 out of the following 3 criteria: (1) Characteristic ischemic 
symptoms lasting > 20 min, (2) electrocardiographic changes including acute ST elevation followed 
by appearance of Q waves or loss of R waves, or new left bundle branch block, or new persistent T 
wave inversion for at least 24 h, or new ST segment depression which persists >24 h, and (3) a positive 
troponin T, i.e. >0.10 ng/ml, or peak CK-MB >8% of an elevated total creatinine phosphokinase with 
characteristic rise and fall7. Survival status was confirmed by contacting the civil service registry.
Statistical analysis
Continuous data are presented as median values and corresponding 25th and 75th percentiles, 
whereas dichotomous data are presented as percentages. Differences in clinical characteristics 
between patients undergoing endovascular repair or open repair were evaluated by Wilcoxon’s 
nonparametric tests, Chi-square tests or Fisher’s exact tests, as appropriate. The incidence of events 
over time was further examined by the Kaplan–Meier method, whereas a log-rank test was applied 
to evaluate differences between the two treatment modalities. We developed a propensity score for 
the likelihood of undergoing either open or endovascular AAA repair and used applied multivariate 
logistic regression analysis to calculate the propensity score. The association of type of AAA repair, 
cardiovascular risk factors and medication use with long-term events was assessed via multivariate 
Cox regression analysis, including the propensity score, with stepwise backward removal. The limit of 
statistical significance was set at p = 0.05 (two-sided). All analysis was performed using the statistical 
software SPSS for Windows 12.0.1 (SPSS Inc., Chicago, Illinois, USA).
RESuLTS
Patient characteristics
A total of 124 patients with 3 or more clinical cardiac risk factors were included in this study. Of these, 
69 patients underwent open AAA repair and 55 patients underwent endovascular AAA repair. Clinical 
baseline characteristics of these patients are shown in TABLE 34.1. Almost all (92%) patients were 
male, their mean age was 74 ± 6 years, and the median AAA diameter was 60 mm (interquartile range 
55–70 mm). There were no statistically significant differences between patients undergoing open or 
endovascular AAA repair in terms of clinical characteristics or medication use. During non-invasive 
stress testing approximately half (47%) of all patients had stress inducible myocardial ischemia. A 
total of 46 (37%) patients had mild myocardial ischemia while another 12 (10%) patients had exten-
sive myocardial ischemia. There was no difference in, mild or extensive myocardial ischemia between 
the open and endovascular group (respectively 54% vs. 53%, 35% vs. 40% and 12% vs. 7%).
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Perioperative outcome
Overall 30-day mortality was 4.3% for the open group and 0% for the endovascular group. An addi-
tional 3 (4.3%) patients in the open group died during hospitalization but after 30 days of the index 
procedure. The combined 30-day endpoint of non-fatal myocardial infarction and all-cause death 
was 12 (17%) in the open and 2 (4%) in the endovascular group (p = 0.02). The length of hospital stay 
was significantly shorter in patients with endovascular AAA repair (median 3 vs. 11 days, p < 0.001).
Long-term outcome
Type of repair
During a median follow-up of 3.3 years (interquartile range 1.8–5.6 years) a total of 39 (31%) patients 
died and a total of 55 (45%) patients reached the combined endpoint of all-cause death and MI. As 
is shown in FIGURE 34.1A, during long-term follow-up there was no significant difference in overall 
survival between endovascular and open AAA repair (p = 0.38). Also in multivariate analysis patients 
treated with endovascular had no significant better survival rate (HR 0.73, 95% CI 0.37–1.46, TABLE 
34.2). However, patients who underwent endovascular AAA repair did have a statistically significant 
better cardiac event free survival as compared to patients treated with open repair (FIGURE 34.1B) 
Table 34.1
Baseline clinical characteristics of patients undergoing open and endovascular abdominal aneurysm 
repair.
All patients
(N =124)
Open
(N = 69)
Endovascular
(N = 55)
p-value
Men 114 (92%) 64 (93%) 50 (91%) 0.75
Age (mean, SD) 74 ± 6 74 ± 6 74 ± 7 0.66
Heart rate prior to surgery 65 ± 12 66 ± 13 64 ± 9 0.23
Risk factors
 Previous angina pectoris 77 (62%) 41 (59%) 36 (64%) 0.71
 Previous myocardial infarction 107 (86%) 60 (87%) 47 (84%) 0.80
 Previous heart failure 25 (20%) 12 (17%) 13 (23%) 0.50
 Previous CABG or PTCA 60 (48%) 33 (48%) 27 (48%) 0.99
 CVA or TIA 46 (37%) 29 (42%) 17 (30%) 0.20
 Diabetes Mellitus 18 (14%) 10 (15%) 8 (14%) 0.95
 Renal failure 28 (22%) 14 (20%) 14 (25%) 0.67
 Systemic hypertension 52 (42%) 32 (46%) 20 (36%) 0.28
 COPD 48 (38%) 28 (41%) 20 (36%) 0.57
Stress echocardiography
 No ischemia 66 (53%) 37 (54%) 29 (53%) 0.66
 Limited ischemia 46 (37%) 24 (35%) 22 (40%)
 Extensive ischemia 12 (10%) 8 (12%) 4 (7%)
Medication at screening
 Platelet aggregation inhibitors 90 (72%) 50 (73%) 40 (71%) 0.84
 ACE-inhibitors 51 (41%) 32 (47%) 19 (34%) 0.15
 Diuretics 42 (34%) 25 (59%) 17 (41%) 0.57
 Nitrates 35 (28%) 19 (27%) 16 (29%) 0.95
 Beta-blockers 108 (86%) 60 (87%) 48 (86%) 0.88
 Statins 78 (63%) 41 (59%) 37 (67%) 0.46
 Calcium-antagonists 42 (34%) 24 (35%) 18 (32%) 0.85
CABG = coronary artery bypass graft; percutaneous transluminal coronary intervention; CVA = cerebrovascular accident; 
TIA = transient ischemic attack; COPD = chronic obstructive pulmonary disease; ACE = angiotensin converting enzyme
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(HR 0.54, 95% CI 0.30–0.98, TABLE 34.3). It should be noted however that this benefit was mainly 
driven by the 30-day events. If the first 30 days after surgery were not taken into account there would 
have been a similar cardiac event free survival among patients treated by endovascular or open repair 
(HR 0.89, 95% CI 0.44–1.77, p = 0.73).
Medical therapy
While type of AAA repair did not have a significant impact on overall long-term survival aggressive 
medical therapy did seem to be associated with improved overall survival. Patients on statin therapy 
had a significant survival benefit over patients not on statin therapy; 5-year overall survival 77% 
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Figure 34.1a Overall survival of patients undergoing 
endovascular or open AAA repair.
Figure 34.1b Cardiac event free survival of patients 
undergoing endovascular or open AAA repair.
Table 34.2
Significant predictors of long-term overall survival status when clinical characteristics, propensity score 
for type of surgery, medication use and  year of surgery were entered as independent variables into a Cox 
regression model with stepwise backward removal.
hR 95% CI P-value
Endovascular treatment 0.73 0.37 – 1.46 0.37
Age (per year increase) 1.10 1.03 – 1.17 0.003
Stress inducible myocardial ischemia 1.95 1.03 – 3.89 0.04
Statin use 0.42 0.21 – 0.83 0.01
Heart rate < 70 bpm 0.26 0.13 – 0.54 <0.001
Platelet aggregation inhibitor 0.47 0.23 – 0.97 0.04
Table 34.3
Significant predictors of long-term cardiac event free survival status when clinical characteristics, propensity 
score for type of surgery, medication use and  year of surgery were entered as independent variables into a 
Cox regression model with stepwise backward removal.
hR 95% CI P-value
Endovascular treatment 0.54 0.30 – 0.98 0.04
Age (per year increase) 1.05 1.01 – 1.10 0.03
Stress inducible myocardial ischemia 2.60 1.45 – 4.67 0.001
Statin use 0.45 0.23 – 0.86 0.02
Heart rate < 70 bpm 0.53 0.29 – 0.97 0.04
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vs. 53% respectively (HR 0.42, 95% CI 0.21–0.83, TABLE 34.2). Also cardiac survival event free was 
significantly better in patients on statin therapy (HR 0.45, 95% CI 0.23–0.86, TABLE 34.3). As is shown 
in FIGUREs 34.2A and 34.2B the perioperative benefit of endovascular repair was only sustained in 
patients on statin therapy in contrast to patients not on statin therapy (FIGURE 34.3). The prescription 
rate of statins gradually increased over the studied years, from 38% in 2001/2002 to 67% in 2003/2004 
and 88% in 2005/2006 (p < 0.001). The vast majority of patients were on beta-blocker therapy. 
Importantly the mean heart rate prior to surgery was 65 beats per minute, indicating adequate beta-
0
20
40
60
80
100
Su
rv
iv
al
 (%
)
0 1 2 3 4 5 6
Follow-up (years)
Statin + endovascular
Statin + open
No statin + endovascular
No statin + open
Figure 34.2a Overall survival of patients undergoing endovascular or open AAA repair, divided into statin users or 
non-users.
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Figure 34.2b Cardiac event free survival of patients undergoing endovascular or open AAA repair, divided into statin 
users or non-users.
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blocker dosing in most patients. However, 35 (28%) patients had inadequate heart rate control with 
a rate of >70 beats per minute. Patients on adequate beta-blocker therapy had a significantly better 
overall survival (HR 0.26, 95% CI 0.13–0.54, TABLE 34.2) and cardiac event free survival (HR 0.53, 95% 
CI 0.29-0.97, TABLE 34.3). Importantly, there was no significant interaction between statin use and 
adequate beta-blocker dosing. Furthermore, as shown in TABLE 34.2 patients who were on platelet 
aggregation inhibitors had a better overall survival than did patients who were not on antiplatelet 
therapy (HR 0.47; 95% CI 0.23–0.97, p = 0.04).
DISCuSSION
This study showed that, despite a reduced incidence of adverse perioperative events, endovascu-
lar repair of elective infrarenal AAA in cardiac high-risk patients has a similar long-term survival, 
compared to patients undergoing open AAA repair. However, the perioperative cardiac benefit is 
sustained during a median follow-up of 3.3 years in this high-risk population provided patients are on 
optimal medical therapy. Furthermore, aggressive medical treatment seems to have more impact on 
overall and cardiac event free survival than does the choice of AAA treatment modality.
Patients undergoing major non-cardiac surgery are at significant risk of cardiovascular morbidity 
and mortality. The prognosis after vascular surgery is predominantly determined by the presence 
and extent of underlying coronary artery disease8. In the landmark study performed over 20 years 
ago Hertzer et al. found that only 8% of a group of 1000 patients undergoing non-cardiac vascular 
surgery had normal coronary angiography results9. This high prevalence of underlying cardiac 
disease has later also been confirmed by functional tests such as dobutamine stress echocardiog-
raphy10. Considering this high prevalence of coronary artery disease in vascular surgery patients it 
is hardly surprising that cardiac death after AAA repair accounts for approximately 40% and 65% of 
all 30-day and long-term mortality, respectively11. It might be argued that optimal medical therapy 
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Figure 34.3 Overall survival of patients undergoing endovascular or open AAA repair, divided into patients not on 
adequate beta-blocker therapy and statin therapy, patients on either adequate beta-blocker therapy or 
statin therapy, and patients on both adequate beta-blocker therapy and statin therapy.
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is warranted to sustain the initial cardiovascular survival benefit in patients who underwent endo-
vascular AAA repair.
In previous studies perioperative and long-term statin therapy have been associated with improved 
outcome in patients undergoing AAA repair. Several recent retrospective studies have shown a ben-
eficial effect of statins on perioperative cardiac outcome with adjusted hazard ratio’s ranging from 
0.20 to 0.6212. Importantly, Kertai et al. also found the effect of statins to be independent of β-blocker 
use13. So far only one placebo-controlled, randomized trial has investigated the influence of statin 
use on perioperative cardiovascular complications. In a group of 100 patients treatment with 20 mg 
of atorvastatin was associated with a significant 3.1-fold (p = 0.022) reduction in cardiovascular com-
plications within 6 months after vascular surgery14. Kertai et al. described the influence of statin use 
on long-term outcome after open AAA repair in 570 patients with a median follow-up of 4.7 years15. 
It was shown that, in this group of unselected AAA patients, statin use was associated with a 2.5-fold 
reduction in the risk of all-cause mortality (HR 0.4; 95% CI 0.3–0.5) and a 3-fold reduction in the risk of 
cardiovascular mortality (HR 0.3; 95% CI 0.2–0.6). Interestingly, the present study included only high 
cardiac risk patients but the reduction in the risk for mortality and cardiovascular complications was 
similar to the reported figures of Kertai et al.
Importantly statin use is advocated in the recent TASC II document16. Patients with symptomatic or 
asymptomatic peripheral arterial disease should have their LDL lowered to less than 2.59 mmol/l. 
Patients with multiple vascular beds affected should be treated even more aggressively with a target 
LDL <1.81 mmol/l. It should be noted that the cardioprotective effect of statins might not only be 
by reducing LDL levels but statins might also exert their protective effects by so-called pleiotropic 
effects.
Another medical intervention that has been proven successful in high-risk patients undergoing 
major vascular surgery is beta-blocker therapy. In the DECREASE I trial patients with preoperative 
stress inducible myocardial ischemia had a mere 10-fold reduction in perioperative cardiac events 
compared to patients who received placebo treatment17. Additionally, during a median follow-up 
of 22 months only 12% of patients on beta-blocker therapy experienced a cardiac event vs. 32% of 
the patients who were not on beta-blocker therapy (p = 0.025)18. This treatment effect was later con-
firmed in the DECREASE I registry patients in which 1299 survivors of vascular surgery were followed 
for a median duration of 23 months19. In multivariable analysis the 360 patients on beta-blockers had 
a significant risk reduction for cardiac events (HR 0.3; 95% CI 0.2–0.6; p < 0.001). However, recently 
some trials were published that questioned the potential benefit of beta-blockers in vascular surgery 
patients. In particular the POISE trial might have a negative impact on the willingness to prescribe 
beta-blockers to patients undergoing major vascular surgery. In the POISE trial the investigators 
found an increased risk for all-cause death in patients using beta-blockers, in particular driven by an 
excess in perioperative strokes20. There are several explanations for the findings in POISE related to 
dosing, duration of therapy, beta-blocker withdrawal and adequate titration21. When keeping this in 
mind, beta-blocker therapy still is safe and effective, in particular in patients at high cardiac risk as in 
the current study.
It should be noted that the patients in the current study were considered to be at high cardiac risk 
which does not imply that they were considered to be unfit for surgery in general. The term cardiac 
high-risk in this study is based on our observations in the DECREASE I and II trials22. Patients with 3 
or more risk factors as in the present study had a 4-fold and 28-fold increased risk for perioperative 
cardiac events as compared to patients at intermediate or low risk respectively. In terms of overall 
Ch
ap
te
r 3
4
382
survival, patients in the current study had a worse outcome compared to patients in EVAR-1 and 
DREAM but a much better outcome compared to patients in EVAR-21,23,24. Furthermore, the current 
study is not a randomized trial and as such has obvious limitations related to the nature of the study. 
However, keeping these limitations in mind, and using multivariable regression analysis with propen-
sity scoring, the results of this study are in line with previous published studies. It reemphasizes the 
need for optimal medical therapy in high-risk patients scheduled for AAA repair irrespective of the 
choice of treatment modality. Physicians should not be pacified by the thought that endovascular 
treatment is a less invasive treatment, therefore being less stressful for the heart and hence requiring 
less aggressive medical therapy. On the contrary, in the end patients undergoing endovascular AAA 
repair could even benefit more from aggressive medical therapy as the initial benefit of endovascular 
repair might be sustained in these patients.
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ABSTRACT
Background: Prophylactic coronary revascularization in vascular surgery patients with extensive 
coronary artery disease is not associated with an improved immediate postoperative outcome. 
However, the potential long-term benefit remains unknown. We performed a study to assess the 
long-term benefit of prophylactic coronary revascularization in these patients.
Methods: Of 1880 patients scheduled for major vascular surgery, 430 had ≥3 risk factors (> 70 yrs, 
angina pectoris, myocardial infarction, heart failure, stroke, diabetes mellitus, and renal failure). All 
underwent cardiac testing using dobutamine echocardiography or nuclear stress imaging. Those 
with extensive stress-induced ischemia (≥ 5 segments or ≥ 3 walls) were randomly assigned for 
additional revascularization.
Results: In total 101 patients showed extensive ischemia and were assigned to revascularization 
(N=49) or no-revascularization (n=52). After 2.8 years overall survival was 64% for patients random-
ized to no preoperative coronary revascularization versus 61% for patients assigned to preoperative 
coronary revascularization (HR 1.18, 95%CI 0.63-2.19, p=0.61). The survival free of all-cause death, 
nonfatal myocardial infarction, and coronary revascularization was similar in both groups: 49% and 
42% respectively for patients allocated to medical treatment or coronary revascularization (HR 1.51, 
95% CI 0.89-2.57, p=0.13). Only 2 patients assigned to medical treatment required coronary revascu-
larization during follow-up. Also in patients who survived the first 30 days after surgery there was no 
apparent benefit of revascularization on cardiac events (HR 1.35, 95% CI 0.72-2.52, p=0.36).
Conclusions: Preoperative coronary revascularization in high-risk patients undergoing major vas-
cular surgery is not associated with an improved postoperative or long-term outcome compared to 
best medical treatment.
Long-term outcome of DECREASE V 387
INTRODuCTION
According to the guidelines of the American College of Cardiology /American Heart Association (ACC/
AHA), it is recommended to perform coronary angiography in patients with high-risk noninvasive test 
results. Subsequently, myocardial revascularization should be performed in patients with prognostic 
high-risk anatomy in whom long-term outcome is likely to be improved1. However in both the CARP 
trial and DECREASE V trial prophylactic preoperative coronary revascularization was not associated 
with improved immediate postoperative outcome2,3. As has been shown recently, early surgery after 
coronary stent placement might actually lead to an increase in adverse cardiac events due to in-stent 
thrombosis or bleeding complications4. This might explain the lack of perioperative benefit. However 
it was expected that at least long term outcome, i.e. after the potentially hazardous perioperative 
period, should be improved in these patients. Therefore, we analyzed the long-term outcome of the 
randomized DECREASE V trial to assess whether there is a long-term benefit of prophylactic coronary 
revascularization in high-risk patients undergoing major vascular surgery.
METhODS
The study design and the perioperative results of the original DECREASE V trial have been published 
previously2. In brief, patients were considered eligible for the study if they were scheduled for an 
elective open abdominal aortic or infrainguinal arterial reconstruction. Patients were screened for 
the prevalence of cardiac risk factors including age over 70 years, angina pectoris, prior myocardial 
infarction, compensated congestive heart failure or a history of congestive heart failure, drug therapy 
for diabetes mellitus, renal dysfunction (serum creatinine >160 µmol/L), and prior stroke or transient 
ischemic attack. All patients with at least 3 risk factors underwent cardiac stress testing prior to 
surgery. Those who experienced extensive stress-induced ischemia were enrolled in the DECREASE 
V trial. All patients provided informed consent, and the Erasmus MC medical ethics committee and 
local research ethics committees approved the study. Out of 1880 screened patients 101 (5.3%) 
were considered eligible, had ≥ 3 risk factors, extensive stress induced myocardial ischemia and 
were subsequently randomized. A total of 49 patients were allocated to best medical treatment and 
preoperative coronary revascularization and 52 patients to best medical treatment only.
Cardiac stress testing was performed by dobutamine echocardiography or dobutamine or dipyri-
damole perfusion scintigraphy, as previously described5,6. Test results were scored by the extent of 
stress-induced ischemia using a 17-segment model in dobutamine echocardiography and a 6-wall 
model in stress perfusion scintigraphy. Limited ischemia was defined by the presence of 1-4 ischemic 
segments or 1-2 ischemic walls, while extensive ischemia was defined by ≥ 5 ischemic segments or 
≥ 3 ischemic walls.
All patients were monitored for cardiac events after screening. Twelve-lead ECG and serum troponin-T 
level were systematically assessed one, three, seven, and 30 days after surgery. Outpatient follow-up 
was performed at 30 days if a patient had been discharged from the hospital. At the outpatient clinic 
all patients were screened at 3-months intervals for cardiac events by clinical history and 12-lead ECG 
and additional tests were performed whenever indicated by the treating physicians. For this report 
the outcomes were long-term all-cause death and a combined end-point of all-cause death, nonfatal 
myocardial infarction, and coronary revascularization during follow-up.
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Myocardial infarction (MI) was defined as the presence of 2 out of the following 3 criteria: (1) Charac-
teristic ischemic symptoms lasting > 20 minutes, (2) electrocardiographic changes including acute ST 
elevation followed by appearance of Q waves or loss of R waves, or new left bundle branch block, or 
new persistent T wave inversion for at least 24 hours, or new ST segment depression which persists 
> 24 hours, and (3) a positive troponin T, i.e. >0.10 ng/ml, or peak creatinine kinase-MB >8% of an 
elevated total creatinine phosphokinase with characteristic rise and fall.
Continuous data are presented as median values and corresponding 25th and 75th percentiles, 
whereas dichotomous data are presented as percentages. Differences in clinical and surgical char-
acteristics between patients allocated to revascularization or no-revascularization were evaluated by 
Wilcoxon’s nonparametric tests, Chi-square tests or Fisher’s exact tests, as appropriate. The incidence 
of outcome events over time was examined by the Kaplan-Meier method. Multivariate (Cox) regres-
sion was used to compare differences in overall survival and cardiac event free survival between 
the allocated treatment strategies, adjusted for baseline clinical risk factors. Patients who had an 
event prior to surgery but after screening were included in the analyses as the day of screening was 
considered to be baseline. Analyses were performed according to the intention to treat principle. All 
statistical tests were 2-sided and a p-value <0.05 was considered significant.
RESuLTS
Baseline variables in patients who underwent preoperative coronary revascularization (n=49) or best 
medical treatment only (n=52) are shown in TABLE 35.1. In patients allocated for coronary revascular-
ization, 32 underwent a percutaneous coronary intervention, bare metal stent in 2 and drug eluting 
stents in 30. Patients continued with dual-antiplatelet therapy during surgery. After surgery, patients 
with bare metal stents stopped dual-antiplatelet therapy after 3 months and continued with aspirin 
afterwards. Patients with drug eluting stent continued dual-antiplatelet therapy during follow-up. A 
bypass procedure was performed in 17 patients. The impact of drug eluting stents versus bare metal 
stents could not be assessed due the number of patients included in the study.
The 30-day outcome of the study population has been described in detail previously2. Two patients 
died prior to vascular surgery because of a ruptured aneurysm after successful bypass surgery and 
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Figure 35.1 Overall survival in 101 randomly assigned 
patients.
Figure 35.2 Cardiac event-free survival in 101 randomly 
assigned patients.
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one patient suffered from a myocardial infarction after an unsuccessful coronary revascularization. 
Revascularization did not improve 30-day outcome after vascular surgery. The incidence of all-cause 
death or nonfatal MI for patients with preoperative revascularization or medical treatment only was 
43 vs. 33% respectively (HR 1.4, 95% CI 0.7- 2.8 p = 0.30).
During a median follow-up of 2.8 years (interquartile range 0.9–4.2 years) 42/101 patients died. After 
2.8 years overall survival was 64% for patients randomized to no preoperative coronary revasculariza-
tion versus 61% for patients assigned to preoperative coronary revascularization (HR 1.18, 95%CI 
0.63-2.19, p=0.61; FIGURE 35.1). As is shown in FIGURE 35.2 the incidence of all-cause death, nonfatal 
myocardial infarction, and coronary revascularization was similar in both groups: event free survival 
after 2.8 years was 49% and 42% respectively for patients allocated to medical treatment or coro-
nary revascularization (HR 1.51, 95% CI 0.89-2.57, p=0.14). In the no-revascularization group 2 (4%) 
patients underwent coronary revascularization during follow-up; one patient underwent coronary 
artery bypass surgery 12 months after vascular surgery because of unstable angina pectoris and 
one patient underwent PCI using drug eluting stents 27 months after vascular surgery because of 
progressive angina pectoris complaints.
It might be argued that preoperative coronary revascularization, in particular stent placement, might 
lead to an increased 30-day risk for in-stent thrombosis or bleeding after discontinuation or continu-
ation of antiplatelet therapy4. Therefore we performed a separate analysis including only patients 
Table 35.1 Baseline characteristics.
Revascularization
Yes No p-value
N=49 N=52
Age (years) 71 (64, 74) 70 (63, 75)
Men – no. (%) 42 (86%) 47 (90%) 0.55
Diabetes mellitus – no. (%) 18 (37%) 15 (29%) 0.53
Current angina pectoris – no. (%) 25 (51%) 22 (42%) 0.43
Prior myocardial infarction – no. (%) 49 (100%) 50 (96%) 0.50
Prior heart failure – no. (%) 23 (47%) 24 (46%) 1.0
Prior CVA – no. (%) 20 (41%) 13 (25%) 0.14
Prior renal failure – no. (%) 9 (18%) 11 (21%) 0.81
Medications
 Aspirin – no. (%) 37 (76%) 30 (58%) 0.09
 Beta-blocker – no. (%) 34 (70%) 36 (69%) 1.0
 ACE-inhibitor – no. (%) 28 (57%) 22 (42%) 0.17
 Statin – no. (%) 34 (69%) 30 (58%) 0.30
Coronary artery narrowed > 50%
 Right coronary – no. (%) 39 (80%) -
 Left artery descending – no. (%) 46 (94%) -
 Left circumflex – no. (%) 37 (76%) -
Number of narrowed arteries – no. (%)
 1 0 -
 2 12 (24%) -
 3 33 (67%) -
Left main – no. (%) 4 (8%) -
CVA = cerebrovascular accident; ACE = angiotensin converting enzyme
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who survived at least 30 days after surgery (n=36 and n=46 respectively for revascularization and 
medical treatment only). As is shown in FIGURES 35.3 and 35.4 also in these survivors no apparent 
benefit of revascularization was observed. Of the revascularized patients 47% had an event within 
a median of 2.8 years of follow-up versus 44% in those who did not undergo preoperative coronary 
revascularization (HR 1.35, 95% CI 0.72–2.52, p=0.36). Also all-cause mortality did not differ between 
both groups (HR 0.79, 95% CI 0.35–1.78, p=0.57).
There was no difference in long-term event free survival between patients who underwent preopera-
tive PCI or CABG (HR 0.91, 95% CI 0.44-1.88, p=0.80). After a median of 2.8 years event free survival was 
41% vs. 44% respectively for PCI and CABG. In addition for the endpoint all-cause death no significant 
difference was observed (HR 0.81, 95% CI 0.33-1.96, p=0.64). However, patients with an incomplete 
revascularization procedure had the worst outcome; 6/7 (86%) patients died within 2 years after the 
attempted revascularization compared to 13/42 (31%) with complete revascularization (HR 4.07, 95% 
CI 1.53–10.82, p=0.005, FIGURE 35.5).
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Figure 35.3 Overall survival of patients who survived 
the first 30 days after surgery.
Figure 35.4 Cardiac event-free survival of patients who 
survived the first 30 days after surgery.
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Figure 35.5 Cardiac event-free survival after successful or not successful preoperative revascularization.
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DISCuSSION
The DECREASE-V study did not show a long-term benefit of prophylactic preoperative coronary 
revascularization in stable patients with multiple cardiac risk factors and extensive stress induced 
myocardial ischemia scheduled for major vascular surgery.
The current findings are in line with results of large randomized trials in the non-surgical population. 
Patients with stable multivessel coronary artery disease do not have a better survival after coronary 
stenting or bypass grafting as compared to medical treatment only. The recently published MASS II 
was the first randomized controlled clinical trial to report on 5-year outcomes of non-surgical patients 
with stable multivessel coronary artery disease treated with either bare metal stenting, CABG, or best 
medical treatment only7. It was shown in this study that optimal medical therapy in patients with 
stable multivessel coronary artery disease results in similar long-term outcome in terms of cardiac 
related death or all-cause mortality. The authors concluded, “patients with mild to moderate angina 
can be safely managed medically, whereas PCI or CABG is appropriate if symptoms are not adequately 
controlled by medication or if other high-risk features are apparent.” The COURAGE trial also found 
no additional benefit of coronary revascularization additionally to optimal medical therapy in 2287 
patients with objective evidence of myocardial ischemia and significant coronary artery disease8. 
During a median follow-up of 4.6 years cumulative event rate of all-cause death and myocardial 
infarction were 19.0% in the PCI group and 18.5% in the medical-therapy group. As discussed by 
the COURAGE trialists, these findings may be explained by differences in atherosclerotic plaque 
morphology and vascular remodeling associated with acute coronary syndromes, as compared with 
stable coronary artery disease. Medical treatment in both MASS II and COURAGE included rigorous 
statin and aspirin therapy. This might have prevented vulnerable plaques, which are usually difficult 
to detect and impossible to treat with coronary angioplasty or bypass, to rupture and cause acute 
coronary syndromes. It is important to realize that vulnerable coronary lesions are not necessarily 
severely stenotic, and severely stenotic lesions are not necessarily unstable. Focal management of 
severely stenotic coronary lesions with PCI in both MASS II and COURAGE did not reduce the rate of 
death and myocardial infarction, presumably because the treated, severely stenotic lesions were not 
likely to trigger an acute coronary event8.
Remarkably, in MASS II and COURAGE annual mortality rates were approximately 1-2% whereas in 
CARP and DECREASE V the annual mortality rates in patients who survived surgery were 6.8% and 
8.2% respectively. Baseline angiographic cardiac status in MASS II and COURAGE was not significantly 
better or worse than CARP and DECREASE V: 3-vessel disease was present in 58% and 31% versus 33% 
and 75% respectively. In line with these findings, it has been recently shown that patients with so-
called “polyvascular” disease, i.e. multiple vascular beds affected, have a significant worse outcome 
compared to patients with coronary artery disease only9. In REACH event rates (cardiovascular death, 
MI, stroke, or hospitalization for a cardiovascular event) increased with the number of symptomatic 
vascular beds: 5.3% of patients with risk factors only to 12.6% with 1, 21.1% with 2, and 26.3% with 3 
disease locations9. As all patients in DECREASE V and CARP had proven coronary artery disease and 
were planned for non-cardiac vascular surgery, these patients can be considered to have polyvascu-
lar disease. This indicates that patients scheduled for vascular surgery with extensive coronary artery 
disease should be considered to be a different population than patients without peripheral arterial 
disease but with coronary artery disease only. However, also in this patient population with stable 
severe coronary artery disease optimal medical therapy seems to be equal to coronary revasculariza-
tion in addition to best medical treatment.
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The findings of both CARP and DECREASE V support the current guidelines of the ACC/AHA on peri-
operative management in high-risk patients to reserve revascularization only for cardiac unstable 
patients. Considering the high long-term mortality and cardiac event rates, these patients should 
be regularly screened for the presence of ischemic complaints and aggressive anti-ischemic medical 
therapy must be installed.
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Summary and conclusions
Cardiac complications are a major cause of perioperative morbidity and mortality in patients undergo-
ing non-cardiac surgery. It is estimated that the incidence of such complications is between 0.5% and 
1.0%. Worldwide, about 100 million adults undergo some form of non-cardiac surgery each year, and 
so between 500,000 and 1,000,000 people will suffer from perioperative cardiac complications; one of 
four of them will die from this cause. In particular patients undergoing vascular surgery are prone to 
develop perioperative cardiovascular complications as they have a high generalized atherosclerotic 
burden. In order to prevent the devastating effects of perioperative cardiovascular complications, it 
is of critical importance to identify those at increased risk and treat them accordingly. In this thesis 
preoperative cardiovascular risk stratification and strategies to reduce perioperative cardiovascular 
risk are evaluated. Furthermore, as discussed in this thesis, preoperative risk evaluation should also 
be considered as an excellent opportunity to take measures to reduce the risk for long-term adverse 
cardiovascular events.   
Part I. Preoperative cardiovascular risk assessment
In part one of this thesis current and new cardiovascular risk stratification strategies are evaluated. 
Chapter 1 provides an overview of the magnitude of the problem of perioperative cardiac com-
plications in patients undergoing vascular surgery. It should be appreciated that nearly all vascular 
surgery patients (i.e. 92%) have some form of coronary artery disease. Therefore, rigorous periop-
erative screening for cardiac complications is warranted. This is of special concern as an estimated 
75% of patients who have objective evidence of MI are not diagnosed as such because symptoms 
are masked by residual anesthetic effects, administration of analgesic agents, competing somatic 
stimuli such as incisional pain, and other factors. If patients are screened adequately, the true inci-
dence of perioperative cardiac complications in this patient population appears to be as high as 
20%. This high incidence of perioperative cardiac events highlights the importance of preoperative 
cardiac screening. This chapter also provides an overview of current screening methods, including 
clinical cardiac risk factor indices, laboratory measurements, cardiac (stress) imaging modalities, and 
invasive coronary testing. Subsequently, risk reduction strategies are discussed including medical 
therapy and prophylactic coronary revascularization. Possible protective medical therapy includes 
perioperative statin use and adequately dosed perioperative beta-blocker therapy. In contrast, 
prophylactic coronary revascularization in high risk patients does not seem to be associated with a 
reduced perioperative cardiac event rate. This chapter also highlights the importance of long-term 
cardiac risk reduction in this patient population as patients undergoing vascular surgery are at high 
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risk for long-term cardiac events, even those without perioperative cardiac complications. In fact, 
patients who undergo vascular surgery have a worse prognosis than patients who experienced an 
acute coronary event. This difference is partially caused by a marked undertreatment of patients 
undergoing vascular surgery compared to patients with established, symptomatic coronary artery 
disease. Optimal medical treatment of these patients is of critical importance and recent guidelines 
such as the ACC/AHA guidelines and the TASC2 guidelines should be adhered to, so that the patient 
lives long enough to enjoy the benefits of vascular surgery.  
Chapter 2 provides an overview of cardiac complications in the general non-cardiac surgery popula-
tion. Although the pathophysiology of perioperative myocardial infarction is not entirely clear, plaque 
rupture, leading to thrombus formation and subsequent vessel occlusion, is implicated in a similar 
manner to that causing myocardial infarctions in the non-operative setting. The incidence of plaque 
rupture may be increased by the stress response to major surgery. This response includes sympathetic 
activation promoting sheer stress on arterial plaques, enhanced vascular reactivity conducive to the 
development of vasospasm, reduced fibrinolytic activity, platelet activation and hypercoagulability. 
Heightened sympathetic tone also increases myocardial oxygen requirements (for example through 
tachycardia and increased contractility), leading to a mismatch between oxygen supply and demand 
that, when sustained, can lead to infarction. Therefore, to improve postoperative cardiac outcome 
after non-cardiac surgery a dual approach is required. First, one must focus on correcting the mis-
match of myocardial oxygen supply and demand. Second, one must stabilize the coronary artery 
atheromatous plaque. At present, these needs seem to be best met with a combined medical therapy 
of cardioselective beta-blockers, statins and, if possible, aspirin.
Chapters 3 and 4 describe current evidence on preoperative cardiac risk evaluation strategies. In 
chapter 4 a simple normogram of nine steps is presented to optimize patients scheduled for non-
cardiac general surgery. The combination of clinical cardiac risk factors, type of surgery and ECG 
results allows to make an initial crude assessment of a patient’s perioperative cardiac risk. This risk 
estimation can be used to identify those patients at increased risk who should undergo further 
cardiac testing. If a patient is at increased risk, further cardiac (stress) testing might be warranted and 
appropriate medical therapy should be initiated.
Based on over 100,000 non-cardiac surgical procedures, chapter 5 describes a refinement of the 
widely used Revised Cardiac Risk Index. When more detailed information, including age, the type of 
surgery (defined as low, low-intermediate, intermediate-high, and high), whether it was laparoscopic 
or open, and whether it was emergent, was added to the Revised Cardiac Risk index, the predictive 
value increased significantly. This refinement of the Revised Cardiac Risk Index might be most appli-
cable to situations in which administrative data are to be used to assess outcomes and to compare 
outcomes in different hospitals or regions. 
The Revised Cardiac Risk Index is also widely used for risk stratification of patients scheduled for 
vascular surgery. However, age is not taken into account in this index. As shown in chapter 6, the 
value of the Revised Cardiac Risk Index varies significantly among different age categories in vascular 
surgery patients. In chapter 6 it is shown that including age, risk of surgery and hypertension as 
factors in the Revised Cardiac Risk Index improves the predictive value considerably. It clearly strati-
fies vascular surgery patients into low, intermediate and high risk. In addition, this model provides 
long-term prognostic value.
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In surgical patients at increased cardiac risk based on clinical risk factors, further cardiac stress test-
ing might be warranted. Chapter 7 describes different cardiac stress testing modalities and their 
possible use for preoperative cardiac risk stratification. While there is no direct comparison, several 
meta-analyses compared different techniques with respect to sensitivity and specificity. A positive 
trend in favor of dobutamine stress echocardiography was found. Nevertheless, because the tests 
have comparable accuracy, there is no definite answer to the question of which test to choose. The 
choice of test should be based on the center’s experience and short-term availability. 
Another important question is which patients should undergo additional cardiac stress testing. In 
other words, in which patients do stress test outcomes change perioperative management. In chap-
ter 8 the value of preoperative cardiac testing in intermediate-risk vascular surgery patients receiving 
beta-blocker therapy was assessed. In 770 randomized intermediate risk patients, those assigned to 
no cardiac stress testing had a similar incidence of cardiac death or myocardial infarction at 30-days 
after surgery as those assigned to testing. The strategy of no testing brought surgery almost 3 weeks 
forward. Therefore, cardiac testing can safely be omitted in intermediate-risk patients, provided that 
beta-blockers aiming at tight heart rate control are prescribed.
In chapter 9 the impact of abdominal aortic aneurysm size on perioperative cardiac events is studied. 
Abdominal aortic aneurysm size and growth has been found to be associated with local generation 
of inflammation markers. As inflammation also plays a pivotal role in perioperative adverse cardiac 
events, it was hypothesized that patients with a large abdominal aortic aneurysm are at increased 
risk for cardiac events. As shown, indeed abdominal aortic aneurysm size is independently associated 
with perioperative nonfatal myocardial infarction and cardiovascular death in 500 patients undergo-
ing open abdominal aortic aneurysm repair. Patients with a larger aneurysm have a higher risk of 
perioperative cardiac complications. 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is secreted by the heart in response to ven-
tricular wall stress and has prognostic value in patients with heart failure, coronary artery disease 
and heart valve abnormalities. It was hypothesized that NT-proBNP might have additional prognostic 
value as a simple objective risk marker for postoperative cardiac events among vascular surgery 
patients. As shown in chapter 10, NT-proBNP is an excellent tool for further risk stratification with an 
optimal cut-off value of 350 pg/ml. In multivariate analysis, NT-proBNP > 350 pg/ml was significantly 
associated with a 4.7-fold increased risk for perioperative cardiac events. NT-proBNP > 350 pg/ml was 
also associated with an independent 1.9-fold increased risk for long-term mortality during a median 
follow-up of 2.4 years.
Part II. Perioperative risk reduction
In part two of this thesis perioperative cardiovascular risk reduction strategies are described, i.e. beta-
blocker therapy, statin therapy, prophylactic coronary revascularization and endovascular treatment 
modalities.
In chapters 11 and 12 the design and results of the DECREASE IV study are described. Beta-blockers 
and statins reduce perioperative cardiac events in high-risk patients undergoing vascular surgery 
by restoring the myocardial oxygen supply/demand balance and/or stabilizing coronary plaques. 
However, their effects in intermediate risk patients remained ill-defined. The DECREASE IV study 
evaluated the effectiveness and safety of beta-blockers and statins for the prevention of periopera-
tive cardiovascular events in intermediate-risk patients undergoing non-cardiovascular surgery. In 
this randomized trial, including 1066 patients at intermediate cardiac risk, bisoprolol was associated 
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with a significant decrease in the incidence of cardiac death and nonfatal myocardial infarction while 
statin therapy was associated with a trend towards improved postoperative cardiac outcome. Impor-
tantly, there was no increased risk for postoperative stroke in patients on beta-blocker therapy. 
The positive findings of DECREASE IV for perioperative beta-blocker therapy were confirmed in a 
meta-analysis described in chapter 13. In 15 randomized trials including 1077 patients perioperative 
beta-blocker therapy was associated with a 65% reduction in perioperative myocardial ischemia, a 
56% reduction in myocardial infarction, and a 67% reduction in the composite endpoint of cardiac 
death and non-fatal myocardial infarction. 
Major concerns of perioperative beta-blocker use are ischemic complications, such as stroke. In chap-
ters 14, 15, and 16 the impact of beta-blocker therapy on this type of complications is evaluated. 
As shown, beta-blocker therapy is not associated with an increase in ischemic complications of the 
esophagogastric anastomosis in patients undergoing esophagectomy for cancer. Furthermore, it is 
highlighted that perioperative beta-blockers are not a “fire-and-forget” type of medication. It should 
be started well ahead of surgery to allow a safe and adequate titration of beta-blockers. It is shown 
that if prophylactic beta-blocker therapy is initiated at a low dose and up titrated in the preopera-
tive period, the risk of stroke seems to be similar to that of patients not on beta-blockers while the 
cardioprotective effect is maintained. 
In chapters 17, 18, 19, 20, 21, and 22 the benefits and possible pitfalls of perioperative statin use 
in vascular surgery patients are investigated. Several retrospective studies have demonstrated an 
association between perioperative statin therapy and a reduction in perioperative cardiac events. 
However, there were also concerns regarding the safety of perioperative statin therapy. In chapter 
18 a cohort of 981 vascular surgery patients is studied. In this study we found that perioperative 
statin use in a large group of patients was not associated with an increased risk of myopathy, i.e. CK 
elevation with or without muscle complaints, after major vascular surgery. 
As shown in chapters 19 and 20, statin use is associated with improved recovery from acute kidney 
injury after major surgery and a beneficial effect on long-term survival. Also in patients requiring 
suprarenal clamping during abdominal aortic aneurysm repair perioperative statin therapy is associ-
ated with a preserved renal function. On the other hand, it must be realized that perioperative statin 
therapy discontinuation, which is inevitable in approximately 25% of patients undergoing major vas-
cular surgery, might be associated with an increase in cardiac events as is shown in chapter 21. Statin 
discontinuation was associated with an increased risk for postoperative troponin release, and the 
combination of myocardial infarction and cardiovascular death. Interestingly, fluvastatin extended 
release was associated with less perioperative cardiac events compared to atorvastatin, simvastatin, 
and pravastatin. 
In chapter 22 the results of the DECREASE III trial are described. In this double-blind, placebo-
controlled trial, statin naïve patients were randomly assigned to receive, in addition to beta-blocker, 
either 80 mg fluvastatin extended release once daily or placebo, starting 37 days prior to surgery. Two 
hundred fifty patients were assigned to fluvastatin and 247 to placebo. The incidence of myocardial 
ischemia in the fluvastatin group was significantly lower compared to the placebo group, respectively 
10.8% vs. 19.0%. The incidence of cardiac death or myocardial infarction was also significantly reduced 
in the fluvastatin group. Importantly, fluvastatin use was not associated with an increased risk for 
myopathy, liver dysfunction or all-cause death. Therefore, it is concluded that in patients undergoing 
vascular surgery, fluvastatin therapy is associated with an improved postoperative cardiac outcome. 
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In chapters 23, 24, 25, and 26 perioperative treatment of patients with coronary stents as well as the 
impact of prophylactic coronary revascularization in high cardiac risk patients are described. 
Recent coronary stent placement might be potentially harmful for patients undergoing non-cardiac 
surgery. Surgery increases the thrombosis risk due to a perioperative stress response, including 
sympathetic activation promoting sheer stress on arterial plaques, enhanced vascular reactivity 
conducive to vasospasm, reduced fibrinolytic activity, platelet activation, and hypercoagulability. In 
addition, while the surgical patient is in a hypercoagulable state dual antiplatelet therapy is often 
interrupted because of the fear for excessive bleeding complications during surgery. As shown in 
these chapters, there is an association between early non-cardiac surgery after coronary artery stent-
ing and perioperative adverse cardiovascular events. Importantly, in patients undergoing early sur-
gery, discontinuation of antiplatelet therapy during the perioperative period may be a major cause of 
the increase in major adverse cardiac events. The type of stent (i.e. bare-metal or drug-eluting) does 
not seem to influence cardiovascular outcome.
It was also hypothesized that some very high cardiac risk patients might benefit from preoperative 
prophylactic coronary revascularization. Therefore, the randomized DECREASE V pilot study was 
conducted. As shown in chapter 25, 1888 patients scheduled for vascular surgery were screened. 
Those at high cardiac risk based on clinical risk factors, i.e. ≥ 3 risk factors, and with extensive stress-
induced ischemia were randomly assigned for additional revascularization or best medical treatment 
only. Of 430 high-risk patients, 101 (23%) showed extensive ischemia and were randomly assigned 
to revascularization or no revascularization. Revascularization did not improve 30-day outcome. Also, 
no benefit during 1-year follow-up was observed after coronary revascularization. 
Endovascular treatment of abdominal aortic aneurysms is possibly associated with a reduced inci-
dence of perioperative cardiovascular complications. This might be due to the reduced myocardial 
stress during an endovascular procedure. In patients undergoing an endovascular procedure no aor-
tic clamping and declamping are performed, the procedure is done under loco-regional anesthesia, 
and in combination with a reduced blood loss a more hemodynamic stable condition is achieved. As 
is shown in chapters 27, 28, and 29, indeed endovascular treatment is associated with an improved 
perioperative cardiac outcome. In chapter 28 patients at high cardiac risk, i.e. 3 or more cardiac risk 
factors, undergoing endovascular abdominal aortic aneurysm repair had a significantly reduced inci-
dence of perioperative myocardial damage compared to patients undergoing open repair. As shown 
in chapter 27 and 28, the perioperative cardiac benefits of endovascular therapy are irrespective 
of the presence and extent of underlying coronary artery disease. However, as indicated in these 
chapters the long-term durability of this perioperative cardiac advantage remains to be awaited.
Part III. Long-term risk reduction
The preoperative evaluation offers a unique opportunity to identify patients at increased periop-
erative risk and initiate appropriate lifestyle changes and risk reduction therapy, as these will also 
improve long-term outcome. In chapters 30, 31, 32, 33, 34, and 35 the long-term prognosis and 
factors influencing the long-term outcome of vascular surgery patients are described.
Chapter 31 describes a study involving a total of 2,730 patients undergoing vascular surgery and 
a matched cohort, using propensity scores, of 2,730 patients with coronary artery disease who 
underwent coronary angioplasty. Vascular surgery patients had a worse long-term prognosis and 
received less medication (beta-blockers, statins, angiotensin-converting enzyme inhibitors, aspirin, 
nitrates, and calcium antagonists) than patients with coronary artery disease did. Based on these 
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results, it is concluded that long-term prognosis of vascular surgery patients is significantly worse 
than for patients with coronary artery disease, which might be attributable to the undertreament of 
patients with peripheral arterial disease. 
As shown in chapter 32, patients with temporary worsening of renal function after open abdominal 
aortic aneurysm repair are at high risk for poor long-term outcome. During 6.0 ± 3.4 years follow-up, 
the risk of late mortality was 1.7-fold increased in the persistent renal function worsening group, 
followed by those with temporary renal function worsening. 
Screening for abdominal aortic aneurysms in populations at increased risk, i.e. elderly males, to 
detect those who will benefit from elective repair seems to be safe and cost-effective. However, peri-
operative complications of elective abdominal aortic aneurysm repair remain a significant problem. 
Therefore, an attractive option would be the slowing of abdominal aortic aneurysm growth, thereby 
preventing the abdominal aortic aneurysm to reach a size requiring surgical intervention. In chapter 
33 the effect of statin therapy was studied. In 150 patients under surveillance for infrarenal aortic 
aneurysms, statin users had a 1.16 mm/year lower abdominal aortic aneurysm growth rate compared 
to non-users, irrespective of other known factors influencing aneurysm growth.
As indicated in chapters 27 and 28, patients undergoing endovascular abdominal aortic aneurysm 
repair experience significantly less perioperative cardiac events compared to patients undergoing 
open repair. In chapter 34 the long-term outcome of endovascular abdominal aortic aneurysm 
repair is described for patients at high cardiac risk, i.e. those with ≥ 3 clinical cardiac risk factors. In 
124 patients, endovascular repair was associated with improved cardiac event free survival during 
a median follow-up of 3.3 years but not with an overall survival benefit. Importantly, statin therapy 
was associated with both improved overall survival and cardiac event free survival. Therefore, it was 
concluded that the perioperative cardiac benefit of endovascular abdominal aortic aneurysm repair 
in high cardiac risk patients is sustained during long-term follow-up provided patients are on optimal 
medical therapy but it is not associated with improved overall long-term survival.
Finally, the long-term outcome of the randomized DECREASE V pilot study is described in chapter 
35. As was shown in chapter 25, prophylactic coronary revascularization in vascular surgery patients 
was not associated with an improved perioperative cardiac outcome. As shown in this chapter also 
long-term outcome is not improved after prophylactic coronary revascularization. After 2.8 years 
overall survival was 64% for patients randomized to no preoperative coronary revascularization ver-
sus 61% for patients assigned to preoperative coronary revascularization. Therefore, it is concluded 
that preoperative coronary revascularization in high-risk patients undergoing major vascular surgery 
is not associated with an improved postoperative or long-term outcome compared to best medical 
treatment only.
Samenvatting en conclusies
Cardiale complicaties zijn een belangrijke oorzaak van mortaliteit en morbiditeit rond niet-cardiale 
operaties. Bij ongeveer 0,5% tot 1,0% van alle operaties treedt een cardiale complicatie op. Wereld-
wijd worden jaarlijks circa 100 miljoen operaties uitgevoerd. De incidentie van perioperatieve 
cardiale complicaties wordt geschat op 500.000 tot 1.000.000 per jaar. Ongeveer een kwart van deze 
complicaties leidt tot het overlijden van de patiënt. In het bijzonder patiënten die een operatie aan 
de slagaders ondergaan hebben een verhoogde kans op het ontwikkelen van perioperatieve cardiale 
complicaties. Dit is vooral het gevolg van de uitgebreide atherosclerose bij deze patiëntengroep. Om 
perioperatieve cardiale complicaties bij deze patiënten te voorkomen, is het uitermate belangrijk om 
een goede inschatting van het perioperatieve risico te maken. Op basis van deze risico-inschatting 
kan de juiste perioperatieve therapie worden ingesteld. Het onderzoek beschreven in dit proefschrift 
was gericht op het optimaliseren van de preoperatieve inschatting van het cardiale risico en het ver-
minderen van het perioperatieve cardiale risico. De preoperatieve risico-inschatting moet eveneens 
gezien worden als een uitgelezen mogelijkheid om de juiste therapie te starten om ook complicaties 
op lange termijn te voorkomen. 
Deel I. Preoperatieve cardiovasculaire risico-inschatting
In deel één van dit proefschrift worden bestaande en nieuwe modellen voor het inschatten van het 
perioperatieve cardiovasculaire risico besproken. 
hoofdstuk 1 geeft een overzicht van de omvang van het probleem van perioperatieve cardiale 
complicaties bij patiënten die een operatie aan een slagader (vaatchirurgie) ondergaan. Bijna alle 
patiënten (92%) die een vaatchirurgische ingreep ondergaan, hebben ook een vorm van coronair-
lijden. Daarom is het bij deze patiënten uitermate belangrijk om rond de operatie te screenen op 
het ontstaan van cardiale complicaties, zodat tijdig adequate therapie kan worden gestart. Wanneer 
patiënten die een grote operatie van de vaten ondergaan systematisch worden gescreend, blijkt de 
incidentie van cardiale complicaties rond 20% te liggen. Men moet zich hierbij realiseren dat 75% 
van alle cardiale complicaties bij deze patiënten niet als zodanig wordt gediagnosticeerd doordat de 
symptomen vaak, door bijvoorbeeld pijnstilling en pijnklachten van andere organen, gemaskeerd 
worden. 
hoofdstuk 2 geeft een overzicht van perioperatieve cardiale complicaties bij patiënten die een 
niet-vaatchirurgische, niet-cardiale operatie ondergaan. De pathofysiologie van het perioperatieve 
hartinfarct is niet volledig duidelijk. Coronaire plaque ruptuur, leidend tot formatie van trombus en 
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afsluiting van de kransslagader, lijkt een belangrijke rol te spelen bij het ontstaan van het periope-
ratieve hartinfarct. Het optreden van deze plaque rupturen wordt versterkt door de lichamelijke 
stress respons die ontstaat tijdens grote chirurgische ingrepen. Ook leidt deze stress respons tot 
een verhoogde zuurstofbehoefte van het hart zelf. Echter, wanneer in de kransslagaders een ver-
nauwing aanwezig is als gevolg van atherosclerose kan er door het hart niet voldaan worden aan 
deze verhoogde zuurstofbehoefte. Als deze situatie te lang voortduurt, zal dit uiteindelijk leiden tot 
een hartinfarct. Daarom is het van belang om een tweesporen beleid te volgen bij de preventie van 
perioperatieve cardiale complicaties. Ten eerste dient de behoefte en aanbod van zuurstof te worden 
gebalanceerd. Ten tweede moet de zogenaamde instabiele coronaire plaque, die op het punt staat te 
ruptureren, worden gestabiliseerd. Het lijkt dat dit het beste te bereiken is door een combinatie van 
statines, bètablokkers en, indien mogelijk, aspirine. 
In hoofdstukken 3 en 4 worden modellen voor het inschatten van het perioperatieve cardiale risico 
besproken. In hoofdstuk 4 wordt een normogram van negen stappen beschreven om de patiënt 
preoperatief te optimaliseren. De combinatie van klinische risicofactoren, type operatie en ECG resul-
taten maakt het mogelijk een eerste, ruwe, schatting van het operatierisico te maken. Deze schatting 
kan worden gebruikt om te beslissen of een patiënt nadere cardiale evaluatie nodig heeft en welke 
medicamenteuze therapie gestart moet worden. 
Gebaseerd op gegevens van meer dan 100.000 operaties, wordt in hoofdstuk 5 een verbetering van 
de veel gebruikte Revised Cardiac Risk Index voorgesteld. Wanneer meer gedetailleerde informatie, 
zoals type operatie en leeftijd, wordt toegevoegd, neemt de voorspellende waarde aanzienlijk toe.
De Revised Cardiac Risk Index wordt ook veel gebruikt voor het schatten van het perioperatieve car-
diale risico van patiënten die een vaatchirurgische operatie ondergaan. In hoofdstuk 6 is de invloed 
van leeftijd op de voorspellende waarde van de Revised Cardiac Risk Index onderzocht. Deze bleek 
verschillend te zijn voor verschillende leeftijdsgroepen. Het onderzoek toont aan dat de voorspel-
lende waarde van de Revised Cardiac Risk Index aanzienlijk is te verbeteren indien leeftijd als factor 
wordt meegenomen in deze index. 
Bij patiënten die op basis van klinische risicofactoren een verhoogd perioperatief cardiaal risico 
hebben, kan verdere cardiale analyse middels een zogenaamde cardiale stress test nodig zijn. hoofd-
stuk 7 geeft een overzicht van verschillende stress test modaliteiten. Hoewel er nauwelijks directe 
vergelijkingen zijn gemaakt tussen de verschillende modaliteiten, is wel een aantal meta-analyses 
verschenen. Deze laten een trend ten faveure van de dobutamine stress echocardiografie zien. 
Echter, de verschillen met de andere modaliteiten zijn klein. Daarom is het niet mogelijk te zeggen 
welke test het meest geschikt is voor perioperatieve risico-inschatting. Het verdient aanbeveling de 
keuze voor een bepaalde test af te laten hangen van de ervaring van een medisch centrum met een 
bepaalde test. 
Een ander belangrijk vraagstuk is welke patiënt baat heeft bij een aanvullende cardiale stress test. In 
hoofdstuk 8 wordt de waarde van preoperatieve cardiale stress tests onderzocht in patiënten met 
een gemiddeld risico die een vaatchirurgische ingreep ondergaan. In 770 gerandomiseerde patiën-
ten was de incidentie van perioperatieve cardiale complicaties gelijk in de groep die had geloot voor 
aanvullende stress test en de groep die had geloot voor geen aanvullende stress test. Patiënten die 
geen cardiale stress test ondergingen konden gemiddeld drie weken eerder geopereerd worden. 
Daarom is geconcludeerd dat een aanvullende cardiale stress test, bij patiënten met een gemiddeld 
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hoog risico op perioperatieve cardiale complicaties, achterwege gelaten kan worden mits de patiënt 
op adequate medicamenteuze therapie is ingesteld. 
hoofdstuk 9 laat, op basis van een studie met 500 patiënten, zien dat de grootte van een aneurysma 
van de abdominale aorta geassocieerd is met de cardiale uitkomst na operatieve correctie van dit 
aneurysma. Patiënten met een groter aneurysma hebben een significant grotere kans op periopera-
tieve complicaties.
N-terminal pro-B-type natriuretic peptide (NT-proBNP) wordt afgescheiden door het hart als reactie 
op stress op de wand van het hart. NT-proBNP heeft prognostische waarde voor patiënten met 
hartfalen en voor patiënten met coronairlijden. In hoofdstuk 10 is onderzocht of NT-proBNP ook 
prognostische waarde heeft voor patiënten die een vaatchirurgische ingreep ondergaan. Inderdaad, 
NT-proBNP bleek een zeer goede marker voor perioperatief cardiaal risico te zijn. Een verhoogd 
NT-proBNP was geassocieerd met een bijna vijf maal zo grote kans op perioperatieve complicaties. 
Ook was een verhoogd NT-proBNP geassocieerd met een bijna twee maal zo grote kans op sterfte 
gedurende een follow-up van 2,4 jaar.
Deel II. Perioperatieve risicoreductie
In deel twee van dit proefschrift worden verschillende strategieën besproken gericht op risicoreduc-
tie: bètablokker therapie, statine therapie, profylactische revascularisatie van de kransslagaders en 
endovasculaire behandelingsopties. 
In hoofdstuk 11 en 12 worden de opzet en de resultaten van de DECREASE IV studie beschreven. In 
de DECREASE IV studie is de effectiviteit en veiligheid van het perioperatief gebruik van statines en 
bètablokkers onderzocht in 1066 patiënten met een gemiddeld hoog cardiaal risico. Bètablokkers 
bleken geassocieerd te zijn met een significante reductie in het aantal perioperatieve cardiale com-
plicaties. Voor statines werd een niet-significante trend gevonden voor een betere perioperatieve 
cardiale uitkomst. 
Deze positieve bevindingen voor bètablokkers werden bevestigd in een meta-analyse (hoofdstuk 
13). Bij 1077 patiënten uit 15 gerandomiseerde studies werd een significant voordeel voor bètablok-
kers gevonden wat betreft perioperatieve myocardischemie, perioperatief hartinfarct en de combi-
natie van cardiale sterfte en hartinfarct. 
Recentelijk is er twijfel ontstaan over de veiligheid van perioperatief bètablokker gebruik. Het zou 
mogelijk geassocieerd zijn met een grotere kans op een beroerte en andere complicaties ten gevolge 
van een verminderde doorbloeding. hoofdstukken 14, 15 en 16 behandelen de invloed van bèta-
blokker therapie op dit soort complicaties. Bètablokker therapie is niet geassocieerd met een grotere 
kans op doorbloedingsproblemen van een buismaagreconstructie bij patiënten bij wie de slokdarm 
is verwijderd in verband met kanker. Ook wordt in deze hoofdstukken benadrukt dat bètablokkers 
met verstand gedoseerd moeten worden. Men moet tijdig beginnen met bètablokker therapie en de 
dosis op geleide van bloeddruk en hartslagfrequentie aanpassen. Wanneer bètablokkers tijdig in een 
lage dosering worden gestart en de dosis, indien nodig, adequaat wordt aangepast, is het risico op 
beroerte niet verhoogd terwijl de kans op cardiale complicaties wel verlaagd is. 
In hoofdstukken 17, 18, 19, 20, 21 en 22 zijn de voordelen en mogelijke nadelen van perioperatief 
gebruik van statines onderzocht. Meerdere retrospectieve studies suggereren een verband tussen 
statine gebruik en een kleinere kans op perioperatieve cardiale complicaties. Echter, er zijn ook 
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bedenkingen ten aanzien van de veiligheid van perioperatief statine gebruik. In hoofdstuk 18 zijn 
981 vaatchirurgische patiënten onderzocht. Perioperatieve behandeling met statines bleek niet geas-
socieerd met een verhoogd risico op aan statine gerelateerde bijwerkingen zoals myopathie. Uit de 
hoofdstukken 19 en 20 blijkt, dat statine gebruik is geassocieerd met een beter herstel van nierfunc-
tie na acute nierschade die op kan treden tijdens een operatie. Ook lijkt statine gebruik geassocieerd 
te zijn met een betere uitkomst op de lange termijn. Men moet zich echter wel realiseren dat het stop-
pen van statines rond een operatie geassocieerd is met een grotere kans op cardiale complicaties, 
vergeleken met patiënten die niet stoppen met statine gebruik, zoals blijkt uit hoofdstuk 21. Het zo 
snel mogelijk hervatten van statine gebruik na een operatie lijkt daarom uitermate belangrijk. 
In hoofdstuk 22 worden de resultaten van de DECREASE III studie beschreven. In deze dubbel-
geblindeerde, placebo-gecontroleerde studie werden patiënten die nog niet met statines werden 
behandeld voor een vaatchirurgische operatie gerandomiseerd. In totaal lootten 250 patiënten voor 
behandeling met fluvastatine en 247 voor placebo. De incidentie van myocardischemie was twee 
maal lager in de groep patiënten die fluvastatine gebruikte. Ook de incidentie van cardiale sterfte 
en hartinfarct was significant verlaagd in de groep van fluvastatine gebruikers. Dit leidde tot de 
conclusie dat perioperatieve behandeling met fluvastatine geassocieerd is met een betere cardiale 
uitkomst in patiënten die een vaatchirurgische operatie ondergaan. 
In hoofdstukken 23, 24, 25 en 26 wordt de perioperatieve behandeling van patiënten met stents in 
de kransslagaders besproken. Ook werd de invloed van profylactische revascularisatie van de krans-
slagaders in hoog risico patiënten onderzocht. Uit dit onderzoek komt naar voren dat patiënten die 
een operatie ondergaan, vlak nadat ze een stent in één of meer kransslagaders hebben gekregen, 
een verhoogde kans hebben op perioperatieve complicaties. Ook blijkt het stoppen van aspirine en 
clopidogrel bij deze patiënten de kans op cardiale complicaties te vergroten. 
Zeer hoog risico patiënten zouden mogelijk baat kunnen hebben bij het profylactisch revascular-
iseren van afwijkingen in de kransslagaders. Zoals blijkt uit de DECREASE V pilot studie, beschreven 
in hoofdstuk 25, is dit echter niet het geval. In 101 gerandomiseerde patiënten hadden patiënten, 
die geloot hadden voor profylactische revascularisatie geen betere uitkomst rond de operatie, dan 
patiënten die alleen met medicijnen behandeld werden. 
Endovasculaire behandeling van het aneurysma van de abdominale aorta is mogelijk geassocieerd 
met een kleinere kans op perioperatieve cardiale complicaties. Zoals in hoofdstukken 27, 28 en 
29 wordt beschreven lijkt endovasculaire behandeling inderdaad te resulteren in minder periope-
ratieve complicaties. In hoofdstuk 28 werden patiënten met een zeer hoog cardiaal risico die een 
endovasculaire of open behandeling van het aneurysma van de abdominale aorta ondergingen met 
elkaar vergeleken. Patiënten die endovasculair werden behandeld hadden een significant kleinere 
kans op perioperatieve cardiale schade. De kleinere kans op complicaties was onafhankelijk van de 
aanwezigheid en ernst van het onderliggend cardiaal lijden. Echter, het is de vraag of endovasculaire 
behandeling ook op de lange termijn een voordeel biedt ten opzichte van de open behandeling van 
het aneurysma van de abdominale aorta. 
Deel III. Langetermijns risico reductie
De preoperatieve evaluatie biedt een unieke kans om patiënten te identificeren die ook op de lan-
gere termijn een grotere kans op cardiale complicaties hebben. De preoperatieve evaluatie is daarom 
ook een uitgelezen mogelijkheid om door middel van veranderingen in levensstijl en medicatie de 
prognose van patiënten te verbeteren. In hoofdstukken 30, 31, 32, 33, 34 en 35 wordt de prognose 
op langere termijn van patiënten die een vaatchirurgische ingreep moeten ondergaan uiteen gezet. 
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In hoofdstuk 31 is in een groep van 2730 vaatchirurgische patiënten aangetoond dat de kans op 
overlijden gedurende een follow-up van gemiddeld 6,4 jaar ruim 2 maal zo groot is als bij hartpa-
tiënten die een dotterbehandeling van de kransslagaders hebben ondergaan. Dit heeft mogelijk te 
maken met de onderbehandeling van vaatchirurgische patiënten. Hartpatiënten kregen significant 
vaker de juiste medicatie. Op basis hiervan is geconcludeerd dat de prognose van vaatchirurgische 
patiënten slechter is dan van hartpatiënten en dat dit mogelijk te maken heeft met medicamenteuze 
onderbehandeling. 
Zoals in hoofdstuk 32 wordt beschreven, hebben vaatchirurgische patiënten die kort na de operatie 
tijdelijk of permanente nierfunctiestoornissen hebben gehad een slechtere prognose op de langere 
termijn. Gedurende een follow-up van 6 jaar hadden patiënten met tijdelijke nierfunctiestoornis-
sen een 1,5 maal grotere kans en patiënten met permanente nierfunctiestoornissen een 1,7 maal 
grotere kans op mortaliteit. Behandeling met statines is in deze patiëntengroepen geassocieerd met 
verbeterde uitkomsten. 
Screenen op het aneurysma van de abdominale aorta in groepen met een grotere kans hierop is vei-
lig en kosteneffectief. Echter, ook het electieve herstel van het aneurysma van de abdominale aorta 
gaat gepaard met een aanzienlijke kans op morbiditeit en mortaliteit. Het vertragen van de groei van 
een aneurysma, waardoor er niet geopereerd hoeft te worden, is daarom een aantrekkelijke optie. 
In hoofdstuk 33 wordt de associatie tussen statine gebruik en een tragere groei van het aneurysma 
van de abdominale aorta beschreven. Deze lijkt onafhankelijk te zijn van andere bekende factoren 
die invloed hebben op aneurysmagroei.
In hoofdstuk 34 wordt de langetermijns uitkomst van patiënten met een zeer hoog cardiaal risico 
die een endovasculair herstel van het aneurysma van de abdominale aorta hebben gehad vergeleken 
met de uitkomst van patiënten die een open herstel hebben ondergaan. Na een gemiddelde follow-
up van ruim 3 jaar was endovasculaire behandeling geassocieerd met minder cardiale complicaties. 
Echter, de totale overleving verschilde niet tussen beide groepen. Verder kwam naar voren dat met 
name het gebruik van statines een gunstig effect heeft op de langetermijns uitkomsten. 
In hoofdstuk 35 worden de langetermijns resultaten van de DECREASE V pilot studie beschreven. 
Ook op de langere termijn bleek preoperatieve profylactische coronair revascularisatie van zeer hoog 
risico patiënten niet geassocieerd te zijn met een betere uitkomst. Daarom is geconcludeerd dat 
preoperatieve coronair revascularisatie in zeer hoog risico, maar stabiele, patiënten niet zinvol is. 
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